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Abstract 
 
Introduction: Cellular membrane proteins, such as the cytochrome P450 
enzyme superfamily (P450), have important roles in the physiology of the 
cell. P450s are important in metabolising endogenous molecules, as well as 
metabolising xenobiotic substances for detoxification and excretion. P450s 
are also implicated in cancer as they can act to ‘negatively’ de-activate or 
‘positively’ activate cancer therapeutics. Identifying specific P450s that are 
highly up-regulated at the tumour site could be used to predict drug response 
and formulate targeted cancer therapy to help diminish systemic side-effects.  
Methods: Previous enrichment strategies have been unable to isolate the full 
complement of the P450 superfamily. To develop enrichment procedures for 
the P450s, a proteomic strategy was developed so that compounds could be 
screened for their effectiveness as general P450 probes. A standardised 
work-flow was created, encompassing affinity chromatography, protein 
concentration/desalting, followed by sodium dodecyl sulphate polyacrylamide 
gel electrophoresis (SDS-PAGE) and high performance liquid 
chromatography-mass spectrometry (HPLC-MS). A ketoconazole analogue 
and a 2-EN analogue, with known P450 inhibition, were immobilised on a 
solid support for comparison to immobilised histamine. Co-factor removal, 
competitive elution and DTT cleavage of disulfide bonds of probes were 
utilised to elute bound proteins.  
 iii 
 
Results/Discussion: Inhibitor-beads bound a large range of proteins, 
including P450’s, of which some were eluted by co-factor removal, some by 
competitive elution. Specificity of binding was improved by optimising buffer 
conditions and solid supports, however non-specific binding was not totally 
eradicated. All human P450s from spiked samples and 18 P450s from more 
complex mouse liver samples were recovered using one or more ligands. 
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Development of novel methods for purifying and characterising 
membrane proteins from cancer related samples 
 
 
1.0 Introduction 
 
1.1  Membrane proteins 
1.1.1 Structure and function of cellular membranes 
 
The eukaryotic cell consists of cytosol, many organelles and is enclosed by a 
phospholipid bilayer called the plasma membrane (Figure 1.1). Each 
organelle or group of organelles have different structures and functions, and 
consequently contain different molecules and proteins specific to their 
requirements. Some of these molecules and proteins have to be kept 
together so that they can work efficiently, others may need to be kept 
separate to prevent unwanted reactions, metabolism and degradation. To do 
this, the organelles of the eukaryotic cells have membranes that are similar to 
the outer plasma membrane, however the exact content of the membrane 
may change dependent on organelle function. The composition of the plasma 
membrane may also change dependent on the cellular environment, the cell 
type of the organism being studied and the species from which the cell 
originates. 
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Figure 1.1: Structure of a biological membrane showing some examples of 
proteins and carbohydrates that can associate with the lipid bilayer. 
Membrane proteins can fully integrate and span the membrane (integral 
proteins) or associate with the membrane by non-covalent bonds (peripheral 
proteins) (Lodish, 1999) 
 
 
Cellular membranes are not solely composed of lipids, most also contain a 
phosphate group, forming phospholipids. The phosphate group can interact 
and bind additional groups including choline, ethanolamine, serine and 
inositol (Christie, 2009). If the phosphate group does not interact with any 
additional groups then the molecule is phosphatidic acid, but this is rarely 
seen. In membranes the additional group coupled with the phosphate group 
enhances the hydrophilic nature of the head group, promoting binding (Karp, 
1999). 
 
Although phospholipids make up a large portion of the lipid content of most 
membranes, there are two additional major lipid classes that do not bind 
phosphate groups. Sphingolipids have long highly saturated acyl chains and 
are derivatives of the amino alcohol sphingosine, but are otherwise similar in 
structure to phospholipids. Due to the difference in structure of sphingolipids 
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they can tightly pack. This is responsible for the phase separation between 
the sphingolipids and the loosely packed phospholipids in the lipid-raft 
regions which contain a large proportion of membrane receptors (Brown and 
London, 2000). There are many forms of sphingolipids based on associating 
molecules. If a phosphorylcholine binds the terminal alcohol then it becomes 
a sphingomyelin. If a carbohydrate binds it becomes a glycolipid, and is also 
known as either a cerebroside if a simple sugar binds, or a ganglioside if an 
oligosaccharide binds (Karp, 1999).  
 
The other lipid molecule found in membranes of mammals is cholesterol. 
Cholesterol is a sterol lipid that also acts to aid in membrane lipid phase 
separation and molecular targeting to the lipid-raft regions (Rothberg et al., 
1990). The overall distribution of the differing varieties of lipids (Figure 1.2) in 
an average cellular membrane is made up of approximately 50% 
phosphatidylcholine, 15% phosphatidylserine, 10% 
phosphatidylethanolamine, 10% sphingolipids, 10% cholesterol and 1% 
phosphatidylinositol (Muller et al., 2008).  
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Figure 1.2: Chemical structure of phospholipids, sphingolipids and 
cholesterol. (A) phosphatidylcholine; (B) phosphatidylserine; (C) 
phosphatidylethanolamine; (D) sphingomyelin; (E) cholesterol; and (F) 
phosphatidylinositol  
 
1.1.2 Characteristics and functions of membrane proteins 
Various protein molecules can associate with the plasma membrane. All 
these proteins will be hydrophobic or contain hydrophobic regions that can 
interact with the hydrophobic lipids molecules. This association may be on 
the inner or outer surface of the membrane via non-covalent interactions 
(peripheral proteins), or be via covalent interactions (lipid-anchored proteins). 
Another form of association is via membrane penetration and integration 
where the protein may have only one or many segments that pass through 
the whole membrane (Muller et al., 2008). Integral proteins with multiple 
spanning segments contain hydrophobic -helices that integrate within the 
membrane, whereas proteins containing -barrels form pores (Figure 1.3). -
A B 
C D 
E F 
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barrels have hydrophilic regions on the inner surface of the pore to allow the 
passage of hydrophilic molecules through the membrane and hydrophobic 
regions on the outer surface that interact with the membrane (Tan et al., 
2008).  
 
 
Figure 1.3: Model of β-barrel pore formed by voltage-dependent anion-
selective channel protein. Structural organisation of β-sheets (yellow) form 
pores to allow passage of low molecular weight solutes through mitochondrial 
membrane. α-helices (purple) (Tan et al., 2008) 
 
Membrane proteins have a range of functions in a healthy cell as well as 
transporting molecules across the membrane. Membrane proteins are 
important in cell adhesion, for example the integrin and selectrin protein 
families, whereby they act in the regulation of cell-cell and cell-matrix 
interactions important for localisation and cellular movement. Membrane 
proteins also form receptors for ligands and are involved in signal 
transduction within the cell, for example tyrosine kinase receptors and G 
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protein coupled receptors. Signal transduction is important for maintaining 
homeostasis and cellular response to environmental changes, including 
infection. 
 
If membrane protein expression is changed, or if the membrane proteins are 
altered or inactivated in states of disease, it can cause severe disruption to 
normal cellular functioning. Certain membrane proteins have key roles in 
tumourigenesis, such as the human epidermal growth factor protein receptor 
(HER) and signal transducers. In particular, over-expression of HER2 has 
been correlated with aggressive progression breast cancer (Slamon et al., 
1987).  
 
Unfortunately, it is difficult to study membrane proteins because of their 
structure and properties. The isolation of membrane proteins using 
conventional differential centrifugation techniques without contamination from 
unwanted non-membranous proteins is difficult due to the interaction 
between the two protein types. The problems of attaining good quality 
samples, with the low abundance of membrane proteins, means that 
conventional methods of studying membrane proteins are ineffective. The 
need for strong solubilising agents such as detergents has also proven to be 
problematic for structural analysis. An enrichment procedure currently 
available uses biotinylation reagents to label the membrane proteins and 
then an avidin based chromatography to separate (Macher and Yen, 2007). 
This method has several drawbacks, the procedure cannot be used on 
tissues homogenates as proteins need to be artificially labelled over several 
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cell cycles. Another enrichment procedure uses lectin affinity 
chromatography to purify glycosylated proteins with some success (Ghosh et 
al., 2004). The advantage of this method is that it can be used to purify 
proteins from tissue and blood samples. 
 
 
1.2  Cytochrome P450s 
1.2.1 Structure of cytochrome P450s and their interaction with 
membranes 
 
Eukaryotic cytochrome P450 enzymes (P450s) are examples of integral 
membrane proteins. Although there are a large number of eukaryotic P450s, 
there are conserved elements between the species. Eukaryotic P450s 
contain a hydrophobic N-terminal helix that integrates into cell membranes, 
which is the main difference between eukaryotic and prokaryotic P450s 
(Ioannides, 2008). The hydrophilic C-terminal is left exposed in the cytosol 
(Williams et al., 2000).  
 
A large proportion of the P450 enzyme has a helical structure, containing A-L 
helices (Figure 1.4). Between the B and C helices is the B-C loop region, and 
between the F and G helices is the F-G loop region. These loop regions help 
mediate the access of molecules to the P450 active site. With the G’ helix of 
the F-G loop partially embedded in the membrane, hydrophobic substrates 
can enter and be metabolised by the P450 enzyme, leaving the site into the 
cytosol if the products are now hydrophilic (Williams et al., 2000).  
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Another common feature between the P450s is that of an associated haem 
moiety. The iron (III) protoporphyrin IX associates with the sulphur group of a 
cysteine amino acid in the ‘cys-pocket’. This conserved pocket is comprised 
of the cysteine as well as phenylalanine and glycine amino acids. The haem 
group positions itself between the I and L helices (Otyepka et al., 2007).  
 
 
 
Figure 1.4: Typical P450 structure and haem association. (A) A-L helices 
drawn as representative helical structures, with each helix having different 
shading. -sheets, the amino and carboxyl terminals, loop regions, and 
associated haem moiety are also labelled showing the interactions of all of the 
components and the common folding of the P450. (B) Alignment of the haem 
moiety in the conserved haem binding site. Modified from Williams et. al (2000)  
 
A B 
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1.2.2 Interactions of P450s in the multicomponent monooxygenase 
system 
 
P450s interact with another integral membrane enzyme, NADPH-cytochrome 
P450 reductase (CPR). This enzyme associates with both flavin 
mononucleotide and flavin adenine dinucleotide. The CPR enzyme accepts a 
pair of electrons from β-nicotinamide adenine dinucleotide phosphate 
reduced (NADPH) and transfers them one at a time to a P450 molecule, and 
it is this that gives the P450s the ability to hydroxylate and metabolise its 
substrates (Wang et al., 1997). Figure 1.5 illustrates the details of electron 
acceptance, reduction/oxidation and splitting of molecular oxygen in a typical 
P450 catalytic cycle. 
 
 
 
Figure 1.5: Typical P450 (R) catalytic cycle, showing reduction, oxidation and 
electron transfer reactions. Modified from Ioannides (2008) 
 
 
Another molecule that associates with P450s is cytochrome b5. It is a 
microsomal anchored protein that also associates with CPR at a site that 
overlaps P450 binding to the CPR molecule. Cytochrome b5 can act as an 
electron donor to the P450s, but it can only donate the second electron, the 
first must come from CPR. However, the transfer of the electron from 
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cytochrome b5 may on occasions be much faster than the transfer from CPR 
to certain P450s, which may be a safeguard against excessive superoxide 
free radical production (Bridges et al., 1998). The binding sites of CPR and 
cytochrome b5 molecules in a typical P450 enzyme are shown in Figure 1.6. 
 
It is only possible for P450s to associate with CPR and cytochomre b5 in their 
active state. Irreversible P450 transformation to the enzymatically inactive 
cytochrome P420 can occur. In nature this can be due to changes in pH or 
exposure to organic solvents.  
 
 
 
Figure 1.6: Positioning and interactions of the P450 redox partners CPR 
and cytochrome b5. (A) Highlighted are key amino acids in the binding sites of 
CPR in a typical P450 enzyme. (B) Highlighted are key amino acids in the 
binding sites of cytochrome b5 in a typical P450 enzyme. Modified from Otyepka 
et. al (2007)  
 
A B 
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1.2.3 Nomenclature and classes of the cytochrome P450s 
 
The P450 enzyme superfamily contains a vast array of enzymes with various 
substrate specificities. The exact number of P450s identified across all 
species, including prokaryotic, eukaryotic and fungal organisms, has 
increased from 753 in August 1998 to 3811 in September 2004. There is a 
system by which nomenclature of newly identified P450s should follow to 
ensure that P450s are named based on evolutionary roots and therefore 
decrease the number of name changes made after the initial name is 
assigned. David Nelson chairs a Committee on Standardised Cytochrome 
P450 Nomenclature where newly sequenced P450 genes can be submitted 
to be assigned an appropriate name (Nelson, 2009). All P450s within the 
same family need at least 40% homology and P450s within the same 
subfamily need at least 55% homology (Phillips and Shephard, 2006).  
 
P450 families are identified by a number, for example CYP1, CYP4 and 
CYP19 are all different P450 families. The subfamily is denoted by the 
addition of either a single or double letter, for example CYP4A, CYP4B and 
CYP4AX are different subfamilies. The only letters that are not assigned as 
subfamily names are ‘O’ and ‘I’ to prevent confusion with the numbers ‘0’ and 
‘1’. After this, the individual P450 protein is identified by a number, for 
example CYP1A1 is a different P450 from CYP1A2, within the family of 
CYP1 and subfamily of CYP1A (Phillips and Shephard, 2006). Table 1.2 lists 
the human and mouse P450s, catergorising the P450s into their families and 
sub-families. 
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P450 family P450 sub-family Human P450 Mouse P450 
CYP1 CYP1A CYP1A1 
CYP1A2 
CYP1A1 
CYP1A2 
CYP1B CYP1B1 CYP1B1 
CYP2 CYP2A CYP2A6 
CYP2A7 
CYP2A13 
CYP2A4 
CYP2A5 
CYP2A12 
CYP2A22 
CYP2B CY2B6 CYP2B9 
CYP2B10 
CYP2B13 
CYP2B19 
CYP2B23 
CYP2C CYP2C8 
CYP2C9 
CYP2C18 
CYP2C19 
CYP2C29 
CYP2C37 
CYP2C38 
CYP2C39 
CYP2C40 
CYP2C44 
CYP2C50 
CYP2C54 
CYP2C55 
CYP2C65 
CYP2C66 
CYP2C67 
CYP2C68 
CYP2C69 
CYP2C70 
CYP2D CYP2D6 CYP2D9 
CYP2D10 
CYP2D11 
CYP2D12 
CYP2D13 
CYP2D22 
CYP2D26 
CYP2D34 
CYP2D40 
CYP2E CYP2E1 CYP2E1 
CYP2F CYP2F1 CYP2F2 
CYP2G  CYP2G1 
CYP2J CYP2J2 CYP2J5 
CYP2J6 
CYP2J7 
CYP2J8 
CYP2J9 
CYP2J11 
CYP2J12 
CYP2J13 
CYP2R CYP2R1 CYP2R1 
CYP2S CYP2S1 CYP2S1 
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P450 family P450 sub-family Human P450 Mouse P450 
CYP2 CYP2T  CYP2T4 
CYP2U CYP2U1 CYP2U1 
CYP2W CYP2W1 CYP2W1 
CYP2AB  CYP2AB1 
CYP2AC  CYP2AC1 
CYP3 CYP3A CYP3A4 
CYP3A5 
CYP3A7 
CYP3A43 
CYP3A11 
CYP3A13 
CYP3A16 
CYP3A25 
CYP3A41 
CYP3A44 
CYP3A57 
CYP3A59 
CYP4 CYP4A CYP4A11 
CYP4A22 
CYP4A10 
CYP4A12a 
CYP4A12b 
CYP4A14 
CYP4A29 
CYP4A30b 
CYP4A31 
CYP4A32 
CYP4B CYP4B1 CYP4B1 
CYP4F CYP4F2 
CYP4F3 
CYP4F8 
CYP4F11 
CYP4F12 
CYP4F22 
CYP4F13 
CYP4F14 
CYP4F15 
CYP4F16 
CYP4F17 
CYP4F18 
CYP4F37 
CYP4F39 
CYP4F40 
CYP4V CYP4V2 CYP4V3 
CYP4X CYP4X1 CYP4X1 
CYP4Z CYP4Z1  
CYP5 CYP5A CYP5A1 CYP5A1 
CYP7 CYP7A CYP7A1 CYP7A1 
CYP7B CYP7B1 CYP7B1 
CYP8 CYP8A CYP8A1 CYP8A1 
CYP8B CYP8B1 CYP8B1 
CYP11 CYP11A CYP11A1 CYP11A1 
CYP11B CYP11B1 
CYP11B2 
CYP11B1 
CYP1B2 
CYP17 CYP17A CYP17A1 CYP17A1 
CYP19 CYP19A CYP19A1 CYP19A1 
CYP20 CYP20A CYP20A1 CYP20A1 
CYP21 CYP21A CYP21A2 CYP21A1 
CYP24 CYP24A CYP24A1 CYP24A1 
CYP26 CYP26A CYP26A1 CYP26A1 
CYP26B CYP26B1 CYP26B1 
CYP25C CYP26C1 CYP26C1 
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P450 family P450 sub-family Human P450 Mouse P450 
CYP27 CYP27A CYP27A1 CYP27A1 
CYP27B CYP27B1 CYP27B1 
CYP27C CYP27C1  
CYP39 CYP39A CYP39A1 CYP39A1 
CYP46 CYP46A CYP46A1 CYP46A1 
CYP51 CYP51A CYP51A1 CYP51A1 
 
Table 1.2: Collated human (57) and mouse (103) functional P450 proteins 
 
1.2.4 Physiological and pathological roles of the cytochrome P450s 
 
P450s enzymes have very important roles in the physiology of the cell by 
metabolising many types of molecules, for example steroids, fatty acids, 
eicosanoids and vitamins, whose metabolites are vital for proper cellular 
function. P450s also have another major role by metabolising xenobiotic 
substances that may be harmful or toxic to the cell, acting to eradicate the 
problem and make it possible to use or excrete the metabolites (Ioannides, 
2008). 
 
Unfortunately P450 activity can be compromised or induced in a number of 
situations. Certain xenobiotic substances can transiently or permanently 
inhibit P450s by binding and altering the endogenous activity and possibly 
the conformation of the P450 molecule (Ioannides, 2008). Various P450s 
have been shown in a number of studies to have altered expression at the 
protein level in certain tumours (McFadyen et al., 2004).  
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1.3 Cytochrome P450s in cancer 
1.3.1 Cancer and current therapeutic strategies 
 
Cancer arises from the abnormal and uncontrolled division of cells (Martin, 
2007). The versatility of metazoan cells, allowing each cell to possess a vast 
array of genomic information, and the retention of proliferative ability, even 
after normal cell division has ceased, makes the cell vulnerable to corruption. 
There are many causes for cell corruption, but the affect may lead to the cell 
accessing alternate genomic information, changing its phenotype, and 
causing continued cell proliferation (Weinberg, 2007). 
 
The treatment options available to patients will differ depending on a number 
of factors including tumour location, aggression, and source of treatment 
funding. Removal of all or part of the tumour tissue will take place if the risks 
of surgery do not out-weigh the risk of fatality from the cancer. Removing 
only part of the tumour (biopsy) can help with diagnosis and prognosis, and 
can influence further treatment by providing a sample for tumour type, grade, 
and hormonal/receptor status identification. Radiation therapy targets the 
highly proliferative and disorganised nature of tumour cells, causing damage 
from which they cannot recover but healthy non-proliferating cells can 
because they still have functioning repair systems. Unfortunately, the 
success of this therapy is tumour- and patient-specific, and can sometimes 
affect other actively dividing cells in the body like the gametes and blood 
cells. Another therapeutic option is to treat the patient with chemotherapy. 
Chemotherapy targets differ greatly, but current chemotherapeutics do not 
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always show good tumour specificity. This introduces problems with adverse 
symptoms and dose-limiting factors, due to their narrow therapeutic index.  
 
1.3.2 Therapeutic strategies in development  
 
Rather than using cytotoxic drugs that work systemically throughout the 
body, new ideas for tumour targeting have been researched and developed. 
For example, epidermal growth factor receptor inhibitors that target tumour 
cell proliferation and differentiation by the tyrosine kinase pathway have been 
investigated, and some of these drugs have already been approved for 
clinical use. Another target example is tumour angiogenesis induction. 
Monoclonal antibodies against vascular endothelial growth factor, important 
in new blood vessel formation, have proven to have good anti-angiogenesis 
and anti-malignant activity (Chu and Lu, 2008).  
 
A different form of treatment being studied involves the use of active drugs 
that can be metabolised by tumour cells to more potent compounds, for 
example tamoxifen, or inactive pro-drugs that are converted to the active 
form only at the target tumour site, for example AQ4N (Atkinson et al., 2007). 
These pro-drugs can take advantage of the differing expression levels of 
several classes of enzymes at the tumour site compared to the normal 
healthy cells in the body. Examples of enzymes thought to be of great 
importance in tumour growth and progression are P450s and matrix 
metalloproteases (MMPs).  
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1.3.3 P450 pharmacogenetics in cancer   
Choudhary et al. (2005) monitored CYP1A1, 1A2, 1B1, 2E1, 2R1, 2S1, 2U1, 
2W1, 4B1 and 4X1 expression in healthy adult tissues using PCR. This 
served as a useful cross-sectional indicator of differing P450 expression 
levels in many human tissues (Figure 1.7). In comparison, Yu et al. (2001) 
used P450 activity assays (ECOD, coumarin 7-hydroxylase, 7-EROD and 7-
BROD) to monitor enzyme activity across the NCI human tumour cell line 
panel, containing more than 50 types of tumour cell lines (Figure 1.8).  
 
CYP1B1 is overexpressed in a wide variety of tumours (McFadyen et al., 
2001; Murray et al., 2001). El-Rayes et al. (2003) showed CYP1A1, CYP2B6, 
CYP2E1 and CYP3A4 to have decreased expression in patients with breast 
cancer (Figure 1.9). CYP3A4 and CYP3A5 have been shown to have 
increased expression in metastatic osteosarcomas (Dhaini et al., 2003). 
These two studies show that expression of P450s is tumour-specific, and 
with varying tumour types, P450s, such as CYP3A4 detailed here, can have 
increased and decreased expression. It may be that P450 
deactivation/activation is just one part of a pleiotropic response, but so far 
only a correlation between altered levels in primary and metastatic tumours 
has been made (McFadyen et al., 2004). 
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Figure 1.7: Cytochrome P450 expression profile in healthy human tissue (Choudhary et al., 
2005) 
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Figure 1.8: P450 activity of NCI human tumour cell line panel. (A) 7-ECOD activity assay 
(CYP1A1, 1A2, 2A6, 2B6, 2C8, 2E1, 3A4). (B) Coumarin 7-hydroxylase activity assay 
(CYP2A6, 2B6). (C) 7-EROD activity assay (CYP1A1, 1A2, 1B1). (D) 7-BROD activity assay 
(CYP1A1, 1A2, 1B1, 2A6, 2B6, 2C8, 2C9, 2C19, 2E1, 3A4, 4A11) (Yu et. al  2001) 
 38 
 
 
Figure 1.9: Mean P450 enzyme expression in tumour (T) and adjacent 
normal tissue (N) in breast cancer patients. Results collated from 33 female 
breast cancer patients patients. Solid line extensions (whisker plot) indicate 
standard error; significance *p<0.05 (El-Rayes et al., 2003) 
 
P450s are responsible for the ‘negative’ metabolism of anti-cancer drugs, 
whereby the drug becomes less active after metabolism (inactivation). 
Tamoxifen is an example of a drug that is metabolised by CYP3A family of 
P450 enzymes. Using specific inhibitors it has been possible to show that it is 
CYP3A activity, via N-demethylation, that causes the inactivation of 
tamoxifen. However CYP3A activity is also responsible for some of the 
positive metabolism of the drug (Figure 1.10). P450 enzymes can also be 
responsible for activating the toxic affect of precarcinogens (Table 1.1). 
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Table 1.1: Activation of pre-carcinogens to carcinogenic compounds by 
P450 metabolism.   DMBA, 7,12,-dimethylbenz[a]anthracene; IQ, 2-amino-3-
methylimidazo[4,5-f]quinoline; NATB, N-nitrosoanatabine; NDEA, N-
nitrosodiethylamine; NNAL, 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanol; 
NNK, 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone; NNN, N9-
nitrosonornicotine; PhIP, 2-amino-1-methyl-6-phenylimidazo-[4,5-b]pyridine. 
(Rodriguez-Antona and Ingelman-Sundberg, 2006). 
 
 
However, P450s can also be responsible for the ‘positive’ metabolism of 
cancer therapeutics, whereby the drug becomes more active after 
metabolism (bioactivation). Ifosfamide is also metabolised by a CYP3A 
enzyme, however it is the 4-hydroxylation by CYP3A4 that activates the 
therapeutic agent producing cytotoxic activity (Jacolot et al., 1991). This 
positive metabolising activity, coupled with the up-regulation of certain P450s 
in tumours, has brought about the idea of using P450s as a target for pro-
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drug therapy in cancer therapeutics. Due to the up-regulation of CYP1B1 in a 
wide variety of tumour sites, as previously mentioned, clinical evaluation of 
P450-based pro-drugs has centered on this enzyme as a target. Aryl oxime 
prodrugs are metabolised by CYP1B1 to produce toxic levels of nitric oxide, 
targeting the tumour site due to the high expression levels of CYP1B1 in 
comparison to normal healthy tissue (McFadyen et al., 2004). The prodrug 
resveratrol also targets CYP1B1 at the tumour site via metabolism of the 
phytoestrogen prodrug into the active anticancer agent piceatannol (Potter et 
al., 2002). 
 
1.3.4 P450 polymorphisms 
 
There are 57 known active human P450 genes and 58 pseudogenes, and 
102 known active murine P450 genes and 88 pseudogenes (Nelson et al., 
2004). There are over 400 known single nucleotide polymorphisms (SNPs) in 
human P450 alleles. These mutations in the amino acid sequence (primary 
structure) can cause conformational changes by affecting the secondary and 
tertiary structure due to the differing physical and chemical properties of the 
amino acids involved. Altered conformation may lead to changes in substrate 
specificity or metabolising ability of the enzyme, changes in gene/protein 
regulation of the P450s and transportation and localisation of the enzyme in 
the hydrophobic membrane.  
 
Differences between polymorphic variants may be visualised metabolically as 
an increase or decrease in expression, or an increase or decrease in activity. 
Individuals can be split into four categories based on the differing 
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phenotypes; poor metabolisers (non-functional alleles), intermediate 
metabolisers (one functional allele), extensive metabolisers (two functional 
alleles), and ultrarapid metabolisers (three or more functionally active alleles) 
(van der Weide and Steijns, 1999). Rodriguez-Antona and Ingelman-
Sundberg (2006) distribute the polymorphic P450s into two classes based on 
frequency of polymorphism and metabolism of precarcinogens. Class I 
contains P450s that are well conserved, lacking in important functional 
polymorphisms and P450s that metabolise drugs as well as precarcinogens. 
CYP1A1, CYP1A2, CYP2E1 and CYP3A4 are all Class I enzymes. Class II 
contains P450s that are highly polymorphic and P450s that metabolise drugs 
but not precarcinogens. CYP2B6, CYP2C9, CYP2C19, and CYP2D6 are all 
Class II enzymes. 
 
There are over 54 different CYP2B6 alleles with varying functional 
significance (Sim, 2011). CYP2B6*5 and CYP2B6*7 alleles are suggested to 
cause reduced protein expression (Lang et al., 2001). CYP2B6*6 allele has 
been shown to exhibit differing metabolism properties for cyclophosphamide 
(Xie et al., 1996) and efavirenz (Tsuchiya et al., 2004). There are also rare 
SNPs in the CYP2B6 gene that can lead to non-functional or absent proteins, 
causing problems for metabolism of cyclophosphamide, ifosamide, thiotepa 
and procarbazine anticancer prodrugs (Rodriguez-Antona and Ingelman-
Sundberg, 2006). 
 
There are over 41 different CYP2C9 alleles with varying functional 
significance (Sim, 2011). CYP2C9*2 and CYP2C9*3 result in decreased 
enzyme activity (Kirchheiner and Brockmoller, 2005). There are over 33 
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different CYP2C19 alleles with varying functional significance (Sim, 2011). 
CYP2C19*2 and CYP2C19*3 alleles result in reduced enzyme expression 
(Desta et al., 2002), whereas the CYP2C19*17 allele results in an increased 
enzyme expression (Sim et al., 2006). 
 
There are over 123 different CYP2D6 alleles with varying functional 
significance (Sim, 2011). CYP2D6*4, CYP2D6*5, CYP2D6*10 and 
CYP2D6*17 alleles all result in defective genes. Figure 1.10 shows the role 
of CYP2D6 in the metabolism of the anticancer agent tamoxifen, as well as 
the role of the other polymorphic enzymes mentioned above. The 
antioestrogenic metabolites of tamoxifen are more potent, especially 4-
hydroxytamoxifen and endoxifen, which are both primarily formed by 
CYP2D6 metabolism, and also N-desmethyltamoxifen by CYP3A4 
metabolism.  
 
 
 
Figure 1.10: P450 mediated biotransformation pathways involved in tamoxifen 
metabolism (Rodriguez-Antona & Ingleman-Sundberg, 2006) 
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To efficiently target a particular P450 or set of P450s in a patient’s tumour, it 
would be vital to analyse the exact P450 profile of the patient and the tumour 
to determine which therapy would be most effective. The difficulty of this will 
be investigated through the following sections, due to the large range of 
enzyme structural and functional variability. 
 
1.4 Detection of P450s 
1.4.1 P450 activity assays 
 
 
The P450s can be detected using their known substrates whilst monitoring 
for the products, using techniques such as ultra-violet (UV) or fluorescent 
spectroscopy, and high performance liquid chromatography (HPLC). 7-
ethoxyresorufin is an example of a P450 substrate that utilises fluorescent 
spectroscopy analysis in the EROD assay. This substrate is O-deethylated to 
resorufin (Figure 1.11), with varying enzyme specific activity by the CYP1 
family of enzymes. The rank order of specific activity is 
CYP1A1>CYP1B1>CYP1A2 (Shimada et al., 1997). The fluorescent 
resorufin product can be detected fluorimetrically (590nm) in real time, 
making it possible to detect (qualitative method) and obtain activity rates 
(quantitative method) of the enzymes involved. The EROD assay can 
consequently be used as a relatively quick method of monitoring the 
presence/activity of the CYP1 enzymes throughout an investigation.  
 
Other P450 activity assays, such as the P450 glo assay, use a range of 
substrates to monitor the activity of a number of P450s. The P450 glo assay 
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is a luminescent-based assay, with pro-luciferin substrates that are 
metabolised by P450s to active luciferin, which luminesce upon incubation 
with detection reagent (Figure 1.12). 
 
The activity assays do require fully functional P450s within the sample, and 
many different substrates would be required to monitor all of the P450s in a 
protein sample. This would consequently mean large volumes of protein 
samples would be required for multiple assays to assess the full range of 
P450s. 
 
 
Figure 1.11: P450 metabolism of 7-ethoxyresorufin to fluorescent product resorufin by O-
deethylation  
 
Figure 1.12: Overview of the principles of the P450 glo assay (Promega Corporation, 2009) 
 
7-ethoxyresorufin resorufin 
CYP1A 
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1.4.2 Western blotting and P450 immunoassays 
 
Another technique available for the detection of P450s is the Western blot 
procedure. This procedure is used to transfer the proteins separated by gel 
electrophoresis onto a membrane, such as nitrocellulose, and then uses 
specific primary antibodies and secondary anti-antibodies linked to reporter 
enzymes to give a visual response. This procedure therefore gives 
information on protein expression, without requiring enzyme activity. The 
assay is also very sensitive and usually is very specific, with antibodies 
binding to only one or a few proteins (Burnette, 1981). The enzyme-linked 
immunosorbent assay (ELISA) was first described by Engvall and Perlmann 
(1971). ELISA uses the ability of an antibody to interact with a targeted 
antigen in a sample for detection. Unfortunately, antibodies against the 
P450s for use in Western blotting and ELISA techniques are often cross 
reactive with other P450s as well as other proteins from the cellular proteome 
(Berglund et al., 2008). The other issue when utilising P450 antibodies in 
animal models and human tissue, is that the epitope region of the P450s can 
differ, preventing cross-species analysis and so additional antibodies are 
required. Antibodies against the animal model P450s are not as readily 
available as the human antibodies, which makes the process more difficult, 
less specific and more time-consuming. 
 
1.4.3 P450 DNA product analysis  
 
Real time polymerase chain reaction (RT-PCR) has been used to amplify and 
quantify P450 DNA products from mouse and human tissue (Figure 1.13). 
Choudray et al. (2005) determined the P450 expression profiles of 10 P450s 
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(CYP1A1, CYP1A2, CYP1B1, CYP2E1, CYP2R1, CYP2S1, CYP2U1, 
CYP2W1, CYP4B1, CYP4X1). The data shows that some P450s are only 
expressed in selected tissues, such as CYP1A2 which is only expressed in 
mouse and human liver tissue, whereas P450s such as CYP2U1 are more 
ubiquitously expressed. This study also highlighted differences in expression 
profiles between human and mouse tissues. CYP4X1 was expressed 
relatively exclusively in mouse brain tissue, whereas it is more widely 
expressed throughout human tissues. 
 
 
 
Figure 1.13: PCR amplified P450 products from mouse (A) and human 
(B/C) panels. Products separated on agarose gel and ethidium bromide 
stained. Low DNA mass ladder (A, lanes 1/14; B, lanes 1/10; C, lanes 1/10), 
four developmental stages in mouse (E7, gastrulation; E11, neural patterning 
and somitogensis; E15, organogenesis; E17, feotal period), mouse tissue panel 
from pooled 200 BALB/c males 8-12 weeks, human tissue panel from 
Caucasians 15-64 years. Modified from Choudhary et al., (2005) 
A B C 
 47 
 
1.4.4 Overview of proteomic techniques and practical considerations  
 
Proteomics closely studies proteins, their interactions with each other, their 
structure and function, as well as their expression, localisation and 
regulation. Changes in any of these characteristics can also be monitored in 
relation to pathogenesis or therapeutic treatment to increase understanding 
of signalling and reaction pathways, interactions and metabolism. The sum of 
all the proteins in a cell is termed the proteome. Due to the large range of 
proteins and their many different states within the proteome, there is a high 
degree of complexity in most samples, therefore a number of purification or 
separation stages may be required before analysis. This can lead to losses of 
protein yield and if the target protein is in low abundance in the original 
sample, it may be lost completely before detection has occurred.  
 
There are a number of proteomic techniques that help minimise losses as 
well as those enriching for target proteins and so increasing detection of 
otherwise undetectable proteins. The study of low abundance proteins, and 
often limited sample volumes, means that highly sensitive instruments are 
required (Aebersold and Mann, 2003). Examples of instruments used to look 
at minute samples include nano-HPLC systems which separate complex 
mixtures of molecules into multiple peaks, and mass spectrometers which 
are highly sensitive weighing instruments, in that they can accurately 
determine the mass of a compound. These processes can be used 
sequentially, with HPLC linked directly to the column flow, as in electrospray 
ionisation (ESI) mass spectrometry (MS), or by immobilising discrete 
fractions of the column flow on a plate that can be inserted into a matrix-
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application ESI MALDI
complex mixtures no yes
biomarker discovery no yes
imaging mass spectrometry no yes
PKPD yes no
protein identification
peptide mass fingerprinting (PMF) no yes
peptide fragment fingerprinting (PFF) yes yes
quantitative proteomics
stable isotope labelling yes yes
spectral counting yes no
top-down proteomics yes yes
bottom-up proteomics yes yes
characteristic ESI MALDI
ion generation electrospray matrix assisted 
laser desorption
continuous pulse
time-dependent analysis yes no
speed very fast fast
sample range wide very wide
charge state multiple 1+
ease of use complex sample
ion fragmentation very efficient efficient
fragmentation types ISD, PSD, CID CID, ECD, ETD
buffer tolerance low high
assisted laser desorption/ionisation (MALDI) mass spectrometer (described 
in more detail in Section 1.4.8). A comparison of ESI and MALDI mass 
spectrometers and their applications is given in Table 1.3. 
 
A 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.3: Comparison of ESI and MALDI mass spectrometers (A) with 
their associated applications (B). ISD, ion source decay ; PSD, post source 
decay; CID, collision-induced dissociation; ECD, electron-capture dissociation; 
ETD, electron transfer dissociation; PKPD, pharmacokinetic/pharmacodynamics 
studies (Bateson et al., 2011)  
 
 
si ple 
 49 
 
Total protein assays, such as the Bradford assay (Bradford, 1976), are 
another alternative to the HPLC-MS or gel techniques. The protein assay 
techniques are often useful for a quick overview of sample content before 
continuing with another more specific detection technique. These techniques 
are very useful if protein yield is to be quickly measured at each stage of 
analysis to help method optimisation and determine protein losses. Activity 
assays investigate more specifically the presence of a particular functional 
protein or group of proteins. Unfortunately both protein and activity assays 
are affected by interfering substances such as buffer additives and 
detergents. 
 
1.4.5 General principles of affinity chromatography 
 
Chromatographic techniques separate complex mixtures of liquids or gases, 
and the techniques can be analytical or used as a preparative step for further 
downstream analysis. Affinity chromatography is a method that can target a 
more specific set of binding properties than alternative methods of 
chromatography. It uses the ability of the substrate-enzyme, antibody-antigen 
or ligand-receptor relationships to bind a particular target protein or group of 
proteins with high affinity, and to separate these from a somewhat more 
complex mixture of molecules. It is possible to bind many kinds of molecules 
to solid supports and beads to help capture specific proteins from a complex 
sample. Different approaches can be taken to bind the molecules to the solid 
support, such as epoxy- or N-hyroxysuccinamide derivatisation. Beads that 
have different properties for binding and are compatibility with elution 
conditions are chosen to match the molecule in question. Sometimes, 
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however, it may not be possible to bind the desired molecule directly to the 
bead, especially if it does not possess the correct reactive group for 
attachment. This may mean that derivatisation of the molecule is needed to 
add the required reactive group or a linker chain for coupling to the bead.  
 
1.4.5.1 Immuno-affinity chromatography 
It is possible to immobilise an antibody that is specific to a target protein. The 
target protein contains an epitope or epitiopes that will be recognised as the 
antigen for the antibody used. To raise antibodies against the antigen it is 
necessary to inject the antigen molecule into an animal. If the antigen is small 
it is necessary to attach it to a carrier protein such as keyhole limpit 
heamocyanin (KLH), and this antigen-carrier protein complex is called a 
hapten. Blood samples of the innoculated animal will be taken and screened 
for antibodies towards the antigen. If reactive antibodies are found, they can 
be purified from the animal plasma (polyclonal) or from spleen-derived B-cell 
secretions (monoclonal). The coupling of antibodies to the solid support will 
usually use the carboxyl or amino groups of the antibody to react with the 
activated solid support matrix (Stevenson, 2000). Polyclonal antibodies are 
relatively non-specific, recognising multiple epitopes on an antigen, whereas 
monoclonal antibodies are specific, recognising one epitope. 
 
1.4.5.2 Protein-protein interaction-based, substrate and co-factor based 
affinity chromatography 
Immobilisation of a substrate or co-factor of target enzyme proteins can be 
employed to help capture the desired protein (Figure 1.14). This method uses 
the proteins natural affinity for the immobilised material. Other proteins that 
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are known to interact with the target proteins can also be used or modified for 
coupling with a solid matrix. Depending on the sample source, it is 
sometimes possible to add tags to proteins for quicker and easier sample 
separation and purification. It is not always possible to use recombinant 
protein, however the tag system can be used as a linker system to 
immobilise different capture materials to the solid support. An example of this 
might be to immobilise a small molecule to a streptavidin-sepharose bead via 
a bound biotin molecule, which will give a strong link between the biotin-
molecule and streptavidin-sepharose complex. 
 
1.4.5.3 Membrane-based affinity chromatography 
 
Membrane-derived molecules may be immobilised on to a solid support to 
capture membrane proteins. This takes advantage of the natural affinity of 
membrane proteins for membrane-derived molecules. Currently the 
membrane lipid phosphatidylcholine bound to a solid support is commercially 
available (Regis Technologies Inc., 2009). This approach will be described 
further in Chapter 4. 
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Figure 1.14: Principles of affinity chromatography. (A) Use of spacer arms to prevent 
steric hinderance from the bead support and allow proper ligand-protein binding. (B) Beads 
are conditioned with binding buffer (i) before addition of sample (ii) and subsequent elution 
(iii). (C) Elution using free-ligand to displace bound proteins. Modified from GE Healthcare 
(2007).
A 
B 
C 
i 
ii iii 
Affinity ligand Spacer arm 
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1.4.5.4 Inhibitor-based affinity chromatography 
Known inhibitors of enzymes can be immobilised onto solid supports to take 
advantage of the ability of the inhibitor to bind to the target enzyme protein. 
Inhibition can be competitive, non-competitive or irreversible. Competitive 
inhibitors act via binding the same active site as the substrate of the target 
enzyme to block the site from the useful metabolism of the substrate, but 
without being metabolised itself. Non-competitive inhibitors bind at a different 
site from the substrate active site, but act to inhibit substrate binding by 
causing a conformational change as the enzyme-inhibitor complex is formed. 
This conformational change affects the physical ability of the enzyme to bind 
the substrate, but leaves the binding affinity unaffected, unlike the apparent 
decrease in binding affinity seen during competitive inhibition. Irreversible 
inhibition occurs when the inhibitor covalently binds to the enzyme, or binds 
with such high affinity that it is extremely difficult and unlikely to ever be 
removed, leaving that particular protein unable to regain enzymatic activity. 
This will be described further in Chapters 5 and 6. 
 
1.4.6 Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) 
 
SDS-PAGE can be used to separate proteins based on molecular weight, 
using sodium dodecyl sulphate to unfold and linearise the protein, as well as 
binding the protein in a uniform ratio to give an overall negative charge. The 
application of electric current is then used to separate the proteins based on 
size difference, irrespective of the original net protein charge (Shapiro et al., 
1967). To visualise the proteins present there are a number of stains 
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available. Coomassie Brilliant Blue is a blue dye that can bind proteins at 
arginine, histidine, and aromatic amino acids (de Moreno et al., 1986). The 
dye binds by Van der Waals interactions as it is adsorbed on the surface of 
the protein. It has the ability to stain most protein bands present if the protein 
is found at greater than 50 nanogram concentrations (Shevchenko et al., 
1996). Silver staining is a more sensitive staining method and can be 
performed on the same gel as a Coomassie Brilliant Blue stain after complete 
destain. This method has the ability to stain protein bands of 1 nanogram 
quantities, but modifications to the original methods are needed to make it 
compatible with mass spectrometery, with some loss of sensitivity 
(Shevchenko et al., 1996). Silver staining uses the ability of silver ions to bind 
to amino acid side chains, mainly carboxyl and sulphydryl groups, which 
have been reduced to free metallic silver forming proteins bands (de Moreno 
et al., 1986). Another alternative approach to visualise the samples is to use 
the Western blot procedure to transfer the proteins and visualise the 
response using antibodies and reporter tags (Burnette, 1981) as previously 
discussed in Section 1.4.2. These gel procedures, in comparison to the MS 
approach, make it possible to test multiple samples at the same time 
reducing the analysis and detection time greatly. The MS approach however, 
can be used to detect nanogram (picomole) to picogram (femtomole) 
quantities of a protein and gives statistical results of the exact identification of 
the proteins found in the sample. 
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1.4.7 Protein desalting and concentration  
During sample preparation and separation steps, unwanted small molecules, 
such as salts, denaturants, and detergents, can be introduced in the buffers 
used, and protein concentration can be dramatically diluted. Buffer 
composition can affect many different analytical procedures, whether it be 
interfering with the signal directly or affecting the protein under investigation, 
inhibiting enzyme activity. NAP-5 desalting using illustra NAP columns pre-
packed with Sephadex G-25 resin allows separation of small (for example 
salts) and large (protein) molecules. The sample flows through the vertical 
column by gravity. Large molecules cannot enter all the pores in the 
Sephadex resin material so elute quickly, whereas the small molecules can 
enter the pores, retarding their progress through the column. The eluate 
containing the protein sample can then be lyophilised on a centrifugal 
evaporator to remove the liquid from the sample, concentrate the dried 
protein material, and allow resuspension in a buffer compatible with analysis. 
Care must be taken when choosing the equilibration and elution buffer for 
use with NAP-5 desalting to avoid concentration of buffer molecules during 
the evaporation process that may themselves affect downstream analysis. 
 
1.4.8 HPLC and MALDI MS 
As previously mentioned (Section 1.4.4), HPLC protein/peptide separation 
and MADLI MS analysis techniques can be linked by immobilisation of HPLC 
fractions for insertion into the mass spectrometer. An example overview of 
the proteomics workflow for samples processed by HPLC-MALDI MS is 
shown in Figure 1.15.  
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Figure 1.15: Typical example of bottom-up proteomics workflow 
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The bottom-up approach involves digestion of proteins to peptides before MS 
analysis. Proteases are used to cleave the proteins; trypsin is commonly 
used, which cleaves at the carboxyl side of lysine and arginine amino acids, 
to generate peptides. The peptide fragments can be analysed, the amino 
acid sequence identified by database searching and the original protein 
determined based on the combination of these peptide fragments. If details 
on post-translation modifications are required then the top-down approach 
would be preferable as the proteins are not digested prior to MS analysis. In 
the MALDI mass spectrometer, ion source decay delays the ions after laser 
desorption before analysis continues which makes this approach possible. 
 
1.4.5.1 Reverse phase HPLC 
Reverse phase HPLC separates proteins and peptides based on their 
hydrophobic interaction with the chromatography material, for example C18 
(peptides) or C4 (proteins). Protein/peptide sample is usually applied in a 
mobile phase containing low concentrations of organic solvent (low 
hydrophobicity of mobile phase in comparison to stationary phase). This 
allows protein/peptide binding to the column material. Protein/peptide 
separation occurs due to gradient elution as increasing concentrations of 
organic solvents cause a shift in the ratio of hydrophobicity between the 
mobile and stationary phases. Eluted proteins/peptides can be collected 
automatically using a robotic arm system onto target plates for direct use with 
MALDI MS. 
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1.4.5.2 MALDI time-of-flight mass spectrometry (MALDI-TOF/TOF) 
MALDI MS is routinely used for proteomics using instruments such as the 
Ultraflex II MALDI-TOF/TOF (Bruker Daltonics, Bremen, Germany). An 
overview of the instrument layout is shown in Figure 1.16. Samples to be 
processed using MALDI MS are first mixed with a matrix material, for 
example α-cyano-4-hydroxycinnamic acid (CHCA), which is vital for this form 
of analysis. It is the dried matrix and sample spot that is targeted by an 
intense pulsed laser beam, with the matrix having several functions. The 
matrix must absorb energy at the wavelength of the laser being used as it is 
this that causes matrix excitation, heating, expansion into a gaseous phase 
and consequent analyte ionisation. The matrix also holds the analyte 
molecules separate in the matrix-sample mixture, increasing molecular ion 
formation for better analysis. Finally the matrix absorbs energy from the laser 
and transfers this to the sample to prevent damage occurring to the sample 
from direct exposure of the sample to the laser source (Hoffmann and 
Stroobant, 2001). On the Ultraflex II the sample is loaded onto a microtitre 
plate format MALDI target which provides a solid support for 384 samples. 
 
The target plate with applied matrix-sample spots is loaded into the ion 
source (IS1) which is charged (P1) and a laser beam is fired at the sample on 
the target plate. Ions formed by this process accelerate due to a nano-
second delay in electrical field alteration on the second voltage plate (P2). 
The deflection plate prevents all of the matrix ions passing through the 
instrument and saturating the detectors. For MS/MS analysis the collision 
induced dissociation (CID) cell is filled with gas that will increase molecule 
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decay and low fragment mass intensities as the matrix ions pass through 
(Figure 1.17) (Bruker Daltonik GmbH, 2001). 
 
After leaving the ion source, and travelling through the CID cell, the matrix 
ions then enter the precursor ion selector (PCIS). The PCIS has layers of 
deflector plates (Figure 1.18) that select for a particular parent ion and its 
fragments, switching deflection off as the target ions enter the deflection field, 
and then back on again once the selected ions leave the deflector. Deflection 
is achieved by alternating the polarity of the high voltage creating an 
electrostatic field perpendicular to the matrix ion flight path (Bruker Daltonik 
GmbH, 2001).  
 
 
 Figure 1.16: Overview of the Ultraflex TOF/TOF mass spectrometer. Ion 
source region contains the target plate at IS1, as well as containing IS2 and 
ground potential for ionisation by laser beam. In the drift region, the PCIS 
(precursor ion selector) module contains layers of deflector plates to select for 
particular ion masses, followed by the LIFT module to increase the kinetic 
energy of parent and fragment ions for detection. The PLMS (post-LIFT 
metastable suppressor) module can be used to deflect parent ion signals for 
better fragment ion detection. The signals are either measured in linear mode 
(MS mode) or reflected and detected by the reflector detector (MS/MS mode) 
(Bruker Daltonik GmbH, 2001)  
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Figure 1.17: Schematic of ion source from Ultraflex TOF/TOF mass spectrometer. 
Laser beam is focussed on correct position of the target plate by a lens series, and the target 
plate position is altered for sample spot positioning by the x-y-stage. A camera is focussed to 
the same point as the laser so the user can calibrate the system to fire the laser with the 
highest degree of accuracy.  After ionisation the parent ions are propelled towards the drift 
region and through the CID cell, which fragments the parent ions (Bruker Daltonik GmbH, 
2001) 
 
 
 
 
Figure 1.18: Precursor ion selector (PCIS) and high voltage changes during use in 
Ultraflex TOF/TOF mass spectrometer. Layers of deflector plates select for particular 
parent and fragment ion masses by altering the electrical fields during their entry into the 
deflector region to prevent deflection and allow ions to continue through the drift region. 
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LIFT mode enables the kinetic energies of the parent and fragment ions to be 
lifted to a measurable value so detection of both can occur simultaneously 
(MS/MS mode). In MS mode the instrument does not utilise the LIFT module 
and so detects only the parent ions. LIFT consists of the LIFT chamber, 
pulsed acceleration chamber and the acceleration stage (Figure 1.19). 
Fragments of parent ions will have ground energy dependent on the ion size 
in comparison to the parent ion (percentage of 8kV). Once matrix ions enter 
the LIFT chamber both electrodes 1 and 2 are raised from ground (8kV for 
parent ions matching that of ions leaving the ion source) to 19kV. As both 
electrodes have matching energy, this ‘lift’ in energy does not alter kinetics of 
ions. When ions enter the pulsed acceleration chamber the potential of 
electrode 3 is decreased by 2-3kV. Electrode 4 remains at ground potential 
and the difference in electrical potential cause acceleration of the matrix ions 
along the flight tube to the detector (Bruker Daltonik GmbH, 2001). 
 
In linear mode, parent and their fragment ions travel down the flight tube and 
hit the linear detector simultaneously as the velocity of each are the same. In 
reflectron mode  ions with different kinetic energy values, as described 
above, enter the electrical field to different degrees, before being reflected 
and are detected at the reflector detector at different time points (Bruker 
Daltonik GmbH, 2001). 
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Figure 1.19: Electrode arrangement and potential changes in LIFT mode in 
the Ultraflex TOF/TOF mass spectrometer. LIFT module consists of LIFT 
chamber, pulsed acceleration stage and acceleration stage separated by four 
electrodes. Phase 1-4 shows the alterations of the electrical potential of the 
electrodes in relation to sample positioning through the three chambers (Bruker 
Daltonik GmbH, 2001) 
 
 
 
A second PCIS-like module is attached after the LIFT module, the post-LIFT 
metastable suppressor (PLMS). This can select solely for the fragments ions 
and deflect the parent ions. This means that only the fragment ions will be 
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reflected and detected by the micro channel plate detectors (Bruker Daltonik 
GmbH, 2001). Micro channel plate detectors consist of millions of 5-10µm 
pores that multiply the ion signal as shown in (Figure 1.20). The digitizer 
records all incoming analog signals from the detectors and converts them to 
digital signals to be transmitted to an attached computer network system for 
software processing and data storage (Bruker Daltonik GmbH, 2001). 
Theoretical peptide fragmentation, mass spectra and notation patterns are 
shown in Figure 1.21. 
 
 
 
Figure 1.20: Multiplication of matrix ion signal by micro channel plate detector 
in the Ultraflex TOF/TOF mass spectrometer (Bruker Daltonik GmbH, 2001)  
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Figure 1.21: Theoretical peptide fragmentation ion patterns by mass spectrometry. (A) 
Amino terminus (a, b, c) and carboxyl terminus (x, y, z) product ions from fragmentation, with 
bi and yi ions appearing predominantly using CID. (B) Example mass spectra with labelled b i 
(blue) and yi (red) ions from analysis of peptide shown in (C). Modified from Link & LaBaer 
(2009). 
 
 
A 
B 
C 
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1.4.5.3 MASCOT protein database search engine 
 
The MASCOT search engine allows protein database searching of 
experimental and theoretical protein digests for comparison with the peptide 
fragment information gained from mass spectrometry. MASCOT originates 
from the MOWSE molecular weight search engine that Alan Bleasby and 
Darryl Pappin developed in 1993. After collaboration with Matrix Science, 
who developed and distributed the product to a wider audience, the MOWSE 
search engine was renamed MASCOT as a freely-available internet service 
and only those wishing to use MASCOT on internal severs are required to 
pay a licence fee (Matrix Science Ltd., 2007).  
 
The MOWSE scoring scheme (Pappin et al., 1993), used by MASCOT, 
compares the calculated peptide mass to the experimental peptide mass, 
accepting those that fall within a specified mass tolerance. The peptide 
matches are then statistically scored by creating a frequency factor matrix of 
peptide and protein masses. The probability-based scoring scheme assesses 
the absolute probability (P) that the peptide match is a false positive. The 
score is then altered before being reported to produce a positive value on a 
manageable scale (-10*log10(P)). The higher the MASCOT score, the more 
likely the peptide derives from the identified protein. 
 
The BioTools version 3.0 software package (Bruker Daltonics) allows the 
details of the sample and search parameters to be set before MS analysis, 
for automatic database searching once data acquisition is completed using 
the MASCOT search engine. Bruker Daltonics have also designed a software 
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package (ProteinScape version 2.0) that can compare or combine results 
from several samples, allowing re-searching if changes to the search 
parameters are required, and presents results as a visual heat map based on 
MASCOT scores and the HPLC retention time of the peptides identified. 
 
 
1.5 Aims and Objectives 
The problem with techniques available at the start of this project is the 
difficulty in identifying P450s in very complex microsome samples. Liver 
microsomes contain the largest proportion of P450s (Figure 1.13), due to the 
need for xenobiotic metabolism to protect the body from forgein chemicals. 
Unfortunately using gel separating techniques alone prior to LC-MS, only 26 
of the 103 mouse P450s have been identified (Sutton et al., 2010). The main 
aim of this project is to develop enrichment procedures for membrane 
proteins, and more specifically the P450s, for study in the research and 
therapeutic settings. This will lead on to being able to more closely study 
P450s in a less complex sample with fewer unwanted proteins or 
contaminants, making analysis easier and more effective. Enrichment for 
these proteins will make it possible to find specific isoform targets for pro-
drug design and targeting drugs to a patient-specific protein make-up in the 
clinical field of cancer therapeutics in the future.  
 
The focus of this study will be on the use of affinity chromatography ustilising 
immobilisation of membrane phospholipids, as previously demonstrated by 
Pidgeon et al. (1991) and Scharf et al. (1998) (Chapter 4), and using 
bespoke immobilised P450 inhibitors (Chapter 5 and Chapter 7). It is 
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hypothesised that due to the active imidazole group in the antifungal drug 
ketoconazole interacting with the common haem centre of a number of 
P450s (CYP1A2, CYP2C9, CYP2C19, CYP2E1, CYP3A4) (Zhang et al. 
2002), that it would act as a good general P450 inhibitor at concentrations 
possible during enrichment procedures. It is hoped that it will be possible to 
competitively elute P450s from the beads using high concentrations of free 
ketoconazole but there is currently no published data suggesting 
ketoconazole will be soluble in aqueous buffers at the concentrations needed 
(>10mM). Alternative inhibitors will also be investigated once a standardised 
affinity chromatography protocol has been developed for comparison with 
ketoconazole beads.  
 
These goals will be met by completion of the following objectives: 
1. Determine the appropriateness of using a mouse model to mimic 
human P450 expression and activity  
2. Investigate sample and analytical conditions required to develop an 
affinity chromatography method, allowing detection of all bound 
proteins, using buffer systems compatible with sequential steps 
3. Determine limits of detection among the assays used and investigate 
variable factors that may influence accurate detection 
4. Analyse all above sampling techniques using a range of proteomic 
analysis techniques, including HPLC and MS  
5. Investigate the use of various P450 inhibitors as probes for P450 
capture, and critically review the strategies employed 
  
CHAPTER TWO 
Animal model testing 
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2.0 Animal model testing 
 
2.1 Introduction 
Although P450s have high sequence homology, they have very varied 
substrate specificities and enzyme activities (Section 1.2). The amino acid 
sequence is important to determine secondary and tertiary structures of 
proteins, however direct comparison of amino acid sequences on a one-
dimensional level, such as Blast comparison searches, does not allow 
prediction of protein folding patterns. It is possible, however, to predict 
protein folding using computational methods based on principles of 
eigendecomputation of a matrix. Eigendecomputation is the factorisation of a 
matrix into its eigenvalues (scale factor of the eigenvector when multiplied by 
the matrix) and eigenvectors (all non-zero vectors remaining parallel to 
original vector after being multiplied by the matrix), mathematically translated 
in Figure 2.1. 
 
 Av = λv. 
 a1,1   a1,2          a1,n  
A = a2,1   a2,2           a2,n  . 
     
 
 an,1   an,2         an,n 
 
 
Figure 2.1: Matrix definitions. (A) Square matrix, A, multiplied by the 
eigenvector, v, equates to eigenvector multiplied by the scalar eigenvalue, λ. (B) 
A is the square matrix of an n-dimensional space.  
 
A 
B 
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The Miyazawa-Jernigan (MJ) matrix calculates the interaction strength 
between amino acids within a protein using a 20 x 20 matrix, associated with 
the combinations of the 20 amino acids (Miyazawa and Jernigan, 1996). The 
dominant forces applied to amino acid interactions that determine protein 
folding are hydrophobic force and the force of demixing (formation of two 
phases with differing protein compositions) and solubility. Proteins will fold in 
a specified manner to a confirmation with the mimimum free energy based on 
these amino acid interactions (Li, 1997). Wang and Wang (1999) used the 
MJ matrix to divide the amino acids into hydrophobic residues (CIFLMVWY) 
and four groups of polar residues (AHT; DE; GP; KNQRS). Whereas, Cieplak 
(2001) used the MJ matrix and reduction algorithms to divide the amino acids 
into two groups of hydrophobic residues (FIL; CMVWY) and three groups of 
polar residues (AH; DEGNPQRST; K).  
 
Shepherd et al. (2007) developed a method for protein structure 
determination based on Fiedler vector partitioning. This vector splits the 
amino acids into two groups (hydrophobic- CFILMVWY; polar- 
ADEGHKNPQRST), and then these groups were split into two (hydrophobic- 
IFL, CMVWY; polar- AGHPT, DEKNQRS). This method uses the 
eigensystem, a list of the characteristic values (eigenvalues) and vectors 
(eigenvectors), to form a matrix based on the dominant eigenvalue and 
eigenvector instead of the full list used in the MJ matrix. This is possible due 
to the complete dominance of one value and vector over all subsequent 
values and vectors in the list, thus leading to simplification of the linear 
algebraic equations.  
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The major partitions created using the Fielder vector method above were 
used to further divide the groups of amino acids to create eight groups of 
amino acids (hydrophobic- CY, FL, I, MVW; polar- AHT, DEKN, GP, QRS). 
Using the eight group method, similarities in partitioning of the polar residues 
can be seen compared to the method described by Wang and Wang (1999), 
whereas using the four group method, similarities in partitioning of the 
hydrophobic residues can be seen compared to the method described by 
Cieplak et al. (2001). 
 
2.1.1 Aims of chapter 
Determine the appropriateness of using a mouse model to mimic human 
P450 expression and activity, as there are not always equivalent isoform 
sequences in human and mouse species (for example, CYP3A4, a 
pharmacologically important isoform). 
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2.2 Methods 
The proposed animal model (mouse) of the human P450s was tested to 
prove its legitimacy and functional significance, as there is great variety in the 
number of proteins and amino acid sequences between the two species. 
Alternative models frequently used in scientific research covering a range of 
species from different kingdoms, were also tested for comparison to human 
P450s, as well as each other. Homo sapiens (mammal), Mus musculus 
(mammal), Drosophila melanogaster (insect) and Caenorhabditis elegans 
(nematode) P450 amino acid sequences (Appendix A) were computed using 
the eigenfold protein energy conformation visualisation engine (Eigenfold). 
This method is based on Fiedler vector partitioning described by Shepherd 
et. al (2007), as previously discussed (Section 2.1). The P450 sequences of 
each species were computed to determine the 20 x 20 matrix based on the 
combinations of the 20 amino acids. Comparison of eigenvector and matrices 
within and between species were computed using MatLab (MathWorks, MA, 
USA).  
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2.3 Results 
2.3.1 Animal model validity studies 
Amino acid sequences of P450s, obtained from UniProt and Dr Nelsons 
Cytochrome P450 homepage (Appendix A), from a selection of common 
scientific model species (Mus musculus (88 genes for known proteins), 
Drosophila melanogaster (84) and Caenorhabditis elegans (83)) were 
compiled for comparison with the human set (56) of P450s and each other. 
Sequences that were not confirmed by UniProt or the Cytochrome P450 
homepage were not included in this study, as inaccuracies in sequence could 
lead to dramatically different mathematical results and impact on the 
predictive value of this method. 
 
Initially, the sequences of the human set of P450s were computed to 
determine the 20 x 20 matrix based on the combinations of the 20 amino 
acids. Eigenfold and Matlab were used to compute the matrix and determine 
the distance of each individual P450 within the human set from the average 
human data (human centroid) (Figure 2.2). Results showed good correlation 
between the energy folding patterns of the human P450s, with more than 
50% of the P450s less than or equal to 0.6 from the centroid. Human 
CYP19A was furthest from the human centroid with a value of 0.81 showing it 
to have a folding pattern that is most different from the average P450, 
whereas human CYP2C9 was closest to the human centroid (0.45). 
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Figure 2.2: Distance of the human set of P450s from the computed human P450 matrix centroid. (A) Validated P450 sequences (Appendix A) were 
computed using MatLab software to find the distances of each P450 from the human P450 centroid (distance 0). (B) Histogram of distances of the human 
P450 sequences from the human P450 centroid detailed in (A). 
A B 
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The mouse, D. melanogaster and C. elegans P450 sequences were tested 
against the human centroid (Figure 2.3), to measure their distance from the 
average human data. The average distance of the mouse P450 sequences 
from the human centroid was lowest. This shows that, as expected, the 
mammal class species (mouse and human P450s) have more closely related 
energy folding patterns than the insect and nematode classes have with 
human P450s.  
 
Although the D. melanogaster P450 set was further from the human centroid 
than the other models, there were very few outliers above a distance of 1.0 
and a maximum distance of only 1.32.  Surprisingly, the mouse set had 
several outliers over 2.0 (CYP4F41 and CYP21A2), and these mouse P450s 
were also furthest from the mouse centroid (0.9) (Figure 2.4). 
 
When studying the data from the centroids versus the P450 set of the same 
species (Figure 2.4), it indicated that there was good correlation between the 
energy folding patterns of the individual P450s and the reference centroid 
(<1.0). As mentioned above, when comparing P450 sets to different species 
centroids, there is generally less correlation (Figure 2.5). The best model 
centroid, showing the lowest mean distance from the centroid (0.53), was the 
mouse centroid against the human P450 set. The mouse P450 set against 
the C. elegans P450 centroid showed the worst correlation with a mean 
distance from the centroid of 1.0 and a max outlier of 3.5.  
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Figure 2.3: Histogram of distances of the mouse (A), C. elegans (B) and D. melanogaster 
(C) P450 sequences from the human P450 centroid. 
A 
B 
C 
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Figure 2.4: Histogram of distances of the mouse P450 sequences from the mouse P450 
centroid (A), C. elegans P450 sequences from the C. elegans P450 centroid (B) and D. 
melanogaster P450 sequences from the D. melanogaster P450 centroid (C) P450 
sequences.
A 
B 
C 
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Figure 2.5: Histogram of distances of the human (A), C. elegans (B) and D. melanogaster 
(C) P450 sequences from the mouse P450 centroid. Histogram of distances of the human 
(D), M. musculus (E) and C. elegans (F) P450 sequences from the D. melanogaster P450 
centroid. Histogram of distances of the human (G), M. musculus (H) and D. melanogaster (I) 
P450 sequences from the C. elegans  P450 centroid. 
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2.3.2 Energy landscapes 
Energy landscape figures were produced for human and mouse CYP2E1 
using the data collected by Eigenfold (Figure 2.6). The energy landscape is 
based on the principle that the proteins fold based on the mimimal frustrated 
heteropolymer with a rugged funnel-like shape (Onuchic et al., 1997).  
CYP2E1 was chosen as anti-CYP2E1 antibodies have shown cross-reactvity 
against the mouse and human CYP2E1. The heat-maps show clear 
differences in the energy landscape patterns, with human CYP2E1 producing 
results much closer to the theoretical pattern. 
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Figure 2.6: Eigenfold energy landscape of human (A) and mouse (B) 
CYP2E1. Energy level heat-map, spectral shift from high (red) to low (blue) 
energy values 
A 
B 
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2.4 Discussion 
This is the first time that the amino acid partitioning method developed by 
Shepherd et al. (2007) has been used to compare P450 protein similarities 
within and between species. Results from Section 2.3.1 indicate that 
Eigenfold and Matlab produced P450 reference centroids that closely 
correlated the P450 set used to make it, with all sets showing divergence of 
less than 1.0 from their reference centroids. 
 
Mouse CYP4F41 and CYP21A2 showed the greatest divergence from the 
mouse centroid, as well as the three other species centroids. This may 
indicate that these P450s have evolved in the mouse genome alone, 
although the exact functional significance of these proteins is not fully 
understood. The greater divergence of the mouse P450 set, in comparison to 
the human P450 set, may indicate that these P450s will have different 
functional significance, metabolising substrates that the human P450s are 
unable to metabolise. Along with increased enzymatic activity that may be 
seen during future experiments, these P450s could be responsible for 
metabolising the metabolites of reactions involving other P450s. This may 
lead to false negative results if P450s are being monitored by activity assays 
alone. However this may be the case for the P450s in both mouse and 
human microsome samples due to the complexity of metabolism regulation, 
so caution needs to be taken when studying crude microsome samples. 
 
CYP2E1 is found in both human and mouse proteomes, identifiable in liver 
microsome preparations, and so was used as an example P450 to study in 
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more detail. Anti-CYP2E1 antibodies show cross-reactvity with both mouse 
and human forms of CYP2E1, but this only indicates that the small epitope 
region is common to both proteins and does not directly indicate 
similarities/differences in protein folding. A protein energy landscape should 
have a funnel-like appearance, where the protein is guided to the lowest-
energy folding pattern where it will primarily reside in its native state. The 
protein energy landscapes for human and mouse CYP2E1 visually show 
clear differences in energy patterns, with slight differences in amino acid 
sequence between species proving to have some impact on the protein 
structure. However, both human and mouse proteins share the pattern of the 
jagged-edged drop into a lower energy state, indicated by a shift from yellow-
blue (Figure 2.6).  
 
This is the first time that animal model testing has been tested in this 
manner, comparing the P450s across a range of different species based on 
Eigenvectors. Overall the two mammal species showed better correlation 
than that of the cross-class comparisons, which is most likely due to the 
differences in phylogenetic divergence times (divergence of mammals 250-
470 million years ago) and consequent mutations within the P450s after 
these points. The divergence times for the rodent and primate P450s 
however are more recent (50- and 75 million years ago respectively). 
Importantly, these results indicate that using the mouse P450s as a model of 
the human P450 set is functionally acceptable. 
  
CHAPTER THREE 
Characterising mouse liver microsomes 
 
 
 84 
 
3.0 Characterising mouse liver microsomes  
3.1 Introduction 
 
Mouse liver samples were chosen as an available source of P450-containing 
tissue for testing of the P450-inhibitor chromatography materials. It was 
important to understand the P450 content of the microsome extracts created 
from this tissue source, determining which P450 tryptic digests are 
identifiable in the starting material.  
 
A range of analytical techniques were optimised using mouse liver 
microsomes as a preliminary evaluation of those intended for analysis of the 
affinity bead samples. This included total protein assays (Bradford and BCA), 
P450 activity assay (EROD), SDS-PAGE, HPLC and MS.  
 
The EROD assay, as previously discussed in Section 1.4.1, assesses the 
activity of P450s from the CYP1 family. The method will be used to confirm 
the presence of P450’s in the microsome starting material and prior to affinity 
chromatography in later experiments. Although there may only be 
measureable levels of CYP1A2 in the liver microsomes (Figure 1.7), it is 
hoped that sensitivity will be enough to detect low amounts of P450.   
 
3.1.1 Aims of chapter 
The main focus of this chapter is to determine the P450 content of mouse 
liver microsomes and the reproducibility of MS results between batches. 
Mouse liver microsomes are expected to contain a number of P450s (10-15) 
from a number of different families and sub-families, detectable using MALDI 
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MS analysis. The majority of these P450s should be detectable across a 
number of replicate analyses, with only those P450 identifications at the limit 
of detection being affected by problems with reproducibility using these 
proteomic techniques.  
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3.2 Materials and Methods 
3.2.1 Reagents and samples 
Rabbit anti-CYP2E1 antibody (ab28146) was purchased from abcam 
(Cambridge, UK). Acrylamide (30%), Dodeca silver stain kit, and 
trishydroxymethylaminomethane (Tris) were purchased from Bio-Rad 
(Hercules, CA, USA). Peptide calibrant standard II (ACTH clip 1-17, ACTH 
clip 18-39, angiotensin I, angiotensin II, bombesin, bradykinin 1-7, renin 
substrate, somatostatin 28, substance P) was purchased from Bruker 
Daltonics (Bremen, Germany). 7-ethoxyresorufin and CYP1A2 bactosomes 
(10.0mg/ml total protein; 9.3nmol/ml CYP1A2; 5.4% CYP1A2 of total protein) 
were purchased from Cypex (Dundee, UK). InstantBlue stain was purchased 
from Expedeon (Cambridgeshire, UK). HPLC grade acetonitrile, HPLC grade 
water and isobutanol were purchased from Fisher Scientific UK Ltd. 
(Leicestershire, England). Amersham ECL-plus, Amersham hyperfilm ECL 
and ammonium persulfate (APS) were purchased from GE Healthcare. 
Novex sharp protein standard molecular weight markers were purchased 
from Invitrogen (Paisley, UK). Complete mini EDTA-free protease inhibitor 
cocktail tablets and trypsin were purchased from Roche Diagnostics 
(Mannheim, Germany). Acetic acid, albumin from bovine serum (BSA), 
ammonium bicarbonate, ammonium phosphate, anti-rabbit HRP-linked 
antibody, Bradford reagent, α-cyano-4-hydroxycinnamic acid (CHCA), 
dithiothreitol, dodecyl maltoside (DDM), ethanol, formate, glycerol, 4-(2-
Hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), HPLC grade 
methanol, iodoacetamide, isopropanol, magnesium chloride, NADPH, 
‘PhastGel Blue R’ Coomassie Brilliant Blue tablets,  powdered phosphate 
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buffer saline (PBS) sachets, sodium chloride, sodium dodecyl sulfate, 
tetramethylethylenediamine (TEMED), and trifluoroacetic acid (TFA) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA).  
 
3.2.2 Animal treatments and tissue preparation 
Male and female NMRI mice were obtained from Bantin and Kingman (Hull, 
UK) and BALB/c-nude mice were obtained from Harlan (Bicester, UK). Mice 
were housed in cages in an air conditioned room with alternating cycles of 
light and darkness. Mice received water ad libitum and commercial rodent 
diet (SDS, Whitman, UK). Work was carried out following UKCCCR 
guidelines, under a project licence issued by the UK Home Office, and the 
mice were harvested by registered professionals according to a defined 
schedule. The excised livers were sliced using a sterile scalpel and mouse 
liver sections were stored frozen at -80°C. 
 
Liver microsomes were prepared from mouse liver tissue using a differential 
centrifugation method (Figure 3.1). First the liver sections were homogenised 
in PBS containing EDTA-free proteinase inhibitor cocktail using a T25 Ultra-
Turrax basic homogeniser (IKA Werke GmbH & Co. KG, Staufen, Germany). 
Homogenates were centrifuged at 9000 x g for 20 minutes at 4°C to pellet 
cell debris and nuclei producing S9 fractions, which were stored at -80°C for 
future use. The supernatant was transferred to ultracentrifuge tubes and 
centrifuged at 100,000 x g for 1 hour at 4°C to sediment microsomes. The 
cytosolic supernatant was transferred to fresh tubes and stored at -80°C for 
future use. The microsomal pellet was resuspended in PBS, 10% glycerol. 
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The protein concentration of this microsomal fraction was determined using 
the Bradford assay (Section 3.2.3) before the sample was split into 100-
400µl aliquots and stored at -80°C for future use, if not used immediately. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Differential centrifugation protocol 
Homogenise tissue in PBS, EDTA-free 
proteinase inhibitor cocktail 
Centrifuged at 9000 x g, 20 minutes, 4°C 
Centrifuged at 100000 x g, 1 hour, 4°C 
Resuspension in PBS, 10% glycerol 
Pellet 
Supernatant 
Pellet 
Supernatant 
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3.2.3 Bradford assay 
The Bradford total protein assay was used to determine initial liver 
microsome concentrations. A serial dilution of BSA from 1mg/ml to 
0.0625mg/ml was used to create a standard curve of absorbance after the 
addition of Bradford reagent (3ml) to the BSA standards (100µl). The 
standards were incubated at room temperature for 15 minutes. The BSA 
standard concentration was analysed using a Cary 50 Bio UV-visible 
spectrometer (Varian Inc., CA, USA) at a wavelength of 595nm. Samples 
with unknown concentration were prepared in the same manner and the 
results compared to the standard curve, to calculate sample concentration.  
 
3.2.4 7-ethoxyresorufin-O-deethylase (EROD) P450 activity assay 
Magnesium chloride (10µl) and NADPH (10µl) were added to the sample 
(60µl) in a 96-well plate and incubated at 37°C for 15 minutes. 7-
ethoxyresorufin (20µl) was added to the sample well and immediately 
measured using the Cary Eclipse fluorescent spectrophotometer (Varian 
Inc.), continuously for 120 minutes (Figure 3.2). Both the substrate and 
product are fluorescent, however the assay selects for fluorescent 
measurement of resorufin by excitation at 560nm and emission at 590nm. 
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Figure 3.2: EROD protocol detaling differences between control (-NADPH) and 
sample (+NADPH) 
 
3.2.5 SDS-PAGE, staining techniques and Western blotting 
3.2.5.1 Manual gel preparation 
 
Resolving gel (12% acrylamide, 1% SDS, 1% APS, 2µl TEMED in Tris-HCl 
buffer) was poured into the Mini-PROTEAN casting plates attached to the 
casting frame on the casting stand (Bio-Rad). Isobutanol was used to create 
a flat upper surface to the gel. Once the gel had set, after approximately 45 
minutes, the isobutanol was removed and replaced with stacking gel (5% 
acrylamide, 1% SDS, 1% APS, 5µl TEMED in Tris-HCl buffer). The comb 
was immediately inserted to create the wells for sample loading, and the gel 
was left to set for approximately 20 minutes. The gels were removed from 
the casting stand and frames, and immediately utilised for SDS-PAGE. 
 
Magnesium chloride + NADPH + Sample 
15 minutes, 37°C 
Addition of 7-ethoxyresorufin, 
fluorescent spectroscopy 560nm/590nm 
Magnesium chloride + Sample 
15 minutes, 37°C 
Addition of 7-ethoxyresorufin, 
fluorescent spectroscopy 560nm/590nm 
Control (no P450 activity) Sample (P450 activity) 
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3.2.5.2 SDS-PAGE 
 
Manual gels, prepared by the method outlined in section 3.2.5.1, or 4-20% 
Precise Protein pre-cast gels (Pierce, Rockford, IL, USA) were inserted into 
the Mini-PROTEAN electrophoresis system (Bio-Rad). Manual gel analysis 
used Tris-glycine-SDS buffer and involved an initial power pack setting of 15 
minutes at 80V followed by approximately 80 minutes at 150V. Pre-cast gel 
analysis used Tris-HEPES-SDS buffer pH 8.0 and involved a power pack 
setting of approximately 40 minutes at 150V. 
 
3.2.5.3 Coomassie Brilliant Blue stain 
 
To visualise the proteins on the gel it is necessary to remove the gel from the 
casting plates and stain the whole gel. The gel was immersed in a container 
containing Coomassie Brilliant Blue stain for 30-60 minutes. The stain was 
then replaced with destain solution (50% methanol, 5% acetic acid), which in 
turn was replaced with fresh destain solution when the destain solution 
turned blue. This was repeated until the protein bands were distinct from 
background stain. The destain solution was then replaced and washed with 
distilled water to remove traces of stain and rehydrate/expand the gel. 
 
An alternative Coomassie-based stain, is the ready-to-use InstantBlue, for a 
quick one-step stain and fix procedure. The gel was immersed in a container 
containing InstantBlue stain for 15-30 minutes. The stain was then replaced 
and washed with distilled water to remove traces of stain. 
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3.2.5.4 Silver stain 
 
The Bio-Rad Dodeca silver stain kit can detect nanogram quantities of 
protein whilst still being mass spectrometry compatible, which some of the 
silver staining methods are not. The kit includes various ready-made stock 
solutions that were mixed to form working solutions as they need to be made 
fresh as required during the procedure. The exact content of these kit 
solutions is unknown. 
 
The gel was fixed using 40% ethanol, 10% acetic acid for 30 minutes 
followed by sensitising with 30% ethanol, 10% Bio-Rad ‘sensitising 
concentrate’, 1% Bio-Rad ‘background reducer concentrate’. Three 5 minute 
washes with distilled water were used to remove all traces of the sensitising 
solution before staining with 2% Bio-Rad ‘silver reagent concentrate’. During 
the staining procedure the gel must be covered with foil to protect the 
solution and gel from light. The gel was then rinsed for a maximum of 1 
minute with distilled water before immediately being transferred to 
developing solution composed of 10% Bio-Rad ‘development buffer 
concentrate’, 0.02% ‘image development concentrate’, 0.005% Bio-Rad 
‘background reducer concentrate’. At this point the gel was monitored for 
band formation, and when development of background stain was starting to 
become apparent, the reaction was stopped immediately with 5% acetic acid. 
Finally the gel was washed with distilled water for 10 minutes to remove all 
traces of stopping solution and was stored in fresh distilled water at 4°C. 
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3.2.5.5 Western blot 
Proteins from SDS-PAGE gels (Section 3.2.5.2) were transferred to 
membranes to perform Western blotting. SDS-PAGE gels cannot be stained 
prior to protein transfer to the membrane, as this staining process also fixes 
the proteins in the gel. The SDS-PAGE gel is soaked in working transfer 
buffer (39mM glycine, 48mM Tris base, 0.04% SDS, 20% methanol), for 5 
minutes along with the fibre pads and blotting paper cut to be approximately 
1 cm wider and 1 cm longer than the gel. Polyvinylidine fluoride (PVDF) 
membrane was cut to exactly match the size of the gel used, and the 
membrane was soaked in methanol for 2 minutes. After this the membrane 
was also soaked in working transfer buffer for 5 minutes, prior to assembly of 
the transfer stack (Figure 3.3). 
 
Figure 3.3: Correct assembly of Western blot transfer stack for use with Bio-Rad Mini-
PROTEAN system 
 
 
Protein transfer from gel to PVDF membrane was completed at 50mA for 
approximately 2 hours. After this, the gel was stained with Coomassie stain 
(Section 3.2.5.3) to check for successful protein transfer and the PVDF 
membrane was incubated with 3ml 5% milk blocking buffer. After 1 hour 
Gel 
PVDF membrane 
Blotting paper Fibre pad (sponge) 
Black side of cast 
White side of cast 
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incubation in blocking buffer, the membrane was incubated in primary 
antibody (1.5µl rabbit anti-CYP2E1 antibody was added to solution to create 
1:2000 dilution of antibody) for 1.5 hours at room temperature or 1 hour at 
room temperature, then 4°C overnight, followed by 30 minutes at room 
temperature. 
 
The PVDF membrane was washed to remove all traces of primary antibody 
in PBSB (PBS, 0.05% Brij 35) over 1 hour, before incubation for 15 minutes 
in blocking buffer. Polyclonal goat, anti-rabbit HRP-linked antibody (1.5l) 
was added to the PBSB to create 1:2000 dilution of antibody, and was 
incubated at room temperature for 1 hour. All traces of secondary antibody 
were removed after 45 minutes of PBSB washes (15 minutes each).  
 
Excess liquid was removed from the membrane before incubation with ECL 
plus reagent (1:40 reagent B:A) for 5 minutes. After this, excess liquid was 
removed from the membrane before exposure to film in the dark room for 5-
30 minutes. The exposed film was then transferred to developing solution for 
1.5-5 minutes, before a brief wash in tap water and then placed in fixing 
solution for 1 minute. The film was washed well in water before exposure to 
light.  
 
3.2.6 MALDI MS 
3.2.6.1 Trypsin digestion using solid/lyophilised samples 
 
Lyophilised liver microsome protein extracts were resuspended in 8M urea, 
100mM ammonium bicarbonate (10μl), reduced by 50mM dithiothreitol (5μl) 
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and alkylated with 100mM iodoacetamide (5μl). The urea concentration was 
adjusted to 2M by addition of HPLC grade water before addition of 10μg/ml 
trypsin (2μl) and incubation at 37°C for 18 to 20 hours. The digested sample 
was then desalted using an Isolute C18 cartridge (Kinesis Ltd.) equilibrated 
with 2% acetonitrile, 0.05% TFA and peptides eluted with 80% acetonitrile, 
0.05% TFA (1ml). Peptides were then desalted with the Isolute C4 cartridge 
to remove detergents (Section 4.2.3.3). Following this process, the eluted 
samples were concentrated by lyophilisation at 60°C for approximately 90 
minutes and were stored at -20°C. 
 
3.2.6.2 In-gel trypsin digestion 
 
Protein bands of interest from SDS-PAGE gels were excised carefully using 
a scalpel into approximately 5x2 mm sections and placed in separate tubes 
for in-gel digestion. Bands of the same size above and below the band of 
interest were also excised to prevent loss of proteins identifications. Three 
alternate 100% acetonitrile (50µl, 15 minutes), 25mM ammonium 
bicarbonate (10µl, 15 minutes) washes were used to dehydrate and 
rehydrate the gel pieces, respectively. After removal of all remaining liquid 
the gel pieces were left to air dry for approximately 30 minutes, and then 
incubated with 10µl 10µg/ml trypsin in 25mM ammonium bicarbonate at 28°C 
for approximately 20 hours. The incubation liquid was collected, as well as 
the liquid from two alternate 100% acetonitrile (50µl, 15 minutes), 25mM 
ammonium bicarbonate (5µl, 10 minutes) washes. 
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3.2.6.3 Nano-HPLC sample separation and fraction collection 
 
The Dionex Ultimate 3000 system was used for reverse-phase sample 
separation utilising a PepMap 100 C18 3μm, 15cm analytical column and 
PepMap 100 C18 5μm, 5cm guard column (LC Packings, Sunnyvale, CA, 
USA). The system was equilibrated with mobile phase A (2% acetonitrile, 
0.05% trifluoroacetic acid) at a flow rate of 300nl/min. Samples were 
resuspended in 10% acetonitrile and 5μl was injected onto the column via 
the autosampler module and sample loop. After 5 minutes mobile phase B 
was increased to 10%. Mobile phase B (80% acetonitrile, 0.05% 
trifluoroacetic acid) was then increased using a linear gradient between 10% 
to 40%, from 6 to 109 minutes, and from 40% to 100% between 110.9 to 111 
minutes. This mobile phase composition was maintained at this point for 5 
minutes and then changed to 100% mobile phase A for 13.9 minutes. During 
the preparative run, optical density was specifically monitored at 215nm 
(peptide bond) and 280nm (aromatic amino acids). Fractions were collected 
onto a MTP AnchorChip 800/384 target plate (Bruker Daltonics) from 20 to 
116 minutes (384 fractions of 15 seconds each), equivalent to 75nl eluant 
each on the Proteineer Fraction Collector (Bruker Daltonics), with the 
automatic simultaneous addition of 1.2μl of α-cyano-4-hydroxycinnamic acid 
(CHCA) working matrix solution (1.056ml ethanol:acetone, 120μl saturated 
CHCA in 30% acetonitrile, 12μl 100mM ammonium phosphate, 12μl 10% 
TFA). Calibration spots were applied manually using Peptide II calibrant 
standard (0.4μl) and CHCA working matrix solution (1.5μl). 
 
 97 
 
3.2.6.4 MALDI mass spectrometry 
 
The Ultraflex II MALDI-TOF/TOF was used for protein sample analysis. 
Samples prepared on the MTP AnchorChip 800/384 were loaded on the 
machine and an automatic run schedule was set-up via the WarpLC version 
3.0 software package (Bruker Daltonics). The search parameters were set in 
BioTools version 3.0 software package and the parameters were as follows; 
taxonomy mouse or human (as appropriate), trypsin digestion, variable 
modifications (oxidation of methionine residues, carbamyl modification of 
lysine residues and carbamyl modification of N-terminal residues), global 
modification (carbamidomethyl of cysteine residues), 2 partial digests, 100 
parts per million peptide mass tolerance, MS/MS tolerance within 0.7 
Daltons, and using the SwissProt database via the Mascot software 
package. Laser power and target teaching were adjusted manually and 
saved to be included in the automatic run using the FlexControl version 3.0 
software (Bruker Daltonics). Mass spectra were processed to produce mass 
peak lists using the FlexAnalysis version 3.0 software (Bruker Daltonics), 
which were automatically sent to the BioTools software package for 
database searching, using the previously set parameters in BioTools and 
WarpLC. 
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3.3 Results 
3.3.1 Bradford assay 
The Bradford assays indicated that the nine mouse liver microsome 
preparations contained between 30-42mg/ml of protein. Figure 3.4 shows the 
calculation of total protein concentrations of two of the microsome 
preparations (1 in 50 dilution) against the BSA standard curve. 
 
 
 
 
Figure 3.4: Bradford assay calibration curve (BSA standards) used to 
calculate the total protein concentration of two microsome preparations. 
Black circles represent the BSA standards (0.0625 mg/ml to 1mg/ml range). 
Black triangle and hollow circle represent 1 in 50 dilutions of two different 
microsome preparations. 
 
 
3.3.2 P450 acitivity assay 
To assess the working range of the EROD assay in relation to overall 
microsomal protein concentration titration studies of microsomal 
preparations, approximately 20mg/ml, were performed (Figure 3.5A). 
Aliquots from 10μl (equivalent to 0.22mg of microsomal protein) to 60μl 
(equivalent to 1.32mg of microsomal protein) of mouse liver microsomes 
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were used for these studies. Interestingly, as the overall concentration of 
microsomal protein was decreased the fluorescence increased but the 
curves did not plateau as quickly. These studies were extended (Figure 
3.5B) to include much lower concentrations of microsomal protein, namely 
1μl (equivalent to 22μg of microsomal protein) and 0.5μl (equivalent to 11μg 
of microsomal protein), which enables the demonstration that the EROD 
assay correlated with the amount of microsomes used within the linear 
range. 
 
CYP1A2 bactosomes were used as positive controls for the EROD assay. 
Bactosomes produce recombinant human P450s in a bacterial model 
system, therefore contain both bacterial and specific human proteins. A 
titration series was performed to analyse the required amount of CYP1A2, 
and indicated a strong correlation between the rate of 7-ethoxyresorufin 
metabolised and the amount of bactosomes used (Figure 3.6). The results 
indicated that 2 picomoles of CYP1A2 would give positive results if present in 
the microsome sample and that only 2 picomoles P450 from bactosomes 
was sufficient to act as a positive control for future experiments.  
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Figure 3.5: Microsome titration studies using the fluorometric EROD assay. Note 
difference in scales dependent on fluorometric reading A) Mouse liver microsome total 
protein range 220μg to 1.32mg (220μg grey, 440μg green, 660μg red, 880μg blue, 1.1mg 
brown, 1.32mg orange). B) Microsome total protein range 11μg to 220μg (11μg green, 22μg 
red, 220μg brown). 
 
 
 
 
Figure 3.6: CYP1A2 bactosome titration studies using the fluorometric EROD assay. 
Note difference in scales dependent on fluorometric reading. CYP1A2 bactosome dilutions 
used to assess minimum detectable amount (CYP1A2 10ρmoles green, 4ρmoles blue, 
2ρmoles black, 0.4ρmoles red). 
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3.3.3 Western blot analysis 
Western blot analysis using anti-CYP2E1 showed a clear band between 43-
55kDa in the mouse liver microsome sample (Figure 3.7, lane 2) in 
comparison to the bactosome sample which showed cross-reactivity 
throughout the full molecular weight range (Figure 3.7, lane 4). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7: Rabbit anti-CYP2E1 Western blot. Lane positions are labelled 
above gel and Novex relative molecular weight markers labelled on left of 
membrane. Lane 2 contains mouse liver microsome starting material. Lane 4 
contains human CYP2E1 expressed in bactosomes. 
 
3.3.4 MALDI MS 
Table 3.1 shows the consolidated P450 MALDI MS data on 9 mouse liver 
microsome preparations. These preparations were used for analysis of 
affinity chromatography experiments detailed in chapters 4 to 7. This data 
shows the variances between individual preparations and the ability of 
95 
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standard proteomic techniques to identify P450s from crude starting material, 
acting as a basis of comparison for enrichment in future experiments.  
 
It was possible to identify 22 different P450s throughout all 9 replicates. 
CYP2C70, CYP2D26 and CYP2E1 were seen in every replicate, with 
sequence coverage from several locations within the proteins (Appendix A). 
Of the P450s identified, 8 were seen over 50% of the time (CYP2A4, 
CYP2C29, CYP2C37, CYP2C39, CYP2C50, CYP2C54, CYP2D10, and 
CYP2F2). CYP27 and CYP3A41 were only seen in 1 microsome preparation.  
 
 
Table 3.2 shows the P450 peptide data for replicate 7 from Table 3.1. It 
shows the protonated molecular ion mass and sequence of each peptide 
identified for each P450 protein. Sequences identified that are common to 
multiple P450s are highlighted in red, and this shows that in all but one P450 
(CYP2C50) there are at least two unique peptides.  
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Protein 
Accession 
(Mouse) 
MW 
(kDa) 
1  2 3 4 5 6 7 8 9 
Scr #P Scr #P Scr #P Scr #P Scr #P Scr #P Scr #P Scr #P Scr #P 
Cytochrome 
P450 1A1 CP1A1 59.192 48 3 66 3 66 2  - -  -  -  -  -  - - - - - - 
Cytochrome 
P450 1A2  CP1A2 58.147  - - - - - - - - - - - - 39 3 - - 31 2 
Cytochrome 
P450 27 CP27A 60.682 114 2  - - - - - - - - - - - - - - - - 
Cytochrome 
P450 2A12  CP2AC 56.137 57 8 -  - - - - - 37 2 - - - - - - - - 
Cytochrome 
P450 2A4  CP2A4 56.558 98 14 - - - - 41 4 43 5 54 4 81 9 35 7 81 9 
Cytochrome 
P450 2A5  CP2A5 56.704  - - - - - - - - - - 47 7 81 9 40 7 81 9 
Cytochrome 
P450 2B9  CP2B9 55.724  - - - - - - - - - - - - 43 2 - - 34 3 
Cytochrome 
P450 2C29 CP2CT 55.693 133 8 35 3  - - - - 59 9 - - 62 8 69 4 - - 
Cytochrome 
P450 2C37  CP237 55.478 146 7  - - - - 65 6 42 6 - - 101 6 82 3 74 8 
Cytochrome 
P450 2C39 CP239 55.867 204 8 51 2 51 4 47 1 55 2 33 4 89 5  - - 50 6 
Cytochrome 
P450 2C40  CP240 56.485  - - - - - - - - - - 30 1 33 5 - - - - 
Cytochrome 
P450 2C50  CY250 55.638 146 7 137 6 182 7 40 6  - - - - 77 4 82 3 - - 
Cytochrome 
P450 2C54  CP254 55.822  - - 63 3 115 7 45 5 -  - - - 50 6 - - 66 7 
Cytochrome 
P450 2C70  CP270 55.984 83 4 55 2 56 3 39 2 54 2 49 2 53 3 48 3 42 5 
Cytochrome 
P450 2D10  CP2DA 57.197 211 11 237 4 150 6 85 8 157 10  - - - - - - 129 7 
Cytochrome 
P450 2D26  CP2DQ 56.939 183 12 326 7 151 6 114 10 275 11 96 6 143 11 56 6 110 8 
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Protein 
Accession 
(Mouse) 
MW 
(kDa) 
1  2 3 4 5 6 7 8 9 
Scr #P Scr #P Scr #P Scr #P Scr #P Scr #P Scr #P Scr #P Scr #P 
Cytochrome 
P450 2D9 CP2D9 56.912  - - 28 3 34 3 - - - - - - - - - - 40 3 
Cytochrome 
P450 2E1  CP2E1 56.769 273 16 333 13 194 13 114 8 142 10 191 8 185 9 88 10 199 10 
Cytochrome 
P450 2F2 CP2F2 55.913 61 3  - - 45 5 - - 47 4 - - 67 6 34 4 - - 
Cytochrome 
P450 3A11 CP3AB 57.817  - - 95 3 - - - - 37 3 - - 49 2 - - - - 
Cytochrome 
P450 3A16 CP3AG 57.892  - - 33 2 - - - - - - 35 2 - - - - - - 
Cytochrome 
P450 3A41  CP341 58.321  - - - - 104 5 - - - - - - - - - - - - 
 
Table 3.1: P450s identified from 9 replicate mouse liver microsomes fractions. MASCOT score (Scr) and the number of peptide identified for each 
protein (#P) is listed for each liver microsome fraction.
 105 
 
Protein MH+ [Da] 
RT 
[min] Ions Sc. Inten. Area S/N Miss Sequence Variable Mods 
CYP1A2 
  
  
1419.759 52.75 18.92 2613.76 965.47 307.49 0 LSQQYGDVLQIR   
1604.833 63 5.13 294.16 172.58 32.86 1 QWKDPFVFRPER   
2126.055 101.25 39.2 633.08 516.39 86.71 0 DFVENVTSGNAVDFFPVLR   
CYP2A4 
  
  
  
  
  
  
  
  
899.458 44 8.27 860.12 170.33 91.68 0 TLDPNSPR   
1079.552 86.25 2.2 114.44 24.72 21.85 1 DPKFFSNPK   
1125.594 90 39.32 651.71 156.00 204.28 0 DFIDSFLIR   
1219.650 78.75 11.87 176.85 49.27 28.01 0 FADLIPMGLAR Oxidation (M) 
1250.664 25 6.48 4546.84 1567.25 187.96 0 HLPGPQQQAFK   
1372.726 79 16.53 412.04 157.18 72.63 0 YGPVFTIYLGSR   
1413.697 24.5 49.18 1797.69 813.45 70.58 0 STQAPQDIDVSPR   
1524.769 79.25 48.41 618.66 267.28 135.51 0 IQEEAGFLIDSFR   
2189.092 59.5 0.99 164.32 139.65 35.01 0 MELFLFLTNIMQNFHFK Oxidation (M) 
CYP2A5 
  
  
  
  
  
  
  
  
899.458 44 8.27 860.12 170.33 91.68 0 TLDPNSPR   
1079.552 86.25 2.2 114.44 24.72 21.85 1 DPKFFSNPK   
1125.594 90 39.32 651.71 156.00 204.28 0 DFIDSFLIR   
1250.664 25 6.48 4546.84 1567.25 187.96 0 HLPGPQQQAFK   
1382.747 43.25 6.2 336.18 121.71 22.89 0 YGPVFTIYLGPR   
1413.697 24.5 49.18 1797.69 813.45 70.58 0 STQAPQDIDVSPR   
1524.769 79.25 48.41 618.66 267.28 135.51 0 IQEEAGFLIDSFR   
2017.046 101.25 4.82 211.50 287.26 29.22 0 LVGFATIPPTYTMSFLSR Oxidation (M) 
2189.092 59.5 0.99 164.32 139.65 35.01 0 MELFLFLTNIMQNFHFK Oxidation (M) 
CYP2B9 
  
927.489 21.25 3.15 554.23 131.72 58.43 0 ATLDPSAPR   
1171.599 67 42.75 810.99 215.01 99.05 0 DYIDTYLLR   
 
CYP2C29 
  
897.486 63 3.76 513.40 111.65 87.80 0 FTLMTLR Oxidation (M) 
1030.516 22.75 6.84 378.05 80.73 40.21 0 ESLDVTNPR   
1153.575 47.75 3.72 1192.14 324.25 88.84 0 GFGVVFSNGNR   
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Protein MH+ [Da] 
RT 
[min] Ions Sc. Inten. Area S/N Miss Sequence Variable Mods 
 
  
CYP2C29 
  
1189.614 78.75 39.98 393.54 106.31 66.38 0 DFIDYYLIK   
1299.702 28 14 789.26 291.18 68.56 1 VQEEIDRVVGR   
1462.728 40.25 26.7 1137.13 468.46 140.57 1 EALIDRGEEFAGR   
1602.779 60.25 49.71 2064.65 1075.21 148.25 0 VQEEAQCLVEELR   
1846.821 59.5 4.03 501.55 354.70 50.05 0 SHMPYTDAMIHEVQR 2 Oxidation (M) 
CYP2C37 
  
  
  
  
  
781.424 37 11.68 594.77 107.46 29.18 0 NYFIPK   
918.471 37.5 22.59 2959.06 664.61 165.08 0 CLVEELR   
965.520 39.75 8.98 391.21 71.60 53.81 1 GRFPVFDK   
1400.757 73.5 50.32 4916.09 1874.74 594.93 0 VYGPVYTLYLGR   
1429.671 29.5 76.64 1594.91 673.46 213.34 0 EALVDHGEEFAGR   
2553.200 91.25 22.55 90.77 79.11 18.09 0 DFIDYFLINGGQEDGNQPLQNR   
CYP2C39 
  
  
  
  
1189.614 78.75 39.98 393.54 106.31 66.38 0 DFIDYYLIK   
1294.675 31.25 33.01 471.90 152.86 36.67 0 VQEEIDHVIGR   
1296.742 66 49.27 2587.71 883.47 306.04 0 FINLVPNNIPR   
1517.687 32.75 17.84 185.09 90.98 27.57 0 EALIDHGEEFSDR   
1602.779 60.25 49.71 2064.65 1075.21 148.25 0 VQEEAQCLVEELR   
CYP2C40 
  
  
  
  
931.536 35 9.97 518.32 102.31 49.39 1 GRIPVFDK   
1190.678 80 0.44 211.58 55.20 50.88 1 IPVFDKVSTGK   
1329.684 95.5 32.52 556.01 183.22 81.23 0 DFIDYFLIQR   
1485.785 49.5 5.06 1801.99 762.18 155.34 1 DFIDYFLIQRR   
1858.832 84.25 1.88 239.89 159.78 29.44 0 NHMPYTNAMVHEVQR 2 Oxidation (M) 
CYP2C50 
  
  
  
781.424 37 11.68 594.77 107.46 29.18 0 NYFIPK   
918.471 37.5 22.59 2959.06 664.61 165.08 0 CLVEELR   
931.536 35 9.97 518.32 102.31 49.39 1 GRLPVFDK   
1429.671 29.5 76.64 1594.91 673.46 213.34 0 EALVDHGEEFAGR   
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Protein MH+ [Da] 
RT 
[min] Ions Sc. Inten. Area S/N Miss Sequence Variable Mods 
CYP2C54 
  
  
  
  
781.424 37 11.68 594.77 107.46 29.18 0 NYFIPK   
918.471 37.5 22.59 2959.06 664.61 165.08 0 CLVEELR   
931.536 35 9.97 518.32 102.31 49.39 1 GRLPVFDK   
1340.626 48 3.08 1141.78 406.96 87.72 0 DICQSFTNLSR   
1385.681 38 20.02 430.82 141.03 33.35 0 EALVDHGDVFAGR   
1400.757 73.5 50.32 4916.09 1874.74 594.93 0 VYGPVYTLYLGR   
CYP2C70 
  
  
1033.568 55 13.53 659.35 171.32 62.07 0 FILEEINR   
1303.704 72 53.13 3103.08 997.93 524.11 0 YIDFVPIPSPR   
1347.669 20.5 2.56 478.37 160.53 44.23 1 KSDYFVAFSAGR   
CYP2D10 
  
  
  
  
  
  
965.553 34.25 7.95 795.77 159.93 110.42 1 RFSVSTLR   
1212.674 66 60.94 4086.96 1261.55 515.08 0 FGDIAPLNLPR   
1225.560 26.75 26.57 1873.32 573.06 181.94 0 NTWDPDQPPR   
1344.647 62 0.82 215.83 92.44 33.79 0 FEYEDPYLIR   
1454.796 54.25 49.4 3136.59 1371.93 249.93 0 VQQEIDAVIGQVR   
1500.748 58.25 31.19 935.23 378.79 149.48 1 RFEYEDPYLIR   
1573.779 45.25 62.59 2571.67 1398.38 196.07 0 MPYTNAVIHEVQR Oxidation (M) 
 
 
CYP2D26 
  
 
 
 
 
 
 
 
965.553 34.25 7.95 795.77 159.93 110.42 1 RFSVSTLR   
1041.540 67.25 36.47 405.04 98.14 61.69 0 FQDFFIPK   
1357.726 68.5 33.06 3226.77 1067.51 581.90 0 GVILAPYGPEWR   
1376.790 92.25 30.77 1323.49 451.43 316.67 0 AVSNVIASLIYAR   
1477.703 25 6.48 375.03 152.43 20.04 1 GNPESSFNDKNLR   
1519.696 63.75 25.92 1776.11 787.03 334.46 1 RFEYEDPFFNR   
1530.802 42.5 71.4 1685.51 1252.18 109.15 0 VHQEIDEVIGHVR   
1573.779 45.25 62.59 2571.67 1398.38 196.07 0 MPYTNAVIHEVQR Oxidation (M) 
2596.434 98.25 43.31 577.88 569.62 119.70 1 GTTLIPNLSSVLKDETVWEKPLR   
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Protein MH+ [Da] 
RT 
[min] Ions Sc. Inten. Area S/N Miss Sequence Variable Mods 
 
CYP2D26   
3081.446 79 4.46 37.72 46.39 22.08 1 FYPEHFLDAQGHFVKHEAFMPFSAGR Oxidation (M) 
3134.525 72.75 3.65 100.98 120.91 58.62 0 ELLVTYGEDTSDRPLMPIYNHIGYGHK Oxidation (M) 
CYP2E1 
  
  
  
  
  
  
  
  
822.367 29.5 37.82 1705.87 358.60 140.91 0 YSDYFK   
835.504 68.5 12.04 2487.23 441.00 427.04 0 FSLSILR   
974.472 25 40.6 2470.51 592.65 80.96 0 SLDINCPR   
1091.588 41.25 2.54 1790.59 504.68 146.03 1 VMKNVSEIR Oxidation (M) 
1195.599 51.75 33.72 602.19 182.49 87.01 0 GDIPVFQEYK   
1371.753 71.75 26.95 928.52 295.39 157.51 0 FGPVFTLHLGQR   
1527.854 66.75 39.44 1113.44 497.92 112.53 1 RFGPVFTLHLGQR   
1686.906 87.75 93.64 2645.82 1543.72 358.57 0 DIDLSPVTIGFGSIPR   
1707.918 61.25 75.95 4371.09 2633.89 517.37 0 FINLVPSNLPHEATR   
CYP2F2 
  
  
  
  
  
1299.702 28 14 789.26 291.18 68.56 1 VQEEIDRVVGR   
1318.658 83 8.28 857.61 261.29 162.61 0 GAYPVFFNFTR   
1425.731 61 12.8 446.23 199.59 32.72 0 FADVIPMNLPHR Oxidation (M) 
1436.702 28.5 19.42 388.40 167.65 39.17 1 EALVDKGEEFSGR   
1517.857 105.25 69.44 1319.25 543.29 179.12 0 ILEEGSFLLEVLR   
2121.291 105.25 10.1 805.25 669.23 108.09 0 GQLPPGPKPLPILGNLLQLR   
CYP3A11 
  
1159.520 47 10.6 617.75 195.51 42.29 0 ECFSVFTNR   
1751.875 84.5 48.56 938.19 552.40 118.79 0 GSIDPYVYLPFGNGPR   
 
Table 3.2: P450 peptide data for mouse liver microsome starting material (replicate 7). Peptides with sequences present in more than one P450 are 
highlighted in red. Protonated molecular ions (MH+). HPLC retention time (RT). Number of (K/R) missed tryptic cleavage sites (Miss).
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3.4 Discussion 
3.4.1 Total protein and P450 acitivity assays 
The Bradford total protein assay was used to establish the protein 
concentration of mouse liver microsome fractions. The aim was to produce 
preparations with concentrated protein content to allow maximum protein 
loading in chromatography experiments with low volumes. This would 
minimise the amount of chromatography materials required to help minimise 
costs of the assays. The protein content within the preparations ranged from 
30-42mg/ml and so was sufficiently concentrated enough to meet the 
requirements. 
 
The EROD assay measures the ability of a sample to O-deethylate 7-
ethoxyresorufin to resorufin (Figure 1.11) by fluoroscopy. A decrease in 
microsome concentration led to an increase in resorufin fluorescence 
detection. This was hypothesised to be due to one of two reasons, either the 
concentration of the microsome samples was too great, so the complex 
mixture of proteins, causing a ‘cloudy’ solution, was interfering with detection, 
or the contents of the microsome storage buffer (for example glycerol) are 
quenching fluorescence. As the microsome concentration decreased further, 
the rate of reaction slowed dramatically, which was estimated from the 
qualitative results. The decrease in reaction rate was proportional to the 
decrease in microsome concentration, until reaching the limit of detection 
(linear range). 
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Based on the specificity of the EROD assay for CYP1 isoforms, it has been 
successfully utilised to assess P450 activity in mouse liver microsomes. The 
method has been used to confirm the presence of P450’s in the microsome 
starting material prior to affinity chromatography. The disadvantage of using 
this method to assess P450 activity in these samples is that the liver only 
contains measureable protein levels of CYP1A2, with lower expression of 
CYP1A1, but there is no strong evidence that CYP1B1 is expressed in liver 
(Figure 1.7). As a general indicator of P450 content, this method of detection 
may therefore not be the best available as 7-ethoxyresorufin is not 
metabolised by other P450s in the mouse liver.  
 
3.4.2 MALDI MS 
Detection of P450s from mouse liver microsomes is possible using HPLC 
separation of trypsin-digested proteins and MALDI MS analysis. Due to the 
complex nature of mouse liver microsomes, it is not possible to detect all of 
the P450s present (Sutton et al., 2010). Although it is possible to identify 
some of the more abundant P450s (up to 26) using gel-based preparation 
before MS analysis, other proteins within the microsome preparation mask 
the identification of the less abundant P450s (Sutton et al., 2010). 
 
To characterise the P450 content within mouse liver microsomes 9 replicate 
experiments were conducted to determine which proteins were commonly 
identified and which were only found in some mouse livers. This variation 
may be due to differences in the P450 content within each mouse liver or be 
 111 
based on analytical variation (such as trypsin digestion, HPLC separation, 
peptide ionisation). 
 
Results from Section 3.3.4 show that there is variation in protein identification 
between runs, although a common core set of P450s are present in the 
majority of preparations (Table 3.1). Identification of CYP2C70, CYP2D26 
and CYP2E1 was most successful as they were seen in all 9 replicates, 
however the MASCOT scores (39-83, 56-326, 88-273 respectively) and 
peptide number (2-4, 6-12, 8-16 respectively) did vary significantly. It is also 
vital to assess the quality of the data by looking at the individual peptide 
spectra for each protein identification (Table 3.2). The detected mass value 
of the protonated molecular ions is used to identify the possible peptide 
sequence, and is used to identify the protein from which the peptide was 
cleaved. Due to the highly homologous nature of the P450s it is expected 
that some peptides may match several of the P450s, so it is only in 
conjunction with unique peptides that have no other matches that a confident 
protein identification can be made. In Table 3.2 any common sequences are 
highlighted in red. For example, CYP2C50 has a MASCOT score of 77 from 
4 peptides. This may seem to be an acceptable score, but with further 
investigation, it is possible that all 4 peptides came from other closely related 
CYP2C isoforms that also have their own unique peptides. In this case, 
CYP2C50 would then be excluded from the data set as its identification is 
questionable.  
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CYP2A4 and CYP2A5 have 7 peptides identified that are in common. As 
both P450s are in the same sub-family of P450 they have very high 
sequence homology (97.7%), which means that peptides cleaved from both 
CYP2A4 and CYP2A5 may have identical sequences. However, it was 
possible to find 2 unique peptides (with significant MASCOT scores) from 
each, allowing for a more confident conclusion that both are present. 
 
This form of scrutiny is to be applied in the data analysis of subsequent 
experiments detailed in Chapters 4-7. To increase the confidence in 
comparisons of various chromatography methods used during this study a 
MASCOT score threshold value of greater than or equal to 45 will be used, 
from at least 3 peptides, with one or more being unique. 
  
CHAPTER FOUR 
Immobilised artificial membrane phosphotidyl choline (IAM.PC) 
chromatography 
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4.0 Membrane-based affinity chromatography  
 
4.1 Introduction 
 
Immobilised artificial membrane phophytidyl choline (IAM.PC) 
chromatography columns utilise the natural affinity of membrane proteins for 
membrane-derived molecules. The membrane lipid phosphatidylcholine has 
been bound to a solid support for use in HPLC, developed by Dr Charles 
Pidgeon at Purdue University, Indiana, and manufactured by Regis 
Technologies (Figure 4.1). 
 
 
 
 
Figure 4.1: Structure of the IAM.PC column manufactured by Regis 
Technologies. Phosphatidylcholine is covalently bound to a silica-based 
medium via amide bonds to propylamine groups on the solid support surface 
(Regis Technologies Inc., 2009) 
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Membranes of plants and animal cells naturally possess up to 50% 
phosphatidylcholine and so it is understandable why this has been the first 
phospholipid targeted for immobilisation. Proteins that are to be transported 
to the membrane after production in the Golgi apparatus need to have certain 
properties for successful interaction and integration into the membrane. 
These proteins need to be able to interact with other membrane constituents 
with hydrophobic properties. 
 
For successful IAM.PC chromatography, the column needs to be equilibrated 
with a low percentage detergent (0.6% w/v sodium cholate) to allow correct 
protein suspension and interaction with the membrane-like chemical surface. 
To remove P450s from the column, elution with a stronger detergent (1.3% 
w/v Lubrol) is required (Pidgeon et al., 1991; Scharf et al., 1998). 
 
4.1.1 Removal of buffers and additives before analysis 
Removal of certain buffers and additives is vital for good, consistent and 
reliable results. Interference of buffers can cause false positive or negative 
results, for example ethylenediamine-tetraacetic acid (EDTA) concentrations 
greater than 10mM cause more than a 10% error in protein concentration 
determination by the bicinchoninic acid (BCA) assay results (Thermo Fisher 
Scientific Inc., 2007). Interference can also be seen using some of the more 
advanced protein analysis and detection techniques, for example, most 
detergents will produce much stronger signals than peptides during MS 
analysis, and as they can be spread throughout the spectra, can make full 
peptide detection and protein analysis extremely difficult.  
 116 
A 
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Figure 4.2: Interference of Lubrol detergent during detection of myoglobin 
peaks via manual mass spectrometry analysis. (A) Lubrol interference 
showing typical bell shape of closely repeating signals, masking the myoglobin 
peaks. (B) Lubrol content reduced by factor of 100; peaks present now 
represent the desired trypsin-digested myoglobin spectrum.  
 
 
MALDI MS analysis of proteomic standards spiked with IAM.PC mobile 
phases indicated limited compatibility (Figure 4.2). This was mainly due to 
detergent interference, namely sodium cholate and Lubrol WX. Very low 
protein concentrations in the 1ml IAM.PC HPLC fractions also presented a 
challenge.  
 
When dealing with certain proteins, especially the hydrophobic membrane 
proteins, addition of detergents for solubilisation and preparation of the 
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protein sample is vital. This causes a dilemma between the conditions 
required to work with the sample and those required for analysis (Prive, 
2007). There are a number of techniques that have previously been used to 
remove unwanted additives, including detergents. Ice-cooled organic solvent, 
acetone, precipitates protein, with contaminants and some detergents 
remaining in the liquid portion. Micro Bio-Spin columns (Bio-Rad) can aid in 
removal of dyes, salts and unincorporated nucleotides from protein/peptide 
solutions (Bio-Rad Laboratories, 2000). The Vivaspin 500 centrifugal 
ultrafiltration device (GE Healthcare) can be used to remove small molecules 
via a molecular weight cut-off membrane, as well as concentrating the protein 
sample (GE Healthcare Bio-Sciences AB, 2008). As part of IAM.PC 
evaluation, some of these methods were tested for suitability in enrichment of 
P450s from mouse liver microsomes. 
 
4.1.2 Aims of chapter 
The main focus of this chapter is to evaluate the use of IAM.PC 
chromatography to purify P450s, determining the sample and analytical 
conditions required for proteomic analysis, including detergent removal 
protocols. It is expected that results would be similar to those as seen by 
Pidgeon et al. (1991) and Scharf et al. (1998) and that by coupling this 
technique to MALDI MS, further identification of the eluted P450s would be 
possible. The EROD assay will be used to detect the presence of P450s in 
chromatography fractions as a quick indicator before and after protein 
concentration and detergent removal steps, to help with selection of samples 
for further analysis. 
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4.2 Materials and Methods 
4.2.1 Reagents and samples 
Lubrol WX was purchased from MP Biomedicals (Solon, OH, USA). The BCA 
reagent kit was purchased from Pierce (Rockford, IL, USA). Acetone was 
purchased from Sigma-Aldrich (St. Louis, MO, USA). For information on 
mouse liver microsome preparation refer to Section 3.2.2 and all other 
materials refer to Section 3.2.1. 
 
4.2.2 BCA assay 
The BCA assay chelates protein to form a detectable blue BCA-copper-
protein complex (Figure 4.3). The BCA reagents do not arrive ready-to-use 
because the working reagent is light sensitive and cannot be stored for 
prolonged periods. Working reagent must be prepared by mixing BCA 
reagent B with BCA reagent A in a 1:50 ratio, respectively. A serial dilution of 
BSA from 1mg/ml to 0.0625mg/ml was used to create a standard curve of 
absorbance after the addition of working reagent (2ml) to the BSA standards 
(100µl). The standards were incubated at 37°C for 30 minutes. The BSA 
standard concentration was analysed using a Cary 50 Bio UV-visible 
spectrometer (Varian Inc.), at a wavelength of 562nm. The sample with 
unknown concentration was prepared in the same manner and the result was 
compared to the standard curve, calculating the sample concentration.    
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Figure 4.3: BCA assay reaction scheme. Copper 
2+
 chelates the protein 
present in the sample and is reduced to copper
 1+
, which reacts with the BCA 
reagent forming a copper-BCA-protein complex (blue coloured product, absorbs 
light at 540nm). Modified from Thermo Fisher Scientific Inc. (2009) 
 
 
4.2.3 Protein recovery and detergent removal experiments 
To analyse the impact of detergents on the analysis of the fraction samples 
produced by IAM.PC HPLC, initial protein recovery and detergent removal 
experiments were evaluated. These experiments included a range of protein 
concentration and desalting methods. 
 
4.2.3.1 Acetone precipitation  
 
Ten volumes of pre-cooled (-20°C) acetone were added to the sample, and 
the suspension was placed in a freezer (-20°C) overnight. The suspension 
was spun for 5 minutes at either 14,100 x g for 5 minutes if the total acetone 
sample volume was below 2ml, or at 3,000 x g for 8 minutes if the total 
acetone sample volume was between 2-15ml. The supernatant was 
discarded and the pellet, containing the proteins of interest, was left to air dry 
for approximately 30 minutes before resuspending in an appropriate buffer 
for downstream analysis, for example PBS, urea or SDS-PAGE loading 
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buffer. For samples with a total acetone sample volume of between 2-15ml, a 
‘transfer method’ was also used for the centrifugation step to decrease 
protein loses in the discarded supernatant. This technique involved 
transferring samples into a microcentrifuge tube (1.2ml), spinning for 5 
minutes at 14,000 x g, discarding the supernatant to waste, sequentially, and 
collecting the increasing pellet in the tube. 
 
4.2.3.2 NAP-5 column  
 
The illustra NAP-5 column was secured in a clamp stand above a waste 
container and equilibrated with approximately 9ml of 25mM ambic containing 
10% acetonitrile. This process allows gravity to pull the solution through the 
column. After this, 500µl of sample was added and left to drip through the 
column. Exactly 1ml of 25mM ambic containing 10% acetonitrile was then 
used to elute the sample from the column, and the elution fraction (1ml) was 
manually collected into a microcentrifuge tube. Samples were evaporated to 
dryness for storage at -20C and for resuspension in a buffer compatible with 
subsequent analysis techniques. 
 
4.2.3.3 C4 cartridge  
 
Isolute C4 cartridges (Kinesis Ltd., Cambridgeshire, England) were wet with 
methanol (1ml) and then equilibrated with 2% acetonitrile (2ml). Microsome 
liver sample (100 -500µl) was added to the cartridge, with the total volume 
being adjusted to a final volume of 500µl. The cartridge was then washed 
with 2% acetonitrile (2ml) before eluting the proteins bound to the C4 
cartridge using 50% acetonitrile (1ml), which was collected in a 
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microcentrifuge tube. The flow rate was kept at approximately 1ml/min 
manually using a syringe attachment. Samples were evaporated to dryness 
for storage at -20C and for resuspension in a buffer compatible with 
sequential analytical techniques. 
 
4.2.3.4 Micro Bio-spin column  
Micro Bio-spin columns are distributed in buffer, which first needs to be 
mixed by inversion to resuspend the settled gel, and then drained before use. 
After allowing the buffer to drain by gravity the column was centrifuged at 
1,000 x g for 2 minutes in a microcentrifuge tube (2.2ml) supplied to ensure 
that sample is not diluted by residual buffer. This solution was collected, and 
the microcentrifuge tube, was then discarded to waste. The column itself was 
transferred to another microcentrifuge tube (1.2ml) and the 20-75µl sample 
added. The column and microcentrifuge apparatus was then centrifuged at 
1,000 x g for 4 minutes. The sample was present in the solution in the 
microcentrifuge tube and the column discarded. 
 
4.2.3.5 Vivaspin filter 
 
The Vivaspin 500 ultrafiltration device is distributed ready-to-use and can be 
directly placed in microcentrifuge tubes (1.2ml). The sample was transferred 
to the filter pocket, and the microcentrifuge tube and filter apparatus were 
centrifuged at 13,000 x g for 6 minutes. The solution present in the 
concentration pocket of the Vivaspin 500 filter contained the protein from the 
sample and was decanted to a suitable tube for storage. The solution present 
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in the microcentrifuge tube contained waste buffer and other contaminants 
below the molecular weight cut-off of the filter. 
 
4.2.4 IAM.PC chromatography (Preparative affinity HPLC) 
 
The IAM.PC protocol was based on work completed by Pidgeon et al. (1991) 
and Scharf et al. (1998). An IAM.PC 10μm, 15cm analytical column and 
IAM.PC 10μm, 1cm guard column (Regis, Morton Grove, IL, USA) were 
connected to a Waters 2695 separation module HPLC system (Milford, MA, 
USA) with an in-line Waters 2996 photodiode detector. The system was 
equilibrated with mobile phase A consisting of 0.1M potassium phosphate, 
pH 7.25, 20% v/v glycerol, 1mM EDTA, 0.6% w/v sodium cholate at a flow 
rate of 0.5ml/min. Mouse liver microsomes (60µl), used fresh or stored at -
80˚C and thawed only once, were injected onto the column, with the flow rate 
kept at 0.5ml/min and the back pressure under 800lb/in2, in mobile phase A 
for 50 minutes.  
 
A one-step linear gradient (Figure 4.4) of mobile phase B (2% w/v Lubrol in 
mobile phase A) was used, from 0% to 65% mobile phase B, started at 50 
minutes for 15 minutes, followed by mobile phase B kept constant at 65% 
from 65 to 85 minutes, and then the mobile phase B gradient was reduced 
from 65% to 0% from 85 to 100 minutes. Mobile phase A was then kept at 
100% from 100 to 130 minutes. The optical density of the analytical run was 
measured using a photodiode array ranging from 215-500nm. During the 
analytical run optical density was specifically monitored at 215nm, 280nm 
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and 405nm. Fractions of equivalent to 2 minutes of eluent (1ml) were 
manually collected. 
 
 
Figure 4.4: Mobile phase gradient used in one-step linear gradient IAM.PC 
HPLC method. Mobile phase B percentage of total flow shown by grey area 
(left vertical axis) and overall concentration of Lubrol (w/v) indicated by the blue 
line (right vertical axis). 
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4.3 Results 
4.3.1 Total protein assays 
Total protein assays were intended to be used to determine initial microsome 
total protein concentration, and then be used to track protein concentrations 
through chromatography, concentration/desalting and detergent removal 
steps, before analysis. This would give an indication of where contaminating 
proteins were most effectively removed, as well as highlighting which 
fractions needed to be targeted for further analysis.  
 
The Bradford assay was not compatible with the use of detergents, as 
described by the manufacturer (Thermo Fisher Scientific Inc., 2009), and so 
was used only for the initial microsome sample total protein concentration 
determination (Section 3.3.1). The BCA assay however, was reported to be 
compatible with some detergents (Thermo Fisher Scientific Inc., 2009), so 
the assay was tested for compatibility with the detergents in use in the 
IAM.PC chromatography method. 
 
 
4.3.1.1 BCA assay 
 
It was clear after initial detergent testing that both mobile phase A and mobile 
phase B used in the IAM.PC method were not compatible with the BCA 
assay, as both gave strong positive results in protein-free controls. After 
further investigation, a 1-in-20 fold dilution of these buffers was found to 
produce results equivalent to the baseline absorbance using protein-free 
controls and a linear curve for BSA standards over the concentration range of 
0.625-1mg/ml (Figure 4.5). Unfortunately when performing a 1-in-20 fold 
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dilution to negate the effects of the detergents on sample analysis, the 
protein content in IAM.PC fractions dropped below the level of detection in 
the BCA assay. 
 
Figure 4.5: Comparison of BSA standard curves using sample buffer 
containing 5% buffer A and 5% buffer B for the BCA assay. All sample 
absorbance points are minus blank control absorbance. Range of BSA 
standards in 5% Buffer A (black circles, solid line) and 5% Buffer B (white 
circles, dotted line), with blank (protein-free) 5% buffer A (blue circle) and 5% 
buffer B (red circle) controls. 
 
 
Figure 4.6 shows the calculated starting material concentration (taking into 
account the 20-fold dilution), indicating that the original starting sample needs 
a protein concentration of more than 1mg/ml prior to dilution to give a result 
within the linear range of the BCA assay, due to detergent interference. A 
sample as concentrated as this is unlikely to be found in most IAM.PC 
fractions, so methods for detergent removal and protein concentration were 
investigated. 
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Figure 4.6: Comparison of a range of buffer conditions for detection of 
BSA standards using the BCA assay. All sample absorbance points are 
minus blank control absorbance. BSA standard curve produced using the BCA 
assay, comparing the use of 5% buffer A (0.1M potassium phosphate, pH 7.25, 
20% v/v glycerol, 1mM EDTA, 0.6% w/v sodium cholate; white circles, dotted 
line) and 5% buffer B (buffer A plus 2% Lubrol; black triangles, dotted line), with 
that of distilled water in the low sensitivity range. Note buffer A (red triangle) and 
buffer B (blue square) controls were plotted based on calculations from the BSA 
in DI water (green circles, solid line) standard curve to show false positivity. 
 
 
 
The results in Figure 4.7 show that mobile phase A and mobile phase B 
affects the samples following acetone precipitation by differing amounts. This 
is most likely due to the varying residual detergent after acetone precipitation 
in each case, and therefore proves problematic when dealing with fractions of 
unknown detergent ratio, as would be produced by the gradient conditions of 
the IAM.PC method. The concentration of Lubrol in the acetone precipitate 
control seemed to be similar to the un-concentrated control before acetone 
precipitation as the effect on the BCA assay is unchanged. This means that 
the protein content can be concentrated without the detergent also being 
concentrated, decreasing the detergent-to-protein ratio in the sample. 
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Unfortunately mobile phase A does not have the same affect, as it seems to 
have a greatly increased concentration in the control post-acetone 
precipitation compared to those prior to acetone precipitation. This negates 
any concentration effects of acetone precipitation, increasing the threshold of 
mobile phase A interference in the BCA assay. Consequently no IAM.PC 
fractions were analysed for protein concentration. 
 
 
 
Figure 4.7: Compatibility of the BCA assay with acetone precipitation 
sample preparation of detergent containing samples. All sample 
absorbance points are minus blank control absorbance. BSA standard curve 
(black circle, solid line) produced using the BCA assay, comparing effects of 5% 
buffer A (red circle) and 5% buffer B (blue triangle) on acetone precipitation 
protein concentration and BCA assay interference. Pre-acetone precipitation 
buffer A (pink circle) and buffer B (blue circle) controls are also shown.  
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4.3.2 P450 activity assay 
The EROD assay was tested for compatibility with the buffers used during 
the IAM.PC experiments (Figure 4.8). Triplicate analysis of mobile phase A 
(50μl) containing mouse liver microsomes (10μl equivalent to 220μg of 
microsomal protein) showed decreased activity from microsomes in PBS, 
indicating that sodium cholate negatively affected CYP1A2, however some 
activity remained. In comparison, triplicate analysis of mobile phase B (50μl) 
containing mouse liver microsomes (10μl equivalent to 220μg of microsomal 
protein) showed results similar to the blank controls, indicating that Lubrol is 
either inhibiting the P450 activity or quenching fluorescence.  
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Figure 4.8: Effect of detergent containing solutions on EROD activity in 
mouse liver microsomes. Note difference in scales dependent on fluorometric 
reading; A) Mouse liver microsome starting material sample (220μg red) and 
three repeats in IAM.PC mobile phase A containing sodium cholate (220μg 
grey, blue orange). B) Microsome starting material sample (220μg red) and 
three repeats in IAM.PC mobile phase B containing sodium cholate and Lubrol 
(220μg grey, blue, orange). 
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4.3.3 Protein recovery and detergent removal experiments 
The main issue with the IAM.PC chromatography method was the lack of 
compatibility of the mobile phase contents with most techniques used to 
analyse the fraction samples. A range of techniques were tested to determine 
the optimal method for concentrating proteins whilst at the same time 
removing the detergents sodium cholate and Lubrol. The removal of these 
two detergents is important following IAM.PC protein separation as both are 
present in the mobile phase used to equilibrate the column and elute proteins 
of interest. Samples from each method were analysed and compared by 
SDS-PAGE (Figure 4.9).  
 
Acetone precipitation was the most successful method for concentrating 
proteins, either in the presence or absence of detergent in the sample buffer. 
This is visualised in Figure 4.9A and B by many protein bands throughout the 
full molecular weight range consistent with the bands seen in the original 
starting material. The Vivaspin ultrafiltration device proved to be the least 
useful for liver microsome protein recovery, as no protein bands were seen 
(Figure 4.9A). Although the Micro Bio-Spin and C4 cartridge methods were 
useful for concentrating protein using liver microsomes in PBS (Figure 4.9A), 
in the presence of detergents these methods gave very poor results (Figure 
4.9C), showing no clear bands after electrophoresis comparable to those 
seen in the control liver microsome experiment.  
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B: 
 
 
 
 
 
 
 
 
 
 
 
 
 
C: 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9: Comparison of detergent removal and protein concentration methods, with 
and without the presence of detergent in the mouse liver microsome sample buffer 
analysed on 4-20% precast gels with Coomassie Brilliant Blue staining.  
A) Lane 1 & 11 25mM ambic; lane 2 & 10 Rainbow markers; lane 3 starting material; lane 4 
lyophilised control; lane 5 acetone precipitation; lane 6 NAP-5 without 1% DDM; lane 7 C4 
cartridge; lane 8 Micro Bio-Spin column; lane 9 Vivaspin ultrafilter.  
B) Lane 1 & 12 25mM ambic; lane 2 & 11 Rainbow markers; lane 3 starting material; lane 4 
lyophilised control; lane 5 lyophilised with mobile phase A; lane 6 lyophilised with mobile 
phase B; lane 7 acetone precipitation with mobile phase A; lane 8 acetone precipitation with 
mobile phase B; lane 9 NAP-5 without 1% DDM, with mobile phase A;  lane 10 NAP-5 
without 1% DDM, with mobile phase B.  
C) Lane 1 & 12 25mM ambic; lane 2 & 11 Rainbow markers; lane 3 starting material;  lane 4 
NAP-5 with 1% DDM;  lane 5 NAP-5 with 1% DDM, with mobile phase A;  lane 6 NAP-5 with 
1% DDM, with mobile phase B; lane 7 C4 cartridge with mobile phase A; lane 8 C4 cartridge 
with mobile phase B; lane 9 Micro Bio-Spin column with mobile phase A; lane 10 Micro Bio-
Spin column with mobile phase B 
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DDM was used during the NAP-5 column desalting method as a mass 
spectrometer-friendly detergent to replace the unwanted detergents from the 
IAM.PC mobile phase (sodium cholate and Lubrol), so DDM would still aid in 
protein solubilisation. However, inclusion of DDM proved to be incompatible 
with the SDS-PAGE protein analysis method, causing smearing of the bands 
(Figure 4.9A and B). Although the initial 1% w/v DDM was relatively low, 
concentration by evaporation increased this value twenty-fold, and at these 
vastly increased concentrations DDM prevented proper band formation and 
staining.   
 
Different DDM concentrations were used in a subsequent experiment to 
determine whether lower concentrations would be compatible with SDS-
PAGE analysis. Six buffers with concentrations ranging from 0-1.25% DDM 
were used with molecular weight markers to test the effect of DDM over the 
full range of protein sizes (Figure 4.10). The data showed no interference at 
any of these DDM concentrations. If a sample was to be resuspended (100µl) 
from evaporated NAP-5 fractions (1ml), then elution buffer containing 0.1% 
DDM could be used without causing interference to SDS-PAGE separation. 
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Figure 4.10 : DDM compatibility with SDS-PAGE technique. Lane positions 
are labelled above gel and relative molecular weight Rainbow markers (GE 
Healthcare) labelled on left of gel. Lanes 2, 4, 6, 8, 10, 12 25mM ambic; lane 1 
0% DDM and markers; lane 3 0.25% DDM and markers; lane 5 0.5% DDM and 
markers; lane 7 0.75% DDM and markers; lane 9 1% DDM and markers; lane 
11 1.25% DDM and markers. 
 
4.3.4 IAM.PC chromatography 
IAM.PC separation led to detection (215nm and 405nm) of two main regions, 
the flow-through peak, containing unbound proteins, and the elution fractions 
(Figure 4.11), comprising of a sharp peak with a long trailing shoulder 
containing bound proteins eluted with increasing concentrations of Lubrol (0-
1.3%). 
 
4.3.4.1 Analysis by SDS-PAGE 
 
Due to the high detergent and low protein concentrations of IAM.PC fractions 
in a relatively large volume of mobile phase (1ml per fraction), acetone 
precipitation was performed post-IAM.PC chromatography. Samples were 
selected based on the accompanying chromatogram from the IAM.PC 
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chromatography, measured at 215nm and 405nm, for analysis by SDS-
PAGE.  
 
 
Fractions 2 and 3 of the flow-through peak were the only fraction samples to 
show any staining using Coomassie Brilliant Blue, however the range and 
intensity of bands identified in these fractions increased using the more 
sensitive silver staining technique (Figure 4.13). Fraction 4 of the flow-
through peak also showed some banding using the silver staining technique. 
Lubrol elution fractions 34-37 all showed bands using the silver staining 
technique, where previously no bands had been identified using the 
Coomassie Brilliant Blue staining technique. The elution fractions showed 
relative molecular weight bands at 54.5kDa, 50kDa, 38kDa and 35.5kDa, all 
of which were in the linear range of the gel and calculated using a calibration 
curve (Figure 4.12). Bands of similar molecular weight were also present in 
the flow-through fractions.  
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Figure 4.11: IAM.PC HPLC chromatogram (405nm) of mouse liver microsome sample. 
Flow-through peak (FT1) attained with mobile phase A and elution peak and shoulder 
(Elution) attained with an increasing gradient of mobile phase B. 
 
 
Figure 4.12: Calibration curve for SDS-PAGE using Novex molecular weight markers (black 
circles) and calculated IAM.PC fraction bands (blue triangles). 
FT1 Elution 
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Figure 4.13 : Coomassie Brilliant Blue (Top) and silver stained (Bottom) SDS-PAGE 
acrylamide gel of IAM.PC fractions. Lane positions are labelled above gel and Novex 
relative molecular weight markers (Invitrogen) labelled on left of gel. Lane 3 contains mouse 
liver microsome starting material. Lanes 4-8 contain IAM.PC fraction samples 1-5, and lanes 
9-12 contain IAM.PC fraction samples 34-37, in ascending order, left to right.  
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4.3.4.2 Analysis by mass spectrometry 
 
The acetone precipitated IAM.PC fractions 2, 3, 34, 35 and 36 were reduced, 
alkylated, trypsin digested and separated by nano-HPLC and then analysed 
by mass spectrometry (Section 3.2.6). The data produced, highlighted seven 
proteins in the elution fractions with MASCOT scores greater than or equal to 
45, calculated from at least 3 peptides and at least one unique peptide, of 
which 5 were enriched (Carnitine O-palmitoyltransferase 2, Cytochrome b5,  
Heterogeneous nuclear ribonucleoproteins A2/B1, Membrane-associated 
progesterone receptor component 1, Splicing factor, arginine/serine-rich 1). A 
summary of the data achieved for both the flow-through and elution peaks 
are shown in Table 4.1. As expected, the flow-through peak (fractions 2 and 
3) contained most of the proteins collected from the IAM.PC column. Only 
50% of the proteins identified in the starting material were identified from the 
IAM.PC fractions. This is a very poor yield but may be explained by the need 
for several steps of separation, purification and concentration before MS 
analysis, and the introduction of detergents into the sample, making analysis 
less sensitive. It may also be due to traces of proteins being eluted in some 
of the other fractions at a level below the detectable range of the photdiode 
array. 
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 Proteins with 
≥ 3 peptides 
identified 
Proteins with 
MASCOT 
score ≥ 45 
Proteins with ≥ 
3 peptides and 
MASCOT score 
≥ 45 
Total number 
of proteins 
identified by 
MS/MS 
Starting 
material 
360 313 284 379 
Flow-through 
peak 
111 114 98 166 
Elution peak 7 7 7 25 
 
 
Table 4.1 : Summary of mass spectra data quality, comparing the flow-through 
fractions and the elution fractions of the IAM.PC HPLC method with the starting 
material (Appendix B) 
 
 
4.3.4.3 EROD P450 activity assay 
Apart from the starting material, no CYP1A2 activity was detected using the 
EROD assay due to interference from Lubrol (Figure 4.8). 
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4.4 Discussion 
4.4.1 EROD assay 
The purpose of using the EROD assay was to detect the presence of P450s 
in chromatography fractions as a quick indicator before and after protein 
concentration and detergent removal steps, to help with selection of samples 
for further analysis. Unfortunately the results (Section 4.3.2) show that the 
assay is not directly compatible with the IAM.PC fractions and so the assay 
has not been coupled to the analysis of samples produced by that method. 
This is due to detergent interference which has been shown to decrease 
P450 activity unless the original Lubrol content can be reduced by 
approximately 97% (Pidgeon et al., 1991).  
  
4.4.2 IAM.PC chromatography 
P450s are in relative low abundance in crude liver sample preparations 
compared to the sum total of all other proteins. Scientists have previously 
attempted to separate P450s from other proteins within tissue samples for 
closer study of their active forms.  
 
The commercially available IAM.PC column utilises the ability of the 
membrane phospholipid phosphatidylcholine to bind the P450s (Pidgeon et 
al., 1991; Scharf et al., 1998). The method developed by Pidgeon et al. in 
1991 (using rat liver microsomes) and the method used by Scharf et. al in 
1998 (using homogenised German cockroach microsomes) have strong 
similarities. Both Pidgeon and Scharf used the same mobile phase to 
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equilibrate and the same Lubrol containing mobile phase to elute. The main 
difference is that Scharf used a 1-step gradient HPLC method to form a 
quicker analytical run, whereas Pidgeon used a 2-step gradient which helped 
to separate the inactive P420 form from the active P450 form. To validate the 
method used by Scharf et al., repetition of their experiments were conducted. 
 
4.4.2.1 Protein recovery and detergent removal methods 
 
The main problems encountered during protein analysis of IAM.PC fractions 
were the relative detergent and protein concentrations. The protein 
containing fractions eluted represent approximately two minutes of the HPLC 
run in one millilitre of mobile phase. This means that the detergent 
concentration is often too high for subsequent protein, gel and enzyme 
analysis (Pidgeon et al., 1991). However, protein concentration is very low, 
as the original microsome starting material had approximately twenty to forty 
milligrams of protein per millilitre but this was split over many 
chromatography fractions. If most of the protein was present in the flow-
through, then this same twenty to forty milligrams is now diluted at least three 
times over these three fractions. In the elution fractions, the total volume will 
be a very small percentage of this total protein content. For this reason it was 
vital that the most effective detergent removal and protein recovery methods 
were investigated and coupled to the analysis series.  
 
The acetone protein precipitation method works on the principle that acetone 
precipitates proteins by reducing the preferred hydrophilic aqueous 
environment surrounding the proteins, whilst leaving the interfering 
components in solution (Pierce Biotechnology Inc., 2004). Once the sample 
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has been centrifuged and the supernatant removed the protein pellet can be 
re-suspended in a smaller volume of buffer compatible with downstream 
analyses. This acts not only to remove interfering substances but also to 
concentrate protein, in one step. Acetone precipitation of mouse liver 
microsomes in PBS (Figure 4.9A) showed good recovery of protein 
compared to the starting material over the full range of molecular weights. 
Acetone precipitation was also as good at concentrating samples in the 
IAM.PC mobile phase A and mobile phase B, as lyophilisation alone (Figure 
4.9B). The obvious advantage of acetone precipitation over lyophilisation is 
the ability to reduce the concentration of some, but unfortunately not all, of 
the interfering substances at the same time as concentrating the protein 
sample. On the basis of these results, the workflow from IAM.PC separation 
of mouse liver microsomes to SDS-PAGE or MALDI MS, was linked by 
acetone precipitation of the chromatography fractions before analysis. 
 
4.4.2.2 Analysis by SDS-PAGE 
 
Initially the IAM.PC fractions were analysed by SDS-PAGE with limited 
success due to protein concentrations below the level of detection; only the 
flow-through fractions showed protein bands using the Coomassie Brilliant 
Blue staining technique (Figure 4.13). Using the silver staining technique, 
protein bands appeared in some of the other IAM.PC fractions, including the 
elution fractions, due to increased sensitivity of the technique. The elution 
fractions showed bands with relative molecular weights of 54.5kDa, 50kDa, 
38kDa and 35.5kDa, all of which were in the linear range of the gel (Figure 
4.13). These bands, however, were also present in some of the flow-through 
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fractions indicating that the column was overloaded or there was a low affinity 
for the phosphatidylcholine chromatography material.  
 
A double banding pattern at approximately 20kDa and 17.5kDa is also 
apparent and these bands are in greater abundance in the elution fractions 
than the flow-through fractions. This indicates good binding efficiency of 
these proteins. 
 
4.4.2.3 Analysis by mass spectrometry 
 
The gel work completed on the IAM.PC fractions provided promising results 
as it showed that only a small portion of the original starting material had 
bound, and that some had been selectively eluted by the increased gradient 
of Lubrol. Unfortunately the small amount of eluted material and detergent 
interference had proven problematic during the identification of the proteins 
visualised. Protein identification was possible for some abundant proteins by 
analysing peptide fragments from trypsin-digested proteins, which cleaves 
the proteins at the C-terminal side of lysine and arginine residues (Olsen et 
al., 2004). The mass-to-charge ratio (m/z) of the peptides in the sample were 
computed by the Mascot search engine, which searches primary sequence 
databases and calculated cleavage sites, based on manually entered search 
parameters (WarpLC version 3.0; BioTools version 3.0). The mass values 
were compared to the SwissProt non-redundant primary sequence database.  
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Mass spectra data of the trypsin digested IAM.PC fraction samples 
(Appendix B) were collated and compared to the mouse liver starting material 
(Chapter 3). Five proteins were identified with MASCOT scores greater than 
45.0 from three or more peptides. The highest MASCOT scores were from 
six peptides of cytochrome b5 producing a score of 464. This protein however 
was seen in all flow-through and eluate fractions, as well as in the starting 
material with scores ranging from 73 to 495. Cytochrome b5 in the starting 
material had the greatest score, which was generated from eight peptides. 
The lowest scores came from the tail end of the flow-through UV peak and 
part of the eluate peak, which were generated from one or two peptides only. 
Altogether this suggests that cytochrome b5 associates with the IAM.PC 
column, it is not enriched and therefore binding may be non-specific. This MS 
methodology is not quantitative though and overloading of the IAM.PC 
column could account for these observations. 
 
Membrane-associated progesterone receptor component 1 is a microsomal 
membrane protein that contains a cytochrome b5 haem-binding domain 
(UniProt Consortium, 2009). This protein was present in the flow-through 
fractions (MASCOT score 117, eight peptides), elution fractions (MASCOT 
score 112, five peptides) and starting material (MASCOT score 259, eleven 
peptides). This indicates, as with cytochrome b5, that the column did not 
enrich for the protein as the score was reduced after column separation. The 
decrease in MASCOT score and number of peptides identified is possibly 
due to the proteins being split across several fractions instead of being 
analysed in the same sample run. 
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Heterogenous nuclear ribonucleoprotein A2/B1 (hnRNP A2 / hnRNP B1) 
forms ribnucleosome complexes with other hnRNP proteins and is involved in 
pre-mRNA processing. As a component of a ribonucleosome the protein is 
predominantly found in the nucleus however the hnRNP A2 isoform can also 
be found in the cytoplasm (UniProt Consortium, 2009).  Interestingly, the 
protein was enriched by the IAM.PC membrane as both the MASCOT score 
and number of peptides identified were higher in the eluate than the starting 
material, and the flow-through did not contain the protein at a detectable 
level. 
 
Splicing factor, arginine/serine-rich 2 (ASF/SF2) is a member of the 
ribonucleosome that interacts with hnRNP A2 / hnRNP B1. ASF/SF2 forms a 
bridge between the 5’- and 3’- splice sites (UniProt Consortium, 2009). This 
member of the ribonucleosome also had a high MASCOT score (123) from 
nine peptides. ASF/SF2 was not identified in the starting material, however, 
two other members of the splicing factor SR family were identified, splicing 
factor arginine/serine-rich 3 and splicing factor arginine/serine-rich 7. Neither 
of these splicing factor proteins were visualised in the flow-through or elution 
fractions. The presence of several members of the splicing factor SR family 
may be an artefact of database searching, where conserved residues within 
the proteins may lead to several identical peptide fragments. The protein 
identified statistically to be the best candidate to be present in the sample is 
dependent on which peptide fragments are detected when analysing the 
different fractions. Proteins that have high homology are more likely to give 
false positive results. Figure 4.14 shows the sequence alignment for the 
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detected members of the splicing factor SR family, indicating that there are 
common residues present in two or three of the proteins. Importantly there 
are many regions where amino acid sequences differ, producing unique 
trypsin digests, allowing for confident MS identification of each isoform. There 
is no obvious functional reason why these two spliceosome proteins, hnRNP 
A2 / hnRNP B1 and SF2, should bind to IAM PC unless they have an 
additional membrane linking role, previously not reported.  
 
 
Figure 4.14 : Amino acid sequence alignment of three of the splicing factor SR 
family highlighting conserved residues between all three proteins (dark grey), 
and those present in two of the three proteins (light grey). 
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Carnitine O-palmitoyltransferase 2, mitochondrial precursor is a protein found 
in the mitochondrial membrane and is responsible for transfer of palmitoyl to 
L-carnitine (UniProt Consortium, 2009). This protein had a MASCOT score of 
95 from three peptides. It was also present in the starting material but with a 
lower score of 53 however the score was generated from eleven peptides. 
Binding of carnitine O-palmitoyltransferase 2 might be expected due to the 
close structural similarity of IAM.PC functional moieties to palmitoyl.  
 
No P450s were detected in the IAM.PC elution or flow-through fractions, 
compared to 12 in the starting material. This suggests the low abundance 
P450s are being lost by the dilution effect of large fraction volumes or by the 
need for multiple steps to remove detergent and prepare the samples for 
analysis.  
 
These results show that either the chromatography conditions are not 
allowing good separation, as visualised by Pidgeon et al. (1991) and Scharff 
et al. (1998), possibly indicating that the proteomic analytical techniques are 
not compatible due to trace amounts of detergent causing interference. 
However, the results do indicate that a component of the ribosonucleosome 
complex (containing hnRNP A2/hnRNP B1 and ASF/SF2) interacts with the 
column. The binding of membrane-associated progesterone receptor 
component 1 may be explained by its known interaction with cytochrome b5, 
which is known to elute along with P450 using the IAM.PC column method 
(Pidgeon et al., 1991). 
  
 
 
CHAPTER FIVE 
Inhibitor-sepharose chromatography 
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5.0 Inhibitor-sepharose chromatography 
5.1 Ketoconazole affinity chromatography 
 
It is possible to chemically immobilise known inhibitors of the P450s onto 
solid supports to capture the proteins specifically and to enrich for P450s. 
Ketoconazole is an anti-fungal drug which inhibits P450s (Ekroos and 
Sjogren, 2006). Figure 5.1 shows ligand-bound CYP3A4 and the associated 
structural changes caused by direct ligand binding to the haem moiety within 
the P450 molecule. It was hypothesised that due to ketoconazole binding 
directly to the haem moiety of the P450 structure, which all P450’s have in 
common, that this inhibitor would make a good immobilisation reagent for 
inhibitor-bead studies. 
 
 
Figure 5.1: Structural changes of CYP3A4 protein when in complex with 
ketoconazole.  Ligand-bound CYP3A4 (dark grey) is superimposed on ligand-
free CYP3A4 (light grey), with F-G helices in dark red, I helix in dark green, and 
the C-terminal loop in dark blue. Orange arrows indicate CYP3A4 structure 
shifting after ligand binding, with helices and loop of ligand-free CYP3A4 in light 
colours. Modified from Ekroos and Sjogren (2006).  
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STITCH (search tool for interactions of chemicals) integrates compound 
information from PubChem, experimental data, database searches, and text 
mining (co-occurrence within MEDLINE and OMIM), and was used to identify 
a network of ketoconazole-protein interactions (Kuhn et al., 2008). This 
information was then combined with data from its sister site, STRING (search 
tool for retrieval of interacting genes/proteins), to provide protein-protein 
interaction networks (Figure 5.2) (Jensen et al., 2009).  
 
The chemical-protein interaction network produced by STITCH (Figure 5.2) 
shows ketoconazole to directly inhibit citron, tumour necrosis factor, 
gonadotropin releasing hormone 1, pro-opiomelanocortin-alpha, sex 
hormone binding globulin, cytochrome P450 family 51 (CYP51) and 
succinate dehydrogenase complex, subunit B, iron sulphur in humans. 
Ketoconazole not only inhibits CYP51 but Figure 5.3 also shows there is a 
binding interaction. This may indicate that upon ketoconazole binding, 
conformational changes occur in the enzyme, inhibiting CYP51 activity, or 
that the compound binds CYP51 with such strong affinity that it is not 
released and so prevents further CYP51 activity. 
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Figure 5.2: Ketoconazole-protein interaction network produced by STRING. Pill-shaped nodes represent compounds and spherical nodes represent 
proteins. Green arrows indicate activation of the arrowed protein/compound upon interaction. Red lines indicate inhibition of the protein at the T-bar. Blue 
arrows indicate a binding interaction. Purple arrows indicate catalysis of the arrowed compound. The black arrows indicate a reaction between two 
compounds. The thickness of the grey lines connecting proteins/compounds represents the strength of association (Kuhn et al., 2008).
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Figure 5.3: Ribbon model of substrate bound CYP51 from C. albicans (pink), 
with haem binding partner (Ji et al., 2000) 
 
 
 
Ji et. al (2000) modelled the tertiary structure of CYP51 (Figure 5.3) from 
Candida albicans to explain experimental evidence, and provide greater 
understanding about CYP51 and the interaction with azole antifungal agents. 
Once a common conformation and orientation of the azoles during CYP51 
interaction had been established using energy difference values (Figure 5.5), 
itraconazole was used as an example inhibitor to model active site 
interactions (Figure 5.4). The chlorinated phenyl group interacts with the 
hydrophobic binding cleft surrounding the haem moiety (highlighted in Figure 
5.5), with the imidazole ring interacting towards the haem moiety, a common 
feature in all fourteen azoles studied. Lamb et. al (1999) used the information 
gained from this research as a basis to further study anti-fungals. 
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Figure 5.4: Docking of the azole inhibitor itraconazole in CYP51 from C. 
albicans. CYP51 amino acid residues labelled and highlighted in red, 
itraconazole highlighted in green and heam group highlighted in yellow (Ji et al., 
2000) 
 
 
CYP51 is a target for the azole antifungals, but the drug has cross-reactivity 
with human CYP51, showing that ketoconazole had poor specificity for the 
fungal P450. This implies that ketoconazole may be appropriate for P450 
targeting as affinity chromatography capture material, and suggests further 
investigation is required. 
 
The information gained from the combination of STITCH and associated 
literature searches in the CYP51 example, illustrates the value of online 
search tools as an addition to proteomic analysis workflow, facilitating post-
chromatographic data processing, and helping to elucidate interactions 
between proteins and the chromatographic material. 
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Figure 5.5: Structures of azole antifungals (A) superimposed on basis of pharmacophoric confirmation during interaction with CYP51 (B) (Ji et al., 2000) 
A: 
A:  
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5.1.1 Chemical synthesis of the ketoconazole analogue, ICT-5074 
An analogue of ketoconazole (ICT-5074) was synthesized by Dr Fanzhi Kong 
of the Institute of Cancer Therapeutics at the University of Bradford (Figure 
5.6-Figure 5.8). The analogue included an ethylamine group attached to the 
non-functional end of the original ketoconazole anti-fungal compound 
(purchased from Cypex), to allow immobilisation to epoxy-activated 
sepharose 6B beads.   
 
5.1.2 Aims of chapter 
This chapter will focus on investigating the sample and analytical conditions 
required to develop an affinity chromatography method using a ketoconazole 
analogue. A range of proteomic techniques will be used to analyse samples 
and determine limits of detection among the assays used, investigating 
variable factors that may influence accurate detection. It is predicted that due 
to ketoconazole interacting with the common haem centre of a number of 
P450s, as discussed in Section 1.5, when at high concentrations present on 
affinity beads, it would act as a general P450 inhibitor. Once bound 
alterations competitive elution using free imidazole and ketoconazole will 
allow release of the specifically bound proteins. 
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Figure 5.6: Structure of the ketoconazole analogue ICT-5074 
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Figure 5.7: ICT-5074 chemical synthesis pathway. (1) Ketoconazole starting material was 
incubated at 100°C for 5 hours with potassium hydroxide (KOH) in dimethyl sulfoxide 
(DMSO). (2) 1-(4-(((2R,4S)-2-((1H-imidazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-
4-yl)methoxy) phenyl) piperazine was incubated at room temperature for 24 hours with 3-
(tert-butoxylcarbonylamino)propanoic acid and 1-Ethyl-3-(3-dimethyl aminopropyl) 
carbodiimide and extracted with dichloromethane. (3) Tert-butyl 12-(4-(4-(((2R,4S)-2-((1H-
imidazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-
yl)-12-oxodo decylcarbamate was incubated at room temperature for 3 hours with 
trifluoroacetic acid and dichloromethane. (4) The 1-(4-(4-(((2R,4S)-2-((1H-imidazol-1-
yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy) phenyl)piperazin-1-yl)-12-
aminododecan-1-one product was purified by silica gel chromatography. Yield at each stage 
of the chemical synthesis pathway is indicated as a percentage of the previous step. 
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Figure 5.8: 
1
H NMR of ICT-5074 
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5.2 Materials and methods 
 
5.2.1 Reagents and samples 
CYP1A2 bactosomes (10mg/ml total protein; 9.3nmol/ml CYP1A2; 5.4% 
CYP1A2 of total protein) and ketoconazole were purchased from Cypex. 
Epoxy-activated sepharose 6B was purchased from GE Healthcare. 
Ethanolamine, glycine and imidazole were purchased from Sigma-Aldrich. 
Instant Blue was purchased from Expedeon (Cambridgeshire, UK). ICT-5074 
was prepared by Dr Fanzhi Kong (ICT) (Figure 5.7). For information on 
mouse liver microsome preparation refer to Section 3.2.2 and all other 
materials refer to Section 3.2.1.  
 
5.2.2 Affinity chromatography 
The inhibitor bead affinity chromatography methodology involved 
immobilisation of P450 inhibitor to a solid epoxy-activated sepharose bead 
support. Figure 5.9 shows the general workflow of techniques used in 
processing a mouse liver microsome sample by inhibitor affinity bead 
chromatography, and the post-chromatography sample preparation and 
analytical techniques used. 
 
ICT-5074 was immobilised on epoxy-activated sepharose 6B beads to 
specifically target P450s by affinity purification under a variety of conditions 
summarised in Table 5.1. 
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Figure 5.9: Methodology overview for inhibitor bead chromatography 
experiments 
 
 
5.2.2.1 Inhibitor analogue stability studies (Analytical HPLC)  
 
 A HPLC method was developed using a 15cm x 4.6mm C18 column on a 
Waters 515 pump system, 717 autosampler and 916 photodiode array 
detector system equilibrated with nine parts 70% methanol, 1% formate, to 
one part 5% methanol, 1% formate. ICT-5074 (5µl 10mg/ml in methanol) was 
mixed with 70% methanol, 1% formate (500µl) at room temperature. Sample 
(10µl) was applied and separation of analytes achieved using isocratic 
elution in this solvent at a flow rate of 1ml/min.  
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Experiment 
identification 
Immobilisation 
blocking buffer 
Volume of 
beads 
(packed,µl) 
Volume of 
mouse liver 
microsomes 
(µl) 
Micro Bio-
spin 
column 
packing 
NADPH 
present in 
incubation 
buffer 
Chromatography elution conditions Analytical 
techniques 
Imidazole Ketoconazole 
NADPH 
removal 
Experiment I a 
(Section 5.2.2.3) 
Ethanolamine 250 100      
LC-MS 
Experiment I b 
(Section 5.2.2.3) 
Glycine 250 100      
Experiment I c 
(Section 5.2.2.3) 
Glycine 250 100      
Experiment II a 
(Section 5.2.2.4) 
Glycine 250 100      
SDS, 
(gel) LC-
MS Experiment II b 
(Section 5.2.2.4) 
Glycine 250 100      
Experiment II c 
(Section 5.2.2.4) 
Glycine 250 100      
Experiment III a 
(Section 5.2.2.5) 
Glycine 500 200      
LC-MS; 
SDS, 
(gel) LC-
MS; WB 
Experiment III b 
(Section 5.2.2.5) 
Glycine 500 200      
 
Table 5.1: Summary of affinity chromatography conditions using ICT-5074 inhibitor beads. Direct HPLC-MALDI MS of fractions (LC-MS); SDS-PAGE 
(SDS); In-gel trypsin digestion for  MS analysis ((gel) LC-MS); Western blot analysis of SDS-PAGE (WB).
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5.2.2.2 Coupling to epoxy-activated sepharose beads  
 
Epoxy-activated sepharose 6B beads were hydrated in 8ml of HPLC grade 
water for 15 minutes. The beads were then washed several times, the excess 
water removed. Hydration of 0.5g starting material expanded to 
approximately 3.5ml of swollen beads. The swollen beads were incubated 
with 100nM inhibitor solution at 36.8°C for 18 hours. The inhibitor-beads, 
along with an additional 3.5ml of swollen beads for control-bead studies, 
were then incubated with 1ml 1M ethanolamine at 45°C for 4 hours or 0.2M 
glycine-sodium hydroxide buffer, pH 10.6 at 4°C overnight (Table 5.1). This 
blocked all of the remaining epoxy activated groups that had not bound 
inhibitor in the coupling reaction, or all of sites in the case of the control-
beads. Alternating sodium acetate/Tris-hydrochloric acid washes were used 
to remove unbound ligand and blocking agent. The beads were stored in 
25mM ammonium bicarbonate, 10% acetonitrile, 1% sodium azide at 4°C for 
future chromatography experiments. 
 
5.2.2.3 Inhibitor-bead chromatography experiment I  
 
ICT-5074-sepharose and control beads (250µl packed volume) (Section 
5.2.2.2) were each equilibrated with 25mM ammonium bicarbonate, 10% 
acetonitrile, and 0.15M sodium chloride (Equilibration buffer). Mouse liver 
microsome sample (100μl approximately 30mg/ml) was added to ICT-5074-
sepharose beads and control beads, and incubated at 4°C for 2 hours on a 
carousel. The bead samples were centrifuged at 14,000 x g for 5 minutes at 
4°C and the supernatant decanted and collected (labelled flow-through 1, 
FT1). Equilibration buffer (0.5ml) was added, the solution mixed and the 
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beads left to settle by gravity for 10 minutes. The supernatant was decanted 
to FT1. Equilibration buffer (1ml) was added and mixed as before, with the 
supernatant this time being decanted and collected to flow-through 2 (FT2). 
Each set of beads was washed further with 4 volumes of equilibration buffer 
but the supernatant was discarded to waste. Imidazole (1M) in equilibration 
buffer (0.5ml) was added, the solution mixed and the beads left to settle by 
gravity for 10 minutes. The supernatant was decanted to elution 1 (E1). 
Imidazole buffer (1ml) was added and mixed as before, with the supernatant 
being decanted to E1. Imidazole buffer (two volumes of 1ml) was added and 
mixed as before but this time being decanted and collected to elution 2 (E2). 
The beads were washed further with 4 volumes of equilibration buffer and the 
supernatant was discarded to waste. Ketoconazole (100µM) in equilibration 
buffer (0.5ml) was added, the solution mixed and the beads left to settle by 
gravity for 10 minutes. The supernatant was decanted to elution 3 (E3). 
Ketoconazole buffer (0.5ml) was added and mixed as before, with the 
supernatant being decanted to E3. Ketoconazole buffer (two volumes of 1ml) 
was added and mixed as before but this time being decanted and collected to 
elution 4 (E4). The beads were washed further with 4 volumes of equilibration 
buffer and the supernatant discarded to waste. The remaining bead samples 
were stored in a one-to-one ratio of beads to equilibration buffer with 1% 
sodium azide, and stored at 4°C.  
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5.2.2.4 Inhibitor-bead chromatography experiment II 
 
The affinity chromatography method (Section 5.2.2.3) was altered to enhance 
the efficiency of sample binding and elution collection. The beads were 
incubated with mouse liver microsomes and equilibration buffer containing 
NADPH (20mM). When the sample was centrifuged after the 2 hour 
incubation period, the supernatant was decanted to FT1. At this point the 
bead pellet was resuspended (1:1) in equilibration buffer containing NADPH 
(20mM). This bead solution was transferred to a Micro Bio-spin centrifugal 
column in a 2.2ml eppendorf tube, and the apparatus centrifuged for 2 
minutes, 1000 x g at 4°C. The eluate drained through the filter in the column 
leaving the beads packed in the Micro Bio-spin apparatus. The eluate was 
transferred to FT1 and a further 250µl equilibration buffer containing NADPH 
(20mM) was added to the apparatus and processed in the same way. A final 
500µl was added and also transferred to FT1. At this point equilibration buffer 
only was added, without NADPH, using volumes equivalent to those used in 
Section 5.2.2.3, and collected into elution 5 (E5). The imidazole elution was 
performed in the same manner using the Micro Bio-spin column and 
equivalent volumes to those used in Section 5.2.2.3. The ketoconazole 
elution step was omitted from the chromatography method. 
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5.2.2.5 Inhibitor-bead chromatography experiment III 
 
The inhibitor bead chromatography (Section 5.2.2.4) was repeated except 
using double the quantities of beads, microsomes and buffers at each step.  
 
5.2.3 Chromatography fraction analysis 
For details on sample preparation for trypsin digestion, HPLC separation and 
MALDI MS analysis refer to Section 3.2.6. 
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5.3 Results 
5.3.1 P450 activity assay 
During inhibitor-bead chromatography experiments detergents are not used 
so the previously identified interference with the EROD assay by Lubrol 
(Section 4.3.2) was not observed. Unfortunately it was not possible to attain 
positive signals for the elution samples post-chromatography using the 
EROD assay. This is speculated to be due to one of several reasons. One 
hypothesis is that the original P450 signal has been split amongst the elution 
fractions or that the eluted material has been diluted by the elution buffer to a 
concentration that is below the level of detection. P450s may have been 
separated in different fractions from NADPH reductase, which would also 
have a negative effect on P450 activity. Another possibility is that the NAP-5 
desalting process and subsequent evaporation to concentrate the protein to a 
detectable level, has resulted in losses leading to decreased activity of the 
enzyme. By the nature of this chromatography procedure, a P450 inhibitor is 
used to capture and elute the P450s. This may mean that P450 activity in 
elution fractions has been inhibited by the free inhibitor, although it does not 
account for lack of activity in flow-through peaks if some CYP1 enzymes 
were not bound due to lack of specificity or over-loading. 
 
5.3.2 ICT-5074 analogue stability studies 
If sufficient material can be synthesized, it is important to investigate the 
stability of the inhibitors over time and at a range of pH values. This is 
because during the coupling and chromatography stages, which lasts 3 days, 
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the pH value changes from pH 4.0 during the acid wash after coupling, to pH 
10.6 of the equilibration buffer (Section 5.2.2.2). 
 
Methods to determine the solubility and stability of the ICT-5074 analogue 
showed it to have increased solubility in methanol and the aqueous-based 
affinity bead coupling buffer compared to ketoconazole, and good stability 
over a long time period and wide pH range. Solubility was determined by 
experimenting with various concentrations of methanol, ethanol, and PBS, as 
well as a mixture of each. ICT-5074 was initially solubilised to form a 
concentrated solution in methanol (100mg/ml), and it was possible to achieve 
working solutions up to 50% aqueous solution (50mg/ml) before compound 
precipitation. At lower concentrations of ICT-5074 (less than 10mg/ml) it is 
possible to increase the aqueous content of the buffer.  
 
The chromatogram of ICT-5074 (Figure 5.10) from 0 to 400 minutes shows 
good reproducibility and stability at pH 10.5. Similarly, the chromatograms 
produced after incubating ICT-5074 at pH 2, 4, 7 and 8 all showed good peak 
area, peak intensity and retention time reproducibility, with chromatograms 
similar to that shown in Figure 5.10. Figure 5.11 gives a comparison of peak 
area over time at the five different pH values. 
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Figure 5.10: Chromatogram of ICT-5074 (pH 10) at 265nm at 0, 68, 140, 208, 273, 339, and 
405 minute time points using an automated method set with samples kept at room 
temperature. 
 
 
 
 
Figure 5.11: Comparison of peak area versus time of ICT-5074 measured at 265nm at 
five different pH values over a 0-414 minute time period. Comparison made by the 
analysis of the percentage of peak area compared to the original starting value 
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5.3.3 Inhibitor affinity chromatography 
5.3.3.1 Inhibitor-bead chromatography experiment I 
 
ICT-5074 (pale yellow solution) was attached to epoxy-activated sepharose 
beads and all the remaining binding sites were blocked with ethanolamine. 
Control beads were produced at the same time where all sites were blocked 
with ethanolamine in the absence of ICT-5074. There was a clear colour 
difference between the ICT-5074 beads and control beads, with the ICT-5074 
beads having a pale yellow colour similar to the concentrated ICT-5074 
suspension, in comparison to the white appearance of the control beads. 
 
Initially, after incubation of both control and ICT-5074 bead samples with liver 
microsomes, fractions produced by the wash steps and elution steps 
(competitive imidazole and ketoconazole) were analysed via LC-MALDI. No 
P450s were identified but 99 other microsomal proteins were detected, with 
no known binding associations to ketoconazole. Comparisons were also 
made to the protein identifications from the mouse liver microsome starting 
material (Chapter 3). This led to work investigating non-specific binding of 
proteins to the beads (Chapter 7) and to changes in immobilisation protocol 
to include a glycine blocking buffer instead of an ethanolamine blocking 
buffer. SDS PAGE analysis was not performed on these fractions. 
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Protein  Accession 
(Mouse) 
MW 
(kDa) 
Inhibitor-bead 
chromatography 
experiment II c 
Inhibitor-bead 
chromatography 
experiment III a1 
Inhibitor-bead 
chromatography 
experiment III a2 
Inhibitor-bead 
chromatography 
experiment III 
b1 
Inhibitor-bead 
chromatography 
experiment III 
b2 
Starting material 
Scr #P Scr #P Scr Scr #P #P Scr #P Scr   #P 
26S proteasome non-ATPase 
regulatory subunit 9 
PSMD9 
24.876 - - - - 61 4 
- - 103 4 - - 
40S ribosomal protein S19 RS19 16.076 - - - - 122 4 - - 54 4 145 6 
60S ribosomal protein L13 RL13 24.348 - - - - 48 7 - - 61 3 - - 
60S ribosomal protein L23a RL23A 17.684 
- - - - - - - - 136 5 - - 
78 kDa glucose-regulated protein GRP78 72.378 
- - 
52 6 121 12 156 5 509 17 250 14 
Actin, cytoplasmic 1 ACTB 42.052 - - 63 7 313 14 - - 203 7 - - 
Apolipoprotein E APOE 35.901 - - - - 53 7 
- - 154 7 - - 
ATP synthase subunit beta ATPB 56.266 
132 5 - - 
323 14 305 12 176 8 369 14 
ATP synthase subunit d ATP5H 18.795 
- - - - 
109 5 - - 155 5 59 5 
ATP synthase-coupling factor 6 ATP5J 12.489 
- - - - 
494 10 - - 319 6 - - 
Betaine--homocysteine S-
methyltransferase 1 
BHMT1 
44.992 
- - 77 5 
440 18 
109 8 1557 38 326 12 
Betaine--homocysteine S-
methyltransferase 2 
BHMT2 
40.416 
- - - - 
49 3 
- - 259 14 102 12 
Calreticulin CALR 47.965 
- - 51 4 - - 134 4 177 10 47 3 
Calumenin CALU 37.041 
- - - - 
- - 76 4 812 15 - - 
Carboxylesterase 3 CES3 62.034 
- - 78 5 
- - - - 173 8 71 6 
Clathrin light chain A CLCA 25.598 
- - - - - - - - 300 12 - - 
Cytochrome b5 CYB5 15.236 
- - - - 
300 9 109 4 646 12 163 6 
Cytochrome c oxidase subunit 5A COX5A 16.020 
160 6 - - 
107 7 - - 374 9 268 5 
Cytochrome c oxidase subunit 6B1 CX6B1 10.293 
- - - - 
179 6 - - 208 8 90 4 
Elongation factor 1-alpha 1 EF1A1 50.424 
- - - - - - - - 71 3 - - 
Endoplasmin ENPL 92.704 
- - 58 7 
- - - - 120 6 168 9 
Hemoglobin subunit alpha HBA 15.132 
- - - - 
186 4 
- - 855 16 253 6 
Hemoglobin subunit beta-1 HBB1 15.944 
- - - - 
147 5 
- - 376 10 518 9 
Hemoglobin subunit beta-2 HBB2 15.982 
- - - - 
81 3 - - 552 15 335 9 
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Table 5.2: Mass spectrometry data for imidazole elution (E1) fractions from ICT-5074 affinity chromatography experiments. List of proteins identified 
in at least 2 E1 fractions, a minimum of 3 peptides, MASCOT score ≥45. Inhibitor-bead chromatography experiment II (Section 5.2.2.4) SDS-PAGE sample 
separation, in-gel trypsin digestion. Inhibitor-bead chromatography experiment III a1 (Section 5.2.2.5) SDS-PAGE sample separation, in-gel trypsin digestion 
equivalent to 1ml of the 2ml sample. Inhibitor-bead chromatography experiment III a2 whole 2ml fraction trypsin digested. Inhibitor-bead chromatography 
experiment III b1 SDS-PAGE sample separation, in-gel trypsin digestion equivalent to 1ml of the 2ml sample. Inhibitor-bead chromatography experiment III b2 
whole 2ml sample trypsin digested. (Appendix C) 
Protein  Accession 
(Mouse) 
MW 
(kDa) 
Inhibitor-bead 
chromatography 
experiment II c 
Inhibitor-bead 
chromatography 
experiment III a1 
Inhibitor-bead 
chromatography 
experiment III a2 
Inhibitor-bead 
chromatography 
experiment III 
b1 
Inhibitor-bead 
chromatography 
experiment III 
b2 
Starting material 
Scr #P Scr #P Scr #P Scr #P Scr #P Scr #P 
Liver carboxylesterase 31 EST31 63.677 
83 4 - - 
- - - - 144 8 81 5 
Liver carboxylesterase N ESTN 61.133 
- - - - 
- - 54 6 141 5 - - 
Membrane-associated progesterone 
receptor component 1 
PGRC1 
21.681 
96 3 - - 
182 4 
- - 264 8 238 6 
Myosin light polypeptide 6 MYL6 17.090 
- - - - 
210 8 
- - 59 4 - - 
NADH dehydrogenase 
[ubiquinone] iron-sulfur protein 4 
NDUS4 
19.829 
- - - - 
84 4 
- - 58 5 - - 
Nucleobindin-1 precursor 
(CALNUC) 
NUCB1 
53.376 
- - 112 8 
55 8 
686 23 1534 42 - - 
Peroxiredoxin-1 PRDX1 22.162 
- - - - 
46 4 51 3 298 13 - - 
Peroxiredoxin-6 PRDX6 24.969 
- - - - 
119 6 - - 366 13 72 5 
Protein disulfide-isomerase PDIA1 57.108 
- - 357 15 
197 7 1181 30 1144 41 132 7 
S-adenosylmethionine synthetase 
isoform type-1 
METK1 
43.481 
- - - - 
126 5 
99 4 1036 23 129 5 
Superoxide dismutase [Cu-Zn] SODC 16.104 
- - - - 
53 4 - - 252 3 59 3 
Tubulin beta-2C chain TBB2C 50.255 
- - - - 
51 7 - - 116 8 - - 
Vitamin D-binding protein VTDB 53.565 
- - - - 
- - 66 5 1142 33 - - 
 170 
 
 
5.3.3.2 Inhibitor-bead chromatography experiment II 
 
In experiment II, SDS PAGE was performed before LC MALDI MS analysis. 
Banding patterns of the fractions produced by inhibitor-bead chromatography 
experiment II using ICT-5074 beads and glycine control beads differed in the 
imidazole elution (E1) fractions (Figure 5.13, lanes 5 and 8). ICT-5074 
chromatography fractions showed several bands throughout the full 
molecular weight range of the gel, but bands between the 40-60 kDa relative 
molecular weight range were the most intense. The band between 45-55kDa 
in the imidazole elution fraction led to identification of four proteins (Table 
5.2), ATP synthase subunit beta (MASCOT score 132, 5 peptides), 
cytochrome C oxidase subunit 5A (MASCOT score 160, 6 peptides), liver 
carboxylesterase 31 (MASCOT score 83, 4 peptides), and membrane-
associated progesterone receptor component 1 (MASCOT score 96, 3 
peptides).  A comparison of the HPLC chromatograms shows the different 
profiles produced before MS analysis (Figure 5.12). 
 
 171 
 
 
 
Figure 5.12: HPLC chromatograms of HPLC fraction samples in comparison to on-
bead digests. (A) Flow-through, (B) NADPH-removal elution, (C) Imidazole elution, (D) on-
bead trypsin digests using chromatography protocol from Section 5.2.2.4 
 
 
 
 
Figure 5.13: ICT-5074 bead affinity chromatography (experiment II) with accompanying 
glycine control beads (Section 5.2.2.4). Lane positions are labelled above gel and Novex 
relative molecular weight markers labelled on left of gel. Lane 3 contains mouse liver 
microsome starting material. Lanes 4-6 contain flow-through (FT1), imidazole elution (E1) 
and ketoconazole elution (E3) of control bead chromatography, respectively. Lanes 7-9 
contain the equivalent FT1, E1 and E3 fractions of ICT-5074 bead chromatography, 
respectively.  
A B 
C D 
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5.3.3.3 Inhibitor-bead chromatography experiment III 
Affinity chromatography using ICT-5074 and control beads was repeated 
using Micro Bio-spin columns (rather than suspension, centrifugation and re-
suspension with sequential buffer changes) and increased volumes of all 
chromatography components in an attempt to increase P450 binding and 
reduce binding of non-specific proteins. The fractions were then split for LC 
MALDI and SDS PAGE analysis. SDS-PAGE (Figure 5.14) revealed differing 
profiles between the ICT-5074 and control beads. The ICT-5074 elution 
fractions E1 and E5 (lanes 5-6) show strong bands using Coomassie Brilliant 
Blue stain between the 40-60kDa relative molecular weight range. The 
control bead elution fractions E1 and E5 (lanes 8-9) did not show any strong 
bands using Coomassie Brilliant Blue stain.  
 
Distortion by the flow-through fractions affected the clarity of gel separation 
and staining and so the chromatography was repeated, running only the 
elution samples, in the absence of the flow through fractions (Figure 5.15). 
Instant Blue stain was used, which is a Coomassie-based dye (Section 
3.2.5.3), as the manufacturers report it to have increased sensitivity for 
protein binding compared to Coomassie dye alone. The bands from the 
elution profiles of the control beads were low compared to ICT-5074 beads.
 173 
 
 
 
Figure 5.14: ICT-5074 bead affinity chromatography (experiment III) with 
accompanying glycine control beads (Section 5.2.2.5). Coomassie Brilliant blue stained 
gel. Lane positions are labelled above gel and Novex relative molecular weight markers 
labelled on left of gel. Lane 3 contains mouse liver microsome starting material. Lanes 4-6 
contain flow-through (FT1), NADPH removal elution (E5) and imidazole elution (E1) of ICT-
5074 bead chromatography, respectively. Lanes 7-9 contain FT1, E5 and E1 of control bead 
chromatography, respectively. 
 
 
 
 
 
 
Figure 5.15: ICT-5074 bead affinity chromatography (experiment III) elution profiles 
with accompanying glycine control beads (Section 5.2.2.5). Instant Blue stained gel. 
Lane positions are labelled above gel and Novex relative molecular weight markers labelled 
on left of gel. Lanes 2-3 contain NADPH removal elution (E5) and imidazole elution (E1) of 
control bead chromatography, respectively. Lanes 4-5 contain E5 and E1 of ICT-5074 bead 
chromatography, respectively.  
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Western blot analysis of the fractions showed some of the CYP2E1 present 
in FT1 (Figure 5.16). CYP2E1 was not at a detectable level in the elution 
fractions or in the heat-treated beads. This may indicate that CYP2E1 is still 
present on the beads or that ICT-5074 does not recognise CYP2E1.  
 
A summary of the mass spectrometry data generated from the in-gel trypsin 
digestion of the bands of interest (Figure 5.14, lanes 5-6, 40-60kDa relative 
molecular weight range) showed a number of proteins to be enriched using 
these elution conditions (Table 5 2; Table 5.3). Enrichment was estimated 
based on an increase in MASCOT score and peptide number as previously 
discussed, because the MS data here is only qualitative. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16: Western blot analysis of ICT-5074 bead affinity 
chromatography fractions (experiment III, Section 5.2.2.5). (A) Lane 1 
contains mouse liver microsomes starting material. Lane 2 contains flow-through 
(FT1) of ICT-5074 beads (a) and accompanying glycine control beads (b). (B) 
Lane 3 contains NADPH removal elution from ICT-5074 beads (a) and 
accompanying glycine control beads (b). (C) Lane 4 contains imidazole elution 
from ICT-5074 beads (a) and accompanying glycine control beads (b). (D) Lane 
5 contains heat-treated ICT-5074 beads (a) and accompanying glycine control 
beads (b). 
  
A 
1 2a 2b 
B 
1 3a 3b 
C 
1 4a 4b 
D 
1 5a 5b 
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From imidazole elution and subsequent separation by SDS PAGE, 8 and 11  
proteins were detected (Experiment III a1 and III b1 respectively). Experiment 
III a1 identified three proteins (Actin, cytoplasmic 1; Nucleobindin-1 
precursor; Protein disulphide-isomerase) that were enriched. Experiment III 
b1 identified seven proteins (Calreticulin; Calumenin; Liver carboxylesterase 
N; Nucleobindin-1 precursor; Peroxiredoxin-1; Protein disulphide-isomerase; 
Vitamin D-binding protein) that were enriched.  
 
From NADPH-removal elution and subsequent separation by SDS PAGE, 13 
and 10 proteins were detected (Experiment III a1 and III b1 respectively). 
Experiment III a1 identified eight proteins (Actin, cytoplasmic 1; ATP 
synthase subunit beta; Calreticulin; Liver carboxylesterase 22 precursor; 
NADPH-cytochrome P450 reductase; Nucleobindin-1 precursor; 
Peroxiredoxin-1; Protein disulphide-isomerase) that were enriched. 
Experiment III b1 identified eight proteins (3-hydroxyanthranilate 3,4-
dioxygenase; ATP synthase subunit beta; Betaine-homocysteine S-
methyltransferase 1; Glucosidase 2 subunit beta; Liver carboxylesterase 22 
precursor; Liver carboxylesterase N precursor; Nucleobindin-1 precursor;  
Protein disulphide-isomerase) that were enriched.  
 
The inhibitor-bead chromatography experiment III procedure was repeated, 
however the post-chromatography analysis was altered so that the whole 
fraction was committed to direct trypsin digestion and mass spectrometry 
analysis, thereby increasing signal strength and identification of more 
proteins. In both Experiments III a2 and III b2, 16 proteins were identified as 
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being enriched in the NADPH elution compared to the eight proteins in the 
previous in-gel digest method. Nine proteins that were identified as being 
enriched were common with the previous affinity chromatography run (Table 
5.3) using the in-gel digestion method. These proteins were Actin 
cytoplasmic 1, ATP synthase subunit beta, Betaine-homocysteine S-
methyltransferase 1, Calreticulin, Glucosidase 2 subunit beta, Liver 
carboxylesterase N precursor, Nucleobindin-1 precursor, Peroxiredoxin-1, 
and Protein disulphide-isomerase. The MASCOT scores of Actin cytoplasmic 
1, Betaine-homocysteine S-methyltransferase 1, Glucosidase 2 subunit beta, 
Nucleobindin-1 precursor, Peroxiredoxin-1, and Protein disulphide-isomerase 
proteins were increased up to approximately five-fold when committing the 
whole fraction to trypsin digestion compared to in-gel trypsin digestion using 
sample volumes equivalent to half the fraction. CYP4F3 was detected in the 
NADPH removal elution fraction, and was not found to be present in the 
starting material.  
 
From imidazole elution, 27 and 37 proteins (Experiment III a2 and b2) were 
detected (Table 5 2). Experiment III a2 identified 14 proteins that were 
enriched and experiment III b2 identified 31 proteins that were enriched. All 
of the proteins enriched in Experiments III a1 and III b1 were also enriched in 
Experiments III a2 and b2. Overall the number of proteins increased in both 
of the elution fractions from the previous in-gel digest method, imidazole 
elution increased approximately 3-fold and NADPH removal elution increased 
approximately 7-fold.  
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Protein  Accession 
(Mouse) 
MW 
(kDa) 
Inhibitor-bead 
chromatography 
experiment III a1 
Inhibitor-bead 
chromatography 
experiment III a2 
Inhibitor-bead 
chromatography 
experiment III 
b1 
Inhibitor-bead 
chromatography 
experiment III 
b2 
Starting material 
Scr #P Scr #P Scr #P Scr #P Scr #P 
3-hydroxyanthranilate 3,4-dioxygenase 3HAO 32.783 - - - - 46 3 76 7 - - 
40S ribosomal protein S19 RS19 16.076 - - 58 4 - - - - 145 6 
40S ribosomal protein S28 RS28 7.893 - - - - - - 74 4 - - 
60S acidic ribosomal protein P2 RLA2 11.643 - - - - - - 78 3 - - 
78 kDa glucose-regulated protein GRP78 72.491 277 14 171 12 - - 247 16 250 14 
Actin, cytoplasmic 1 ACTB 41.710 108 7 182 9 - - - - - - 
ATP synthase subunit alpha ATPA 59.716 - - 121 6 - - - - 328 15 
ATP synthase subunit beta ATPB 56.265 585 19 110 9 440 15 210 9 369 14 
ATP synthase-coupling factor 6 ATP5J 12.489 - - 333 6 - - 115 5 - - 
Betaine--homocysteine S-
methyltransferase 1 
BHMT1 45.448 129 5 667 21 614 13 1281 37 
326 12 
Betaine--homocysteine S-
methyltransferase 2 
BHMT2 40.415 - - 48 4 - - 173 7 
102 12 
Calreticulin CALR 48.136 114 4 75 5 117 3 73 5 47 3 
Calumenin CALU 37.155 - - - - - - 291 7 - - 
Carboxylesterase 3 CES3 62.034 145 6 48 4 - - 84 5 71 6 
Cytochrome b5 CYB5 15.232 - - 255 8 - - 210 6 163 6 
Cytochrome c oxidase subunit VIb 
isoform 1 
CX6B1 10.065 - - 285 8 - - - - 
90 4 
Cytochrome P450 4F3 CP4F3 59.803 - - - - - - 46 3 - - 
Dihydrolipoyllysine-residue 
succinyltransferase component of 2-
oxoglutarate dehydrogenase complex 
ODO2 48.964 - - 51 7 - - - - 
- - 
Fatty acid-binding protein, liver (L-FABP) FABPL 14.237 - - 51 6 - - - - - - 
Ferritin light chain 1 FRIL1 20.847 - - 270 6 - - 104 5 299 9 
Glucosidase 2 subunit beta GLU2B 58.756 - - - - 156 3 250 9 - - 
Haptoglobin precursor HPT 38.728 - - 57 3 - - - - - - 
Hemoglobin subunit alpha HBA 15.076 - - 248 5 - - - - 253 6 
Heterogeneous nuclear ribonucleoproteins 
A2/B1 
ROA2 37.437 - - - - - - 80 3 
126 4 
 178 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5.3: Mass spectrometry data for NADPH removal elution (E5) fractions from ICT-5074 affinity chromatography experiments. List of proteins 
identified in at least 2 E5 fractions, a minimum of 3 peptides, MASCOT score ≥45. Inhibitor-bead chromatography experiment III a1 (Section 5.2.2.5) SDS-
PAGE sample separation, in-gel trypsin digestion equivalent to 1ml of the 2ml sample. Inhibitor-bead chromatography experiment III a2 whole 2ml sample 
trypsin digested. Inhibitor-bead chromatography experiment III b1 SDS-PAGE sample separation, in-gel trypsin digestion equivalent to 1ml of the 2ml sample. 
Inhibitor-bead chromatography experiment III b2 whole 2ml sample trypsin digested. (Appendix D) 
Protein  Accession 
(Mouse) 
MW 
(kDa) 
Inhibitor-bead 
chromatography 
experiment III a1 
Inhibitor-bead 
chromatography 
experiment III a2 
Inhibitor-bead 
chromatography 
experiment III b1 
Inhibitor-bead 
chromatography 
experiment III b2 
Starting 
material 
Scr #P Scr #P Scr #P Scr #P Scr #P 
Liver carboxylesterase 22 precursor  EST22 61.543 88 5 - - 88 5 - - - - 
Liver carboxylesterase 31-like ES31L 61.418 - - - - 93 4 55 5 81 5 
Liver carboxylesterase N precursor ESTN 61.133 - - - - 127 5 84 7 - - 
Mannose-binding protein C MBL2 26.340 - - - - - - 165 5 - - 
Mitochondrial import inner membrane 
translocase subunit Tim8 A 
TIM8A 11.263 - - 66 4 - - 214 4 
- - 
NADPH--cytochrome P450 reductase NCPR 76.995 54 3 - - - - - - - - 
Nucleobindin-1 precursor (CALNUC) NUCB 53.376 97 4 - - 241 15 531 23 - - 
Peptidyl-prolyl cis-trans isomerase B PPIB 23.699 - - 116 9 - - 124 3 - - 
Peroxiredoxin-1 PRDX1 22.390 102 4 162 4 - - 235 6 - - 
Peroxiredoxin-6 PRDX6 24.969 - - 161 10 - - 74 3 72 5 
Protein disulfide-isomerase precursor PDIA1 57.108 460 17 541 16 473 12 1254 39 132 7 
Protein disulfide-isomerase A3 
precursor 
PDIA3 56.643 94 5 - - - - - - 
224 10 
Protein disulfide-isomerase A6 
precursor 
PDIA6 48.070 80 3 149 6 - - - - 
88 5 
S-adenosylmethionine synthetase 
isoform type-1 
METK1 44.051 - - - - - - 152 5 
129 5 
Superoxide dismutase [Cu-Zn] SODC 15.933 - - 200 4 - - - - 59 3 
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5.4 Discussion 
5.4.1 ICT-5074 chemical synthesis and stability testing 
ICT-5074 was developed from ketoconazole, an anti-fungal drug with known 
P450 inhibition. It was hypothesised that, due to ketoconazole binding 
directly to the common heam moiety of the P450 structure, this inhibitor 
would make a good affinity capture probe for a broad range of P450s. 
 
 
Chemical synthesis of ICT-5074 was performed by Dr Fanzhi Kong (Institute 
of Cancer Therapeutics) using the process described in Figure 5.7. 
Immobilisation of ICT-5074 was completed after solubilisation of the ICT-
5074 compound in methanol/coupling buffer (1:1). ICT-5074 had much better 
solubility properties than the ketoconazole parent compound, and so 
attaining the required concentration of ICT-5074 (100nM) for immobilisation 
was possible.  
 
The stability studies for ICT-5074 (Section 5.3.2) showed that the ICT-5074 
compound was stable over the full pH range used during compound 
immobilisation and affinity chromatography (pH 2-10.6), for prolonged 
periods. If the compound had become unstable during the process of 
immobilisation the structural changes may have altered the binding 
properties of the compound during affinity chromatography, therefore it was 
important to identify compound stability prior to use. 
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5.4.2 Inhibitor affinity chromatography 
5.4.2.1 Inhibitor-bead chromatography experiment I 
During the initial immobilisation of ICT-5074 to the epoxy-activated 
sepaharose 6B beads, ethanolamine was used as a blocking buffer. Sodium 
chloride was used in the equilibration buffer during bead chromatography to 
help reduce the amount of hydrophilic, non-specific binding. However, these 
results (Section 5.3.3.1) showed a large proportion of non-specific binding 
that might interfere with either P450 detection or P450 binding due to the 
decreased capacity of the beads via non-specific interactions. Conditions 
were altered to use glycine as an alternative blocking buffer based on 
research determined by Williams et. al (2006), discussed in detail in Chapter 
7. 
 
5.4.2.2 Inhibitor-bead chromatography experiment II 
 
Wright et al. (2007) synthesised a series of probes to study P450 activity in 
the treatment of breast cancer. When attempting to bind P450’s from 
microsomal protein preparations, NADPH was used because P450 binds in 
an NADPH-dependent manner. As control samples, Wright et al. incubated 
the probes with the microsome sample but in the absence of NADPH. Based 
on these findings, the affinity chromatography procedure in Section 5.2.2.3 
was altered to include NADPH in the starting sample and equilibration buffers 
to enhance CYP binding, and was subsequently removed from the buffer in 
order to see if CYPs would be eluted.  
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Initial analysis of the control and ICT-5074 bead fractions by SDS-PAGE and 
Coomassie Brilliant Blue staining (Figure 5.13) showed strong banding 
patterns in the flow-through fractions of both bead samples (lanes 4 and 7 
respectively). These results indicated that most of the microsome sample did 
not bind to the chromatography material as would be anticipated. However, 
the affinity beads may have been overloaded with protein sample and 
reached their maximum binding capacity, with no available sites remaining 
for binding of all of the targeted protein. The ketoconazole elution fractions 
(lanes 6 and 9) did not show any banding patterns in the control or ICT-5074 
bead samples, and so the ketoconazole elution step was excluded from 
subsequent chromatography procedures. This lack of binding may be due to 
the low solubility and stability of ketoconazole in the buffers used, requiring 
low molar concentrations (100µM) in comparison to the imidazole elution 
buffer (1M). 
 
The imidazole elution fraction (E1) of the ICT-5074 beads showed several 
strong but discrete bands whereas the control beads did not show any strong 
banding patterns (Figure 5.13, lanes 8 and 5 respectively). This indicated that 
there was a difference in the bead composition of the control and ICT-5074 
beads, which could be attributed to immobilisation of the ICT-5074 
compound. The banding patterns were strongest within the 40-60kDa 
molecular weight region, which is a region of interest, as the P450s should 
run on a gel in this relative molecular weight range. These results were 
therefore in line with what was expected and intended to occur. 
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To clarify which proteins were eluting in the 40-60kDa molecular weight 
regions the samples were processed by MS. Trypsin digested samples 
produced a range of protein identifications in the ICT-5074 flow-through (46 
proteins), imidazole elution (21 proteins) and NADPH-removal (49 proteins) 
fractions. The samples eluted from the imidazole elution fraction (E1) did not 
contain P450s or proteins known to bind to imidazole specifically. This led to 
investigation of non-specific binding and ways to optimise ligand/blocking 
buffer immobilisation and affinity chromatography (Chapter 7).  
 
5.4.2.3 Inhibitor-bead chromatography experiment III 
 
Analysis of the affinity chromatography fractions produced by the method 
detailed in Section 5.2.2.4 was difficult due low sample quantities. SDS-
PAGE analysis was introduced to provide a second method of result 
validation and for screening suitable fractions for LC MALDI mass 
spectrometer. However, splitting of fractions to perform SDS-PAGE analysis 
with parallel trypsin digestion led to weak bands that were only detectable 
using silver staining and MS analysis was unsuccessful. To solve this 
problem, whilst still monitoring each affinity chromatography run by SDS-
PAGE analysis and trypsin digestion, chromatography materials and buffers 
used were increased (Section 5.2.2.5). In addition, using Micro Bio-spin 
columns to pack the affinity material and immobilise the material on a size 
filter was also incorporated into the method to allow more discrete and 
quicker elution steps. 
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Using this chromatography method, it became possible to visualise the 
banding patterns of 1ml aliquots of fraction material post-chromatography 
(SDS-PAGE). Protein identification results from the in-gel digestion of the 40-
60kDa relative molecular weight region in the imidazole and NADPH removal 
elution fractions (Figure 5.14, lanes 5 and 6 respectively), as well as the 
NADPH removal control fraction (lane 9), is summarised in Table 5.2 and 
Table 5.3. The MASCOT scores of several proteins were increased (five-fold) 
when committing the whole fraction to trypsin digestion compared to in-gel 
trypsin digestion using sample volumes equivalent to half the fraction, as 
discussed in Section 5.3.3. SDS-PAGE involves many more steps where 
protein losses may occur in comparison to direct in-solution digestion. Each 
band will also contain less proteins, specific to the molecular weight of 
proteins separated to that location in the gel, so not all proteins visualised in 
these samples are seen in the in-solution digests.  
 
Nucleobindin-1 (CALNUC) is a Golgi membrane protein (Lin et al., 1998) 
important in deoxyribonucleic acid (DNA) and calcium-binding (Wendel et al., 
1995). Nucleobindin-1 binds calcium to aid in calcium homeostasis, but 
calcium also acts to fold the two EF-hand domains of the protein upon 
binding. During DNA damage the protein is phosphorylated and can then 
bind DNA, however this is only common in states of disease, for example 
lupus (Kanai and Tanuma, 1992; UniProt Consortium, 2009).  Nucleobindin-1 
was identified with a MASCOT score of 686 (twenty three peptides) in the 
imidazole elution digested bands, but was also seen in the NADPH removal 
elution digested bands (MASCOT score 241, fifteen peptides). When 
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chromatography was repeated committing the full fraction to direct trypsin 
digestion, MASCOT scores were increased to 1534 (forty two peptides) in the 
imidazole elution and 531 (twenty three peptides) in the NADPH removal 
elution.  This protein was not identified in the starting material or control bead 
fraction and so good enrichment had occurred using the ICT-5074 beads. 
There has been no previous indications that nucelobindin interacts with 
ketoconazole. 
 
 
78 kDa glucose-regulated protein from the heat shock protein family acts as 
a co-chaperone along with DnaJ homolog subfamily B member 11, which it 
binds in an ATP-dependent manner (Meunier et al., 2002). DnaJ homolog 
subfamily B member 11 binds to unfolded proteins and peptide chains, and 
helps recruit 78kDa glucose-regulated protein and other chaperones. DnaJ  
homolog subfamily B member 11 and 78 kDa glucose-regulated protein can 
form part of a large chaperone complex with a wide range of proteins, 
including the UDP-glucotransferases, endoplasmin, protein disulfide-
isomerase, peptidyl-prolyl cis-trans isomerase B, and stromal cell-derived 
factor 2-like protein 1 (Meunier et al., 2002; UniProt Consortium, 2009). 
78kDa glucose-regulated protein, endoplasmin and protein disulphide-
isomerase A4 were found in the ICT-5074 elution fractions and the starting 
material, but not in the control bead sample (E5). This indicates that these 
proteins bound the beads via the ICT-5074 immobilised compound on the 
bead surface. Peptidyl-prolyl cis-trans isomerase B and stromal cell-derived 
factor 2-like protein 1 were only found in the starting material, not binding to 
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the ICT-5074 beads, and therefore not eluted from the beads or were below 
the level of detection by mass spectrometric analysis. If one of the 
components of the complex was interacting with ICT-5074, then some of the 
other components could be co-eluted due to physical association, whilst 
those members of the complex only observed in the starting material could 
have been dissociated by the sample preparation buffers prior to 
chromatography. Further work would be required to determine if this was 
true. 
 
Protein disulfide-isomerase is found in the endoplasmic reticulum lumen and 
in cell membranes. The protein acts as a structural subunit of various 
enzymes where it cleaves disulfide bonds at cell surface and rearranges or 
forms disulfide bonds of nascent proteins in the cell (Ellgaard and Ruddock, 
2005). Protein disulfide-isomerase inhibits the aggregation of misfolded 
proteins at high concentrations however it also facilitates their aggregation at 
low concentrations (Raturi et al., 2008; UniProt Consortium, 2009). The 
MASCOT score for the protein in the NADPH-removal elution from direct 
trypsin digestion was highest (1254) followed by the imidazole elution (1181), 
and the starting material had the lowest score (132). This strongly suggests 
that protein disulfide-isomerase precursor is binding to the chromatography 
material and may be specifically enriched, leading to increased MASCOT 
scores. 
 
Liver carboxylesterase is also located in the endoplasmic reticulum lumen 
and is involved in detoxification of xenobiotics. Liver carboxylesterase has 
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been used as a pro-drug target where it activates ester and amide groups in 
the pro-drug via mechanisms used for xenobiotic metabolism (Djeridane et 
al., 2008; UniProt Consortium, 2009). This xenobiotic activity may account for 
an association with ICT-5074, though there has been no specific report of 
interaction with ketoconazole. Liver carboxylesterase 22 precursor was 
enriched in the in-gel digest fractions of the NADPH-removal elution of the 
ICT-5074 beads (MASCOT score 88, five peptides). Liver carboxylesterase 
31-like protein was present in the NADPH-removal elution direct digest 
fraction (MASCOT score 93, four peptides) and the imidazole elution 
(MASCOT score 144, eight peptides) of the ICT-5074 beads, but was also 
present in the starting material with a lower score (MASCOT score 81, five 
peptides). Liver carboxylesterase N precursor was present in the NADPH-
removal elution direct digest fraction (MASCOT score 127, five peptides), 
and the imidazole elution of the ICT-5074 beads (MASCOT score 141, five 
peptides).  
 
Two P450s were eluted from the ICT-5074 beads, although at very low 
MASCOT scores. Cytochrome P450 4F3 was the only P450 to be enriched 
by ICT-5074 bead chromatography. Cytochrome P450 4F3 is also known as 
Leukotriene-B(4) omega-hydroxylase 2 and is responsible for the 
hydroxylation of LTB4 to inactivate the chemokine (UniProt Consortium, 
2009), which is known to be inhibited by ketoconazole (Swinney et al., 1991). 
Cytochrome P450 4F3 was present in the imidazole elution fraction 
(MASCOT score 46, three peptides), however was not present in the starting 
material. Another P450 was present in the E5 fraction from the ICT-5074 
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bead chromatography, cytochrome P450 2A4. Cytochrome P450 2A4 
(steroid 15 α-hydroxylase) is responsible for hydroxylation of testosterone, 
progesterone and androstenedione (Honkakoski and Negishi, 1997; UniProt 
Consortium, 2009). Only two peptides of cytochrome P450 2A4 were 
identified in the eluate fraction (MASCOT score 46) compared to fourteen in 
the starting material (MASCOT score 98). The difference in the results 
between the starting material and eluate may be due to the P450s still being 
bound to the beads. This would happen if the correct elution conditions had 
not yet been achieved.  
 
The P450 inhibitor ketoconazole is most selective for CYP3A4 of the human 
P450s, however it is also known to be a weaker inhibitor of CYP2C9. At high 
concentrations of ketoconazole (200μM), CYP2C19, CYP2E1 and CYP1A2 
are also weakly inhibited (Zhang et al., 2002). This limited specificity could be 
a reason why only two CYPs were identified, but it could also be due to 
species differences as there is no direct mouse equivalent of CYP3A4.  
 
The inhibitor-bead chromatography experiment III procedure was repeated 
under the same conditions, however the post-chromatography analysis 
concentrated solely on collecting mass spectra data. To aid this, the full 2ml 
fraction samples were committed to trypsin digestion. Altering the post-
chromatography method in this way greatly increased the protein 
identifications of all of the fractions analysed (Table 5 2; Table 5.3), but may 
have also increased the detection of non-specific binding proteins.  
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This led to further optimisation of the chromatography procedures to enhance 
P450 detection, as detailed in Chapters 6 and 7, to ascertain whether it was 
the chromatography beads or ICT-5074 that was resulting in poor 
enrichment.  
 
 
 
  
CHAPTER SIX 
Non-specific binding experiments 
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6.0 Non-specific binding experiments 
6.1 Introduction 
Initial chromatography studies identified a large range of proteins binding not 
only to the inhibitor-beads, but also to the control beads (ethanolamine-
blocked beads). Simultaneous to these experiments, Trinkle-Mulcahy et al. 
(2008) investigated the proteins binding non-specifically to bead supports 
(Table 6.1). SILAC labelled GFP-tagged protein (heavy, C13) and free GFP 
(light, C12), expressed in HeLa cell lines, were captured using anti-GFP 
sepharose beads. It was then possible to determine proteins binding non-
specifically to the sepharose beads by comparing the bead-protein profiles of 
both experiments. This method was used to compare the bead proteomes of 
Sepharose, and magnetic bead supports. They found that the bead 
proteomes showed some similarities, however, Sepharose beads bound 
more nucleic acid binding factors and magnetic beads bound more 
cytoskeletal and structural proteins. 
 
 
 
 
 
 
 
 
 
 
Table 6.1: Proteins binding non-specifically to Sepharose beads forming 
the bead proteome. Modified from Trinkle-Mulcahy et al. (2008)  
Protein Class Most common 
Cytoskeletal/Structural/Motility 
proteins 
Actin 
Cofilin 
Desmin 
Desmoplakin 
Epiplakin 
Filamin 
Myosin 
Peripherin 
Plectin 
Tropomyosin 
Tubulin 
Vimentin 
DEAD box proteins  
Eukaryotic translation elongation 
and initiation factors 
 
Heat shock proteins  
Histones  
hnRNP proteins  
Ribosomal proteins  
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Alternative blocking buffers to aid in decreasing non-specific binding were 
identified. Williams et al. (2006) investigated the ability of ethanolamine to 
block the remaining sites of protein A Sepharose and protein G Sepharose 
beads with increased time (2 hours to overnight) and pH range (pH 8.0 to 
10.6), and compared it to blocking with glycine buffer. The choice of 
ethanolamine and glycine buffers to block the remaining sites was based on 
work by Harlow and Lane (1988), where un-reacted sites of cyanogen 
bromide beads were blocked using the same blocking buffers. The most 
effective blocking was observed using glycine buffer overnight and so this 
was incorporated into the blocking protocol replacing the 1M ethanolamine 
blocking of epoxy-acitvated sepharose beads (Section 5.2.2.2).  
 
6.1.1 Aims of chapter 
It is important to investigate the causes of non-specific binding as it provides 
a severe disruption to affinity chromatography, preventing identification of the 
specifically bound proteins. Development of a series of experiments to 
investigate additional agents to add to chromatography buffers is hoped to 
decrease non-specific binding of microsome proteins to chromatography 
beads. The main objective is to decrease non-specifically to a level that 
allows specifically bound proteins of interest to be detected by subsequent 
MS. To decrease hydrophobic interactions acetonitrile concentrations will be 
increased. To decrease ionic interactions salt concentrations will be 
increased. To block the pores of the bead material the beads will be 
incubated with β-casein protein. This will act as a single protein standard that 
will decrease the complexity of the bead proteome. 
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6.2 Materials and methods 
 
6.2.1 Reagents and samples 
β-casein (bovine) was purchased from Sigma-Aldrich. For information on 
mouse liver microsome preparation refer to Section 3.2.2 and all other 
materials refer to Sections 3.2.1, 5.2.1 and 6.21. 
 
6.2.2 Alternative blocking agents for use with sepharose bead 
chromatography 
 
Control beads were created as described in Section 5.2.2.2 using either 
ethanolamine or glycine for blocking of the active sites. Mouse liver 
microsomes (100µl at 20 mg/ml) were incubated with the 250µl of control 
beads in 400µl equilibration buffer. Bead samples were washed with 10 
volumes of equilibration buffer (FT). Proteins were removed from the beads 
by on-bead digestion (18 hours, 500µl 40 ng/ml trypsin) for further analysis. 
The digested samples were then desalted using an Isolute C18 cartridge 
equilibrated with 2% acetonitrile, 0.05% TFA and peptides eluted with 80% 
acetonitrile, 0.05% TFA (1ml). Following this process the eluted samples 
were concentrated by evaporation at 60°C for approximately 90 minutes and 
were stored at -20°C. These digested and purified peptide samples were 
then analysed by LC MALDI MS (Section 3.2.6).  
 
6.2.2.1 Alterations in acetonitrile concentration 
 
Control beads (glycine-blocked) were incubated with mouse liver microsomes 
in buffers, labelled buffer A-D, which contained increasing concentrations of 
acetonitrile (A, 10%; B, 25%; C, 37.5%; D, 50%), in order to decrease the 
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amount of hydrophobic binding to the beads. After incubation with mouse 
liver microsomes, bead samples were washed with 10 volumes of 
equilibration buffer (FT). Bead samples were then heat-treated (30 minutes, 
50°C) to remove all proteins present for further analysis. These bead 
fractions were then processed by SDS-PAGE (Section 3.2.5) to analyse 
protein content. 
 
6.2.2.2 Alterations in salt concentration 
 
Control beads (500µl, glycine-blocked) were incubated with liver microsomes 
(100µl at 40 mg/ml) in buffers containing increasing concentrations of salt 
(0.15M, 0.3M, 0.5M, 1M) to decrease the amount of ionic interactions to the 
beads. After incubation with mouse liver microsomes, bead samples were 
washed with 10 volumes of equilibration buffer (FT). Proteins were removed 
from the beads by on-bead digestion (18 hours, 500µl trypsin at 40 ng/ml) for 
further analysis. The digested samples were then desalted using an Isolute 
C18 cartridge (Kinesis Ltd.) equilibrated with 2% acetonitrile, 0.05% TFA and 
peptides eluted with 80% acetonitrile, 0.05% TFA (1ml). Following this 
process the eluted samples were concentrated by evaporation at 60°C for 
approximately 90 minutes and were stored at -20°C. These digested and 
purified peptide samples were then analysed by LC MALDI MS (Section 
3.2.6).  
 
6.2.3 Blocking of free sites on bead supports 
Initial blocking experiments involved a short β-casein blocking step in 
addition to the current chromatography protocol. Control beads (750µl, 
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glycine-blocked) were incubated with β-casein (1% w/v in PBS, 500µl beads) 
or PBS (250µl beads) for 30 minutes, before incubation with mouse liver 
microsomes (50µl at 40 mg/ml per 250µl beads, 2 hours). The beads were 
washed with 10 times volume of PBS.  
 
Further blocking experiments involved additional, longer β-casein blocking 
steps. Control beads (750µl, glycine-blocked) were incubated with β-casein 
(1% w/v in PBS, 500µl beads) or PBS (250µl beads) for 2 hours, before 
incubation with mouse liver microsomes (50µl at 40 mg/ml per 250µl beads, 
2 hours). The (250µl) beads were then incubated with PBS for 2 hours 
creating PBS only and pre-incubated β-casein beads (Figure 6.1A, Figure 
6.1C respectively). A further portion of beads pre-incubated with PBS (250µl) 
or β-casein (250µl) were re-incubated with β-casein (1% w/v) for 2 hours 
following exposure to microsomal proteins (Figure 6.1B, Figure 6.1D 
respectively). Bead samples were then heat-treated (30 minutes, 50°C) to 
remove all proteins present for further analysis. These bead fractions were 
processed by SDS-PAGE (Section 3.2.5) to analyse protein content. 
 
 
 
 
 
 
 
 
 
Figure 6.1: PBS and β-casein wash protocols for blocking of free sites  
 
A B C D 
PBS 
PBS 
PBS 
PBS 
Microsomes Microsomes Microsomes Microsomes 
β-casein 
β-casein β-casein 
β-casein 
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6.3 Results 
6.3.1 Alternative buffers for use with sepharose bead chromatography 
Ethanolamine-blocked control beads incubated with mouse liver microsomes 
bound 193 proteins, whereas the glycine-blocked beads bound 154 proteins 
(Appendix E), 90 of which were common to both. This indicated an 
improvement of approximately 20%. 
 
 
6.3.1.1 Alterations in acetonitrile concentration 
 
A range of buffers containing increasing concentrations of acetonitrile were 
used during affinity chromatography to reduce the non-specific binding based 
on decreasing hydrophobic interactions (Figure 6.2). Control bead samples in 
lanes 3, 5, 7 and 9 were incubated with equilibration buffer only, whereas 
lanes 4, 6, 8 and 10 were incubated with mouse liver microsomes. Control 
beads incubated with microsomes showed a general trend of decreasing 
protein banding with increased acetonitrile buffer concentration, with the 
exception of a strong band at approximately 18kDa molecular weight. The 
control beads without microsomes were used to confirm that the beads 
themselves were not a source of proteins contamination. As there were still a 
number of proteins observed in the presence of 50% acetonitrile, LC-MALDI 
MS analysis was not performed. 
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Figure 6.2: Investigation of non-specific binding targeting hydrophobic 
bonds using buffers containing organic solvents. Coomassie Brilliant Blue 
stain of SDS-PAGE of beads resuspended in 50μl SDS loading buffer, boiled, 
and 10μl aliquots used for analysis. Molecular weight markers shown in lane 2 
followed by pairs of increasing concentrations of acetonitrile buffers (10%, 25%, 
37.5% 50%), either with liver microsomes or control beads only without liver 
microsome incubation respectively 
 
 
6.3.1.2 Alterations in salt concentration 
A range of buffers containing increasing concentrations of salt were used 
during affinity chromatography to reduce the non-specific binding based on 
the reduction of ionic interactions. From LC MALDI MS results, control beads 
incubated with microsomes showed a general trend of decreasing non-
specific binding with increased concentrations of salt (Table 6.2).  
 
 
 
Table 6.2: Comparison of P450 and total protin binding to glycine-blocked control 
and beads. 
 0.15M NaCl buffer, 
Control beads 
0.3M NaCl buffer, 
Control beads 
0.5M NaCl buffer, 
Control beads 
1M NaCl buffer, 
Control beads 
Total 
proteins 
26 14 3 0 
18kDa 
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Two buffers (0.15M NaCl and 0.5M NaCl) were chosen for intitial studies to 
compare the affect of increasing the salt concentration on P450 binding to 
ICT-5074-sepharose. If 0.5M sodium chloride buffer had shown good 
reduction in non-specific binding, with P450 binding and identification, studies 
would have progressed for comparisons with 1M sodium chloride buffer. The 
amount of bead and microsome materials were doubled to allow identification 
of low level proteins (Appendix F). Table 6.3 shows that raising the salt 
concentration affects P450 binding to the inhibitor beads, as the number of 
P450s detected decreased slightly. In addition, although significantly 
reduced, there was still a large number of non-specifically binding proteins 
present. 
 
 
Table 6.3: Total number of proteins binding to glycine-blocked control beads and 
ICT-5074 beads using mouse liver microsomes incubated in buffers with different 
salt concentrations. 
 
6.3.2 Blocking of free sites on bead supports 
Casein was used to see if blocking of beads could be achieved in an 
analogous strategy to the use of milk in blocking buffers for Western blotting. 
Casein as a single protein was preferred over milk, (in which casein is an 
abundant component) as milk would offer increased sample complexity, high 
sequence homology of BSA wiith mouse albumin, thereby providing false 
discovery hits in proteomic analysis. The initial blocking experiments involved 
 0.15M NaCl buffer, 
Control beads 
0.15M NaCl buffer, 
ICT-5074 beads 
0.5M NaCl buffer, 
Control beads 
0.5M NaCl buffer, 
ICT-5074 beads 
Total 
proteins 
39 158 31 86 
P450s 0 5 0 3 
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a short (30 minute) β-casein wash, which led to a general decrease in protein 
binding (Figure 6.3). 
 
Pre-incubation of beads with β-casein prevented some non-specific binding 
to glycine-blocked beads (Figure 6.4, Lane 7), although the levels of β-casein 
present on the beads had decreased from the starting material (Lane 2). 
Incubation with β-casein pre- and post-microsome incubation significantly 
decreased the amount of non-specific binding, closely resembling the variety 
and amount of proteins present in the β-casein standard, with only a few 
additional bands.  
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Figure 6.3: Investigation of blocking free binding sites using β-casein protein. 
Coomassie stain of SDS-PAGE separated bead samples resuspended in 20μl SDS loading 
buffer. Lane 2, molecular weight markers; Lane 3, microsome starting material. Control 
beads only (Lane 5), Control beads incubated with microsomes (Lane 8), Control beads pre-
incubated with β-casein, incubated with microsomes (Lane 10).  
 
 
 
 
 
 
 
Figure 6.4: Comparison of β-casein blocking protocols. Silver stain of SDS-
PAGE separated bead samples resuspended in 20μl SDS loading buffer. Lane 1, 
molecular weight markers; Lane 2, β-casein standard. Glycine-blocked beads 
incubated with (Lane 5) and without microsomes (Lane 4). Glycine-blocked beads 
pre-incubated with β-casein, incubated with (Lane 7) and without microsomes 
(Lane 6). Glycine-blocked beads pre-incubated with β-casein, incubated with 
(Lane 9) and without microsomes (Lane 8), followed by β-casein wash. 
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Pre- and post-β-casein washes were incorporated into affinity 
chromatography protocols with histamine and ICT-5074 beads. MS of in-gel 
trypsin digests of the bands of interest (40-60kDa relative molecular weight 
range) showed inhibition of P450 binding to beads using the β-casein 
standard.  From the in-gel digestion of histamine beads with double -casein 
washes, 4 proteins were detected (Table 6.4), whereas the equivalent band 
from histamine-sepharose without -casein treatment showed 21 proteins of 
which 4 were P450s. The in-gel digestion of ICT-5074 beads with double -
casein washes bound 4 proteins (Table 6.4), whereas the equivalent band 
from ICT-5074-sepharose without -casein treatment showed 59 proteins of 
which 7 were P450s.  
 
 
Protein Accession 
(Mouse) 
MW 
(kDa) 
Histamine 
beads 
ICT-5074 
beads 
Actin, cytoplasmic 1 ACTB 41.710 222 (6) 300 (7) 
Argininosuccinate synthase ASSY 46.555 199 (13) 238 (12) 
Betaine--homocysteine S-methyltransferase 1 BHMT1 44.991 484 (14) 759 (23) 
Betaine--homocysteine S-methyltransferase 2 BHMT2 39.846 - 129 (7) 
Glutamine synthetase GLNA 42.092 193 (3) - 
Hydroxymethylglutaryl-CoA synthase HMCS2 56.786 - 102 (6) 
 
Table 6.4: Proteins bound to histamine and ICT-5074 beads after pre- and 
post-β-casein washes  
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6.4 Discussion 
6.4.1 Alternative buffers for use with sepharose chromatography 
Inhibitor-bead chromatography experiments (Section 5.3.3) produced 
evidence of non-specific binding to the beads, even in the control-sepharose 
fractions. Before further ICT-5074 affinity chromatography experiments were 
performed, tests to reduce the non-specific binding were investigated to 
optimise the immobilisation and chromatography conditions. Initially, various 
concentrations of acetonitrile were used to reduce the non-specific binding 
based on decreased hydrophobic interactions. 
 
Control beads produced during the ICT-5074 experiments were incubated 
with or without liver microsomes, in buffers of different acetonitrile 
concentrations (10%, 25%, 37.5%, 50%). Control bead samples did not show 
any protein bands indicating that the proteins visualised are not already 
found on the beads before incubation with the liver microsome sample. The 
beads that had been incubated with liver microsomes showed a general 
trend of decreasing protein banding with increased acetonitrile buffer 
concentration. Although the results in Figure 6.2 seem to suggest that higher 
acetonitrile concentrations would be beneficial, protein precipitation in the 
mouse microsome starting material occurred due to the high proportion of 
organic solvent, counteracting any potential benefit. Protein precipitation 
prevents P450 binding to the beads so the acetonitrile concentration in the 
equilibration buffer was kept at 10%. 
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Investigations into altering the salt content of the buffers to reduce non-
specific binding also showed similar results, as the concentrations are 
increased, P450 binding decreased. The salt content in the equilibration 
buffer was kept at 0.15M NaCl to allow for maximum P450 binding. 
 
6.4.2 Blocking of free sites on bead supports 
The blocking of non-specific binding using β-casein showed the best 
improvement in decreasing non-specific binding throughout the full molecular 
weight range of the gel, using both pre- and post-microsome incubation β-
casein washes. Unfortunately, β-casein binding also impaired P450 binding. 
This may have been due to steric hinderence, as bound β-casein on the 
surface of the bead may prevent proper interaction of the P450 with the 
immobilised P450 inhibitor.  
 
6.4.3 Summary of non-specific binding experiments 
As the investigations described here in Chapter 7 were on-going, many 
groups were also observing similar problems with non-specific binding during 
affinity capture procedures Sutton et al. (2012). Trinkle-Mulcahy et al. (2008) 
used SILAC labelling of green fluorescent protein (GFP) tagged survival 
motor neuron protein (SMN) or free GFP expressing cells. Protein purification 
by anti-GFP affinity capture lead to identification of those proteins binding to 
sepharose in a specific and non-specific manner.   
 
 203 
 
Although it is possible to reduce non-specific binding, attempts also alter or 
prevent specific binding of P450s to the inhibitor-beads. Using a protein 
standard to block sites on the beads where non-specific interactions occur 
showed the best improvement. However further investigation is required to 
find a protein that is large enough to fully block non-specific protein 
interaction with the bead surface but not effect P450 binding by steric 
hinderence or prevent detection. 
 
The only improvement that was introduced into subsequent chromatography 
protocols was the change of buffer for blocking the free chemical sites during 
inhibitor immobilisation from ethanolamine to glycine-based buffers. This 
immobilisation step was chosen to reduce non-specific binding in preference 
to using high acetonitrile/salt concentrations in chromatography buffers as 
these led to poor target protein binding and protein precipitation. Overall, 
these experiments, along with the increasing numbers of articles published in 
this area, have indicated the need for improvements in affinity bead protocols 
to overcome the issue of non-specific binding. 
  
CHAPTER SEVEN 
Inhibitor-probe immobilised-streptavidin chromatography 
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7.0 Inhibitior-probe immobilised-streptavidin chromatography 
7.1 Introduction 
ICT-5074 (ketoconazole analogue) sepharose bead chromatography showed 
high levels of non-specific binding, which may have been limiting P450 
enrichment and detection, as discussed in Chapter 5. To circumvent this 
problem, alternative bead supports were investigated. 
 
7.1.1 Alternative bead supports and immobilisation methods 
Immoblised-streptavidin beads are able to strongly interact with biotin(-linked) 
molecules (Hendrickson et al., 1989). The surface of agarose bead material 
(Figure 7.1A) is coated with streptavidin, but there may also be free 
streptavidin trapped in the pores of the bead. This may aid in preventing 
proteins from the sample being trapped in the pores and possibly result in 
lowering non-specific binding.  
 
An alternative immobilised-streptavidin bead type is that of the smooth, 
magnetic dynabeads (Figure 7.1B). The technology behind these beads 
stems from research and development by Professor John Ugelstad in 1976, 
whereby he created spherical polystyrene beads of exactly equal size. This 
technology was magnetized in the early 1980’s and Ugelstad et. al (1986) 
used the beads to isolate cells from blood and provided a method of HLA 
typing. The beads are now commercially available (Invitrogen) pre-coupled 
with various ligand types, such as antibodies, DNA/RNA probes, or proteins. 
Although much more expensive, these smaller beads without the porous 
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nature of the agarose, were also used pre-coupled to streptavidin, to 
compare the results of P450 enrichment. Any differences in non-specific 
interactions may therefore be due to the interactions with the bead surface, 
and not streptavidin or the immobilised inhibitor. 
 
Figure 7.1: Comparison of agarose-bead (A) and dynabead (B) chromatography 
material 
 
Chemical synthesis of biotinylated-ICT-5074 proved very problematic (data 
from Dr Fanzhi Kong not shown), due to solubility and purity problems, so a 
method using a commercially available crosslinker (Pierce) was adapted to 
produce an inhibitor probe. The linker has four key groups (Figure 7.2), all of 
which have important functions in the immobilisation or chromatography 
processes. The N-hydroxysuccinimide (NHS) group can react with primary 
amines. The crosslinker is designed for protein binding, as all proteins 
contain primary amines, however the chemistry can be readily adapted for 
attachment of ICT-5074. Polyethylene glycol (PEG) increases the solubility of 
the molecule in aqueous-based buffers. The biotin group, as previously 
A B 
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mentioned, is used for attachment to the immobilised-streptavidin. The 
disulphide bond is not important for the immobilisation process, but it is a 
group that can be cleaved by reduction, e.g. with dithiothreitol (DTT). This 
creates a useful option for an elution method, as all proteins bound 
specifically to the linker should be released following a DTT elution wash. 
This may also decrease contamination in the elution fraction from some 
proteins that have non-specifically bound. 
 
 
Figure 7.2: NHS-SS-PEG-Biotin crosslinker. N-hydroxysuccinimide (NHS), 
blue; disulfide bond (SS), green; polyethylene glycol (PEG), yellow; biotin, red. 
 
 
7.1.2 Alternative P450 inhibitors for affinity chromatography 
It is the imidazole group of ICT-5074 that targets the haem-centre of P450s 
(Section 5.1) and the primary amine group that is used for bead attachment. 
Histamine is comprised of an imidazole group attached to a primary amine 
group (Figure 7.3A), so was used as a more economical probe for method 
optimisation and comparison to ICT-5074. This would highlight the 
importance of the additional groups present in ICT-5074. 
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Figure 7.3: Chemical structure of histamine (A) and ICT-5083 (B). 
 
 
Another inihibitor currently in development at the Institute of Cancer 
Therapeutics, is an analogue of 2-ethynylnaphthalene (2EN), ICT-5083 
(Figure 7.3B). This compound has a primary amine group for immobilisation 
to a bead support, and an aryl alkyne group to target P450 activity. The aryl 
alkyne is chemically modified (oxidised) by the P450 to form a reactive 
ketene that irreversibly interacts with the P450. The 2-EN analogue was 
synthesised as a positive control based on published data by Wright et al. 
(2007). 
 
2EN has been used to identify P450s from mouse liver microsomes. The 
2EN-P450 complex was reacted with a reporter tag (azido-rhodamine) via 
click chemistry, allowing for in-gel fluorescent detection. The fluorescent 
band was excised for trypsin digestion and MS analysis. CYP1A1, 1A2, 
2C29, 3A11, 2D9/2D10 were detected by mass spectrometry (Wright and 
Cravatt, 2007). Wright et. al (2009) then went on to test a panel of 
recombinant human P450s (CYP1A1, 1A2, 1B1, 2A6, 2B6, 2C9, 2C19, 2D6, 
A 
B 
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2E1, 2J2, 3A4, 4A11, 4F2, 19A1). Each P450 was reacted separately with 
2EN and the sample was incubated with the rhodamine tag. A fluorescent 
band in the correct region of the gel was taken as a positive result for the 
P450. CYP1A1, 1A2, 1B1, 2B6, 2C19, 2C9, 2D6, 2J2, 3A4, 4F2, and 19A1 
were all detected by this method, showing the inhibitor to be cross-reactive 
amongst the P450s.  
 
7.1.3 Aims of chapter 
The focus of this chapter is to improve P450 detection using affinity 
chromatography procedures. Investigation of alternative bead supports for 
affinity chromatography and expansion of the range of P450 inhibitors used 
will lead to improvements in P450 capture. Any alterations in sample and 
analytical conditions required for proteomic analysis to adapt to these 
changes will be determined. 
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7.2 Materials and methods 
7.2.1 Reagents and samples 
CYP1B1 bactosomes (13.1mg/ml total protein; 7.6nmol/ml CYP1B1; 3.5% 
CYP1B1 of total protein), CYP2B6 bactosomes (12.2mg/ml total protein; 
3.3nmol/ml CYP2B6; 1.5% CYP2B6 of total protein), CYP2C8 (9.0mg/ml total 
protein; 10.9nmol/ml CYP2C8; 6.5% CYP2C8 of total protein), CYP2C19 
(15.0mg/ml total protein; 4.7nmol/ml CYP2C19; 1.8% CYP2C19 of total 
protein), CYP2D6 (14.8mg/ml total protein; 2.8nmol/ml CYP2D6; 1.1% 
CYP2D6 of total protein), CYP2E1 (16.2mg/ml total protein; 5.5nmol/ml 
CYP2E1; 1.9% CYP2E1 of total protein), CYP2J2 (10.0mg/ml total protein; 
1.0nmol/ml CYP2J2; 0.6% CYP2J2 of total protein), CYP3A5 (13.5mg/ml 
total protein; 1.2nmol/ml CYP3A5; 0.5% CYP3A5 of total protein), and 
CYP4A11 (32.0mg/ml total protein; 4.7nmol/ml CYP4A11; 0.9% CYP4A11 of 
total protein) were purchased from Cypex. A bactosome mix (Table 7.1) was 
created using the P450 bactosomes as detailed above, along with CYP1A2 
as detailed in Section 3.2.1. Each of these samples also contained co-
expressed cytochrome b5 and NADPH reductase and the required volume of 
bactosome material was calculated for each P450 stock tube, with a total 
volume of 197µl.  
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CYP 
Mw 
(Da) 
Total 
protein 
conc  
(mg/ml) 
CYP 
conc 
(nmol/ml) 
CYP 
conc 
(µg/ml) 
% CYP 
of total 
protein 
Volume 
containing 
50pmole 
CYP (µl) 
1a2 58407 10.0 9.3 543.2 5.4 5.5 
1b1 60793 13.1 7.6 462.0 3.5 6.5 
2b6 56225 12.2 3.3 185.5 1.5 15 
2c8 53945 9.0 10.9 588.0 6.5 4.5 
2c19 55909 15.0 4.7 262.8 1.8 10.5 
2d6 56107 14.8 2.8 157.1 1.1 18 
2e1 56812 16.2 5.5 312.5 1.9 9 
2j2 57574 10.0 1.0 57.6 0.6 50 
3a4 57343 10.0 1.0 57.3 0.6 50 
3a5 57109 13.5 1.2 68.5 0.5 41.5 
4a11 59348 32.0 4.7 278.9 0.9 10.5 
 
Table 7.1: Details of the P450 bactosome mix  
 
EZ-linker (NHS-SS-PEG-Biotin crosslinker) was purchased from Thermo 
Scientific (Rockford, IL, USA). Histamine and streptavidin-agarose was 
purchased from Sigma-Aldrich. Streptavidin-dynabeads were purchased from 
Invitrogen. ICT-5083 was prepared by Dr Fanzhi Kong (ICT) (Figure 7.4). For 
information on mouse liver microsome preparation refer to Section 3.2.2 and 
all other materials refer to Section 3.2.1 and Section 5.2.1. 
 
7.2.2 Affinity chromatography 
7.2.2.1 Biotinylation of inhibitor 
EZ-linker (60µl, 10.2mM NHS-SS-PEG-Biotin crosslinker, in ethanol) was 
incubated with inhibitor compound (30µl histamine, ICT-5074, or ICT-5083 in 
ethanol) for 1 hour at room temperature to create biotin-linked probe. The 
sample was lyophilised at room temperature to remove ethanol before 
resuspension in 25mM ammonium bicarbonate (90µl). 
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Figure 7.4: ICT-5083 chemical synthesis pathway. (1) Starting material was 
incubated at 90°C for 16 hours with trimethylsilylacetylene. (2) 2-
Trimethylsilanylethynyl-naphthalene-6-carboxylic acid methyl ester was dissolved 
in ethanol:methylene chloride (3:2) and cooled to 0°C before addition of 1M NaOH 
for 2 hours, followed by 12 hours warming to room temperature. (3) 2-Ethynyl-
naphthalene-6-carboxylic acid was dissolved in acetonitrile:N,N-dimethylformamide 
(2:1) and added to N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
(EDC), 1-hydroxybenzotriazole (HOBt), N-methylmorpholine (NMM) and tert-butyl 
3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propylcarbamate.  The reaction was stirred 
overnight at room temperature. (4) Tert-butyl 1-(6-ethynylnaphthalen-2-yl)-1-oxo-
6,9,12-trioxa-2-azapentadecan-15-ylcarbamate was added to dichloromethane 
(DCM) and 10% triflouroacetic acid (TFA) (10:1) at 0°C for 5 hours, to form  N-(3-
(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)-6-ethynyl-2-naphthamide (5). Yield at 
each stage of the chemical synthesis pathway is indicated as a percentage of the 
previous step. 
 
7.2.2.2 Coupling to streptavidin-agarose beads  
Immobilised streptavidin-agarose beads (250µl) were washed with 25mM 
ammonium bicarbonate. Biotin-linked probe (50µl) and 25mM ammonium 
bicarbonate (200µl) was incubated with streptavidin-agarose beads for 30 
minutes at room temperature. The beads were stored in 25mM ammonium 
bicarbonate, 1% sodium azide, at 4°C for future chromatography 
experiments.  
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7.2.2.3 Coupling to streptavidin-dynabeads  
Immobilised streptavidin-dynabeads (100µl) were washed with 25mM 
ammonium bicarbonate. Biotin-linked probe (50µl) and 25mM ammonium 
bicarbonate (50µl) were incubated with streptavidin-dynabeads beads for 30 
minutes at room temperature. The beads were stored in 25mM ammonium 
bicarbonate, 1% sodium azide, at 4°C for future chromatography 
experiments.  
 
7.2.2.4 Inhibitor-bead chromatography experiment IV  
 
A summary of the conditions, immobilised capture material and sample type 
used in the streptavidin-based affinity chromatography experiments is 
detailed in Figure 7.2. The inhibitor-linker-streptavidin agarose beads (250µl 
packed volume) (section 7.2.2.2) were re-equilibrated with PBS. Mouse liver 
microsomes (400μl, 30mg/ml) were added to the inhibitor-linker-streptavidin 
agarose beads, and streptavidin-agarose only control beads, and incubated 
at 37°C for 1 hour on a carousel. The bead solution was transferred to a 
Micro Bio-spin centrifugal column in a 2.2ml eppendorf tube, and the 
apparatus was centrifuged for 2 minutes, 1000 x g at 4°C. The eluate drained 
through the filter in the column leaving the beads packed in the Micro Bio-
spin apparatus. The eluate was transferred to FT1 and a further 500µl PBS 
was added to the apparatus and processed in the same way. A final 500µl 
was added and also transferred to FT1. The bottom cap was replaced on the 
Micro-Bio-spin apparatus, 50mM DTT (250µl) was added and the bead 
solution was incubated at 50°C for 30 minutes. The bottom cap was removed 
and the centrifugal column was transferred to a 2.2ml microcentrifuge tube. 
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The apparatus was centrifuged for 2 minutes, 1000 x g at 4°C, and the eluate 
transferred to E7 (DTT elution fraction). Equilibration buffer (250µl) was 
added to the apparatus and processed in the same way, with the eluate 
being transferred to E7. The bead samples were stored in a one-to-one ratio 
of beads to equilibration buffer with 1% sodium azide, and stored at 4°C.  
 
 
 
 
 
Table 7.2: Summary of affinity chromatography conditions using immobilised-
streptavidin inhibitor beads  
Experiment 
identification 
Inhibitor Streptavidin 
solid 
support type 
Vol. of 
beads 
(packed, µl) 
Vol. of 
mouse liver 
microsomes 
(µl) 
Amount of 
recombinant 
human P450 
mix (µl) 
Experiment IVa 
(Section 7.2.2.4) 
Histamine Agarose 250 400 0 
Experiment IVb 
(Section 7.2.2.4) 
ICT-5074 Agarose 250 400 0 
Experiment Va 
(Section 7.2.2.5) 
Histamine Dynabeads 125 400 0 
Experiment Vb 
(Section 7.2.2.5) 
ICT-5074 Dynabeads 125 400 0 
Experiment VIa 
(Section 7.2.2.6) 
Histamine Dynabeads 125 0 50ρmoles 
Experiment VIb 
(Section 7.2.2.6) 
ICT-5074 Dynabeads 125 0 50ρmoles 
Experiment VIc 
(Section 7.2.2.6) 
ICT-5083 Dynabeads 125 0 50ρmoles 
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7.2.2.5 Inhibitor-bead chromatography experiment V 
 
The affinity chromatography method (Section 7.2.2.4) was repeated with 
dynabeads (125µl packed volume) as the solid support instead of agarose. 
All other method details were kept the same. It is possible to use smaller 
quantities of beads as losses are reduced, using a strong magnet to separate 
the beads from the solution. This was essential when using ICT-5083 as only 
very small quantities of the inhibitor compound were available.  
 
7.2.2.6 Inhibitor-bead chromatography experiment VI 
 
The inhibitor bead chromatography (Section 7.2.2.5) was repeated, with 
histamine, ICT-5074 and ICT-5083 probes using a mix of recombinant 
human P450 from bactosomes. The bactosome mix included 50ρmoles of 
CYP1A2, 1B1, 2B6, 2C8, 2C19, 2D6, 2E1, 2J2, 3A5, and 4A11. The required 
volume of bactosome material was calculated for each P450 stock tube, with 
a total volume of 197µl. Each of these samples also contained co-expressed 
cytochrome b5 and NADPH reductase. This allowed comparison of the 
binding properties of the inhibitors to human P450s compared to the mouse 
model P450s.  
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7.3 Results 
7.3.1 Biotinylated probe affinity chromatography 
The use of the biotinylated inhibitor probes for affinity capture and 
streptavidin bead separation was investigated, with a cleavable linker moiety. 
This may also decrease contamination in the elution fractions from some 
proteins that have non-specifically bound. Addition of the free inhibitor probe 
to liver microsomes before addition to streptavidin beads (2-step) was 
compared to the creation of inhibitor probe-streptavidin beads which was 
added to liver microsomes for one-step capture and separation (Figure 7.5). 
Due to limited supplies of materials this chromatography used half the 
quantities of all reagents, samples and materials involved. The DTT-eluted 
proteins from the ICT-5074-streptavidin beads produced a clear band in the 
45-55kDa region (indicated by arrow, Lane 8), that was not present in the 
other probe captured regions. 
7.3.2 Inhibitor-bead chromatography experiment IV 
A summary of the mass spectrometry data generated from trypsin digestion 
of the bead eluates is shown in Table 7.3, using conditions detailed in 
Section 7.2.2.4. Histamine beads incubated with mouse liver microsomes 
identified 14 P450s with MASCOT scores 45 or above and at least 3 
peptides. ICT-5074 beads incubated with mouse liver microsomes identified 
10 P450s with MASCOT scores 45 or above and at least 3 peptides. 
Although the histamine beads bound more P450s, they also showed a higher 
level of non-specific binding of proteins (53), compared to the ICT-5074 
beads (38). Appendix G details those proteins that were enriched using either 
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histamine (38) or ICT-5074 (14) in comparison to the control beads, with 
respect to MASCOT score and number of peptides. ICT-5074 beads show 
much more specific enrichment, with only 4 additional proteins (fatty 
aldehyde dehydrogenase; protein disulphide-isomerase A6; tubulin beta-2A 
chain; tubuline beta-2C chain) from the P450s listed in Figure 7.3. This 
compares favourably to the histamine beads with 24 additonal proteins 
(Appendix G). 
7.3.3 Inhibitor-bead chromatography experiment V 
Magnetic dynabeads were used to help reduce non-specific binding to the 
bead support due to their smooth, non-porous surface (Figure 7.1). A 
comparison of the P450 binding properties of the two bead supports used in 
inhibitor-bead chromatography experiments IV and V is shown in Table 7.3. 
Histamine beads bound 40 proteins, 8 being P450s (20% total protein), and 
ICT-5074 beads bound 14 proteins, 3 being P450s (21% total protein). 
Appendix H details those proteins that were enriched using either histamine 
(10) or ICT-5074 (11) in comparison to the control beads, with respect to 
MASCOT score and number of peptides. ICT-5074 beads show much more 
specific enrichment, with only 8 additional proteins (actin, alpha cardiac 
muscle 1; actin, aortic smooth muscle; actin, cytoplasmic 1; 
argininosuccinate synthase; calreticulin; delta(3,5)-delta(2,4)-dienoyl-CoA 
isomerase, mitochondrial; protein disulphide-isomerase A6; UDP-
glucuronosyltransferase 1-1) from the P450s listed in Figure 7.3. This 
compares to the histamine beads with 3 additonal proteins (actin, 
cytoplasmic 1; apolipoprotein E; UDP-glucuronosyltransferase 1-1). 
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Figure 7.5: Comparison of 1-step and 2-step affinity probe (ICT-5074) P450 
capture and separation with streptavidin dynabeads. Lane positions are 
labelled above gel and relative molecular weight markers labelled on left of gel. 
Lane 3 contains mouse liver microsome starting material. Lanes 5-6 contain DTT 
eluted (E7) and heat-treated beads, respectively, from 2-step ICT-5074 probe 
P450 capture from microsomes then streptavidin bead separation, Lanes 8-9 
contain DTT eluted (E7) and heat-treated beads, respectively, from 1-step probe 
P450 capture and separation from ICT-5074-streptavidin  beads. 
 
 
7.3.4 Inhibitor-bead chromatography experiment VI 
The dynabead chromatography was repeated using a P450 bactosome mix 
(Section 7.2.2.6) to closely monitor P450 binding using known quantities of 
P450 (50 ρmoles each). An alternative P450 inhibitor, ICT-5083, was also 
used in inhibitor-bead chromatography experiments VI. Table 7.4 compares 
the P450 binding of the 3 P450 inhibitors beads. All 10 P450s from the P450 
bactosome mix were recovered and identified in 1 or more fractions, and 
there were no further P450s incorrectly identified due to sequence similarities 
between the proteins.  
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Table 7.3: Comparison of P450 identification from inhibitor-affinity chromatography experiments IV and V using mouse liver microsome starting 
material. Experiment IV used streptavidin agarose beads for biotin –linked inhibitor attachment. Experiment IV used streptavidin dynabeads for biotin –linked 
inhibitor attachment. MASCOT score (Scr) and the number of peptides identified for each protein (#P) is listed for each liver microsome fraction
Protein Accession   
(Mouse) 
MW  
(kDa) 
Histamine-bead 
chromatography 
experiment IVa 
ICT-5074-bead 
chromatography 
experiment IVb 
Histamine-bead 
chromatography 
experiment Va 
ICT-5074-bead 
chromatography 
experiment Vb 
Starting material 
Scr #P Scr #P Scr #P Scr #P Scr #P 
Cytochrome P450 1A2  CP1A2 58.147 164 11 98 3 367 13 52 6 - - 
Cytochrome P450 1B1  CP1B1 60.807 - - - - 255 17 144 11 - - 
Cytochrome P450 2A4  CP2A4 56.558 187 9 73 4 - - - - 81 9 
Cytochrome P450 2A5 CP2A5 56.704 187 8 - - - - - - 81 9 
Cytochrome P450 2C29  CP2CT 55.694 335 29 76 5 228 15 - - 62 8 
Cytochrome P450 2C37  CP237 55.478 422 27 76 6 56 6 - - 101 6 
Cytochrome P450 2C39  CP239 55.867 260 19 77 5 - - - - 89 5 
Cytochrome P450 2C40  CP240 55.743 161 7 - - - - - - - - 
Cytochrome P450 2C50  CY250 55.638 455 20 76 6 - - - - 77 4 
Cytochrome P450 2C54  CP254 55.821 342 20 53 5 - - - - 50 6 
Cytochrome P450 2D10  CP2DA 57.197 240 10 70 6 851 25 152 8 122 7 
Cytochrome P450 2D11  CP2DB 57.118 122 7 - - - - - - - - 
Cytochrome P450 2D26  CP2DQ 56.939 109 6 - - - - - - 143 11 
Cytochrome P450 2E1 CP2E1 56.769 289 13 117 7 90 9 - - 185 9 
Cytochrome P450 2F2  CP2F2 55.913 190 14 63 6 - - - - 67 6 
Cytochrome P450 2J2  CP2J6 57.761 - - - - 44 11 - - - - 
Cytochrome P450 3A11 CP3A 58.159 - - - - 78 6 - - - - 
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Table 7.4: Comparison of P450 identification from inhibitor-affinity chromatography experiment VI using P450 bactosome mix starting material. 
Experiment VI used streptavidin dynabeads for biotin –linked inhibitor attachment.  MASCOT score (Scr) and the number of peptides identified for each 
protein (#P) is listed for each liver microsome fraction.
Protein Accession 
(Human) 
MW 
(kDa) 
Histamine-bead 
chromatography 
experiment VIa 
ICT-5074-bead 
chromatography 
experiment VIb 
ICT-5083-bead 
chromatography 
experiment VIc 
Starting material 
Scr #P Scr #P Scr #P Scr #P 
Cytochrome P450 1A2  CP1A2 58.147 - - 117 10 288 10 - - 
Cytochrome P450 1B1  CP1B1 60.807 177 13 156 10 156 8 - - 
Cytochrome P450 2B6  CP2B6 56.242 - - - - 45 3 - - 
Cytochrome P450 2C8  CP2C8 55.789 179 11 46 5 126 11 - - 
Cytochrome P450 2C19  CP2CJ 55.895 52 4 - - - - - - 
Cytochrome P450 2D6  CP2D6 55.734 692 23 550 21 630 24 - - 
Cytochrome P450 2E1  CP2E1 56.769 75 3 - - 79 3 75 3 
Cytochrome P450 2J2  CP2J2 57.574 - - - - 78 6 - - 
Cytochrome P450 3A5  CP3A5 57.072 64 5 80 5 194 7 - - 
Cytochrome P450 4A11  CP4AB 59.310 488 13 264 10 486 13 - - 
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7.4 Discussion 
7.4.1 Streptavidin-agarose bead chromatography 
To transfer the chromatography procedure detailed in Chapter 5 from epoxy-
activated sepharose beads to streptavidin-agarose beads it was necessary to 
introduce a new affinity capture strategy. Chemical synthesis of biotin-linked 
inhibitors using a commercially available biotin-linker compound (Figure 7.2) 
introduced the necessary biotin group for bead attachment, as well as the 
ability to bind ICT-5074 via its terminal amine-group targeted by the NHS 
group on the linker.  
 
It was hoped that due to the streptavidin coated surface of the beads, that 
non-specific binding to the bead surface would be insignificant and so P450 
identification would be increased. ICT-5074-bead chromatography 
experiment IVb increased P450 identification from 2 P450s using inhibitor-
sepharose beads (CYP2A4, CYP4F3) to 10 P450s using inhibitor-agarose 
beads detailed in Table 7.2. CYP2A4 was also identified in chromatography 
experiment IVb, but CYP4F3 was not, however a close homolog CYP4F2 
was identified by chromatography experiment IVb. 
 
For experiments IV to VI, an alternative inhibitor compound, histamine, was 
introduced as it shared the same active group as ICT-5074 (imidazole ring). 
This was used to investigate the necessity of the ‘bulky’ structure of ICT-5074 
once attached to the linker and bead for P450 inhibition and to act as a 
cheaper alternative. Overall, histamine showed a higher level of non-specific 
binding, although this led to the capture and identification of more P450s 
 222 
(14). This is not too surprising as histamine has not previously been used to 
target the P450s and is known to be important in many other biochemical 
pathways independent of P450s. 
 
7.4.2 Streptavidin-dynabead chromatography 
The inhibitor chromatography experiments detailed in Section 7.4.1 were 
transferred to streptavidin-dynabeads to further decrease non-specific 
binding due to the smooth, non-porous surface of the magnetic dynabeads 
(Figure 7.1). It was also possible to achieve better bead recovery during 
washing and elution to help improve protein identification and decrease the 
amount of beads required.  
 
Histamine-biotin with streptavidin-dynabeads identified 8 P450s, which 
although less than those observed with immobilised histamine 
chromatography (Experiment IVa), non-specific binding was reduced. This 
may indicate that some of the P450 binding seen in the latter case was due 
to non-specific interactions. ICT-5074-biotin with streptavidin-dynabeads 
identified only 3 P450s, which is less P450s than those observed with 
immobilised ICT-5074 chromatography (Experiment IVb), but again could be 
due decreases in non-specific interactions. Alternatively, this may be an 
indicator that more beads are required for P450 identification, as the smaller 
beads may lead to a greater level of steric hinderance at adjacent binding 
sites.   
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A mix of 10 human recombinant P450s (50ρmoles) covering a range of 
different P450 families and sub-families was used to investigate the P450 
recovery rate of the inhibitor-dynabeads. It was possible to identify all of the 
P450s from the bactosome mix using one or more of the P450 inhibitor 
chromatography beads. Interestingly, the histamine and ICT-5074 beads, 
both of which use an imidazole group to target the P450s, showed similar 
binding profiles. Histamine beads captured 7 out of the 10 P450s and ICT-
5074 beads captured 6 out of the 10 P450s from the bactosome mix.  
 
Less inhibitor is required for coupling to the dynabeads so it became possible 
to use another P450 inhibitor, ICT-5083 (2-EN analogue), which was in 
limited supply. ICT-5083 showed the greatest range of P450 binding, having 
protein identifications with high MASCOT scores. ICT-5083 beads captured 9 
out of the 10 P450s from the bactosome mix. These results reflect the 
predicted nature of binding from previous chromatography experiments 
(Chapter 5) and compound details from literature, as discussed in Section 
7.1.2.  
 
 
 
 
 
 
 
 
  
CHAPTER EIGHT 
Conclusions and Future Work 
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8.0 Conclusions & Future Work 
8.1 P450s in cancer 
P450s are known to have a role in cancer development and therapeutic 
strategies against cancer progression. P450s have been implicated in cancer 
due to their increased protein levels in certain tumour types and the important 
role they play in xenobiotic metabolism. Hormone dependent cancers, such 
as breast cancer, can have links to P450’s, such as the CYP19 aromatase 
enzyme, which when inhibited can prove to be a successful treatment option 
(Brodie et al., 1977). There are three aromatase enzymes currently approved 
by the FDA, anastrozole, exemestane, and letrozole. Abiraterone acetate is a 
pro-drug of abiraterone currently in clinical trials, acting as a selective 
inhibitor of CYP17 (Ryan et al., 2010). CYP17 has been implicated in certain 
prostate cancers. CYP24 is an enzyme implicated in lung and colon cancer 
because it acts to deactivate an active vitamin D metabolite, which is an 
important endogenous anticancer agent (Skowronski et al., 1993). Members 
of the CYP1 family are known to activate pro-carcinogens, and CYP1B1 is 
overexpressed in many tumour types (Murray et al., 1997). The cancer 
therapeutic topoisomerase inhibitor prodrug, AQ4N, is converted to its AQ4 
active form in sites of hypoxia via P450 metabolism and so in this instance 
P450 metabolism acts to enhance therapy (Patterson and McKeown, 2000). 
These studies, as well as those described in Chapter 1, highlight the 
importance of P450s in cancer therapeutics. Development of P450 affinity 
capture materials would be useful in cancer research to identify P450s 
present in an array of tumours types, allowing for more appropriate 
chemotherapy choice. 
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8.2 Conclusions 
The main problem with studying active P450s is their relative low abundance 
in normal tissue. The liver contains the highest P450 levels in healthy tissues, 
but still the levels of the various families and sub-families of proteins are low 
in comparison to the total protein level. The levels of P450s in tumorous 
tissues, although elevated, still show the same problems, with specific 
isoforms still being undetectable in their active protein form. 
 
The aim of this project was to identify and optimise an affinity based method 
for rapid purification of P450s, as well as other membrane proteins which 
may be of interest in the field of cancer therapeutics. Initially membrane-lipid 
based immobilisation was investigated. The commercially available IAM.PC 
column was studied and previous work by Pidgeon et al. (1991) and Scharf 
et al. (1998) was mimicked. Unfortunately the results gained, differed from 
those found by these investigators. This may have been due to the different 
scale of work as the HPLC system utilised here could not load the same 
amount of liver microsomes onto the IAM.PC column, and so levels may 
have been undetectable. Also detergent interference proved to be very 
problematic and when attempts were made to derivitise the lipid-based 
material for manipulation of scales and detergents used, there were problems 
with chemical synthesis and product solubilty.  
 
A P450 inhibitor ketoconazole analogue was derivatised (ICT-5074), which 
was used as a P450 target for immobilisation onto epoxy-activated 
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sepharose beads. Evaluation of the ICT-5074-bead affinity chromatography 
methods showed some interesting results. A trypsin digest protocol was 
standardised providing a good representation of proteins present. When 
comparing the protein identifications of the bound (imidazole, NADPH-
removal elution) to unbound (flow-through) proteins from ICT-5074 beads, 
and also in comparison to the control-bead (glycine-blocked) samples, there 
was evidence that the immobilised compound was making a difference to 
protein-bead interaction. With optimisation of the chromatography 
equilibration and elution conditions, specificity was increased, non-specific 
binding reduced, and it was possibile to identify lower abundance proteins 
that bound, eluted and became detectable by proteomic methods.  
 
Using biotin-linked inhibitor (histamine and ICT-5074) probes, with 
subsequent streptavidin-bead separation, the biggest improvement in P450-
to-total protein ratio was seen, identifying up to 10 (ICT-5074-probe) and 14 
P450s (histamine-probe) in a single chromatography run. Mouse CYP1A2, 
CYP1B1, CYP2A4, CYP2C29, CYP2C37, CYP2C39, CYP2C40, CYP2C50, 
CYP2C54, CYP2D10, CYP2D11, CYP2E1, CYP2F2, CYP2J2 and CYP3A11 
were among those P450s shown to be enriched in comparison to the starting 
material, indicated by improved MASCOT scores and peptide number. 
 
Histamine and ICT-5074 were compared to another alternative P450 
inhibitor, ICT-5083, which has a structure based on a known P450 inhibitor 
(2-EN). This product was in very limited supply, so was only introduced when 
using magnetic dynabeads for smaller scale studies with decreased losses of 
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beads (in liquid fractions) and better recovery of eluates (easier to separate 
from beads due to tight separation of beads using magnets). A mixture of 
human P450s (CYP1A2, CYP1B1, CYP2B6, CYP2C8, CYP2C19, CYP2D6, 
CYP2E1, CYP2J2, CYP3A5 and CYP4A11) from bactosome samples was 
used during the smaller scale studies to identify the ability of the beads to 
bind and recover P450s in the eluate. It was possible to identify all of the 
P450s from the mix using one or more of the P450 inhibitors. ICT-5083 
identified the largest range of P450s (9 of 10), whilst ICT-5074 was the most 
specific P450-capture material (6 of 10). CYP1B1, CYP2C8, CYP2D6, 
CYP3A5 and CYP4A11 were identified by all three chromatographies. This 
study has determined that the use of several immobilised P450 inhibitors can 
lead to differing P450 profiles, and may be of potential benefit to those 
wishing to study the P450 binding profiles of specific P450 inhibitors.  
 
An important part of this project investigated the issues of non-specific 
binding of proteins to the affinity chromatography supports. The use of 
ethanolamine to block the remaining active epoxy- sites on the sepharose 
beads was replaced by glycine based on work by Williams et al. (2006), 
which lead to decreases in proteins binding to blocked-bead control samples. 
Reduction of non-specific binding by aleterations in acetonitirile concentration 
in the chromatography buffers lead to decreased protein binding, but it may 
have been due to protein precipitation. This negatively affected the binding of 
P450s to the inhibitor beads as an active form of the protein is required so 
acetonitrile concentrations were kept at 10%. Increases in salt concentration 
to decrease non-specific ionic interactions to the beads did lead to a 
 229 
generalised decrease in protein binding, but unfortunately also lead to 
decreases in specific binding, indicating that ionic interactions may be 
important for P450 binding.  
 
An alternative approach looked at blocking the beads with β-casein to 
decrease the availability of free sites and pores, allowing only for specific 
binding to the immobilised ligands, extending from the linker spacer arm. 
Again β-casein did decrease general protein binding, but also affected P450 
binding.  
 
To conclude, the application of inhibitor analogues to capture P450s with 
subsequent analysis by MS generated very promising results, but was 
hampered by non-specific binding of proteins to chromatographic media.  
 
8.3 Future studies 
The differing P450 and other microsomal protein binding profiles of the three 
P450 inhibitors used during this project (histamine, ICT-5074, ICT-5083) 
indicated it is possible to closely examine P450 drug binding profiles. The 
limited supply of ICT-5083 did not allow for full examination of this P450 
inhibitor, as was possible with ICT-5074, described in Chapter 5. Before 
extending this project to further investigate alternative inhibitors, it may be 
beneficial to further optimise chromatography protocols to try and reduce 
non-specific binding. An area of great interest for further investigation is the 
use of alternative inert media which do not bind proteins non-specifically.  
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Figure 8.1: Progress of IAM.PC and affinity chromatogrpahy 
throughout project 
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Develop affinity chromatography 
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link IAM.PC to MS 
Enhance protocol for larger scale 
affinity chromatography 
Develop affinity chromatography 
protocol using streptavidin-
agarose beads and alternative 
inhibitors 
Problems with synthesis of novel 
phospholipids for immobilisation 
Investigation of non-specific 
binding 
Develop affinity chromatography 
protocol using streptavidin-
dynabeads and alternative 
inhibitors 
 231 
Investigations using human microsomal proteins will be extremely important, 
as the bactosome studies showed good binding of the inhibitor analogues to 
recombinant human P450s. Although, as discussed in Chapter 2, the mouse 
model is appropriate for human P450 functionality, there are many more 
P450s in mice than humans and the overall consequences on global 
proteome reactions is unknown. There may be P450s present in mouse 
models that interact with the affinity capture material giving false positive 
results. Mouse microsome proteins may also lead to on-bead enzymatic 
modification of the immobilised inhibitor. 
 
It may be possible to adapt the proteomic workflow for MALDI-chip 
technology. Novel MALDI-chip technology has already been developed, 
although the technology is still in its infancy (Brivio et al., 2002). 
Microchannels and inlet/outlet reservoirs on the surface of the glass wafers 
allow for on-chip reactions. The chip can be attached to a carrier MALDI 
target plate for direct MS analysis in real-time. The drawback to this 
methodology is that the resulting purified protein solution needs to be 
simplified as there is no HPLC separation prior to MS. 
 
The following objectives would be important in future investigations:  
1. Investigate alternative bead-blocking proteins, mimicking the β-casein 
protocol (Chapter 6), using proteins of various shapes and sizes 
2. Develop a protocol for use of alternative supports for chromatography, 
with reduced non-specific binding properties, for fraction collection 
using competitive elution or direct trypsin digestion 
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3. Design an alternative proteomics workflow for use with alternative 
chromatography supports 
4. Further investigate ICT-5083 as more becomes available, as well as 
other inhibitors, for improved P450 binding 
5. Use human liver microsomal protein preparations to compare to 
mouse liver microsomal protein chromatography 
 
As an alternative approach to chemical affinity chromatography, protein 
affinity chromatography could lead to advances in P450 enrichment. NADPH-
cytochrome P450 reductase is a protein that all P450s associate with. 
Expression of labelled recombinant NADPH-cytochrome P450 reductase (for 
example biotin labelled), and consequent solid phase purification (for 
example streptavidin beads), could lead to the creation of specific beads that 
have the potential for interaction with all of the P450s in mouse and human 
samples. Possible drawbacks with this method include the fact that P450s 
may not interact with strong enough affinity for the immobilised protein to 
allow washing of all other proteins from the sample without also stripping the 
P450s from the beads.  
 
In summary, the work completed here has shown that immobilised chemicals 
can create affinity bead with differing binding profiles. The protocols created 
and described in this study can be adapted to immobilisation of drugs with 
primary amine groups to monitor P450 and other microsomal protein binding 
profiles. 
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Appendix A: Validated human and mouse P450 sequences used for animal model testing. Sequences taken from Uniprot database and Dr Nelson’s 
cytochrome P450 homepage.Mouse P450 peptides identified by MS in Chapter 3 are highlights in mouse sequences in red. 
 
 
Validated Human P450 sequences 
1. cp11a human (521 residues): 
'MLAKGLPPRSVLVKGCQTFLSAPREGLGRLRVPTGEGAGISTRSPRPFNEIPSPGDNGWLNLYHFWRETGTHKVHLHHVQNFQKYGPIYREKLGNVESVYVIDPEDVALLFKSEGPNPERFLIPPWVAYHQYY
QRPIGVLLKKSAAWKKDRVALNQEVMAPEATKNFLPLLDAVSRDFVSVLHRRIKKAGSGNYSGDISDDLFRFAFESITNVIFGERQGMLEEVVNPEAQRFIDAIYQMFHTSVPMLNLPPDLFRLFRTKTWKDH
VAAWDVIFSKADIYTQNFYWELRQKGSVHHDYRGILYRLLGDSKMSFEDIKANVTEMLAGGVDTTSMTLQWHLYEMARNLKVQDMLRAEVLAARHQAQGDMATMLQLVPLLKASIKETLRLHPISVTLQR
YLVNDLVLRDYMIPAKTLVQVAIYALGREPTFFFDPENFDPTRWLSKDKNITYFRNLGFGWGVRQCLGRRIAELEMTIFLINMLENFRVEIQHLSDVGTTFNLILMPEKPISFTFWPFNQEATQQ' 
2. c11b1 human (503 residues): 
'MALRAKAEVCMAVPWLSLQRAQALGTRAARVPRTVLPFEAMPRRPGNRWLRLLQIWREQGYEDLHLEVHQTFQELGPIFRYDLGGAGMVCVMLPEDVEKLQQVDSLHPHRMSLEPWVAYRQHRGHKCG
VFLLNGPEWRFNRLRLNPEVLSPNAVQRFLPMVDAVARDFSQALKKKVLQNARGSLTLDVQPSIFHYTIEASNLALFGERLGLVGHSPSSASLNFLHALEVMFKSTVQLMFMPRSLSRWTSPKVWKEHFEAW
DCIFQYGDNCIQKIYQELAFSRPQQYTSIVAELLLNAELSPDAIKANSMELTAGSVDTTVFPLLMTLFELARNPNVQQALRQESLAAAASISEHPQKATTELPLLRAALKETLRLYPVGLFLERVASSDLVLQNY
HIPAGTLVRVFLYSLGRNPALFPRPERYNPQRWLDIRGSGRNFYHVPFGFGMRQCLGRRLAEAEMLLLLHHVLKHLQVETLTQEDIKMVYSFILRPSMFPLLTFRAIN' 
3. c11b2 huamn (503 residues): 
'MALRAKAEVCVAAPWLSLQRARALGTRAARAPRTVLPFEAMPQHPGNRWLRLLQIWREQGYEHLHLEMHQTFQELGPIFRYNLGGPRMVCVMLPEDVEKLQQVDSLHPCRMILEPWVAYRQHRGHKCGV
FLLNGPEWRFNRLRLNPDVLSPKAVQRFLPMVDAVARDFSQALKKKVLQNARGSLTLDVQPSIFHYTIEASNLALFGERLGLVGHSPSSASLNFLHALEVMFKSTVQLMFMPRSLSRWISPKVWKEHFEAWD
CIFQYGDNCIQKIYQELAFNRPQHYTGIVAELLLKAELSLEAIKANSMELTAGSVDTTAFPLLMTLFELARNPDVQQILRQESLAAAASISEHPQKATTELPLLRAALKETLRLYPVGLFLERVVSSDLVLQNYHI
PAGTLVQVFLYSLGRNAALFPRPERYNPQRWLDIRGSGRNFHHVPFGFGMRQCLGRRLAEAEMLLLLHHVLKHFLVETLTQEDIKMVYSFILRPGTSPLLTFRAIN' 
4. cp17a human (508 residues): 
'MWELVALLLLTLAYLFWPKRRCPGAKYPKSLLSLPLVGSLPFLPRHGHMHNNFFKLQKKYGPIYSVRMGTKTTVIVGHHQLAKEVLIKKGKDFSGRPQMATLDIASNNRKGIAFADSGAHWQLHRRLAMAT
FALFKDGDQKLEKIICQEISTLCDMLATHNGQSIDISFPVFVAVTNVISLICFNTSYKNGDPELNVIQNYNEGIIDNLSKDSLVDLVPWLKIFPNKTLEKLKSHVKIRNDLLNKILENYKEKFRSDSITNMLDTLMQ
AKMNSDNGNAGPDQDSELLSDNHILTTIGDIFGAGVETTTSVVKWTLAFLLHNPQVKKKLYEEIDQNVGFSRTPTISDRNRLLLLEATIREVLRLRPVAPMLIPHKANVDSSIGEFAVDKGTEVIINLWALHHNE
KEWHQPDQFMPERFLNPAGTQLISPSVSYLPFGAGPRSCIGEILARQELFLIMAWLLQRFDLEVPDDGQLPSLEGIPKVVFLIDSFKVKIKVRQAWREAQAEGST' 
5. cp19a human (503 residues): 
'MVLEMLNPIHYNITSIVPEAMPAATMPVLLLTGLFLLVWNYEGTSSIPGPGYCMGIGPLISHGRFLWMGIGSACNYYNRVYGEFMRVWISGEETLIISKSSSMFHIMKHNHYSSRFGSKLGLQCIGMHEKGIIFN
NNPELWKTTRPFFMKALSGPGLVRMVTVCAESLKTHLDRLEEVTNESGYVDVLTLLRRVMLDTSNTLFLRIPLDESAIVVKIQGYFDAWQALLIKPDIFFKISWLYKKYEKSVKDLKDAIEVLIAEKRRRISTEE
KLEECMDFATELILAEKRGDLTRENVNQCILEMLIAAPDTMSVSLFFMLFLIAKHPNVEEAIIKEIQTVIGERDIKIDDIQKLKVMENFIYESMRYQPVVDLVMRKALEDDVIDGYPVKKGTNIILNIGRMHRLEF
FPKPNEFTLENFAKNVPYRYFQPFGFGPRGCAGKYIAMVMMKAILVTLLRRFHVKTLQGQCVESIQKIHDLSLHPDETKNMLEMIFTPRNSDRCLEH' 
6. cp1a1 human (512 residues): 
'MLFPISMSATEFLLASVIFCLVFWVIRASRPQVPKGLKNPPGPWGWPLIGHMLTLGKNPHLALSRMSQQYGDVLQIRIGSTPVVVLSGLDTIRQALVRQGDDFKGRPDLYTFTLISNGQSMSFSPDSGPVWAAR
RRLAQNGLKSFSIASDPASSTSCYLEEHVSKEAEVLISTLQELMAGPGHFNPYRYVVVSVTNVICAICFGRRYDHNHQELLSLVNLNNNFGEVVGSGNPADFIPILRYLPNPSLNAFKDLNEKFYSFMQKMVKE
HYKTFEKGHIRDITDSLIEHCQEKQLDENANVQLSDEKIINIVLDLFGAGFDTVTTAISWSLMYLVMNPRVQRKIQEELDTVIGRSRRPRLSDRSHLPYMEAFILETFRHSSFVPFTIPHSTTRDTSLKGFYIPKGRC
VFVNQWQINHDQKLWVNPSEFLPERFLTPDGAIDKVLSEKVIIFGMGKRKCIGETIARWEVFLFLAILLQRVEFSVPLGVKVDMTPIYGLTMKHACCEHFQMQLRS' 
7. cp1a2 human (515 residues): 
'MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKNPHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDGQSLTFSTDSGPVWA
ARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELMAGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFPILRYLPNPALQRFKAFNQRFLWFLQKTV
QEHYQDFDKNSVRDITGALFKHSKKGPRASGNLIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLSDRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCC
VFVNQWQVNHDPELWEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLEFSVPPGVKVDLTPIYGLTMKHARCEHVQARRFSIN' 
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8. cp1b1 human (543 residues): 
'MGTSLSPNDPWPLNPLSIQQTTLLLLLSVLATVHVGQRLLRQRRRQLRSAPPGPFAWPLIGNAAAVGQAAHLSFARLARRYGDVFQIRLGSCPIVVLNGERAIHQALVQQGSAFADRPAFASFRVVSGGRSMA
FGHYSEHWKVQRRAAHSMMRNFFTRQPRSRQVLEGHVLSEARELVALLVRGSADGAFLDPRPLTVVAVANVMSAVCFGCRYSHDDPEFRELLSHNEEFGRTVGAGSLVDVMPWLQYFPNPVRTVFREFEQ
LNRNFSNFILDKFLRHCESLRPGAAPRDMMDAFILSAEKKAAGDSHGGGARLDLENVPATITDIFGASQDTLSTALQWLLLLFTRYPDVQTRVQAELDQVVGRDRLPCMGDQPNLPYVLAFLYEAMRFSSFVP
VTIPHATTANTSVLGYHIPKDTVVFVNQWSVNHDPLKWPNPENFDPARFLDKDGLINKDLTSRVMIFSVGKRRCIGEELSKMQLFLFISILAHQCDFRANPNEPAKMNFSYGLTIKPKSFKVNVTLRESMELLDS
AVQNLQAKETCQ 
9. cp20a human (462 residues): 
'MLDFAIFAVTFLLALVGAVLYLYPASRQAAGIPGITPTEEKDGNLPDIVNSGSLHEFLVNLHERYGPVVSFWFGRRLVVSLGTVDVLKQHINPNKTSDPFETMLKSLLRYQSGGGSVSENHMRKKLYENGVTD
SLKSNFALLLKLSEELLDKWLSYPETQHVPLSQHMLGFAMKSVTQMVMGSTFEDDQEVIRFQKNHGTVWSEIGKGFLDGSLDKNMTRKKQYEDALMQLESVLRNIIKERKGRNFSQHIFIDSLVQGNLNDQQ
ILEDSMIFSLASCIITAKLCTWAICFLTTSEEVQKKLYEEINQVFGNGPVTPEKIEQLRYCQHVLCETVRTAKLTPVSAQLQDIEGKIDRFIIPRETLVLYALGVVLQDPNTWPSPHKFDPDRFDDELVMKTFSSLGF
SGTQECPELRFAYMVTTVLLSVLVKRLHLLSVEGQVIETKYELVTSSREEAWITVSKRY' 
10. cp21A human (494 residues): 
'MLLLGLLLLPLLAGARLLWNWWKLRSLHLPPLAPGFLHLLQPDLPIYLLGLTQKFGPIYRLHLGLQDVVVLNSKRTIEEAMVKKWADFAGRPEPLTYKLVSKNYPDLSLGDYSLLWKAHKKLTRSALLLGIR
DSMEPVVEQLTQEFCERMRAQPGTPVAIEEEFSLLTCSIICYLTFGDKIKDDNLMPAYYKCIQEVLKTWSHWSIQIVDVIPFLRFFPNPGLRRLKQAIEKRDHIVEMQLRQHKESLVAGQWRDMMDYMLQGVA
QPSMEEGSGQLLEGHVHMAAVDLLIGGTETTANTLSWAVVFLLHHPEIQQRLQEELDHELGPGASSSRVPYKDRARLPLLNATIAEVLRLRPVVPLALPHRTTRPSSISGYDIPEGTVIIPNLQGAHLDETVWER
PHEFWPDRFLEPGKNSRALAFGCGARVCLGEPLARLELFVVLTRLLQAFTLLPSGDALPSLQPLPHCSVILKMQPFQVRLQPRGMGAHSPGQNQ' 
11. cp24a human (514 residues): 
'MSSPISKSRSLAAFLQQLRSPRQPPRLVTSTAYTSPQPREVPVCPLTAGGETQNAAALPGPTSWPLLGSLLQILWKGGLKKQHDTLVEYHKKYGKIFRMKLGSFESVHLGSPCLLEALYRTESAYPQRLEIKPW
KAYRDYRKEGYGLLILEGEDWQRVRSAFQKKLMKPGEVMKLDNKINEVLADFMGRIDELCDERGHVEDLYSELNKWSFESICLVLYEKRFGLLQKNAGDEAVNFIMAIKTMMSTFGRMMVTPVELHKSLN
TKVWQDHTLAWDTIFKSVKACIDNRLEKYSQQPSADFLCDIYHQNRLSKKELYAAVTELQLAAVETTANSLMWILYNLSRNPQVQQKLLKEIQSVLPENQVPRAEDLRNMPYLKACLKESMRLTPSVPFTTR
TLDKATVLGEYALPKGTVLMLNTQVLGSSEDNFEDSSQFRPERWLQEKEKINPFAHLPFGVGKRMCIGRRLAELQLHLALCWIVRKYDIQATDNEPVEMLHSGTLVPSRELPIAFCQR' 
12. cp26a human (497 residues): 
'MGLPALLASALCTFVLPLLLFLAAIKLWDLYCVSGRDRSCALPLPPGTMGFPFFGETLQMVLQRRKFLQMKRRKYGFIYKTHLFGRPTVRVMGADNVRRILLGEHRLVSVHWPASVRTILGSGCLSNLHDSSH
KQRKKVIMRAFSREALECYVPVITEEVGSSLEQWLSCGERGLLVYPEVKRLMFRIAMRILLGCEPQLAGDGDSEQQLVEAFEEMTRNLFSLPIDVPFSGLYRGMKARNLIHARIEQNIRAKICGLRASEAGQGC
KDALQLLIEHSWERGERLDMQALKQSSTELLFGGHETTASAATSLITYLGLYPHVLQKVREELKSKGLLCKSNQDNKLDMEILEQLKYIGCVIKETLRLNPPVPGGFRVALKTFELNGYQIPKGWNVIYSICDT
HDVAEIFTNKEEFNPDRFMLPHPEDASRFSFIPFGGGLRSCVGKEFAKILLKIFTVELARHCDWQLLNGPPTMKTSPTVYPVDNLPARFTHFHGEI' 
13. cp26b human (512 residues): 
'MLFEGLDLVSALATLAACLVSVTLLLAVSQQLWQLRWAATRDKSCKLPIPKGSMGFPLIGETGHWLLQGSGFQSSRREKYGNVFKTHLLGRPLIRVTGAENVRKILMGEHHLVSTEWPRSTRMLLGPNTVSN
SIGDIHRNKRKVFSKIFSHEALESYLPKIQLVIQDTLRAWSSHPEAINVYQEAQKLTFRMAIRVLLGFSIPEEDLGHLFEVYQQFVDNVFSLPVDLPFSGYRRGIQARQILQKGLEKAIREKLQCTQGKDYLDALD
LLIESSKEHGKEMTMQELKDGTLELIFAAYATTASASTSLIMQLLKHPTVLEKLRDELRAHGILHSGGCPCEGTLRLDTLSGLRYLDCVIKEVMRLFTPISGGYRTVLQTFELDGFQIPKGWSVMYSIRDTHDTA
PVFKDVNVFDPDRFSQARSEDKDGRFHYLPFGGGVRTCLGKHLAKLFLKVLAVELASTSRFELATRTFPRITLVPVLHPVDGLSVKFFGLDSNQNEILPETEAMLSATV' 
14. cp26c human (522 residues): 
'MFPWGLSCLSVLGAAGTALLCAGLLLSLAQHLWTLRWMLSRDRASTLPLPKGSMGWPFFGETLHWLVQGSRFHSSRRERYGTVFKTHLLGRPVIRVSGAENVRTILLGEHRLVRSQWPQSAHILLGSHTLLG
AVGEPHRRRRKVLARVFSRAALERYVPRLQGALRHEVRSWCAAGGPVSVYDASKALTFRMAARILLGLRLDEAQCATLARTFEQLVENLFSLPLDVPFSGLRKGIRARDQLHRHLEGAISEKLHEDKAAEPG
DALDLIIHSARELGHEPSMQELKESAVELLFAAFFTTASASTSLVLLLLQHPAAIAKIREELVAQGLGRACGCAPGAAGGSEGPPPDCGCEPDLSLAALGRLRYVDCVVKEVLRLLPPVSGGYRTALRTFELDGY
QIPKGWSVMYSIRDTHETAAVYRSPPEGFDPERFGAAREDSRGASSRFHYIPFGGGARSCLGQELAQAVLQLLAVELVRTARWELATPAFPAMQTVPIVHPVDGLRLFFHPLTPSVAGNGLCL' 
15. cp27a human (531 residues): 
'MAALGCARLRWALRGAGRGLCPHGARAKAAIPAALPSDKATGAPGAGPGVRRRQRSLEEIPRLGQLRFFFQLFVQGYALQLHQLQVLYKAKYGPMWMSYLGPQMHVNLASAPLLEQVMRQEGKYPVRN
DMELWKEHRDQHDLTYGPFTTEGHHWYQLRQALNQRLLKPAEAALYTDAFNEVIDDFMTRLDQLRAESASGNQVSDMAQLFYYFALEAICYILFEKRIGCLQRSIPEDTVTFVRSIGLMFQNSLYATFLPKW
TRPVLPFWKRYLDGWNAIFSFGKKLIDEKLEDMEAQLQAAGPDGIQVSGYLHFLLASGQLSPREAMGSLPELLMAGVDTTSNTLTWALYHLSKDPEIQEALHEEVVGVVPAGQVPQHKDFAHMPLLKAVLK
ETLRLYPVVPTNSRIIEKEIEVDGFLFPKNTQFVFCHYVVSRDPTAFSEPESFQPHRWLRNSQPATPRIQHPFGSVPFGYGVRACLGRRIAELEMQLLLARLIQKYKVVLAPETGELKSVARIVLVPNKKVGLQFL
QRQC' 
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16. cp27b human (508 residues): 
'MTQTLKYASRVFHRVRWAPELGASLGYREYHSARRSLADIPGPSTPSFLAELFCKGGLSRLHELQVQGAAHFGPVWLASFGTVRTVYVAAPALVEELLRQEGPRPERCSFSPWTEHRRCRQRACGLLTAEGE
EWQRLRSLLAPLLLRPQAAARYAGTLNNVVCDLVRRLRRQRGRGTGPPALVRDVAGEFYKFGLEGIAAVLLGSRLGCLEAQVPPDTETFIRAVGSVFVSTLLTMAMPHWLRHLVPGPWGRLCRDWDQMFA
FAQRHVERREAEAAMRNGGQPEKDLESGAHLTHFLFREELPAQSILGNVTELLLAGVDTVSNTLSWALYELSRHPEVQTALHSEITAALSPGSSAYPSATVLSQLPLLKAVVKEVLRLYPVVPGNSRVPDKDIH
VGDYIIPKNTLVTLCHYATSRDPAQFPEPNSFRPARWLGEGPTPHPFASLPFGFGKRSCMGRRLAELELQMALAQILTHFEVQPEPGAAPVRPKTRTVLVPERSINLQFLDR' 
17. c27c1 human (372 residues): 
'MRSVLRQRILKPKDVAIYSGEVNQVIADLIKRIYLLRSQAEDGETVTNVNDLFFKYSMEGVATILYESRLGCLENSIPQLTVEYIEALELMFSMFKTSMYAGAIPRWLRPFIPKPWREFCRSWDGLFKFSQIHVD
NKLRDIQYQMDRGRRVSGGLLTYLFLSQALTLQEIYANVTEMLLAGVDTTSFTLSWTVYLLARHPEVQQTVYREIVKNLGERHVPTAADVPKVPLVRALLKETLRLFPVLPGNGRVTQEDLVIGGYLIPKGTQ
LALCHYATSYQDENFPRAKEFRPERWLRKGDLDRVDNFGSIPFGHGVRSCIGRRIAELEIHLVVIQLLQHFEIKTSSQTNAVHAKTHGLLTPGGPIHVRFVNRK' 
18. cp2ad human (494 residues): 
'MLASGLLLVTLLACLTVMVLMSVWRQRKSRGKLPPGPTPLPFIGNYLQLNTEQMYNSLMKISERYGPVFTIHLGPRRVVVLCGHDAVKEALVDQAEEFSGRGEQATFDWLFKGYGVAFSNGERAKQLRRFSI
ATLRGFGVGKRGIEERIQEEAGFLIDALRGTHGANIDPTFFLSRTVSNVISSIVFGDRFDYEDKEFLSLLRMMLGSFQFTATSTGQLYEMFSSVMKHLPGPQQQAFKELQGLEDFIAKKVEHNQRTLDPNSPRDFI
DSFLIRMQEEEKNPNTEFYLKNLVMTTLNLFFAGTETVSTTLRYGFLLLMKHPEVEAKVHEEIDRVIGKNRQPKFEDRAKMPYTEAVIHEIQRFGDMLPMGLAHRVNKDTKFRDFFLPKGTEVFPMLGSVLRD
PRFFSNPRDFNPQHFLDKKGQFKKSDAFVPFSIGKRYCFGEGLARMELFLFFTTIMQNFRFKSPQSPKDIDVSPKHVGFATIPRNYTMSFLPR' 
19. cp2a6 human (494 residues): 
'MLASGMLLVALLVCLTVMVLMSVWQQRKSKGKLPPGPTPLPFIGNYLQLNTEQMYNSLMKISERYGPVFTIHLGPRRVVVLCGHDAVREALVDQAEEFSGRGEQATFDWVFKGYGVVFSNGERAKQLRRF
SIATLRDFGVGKRGIEERIQEEAGFLIDALRGTGGANIDPTFFLSRTVSNVISSIVFGDRFDYKDKEFLSLLRMMLGIFQFTSTSTGQLYEMFSSVMKHLPGPQQQAFQLLQGLEDFIAKKVEHNQRTLDPNSPRDF
IDSFLIRMQEEEKNPNTEFYLKNLVMTTLNLFIGGTETVSTTLRYGFLLLMKHPEVEAKVHEEIDRVIGKNRQPKFEDRAKMPYMEAVIHEIQRFGDVIPMSLARRVKKDTKFRDFFLPKGTEVFPMLGSVLRDP
SFFSNPQDFNPQHFLNEKGQFKKSDAFVPFSIGKRNCFGEGLARMELFLFFTTVMQNFRLKSSQSPKDIDVSPKHVGFATIPRNYTMSFLPR'; 
20. cp2a7 human (494 residues): 
'MLASGLLLVALLACLTVMVLMSVWQQRKSRGKLPPGPTPLPFIGNYLQLNTEHICDSIMKFSECYGPVFTIHLGPRRVVVLCGHDAVREALVDQAEEFSGRGEQATFDWVFKGYGVAFSNGERAKQLLRFAI
ATLRDFGVGKRGIEERIQEESGFLIEAIRSTHGANIDPTFFLSRTVSNVISSIVFGDRFDYEDKEFLSLLSMMLGIFQFTSTSTGQLYEMFSSVMKHLPGPQQQAFKLLQGLEDFIAKKVEHNQRTLDPNSPQDFIDS
FLIHMQEEEKNPNTEFYLKNLMMSTLNLFIAGTETVSTTLRYGFLLLMKHPEVEAKVHEEIDRVIGKNRQPKFEDRTKMPYMEAVIHEIQRFGDVIPMSLARRVKKDTKFRDFFLPKGTEVFPMLGSVLRDPSF
FSNPQDFNPQHFLDDKGQFKKSDAFVPFSIGKRNCFGEGLARMELFLFFTTVMQNFRLKSSQSPKDIDVSPKHVVFATIPRNYTMSFLPR’ 
21. cp2b6 human (491 residues): 
'MELSVLLFLALLTGLLLLLVQRHPNTHDRLPPGPRPLPLLGNLLQMDRRGLLKSFLRFREKYGDVFTVHLGPRPVVMLCGVEAIREALVDKAEAFSGRGKIAMVDPFFRGYGVIFANGNRWKVLRRFSVTTM
RDFGMGKRSVEERIQEEAQCLIEELRKSKGALMDPTFLFQSITANIICSIVFGKRFHYQDQEFLKMLNLFYQTFSLISSVFGQLFELFSGFLKYFPGAHRQVYKNLQEINAYIGHSVEKHRETLDPSAPKDLIDTYL
LHMEKEKSNAHSEFSHQNLNLNTLSLFFAGTETTSTTLRYGFLLMLKYPHVAERVYREIEQVIGPHRPPELHDRAKMPYTEAVIYEIQRFSDLLPMGVPHIVTQHTSFRGYIIPKDTEVFLILSTALHDPHYFEKP
DAFNPDHFLDANGALKKTEAFIPFSLGKRICLGEGIARAELFLFFTTILQNFSMASPVAPEDIDLTPQECGVGKIPPTYQIRFLPR' 
22. cp2ci human (490 residues): 
'MDPAVALVLCLSCLFLLSLWRQSSGRGRLPSGPTPLPIIGNILQLDVKDMSKSLTNFSKVYGPVFTVYFGLKPIVVLHGYEAVKEALIDHGEEFSGRGSFPVAEKVNKGLGILFSNGKRWKEIRRFCLMTLRNFG
MGKRSIEDRVQEEARCLVEELRKTNASPCDPTFILGCAPCNVICSVIFHDRFDYKDQRFLNLMEKFNENLRILSSPWIQVCNNFPALIDYLPGSHNKIAENFAYIKSYVLERIKEHQESLDMNSARDFIDCFLIKME
QEKHNQQSEFTVESLIATVTDMFGAGTETTSTTLRYGLLLLLKYPEVTAKVQEEIECVVGRNRSPCMQDRSHMPYTDAVVHEIQRYIDLLPTNLPHAVTCDVKFKNYLIPKGTTIITSLTSVLHNDKEFPNPEMF
DPGHFLDKSGNFKKSDYFMPFSAGKRMCMGEGLARMELFLFLTTILQNFNLKSQVDPKDIDITPIANAFGRVPPLYQLCFIPV' 
23. cp2cj human (490 residues): 
'MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDVSKSLTNLSKIYGPVFTLYFGLERMVVLHGYEVVKEALIDLGEEFSGRGHFPLAERANRGFGIVFSNGKRWKEIRRFSLMTLRNFGM
GKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICSIIFQKRFDYKDQQFLNLMEKLNENIRIVSTPWIQICNNFPTIIDYFPGTHNKLLKNLAFMESDILEKVKEHQESMDINNPRDFIDCFLIKMEKE
KQNQQSEFTIENLVITAADLLGAGTETTSTTLRYALLLLLKHPEVTAKVQEEIERVVGRNRSPCMQDRGHMPYTDAVVHEVQRYIDLIPTSLPHAVTCDVKFRNYLIPKGTTILTSLTSVLHDNKEFPNPEMFDP
RHFLDEGGNFKKSNYFMPFSAGKRICVGEGLARMELFLFLTFILQNFNLKSLIDPKDLDTTPVVNGFASVPPFYQLCFIPV'; 
24. cp2c8 human (490 residues): 
'MEPFVVLVLCLSFMLLFSLWRQSCRRRKLPPGPTPLPIIGNMLQIDVKDICKSFTNFSKVYGPVFTVYFGMNPIVVFHGYEAVKEALIDNGEEFSGRGNSPISQRITKGLGIISSNGKRWKEIRRFSLTTLRNFGMG
KRSIEDRVQEEAHCLVEELRKTKASPCDPTFILGCAPCNVICSVVFQKRFDYKDQNFLTLMKRFNENFRILNSPWIQVCNNFPLLIDCFPGTHNKVLKNVALTRSYIREKVKEHQASLDVNNPRDFIDCFLIKME
QEKDNQKSEFNIENLVGTVADLFVAGTETTSTTLRYGLLLLLKHPEVTAKVQEEIDHVIGRHRSPCMQDRSHMPYTDAVVHEIQRYSDLVPTGVPHAVTTDTKFRNYLIPKGTTIMALLTSVLHDDKEFPNPNI
FDPGHFLDKNGNFKKSDYFMPFSAGKRICAGEGLARMELFLFLTTILQNFNLKSVDDLKNLNTTAVTKGIVSLPPSYQICFIPV' 
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25. cp2c9 human (490 residues): 
'MDSLVVLVLCLSCLLLLSLWRQSSGRGKLPPGPTPLPVIGNILQIGIKDISKSLTNLSKVYGPVFTLYFGLKPIVVLHGYEAVKEALIDLGEEFSGRGIFPLAERANRGFGIVFSNGKKWKEIRRFSLMTLRNFGM
GKRSIEDRVQEEARCLVEELRKTKASPCDPTFILGCAPCNVICSIIFHKRFDYKDQQFLNLMEKLNENIKILSSPWIQICNNFSPIIDYFPGTHNKLLKNVAFMKSYILEKVKEHQESMDMNNPQDFIDCFLMKME
KEKHNQPSEFTIESLENTAVDLFGAGTETTSTTLRYALLLLLKHPEVTAKVQEEIERVIGRNRSPCMQDRSHMPYTDAVVHEVQRYIDLLPTSLPHAVTCDIKFRNYLIPKGTTILISLTSVLHDNKEFPNPEMFDP
HHFLDEGGNFKKSKYFMPFSAGKRICVGEALAGMELFLFLTSILQNFNLKSLVDPKNLDTTPVVNGFASVPPFYQLCFIPV' 
26. cp2d6 human (497 residues): 
'MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQLRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVFLARYGPAWREQR
RFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDKAVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKVLRFQKAFLTQLDELLTEHRMTWDPA
QPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVADLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVIHEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNL
SSVLKDEAVWEKPFRFHPEHFLDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGVFAFLVSPSPYELCAVPR' 
27. cp2e1 human (493 residues): 
'MSALGVTVALLVWAAFLLLVSMWRQVHSSWNLPPGPFPLPIIGNLFQLELKNIPKSFTRLAQRFGPVFTLYVGSQRMVVMHGYKAVKEALLDYKDEFSGRGDLPAFHAHRDRGIIFNNGPTWKDIRRFSLTTL
RNYGMGKQGNESRIQREAHFLLEALRKTQGQPFDPTFLIGCAPCNVIADILFRKHFDYNDEKFLRLMYLFNENFHLLSTPWLQLYNNFPSFLHYLPGSHRKVIKNVAEVKEYVSERVKEHHQSLDPNCPRDLTD
CLLVEMEKEKHSAERLYTMDGITVTVADLFFAGTETTSTTLRYGLLILMKYPEIEEKLHEEIDRVIGPSRIPAIKDRQEMPYMDAVVHEIQRFITLVPSNLPHEATRDTIFRGYLIPKGTVVVPTLDSVLYDNQEFP
DPEKFKPEHFLNENGKFKYSDYFKPFSTGKRVCAGEGLARMELFLLLCAILQHFNLKPLVDPKDIDLSPIHIGFGCIPPRYKLCVIPRS’ 
28. cp2f1 human (491 residues): 
'MDSISTAILLLLLALVCLLLTLSSRDKGKLPPGPRPLSILGNLLLLCSQDMLTSLTKLSKEYGSMYTVHLGPRRVVVLSGYQAVKEALVDQGEEFSGRGDYPAFFNFTKGNGIAFSSGDRWKVLRQFSIQILRNF
GMGKRSIEERILEEGSFLLAELRKTEGEPFDPTFVLSRSVSNIICSVLFGSRFDYDDERLLTIIRLINDNFQIMSSPWGELYDIFPSLLDWVPGPHQRIFQNFKCLRDLIAHSVHDHQASLDPRSPRDFIQCFLTKMAE
EKEDPLSHFHMDTLLMTTHNLLFGGTKTVSTTLHHAFLALMKYPKVQARVQEEIDLVVGRARLPALKDRAAMPYTDAVIHEVQRFADIIPMNLPHRVTRDTAFRGFLIPKGTDVITLLNTVHYDPSQFLTPQEF
NPEHFLDANQSFKKSPAFMPFSAGRRLCLGESLARMELFLYLTAILQSFSLQPLGAPEDIDLTPLSSGLGNLPRPFQLCLRPR' 
29. cp2j2 human (502 residues): 
'MLAAMGSLAAALWAVVHPRTLLLGTVAFLLAADFLKRRRPKNYPPGPWRLPFLGNFFLVDFEQSHLEVQLFVKKYGNLFSLELGDISAVLITGLPLIKEALIHMDQNFGNRPVTPMREHIFKKNGLIMSSGQA
WKEQRRFTLTALRNFGLGKKSLEERIQEEAQHLTEAIKEENGQPFDPHFKINNAVSNIICSITFGERFEYQDSWFQQLLKLLDEVTYLEASKTCQLYNVFPWIMKFLPGPHQTLFSNWKKLKLFVSHMIDKHRK
DWNPAETRDFIDAYLKEMSKHTGNPTSSFHEENLICSTLDLFFAGTETTSTTLRWALLYMALYPEIQEKVQAEIDRVIGQGQQPSTAARESMPYTNAVIHEVQRMGNIIPLNVPREVTVDTTLAGYHLPKGTMIL
TNLTALHRDPTEWATPDTFNPDHFLENGQFKKREAFMPFSIGKRACLGEQLARTELFIFFTSLMQKFTFRPPNNEKLSLKFRMGITISPVSHRLCAVPQV' 
30. cp2r1 human (501 residues): 
'MWKLWRAEEGAAALGGALFLLLFALGVRQLLKQRRPMGFPPGPPGLPFIGNIYSLAASSELPHVYMRKQSQVYGEIFSLDLGGISTVVLNGYDVVKECLVHQSEIFADRPCLPLFMKMTKMGGLLNSRYGRG
WVDHRRLAVNSFRYFGYGQKSFESKILEETKFFNDAIETYKGRPFDFKQLITNAVSNITNLIIFGERFTYEDTDFQHMIELFSENVELAASASVFLYNAFPWIGILPFGKHQQLFRNAAVVYDFLSRLIEKASVNR
KPQLPQHFVDAYLDEMDQGKNDPSSTFSKENLIFSVGELIIAGTETTTNVLRWAILFMALYPNIQGQVQKEIDLIMGPNGKPSWDDKCKMPYTEAVLHEVLRFCNIVPLGIFHATSEDAVVRGYSIPKGTTVITN
LYSVHFDEKYWRDPEVFHPERFLDSSGYFAKKEALVPFSLGRRHCLGEHLARMEMFLFFTALLQRFHLHFPHELVPDLKPRLGMTLQPQPYLICAERR' 
31. cp2s1 human (504 residues): 
'MEATGTWALLLALALLLLLTLALSGTRARGHLPPGPTPLPLLGNLLQLRPGALYSGLMRLSKKYGPVFTIYLGPWRPVVVLVGQEAVREALGGQAEEFSGRGTVAMLEGTFDGHGVFFSNGERWRQLRKFT
MLALRDLGMGKREGEELIQAEARCLVETFQGTEGRPFDPSLLLAQATSNVVCSLLFGLRFSYEDKEFQAVVRAAGGTLLGVSSQGGQTYEMFSWFLRPLPGPHKQLLHHVSTLAAFTVRQVQQHQGNLDAS
GPARDLVDAFLLKMAQEEQNPGTEFTNKNMLMTVIYLLFAGTMTVSTTVGYTLLLLMKYPHVQKWVREELNRELGAGQAPSLGDRTRLPYTDAVLHEAQRLLALVPMGIPRTLMRTTRFRGYTLPQGTEVF
PLLGSILHDPNIFKHPEEFNPDRFLDADGRFRKHEAFLPFSLGKRVCLGEGLAKAELFLFFTTILQAFSLESPCPPDTLSLKPTVSGLFNIPPAFQLQVRPTDLHSTTQTR' 
32. cp2u1 human (544 residues): 
'MSSPGPSQPPAEDPPWPARLLRAPLGLLRLDPSGGALLLCGLVALLGWSWLRRRRARGIPPGPTPWPLVGNFGHVLLPPFLRRRSWLSSRTRAAGIDPSVIGPQVLLAHLARVYGSIFSFFIGHYLVVVLSDFHS
VREALVQQAEVFSDRPRVPLISIVTKEKGVVFAHYGPVWRQQRKFSHSTLRHFGLGKLSLEPKIIEEFKYVKAEMQKHGEDPFCPFSIISNAVSNIICSLCFGQRFDYTNSEFKKMLGFMSRGLEICLNSQVLLVNI
CPWLYYLPFGPFKELRQIEKDITSFLKKIIKDHQESLDRENPQDFIDMYLLHMEEERKNNSNSSFDEEYLFYIIGDLFIAGTDTTTNSLLWCLLYMSLNPDVQEKVHEEIERVIGANRAPSLTDKAQMPYTEATIM
EVQRLTVVVPLAIPHMTSENTVLQGYTIPKGTLILPNLWSVHRDPAIWEKPEDFYPNRFLDDQGQLIKKETFIPFGIGKRVCMGEQLAKMELFLMFVSLMQSFAFALPEDSKKPLLTGRFGLTLAPHPFNITISRR' 
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33. cp2w1 human (490 residues): 
'MALLLLLFLGLLGLWGLLCACAQDPSPAARWPPGPRPLPLVGNLHLLRLSQQDRSLMELSERYGPVFTVHLGRQKTVVLTGFEAVKEALAGPGQELADRPPIAIFQLIQRGGGIFFSSGARWRAARQFTVRAL
HSLGVGREPVADKILQELKCLSGQLDGYRGRPFPLALLGWAPSNITFALLFGRRFDYRDPVFVSLLGLIDEVMVLLGSPGLQLFNVYPWLGALLQLHRPVLRKIEEVRAILRTLLEARRPHVCPGDPVCSYVDA
LIQQGQGDDPEGLFAEANAVACTLDMVMAGTETTSATLQWAALLMGRHPDVQGRVQEELDRVLGPGRTPRLEDQQALPYTSAVLHEVQRFITLLPHVPRCTAADTQLGGFLLPKGTPVIPLLTSVLLDETQW
QTPGQFNPGHFLDANGHFVKREAFLPFSAGRRVCVGERLARTELFLLFAGLLQRYRLLPPPGVSPASLDTTPARAFTMRPRAQALCAVPRP' 
34. cp39a human (469 residues): 
'MELISPTVIIILGCLALFLLLQRKNLRRPPCIKGWIPWIGVGFEFGKAPLEFIEKARIKYGPIFTVFAMGNRMTFVTEEEGINVFLKSKKVDFELAVQNIVYRTASIPKNVFLALHEKLYIMLKGKMGTVNLHQFTG
QLTEELHEQLENLGTHGTMDLNNLVRHLLYPVTVNMLFNKSLFSTNKKKIKEFHQYFQVYDEDFEYGSQLPECLLRNWSKSKKWFLELFEKNIPDIKACKSAKDNSMTLLQATLDIVETETSKENSPNYGLLL
LWASLSNAVPVAFWTLAYVLSHPDIHKAIMEGISSVFGKAGKDKIKVSEDDLENLLLIKWCVLETIRLKAPGVITRKVVKPVEILNYIIPSGDLLMLSPFWLHRNPKYFPEPELFKPERWKKANLEKHSFLDCFM
AFGSGKFQCPARWFALLEVQMCIILILYKYDCSLLDPLPKQSYLHLVGVPQPEGQCRIEYKQRI'; 
35. cp3a4 human (503 residues): 
'MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNILSYHKGFCMFDMECHKKYGKVWGFYDGQQPVLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKSAISIAEDEEWKRLRSLL
SPTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKDVFGAYSMDVITSTSFGVNIDSLNNPQDPFVENTKKLLRFDFLDPFFLSITVFPFLIPILEVLNICVFPREVTNFLRKSVKRMKESRLEDTQKHRVD
FLQLMIDSQNSKETESHKALSDLELVAQSIIFIFAGYETTSSVLSFIMYELATHPDVQQKLQEEIDAVLPNKAPPTYDTVLQMEYLDMVVNETLRLFPIAMRLERVCKKDVEINGMFIPKGVVVMIPSYALHRDP
KYWTEPEKFLPERFSKKNKDNIDPYIYTPFGSGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLSLGGLLQPEKPVVLKVESRDGTVSGA' 
36. cp343 human (503 residues): 
'MDLIPNFAMETWVLVATSLVLLYIYGTHSHKLFKKLGIPGPTPLPFLGTILFYLRGLWNFDRECNEKYGEMWGLYEGQQPMLVIMDPDMIKTVLVKECYSVFTNQMPLGPMGFLKSALSFAEDEEWKRIRTL
LSPAFTSVKFKEMVPIISQCGDMLVRSLRQEAENSKSINLKDFFGAYTMDVITGTLFGVNLDSLNNPQDPFLKNMKKLLKLDFLDPFLLLISLFPFLTPVFEALNIGLFPKDVTHFLKNSIERMKESRLKDKQKHR
VDFFQQMIDSQNSKETKSHKALSDLELVAQSIIIIFAAYDTTSTTLPFIMYELATHPDVQQKLQEEIDAVLPNKAPVTYDALVQMEYLDMVVNETLRLFPVVSRVTRVCKKDIEINGVFIPKGLAVMVPIYALHH
DPKYWTEPEKFCPERFSKKNKDSIDLYRYIPFGAGPRNCIGMRFALTNIKLAVIRALQNFSFKPCKETQIPLKLDNLPILQPEKPIVLKVHLRDGITSGP' 
37. cp3a5 human (502 residues): 
'MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNVLSYRQGLWKFDTECYKKYGKMWGTYEGQLPVLAITDPDVIRTVLVKECYSVFTNRRSLGPVGFMKSAISLAEDEEWKRIRSLL
SPTFTSGKLKEMFPIIAQYGDVLVRNLRREAEKGKPVTLKDIFGAYSMDVITGTSFGVNIDSLNNPQDPFVESTKKFLKFGFLDPLFLSIILFPFLTPVFEALNVSLFPKDTINFLSKSVNRMKKSRLNDKQKHRLD
FLQLMIDSQNSKETESHKALSDLELAAQSIIFIFAGYETTSSVLSFTLYELATHPDVQQKLQKEIDAVLPNKAPPTYDAVVQMEYLDMVVNETLRLFPVAIRLERTCKKDVEINGVFIPKGSMVVIPTYALHHDP
KYWTEPEEFRPERFSKKKDSIDPYIYTPFGTGPRNCIGMRFALMNMKLALIRVLQNFSFKPCKETQIPLKLDTQGLLQPEKPIVLKVDSRDGTLSGE’ 
38. cp3a7 human (503 residues): 
'MDLIPNLAVETWLLLAVSLILLYLYGTRTHGLFKKLGIPGPTPLPFLGNALSFRKGYWTFDMECYKKYRKVWGIYDCQQPMLAITDPDMIKTVLVKECYSVFTNRRPFGPVGFMKNAISIAEDEEWKRIRSLLS
PTFTSGKLKEMVPIIAQYGDVLVRNLRREAETGKPVTLKHVFGAYSMDVITSTSFGVSIDSLNNPQDPFVENTKKLLRFNPLDPFVLSIKVFPFLTPILEALNITVFPRKVISFLTKSVKQIKEGRLKETQKHRVDFL
QLMIDSQNSKDSETHKALSDLELMAQSIIFIFAGYETTSSVLSFIIYELATHPDVQQKVQKEIDTVLPNKAPPTYDTVLQLEYLDMVVNETLRLFPVAMRLERVCKKDVEINGMFIPKGVVVMIPSYVLHHDPKY
WREPEKFLPERFSKKNKDNIDPYIYTPFGSGPRNCIGMRFALVNMKLALVRVLQNFSFKPCKETQIPLKLRFGGLLLTEKPIVLKAESRDETVSGA' 
39. cp46a human (500 residues): 
'MSPGLLLLGSAVLLAFGLCCTFVHRARSRYEHIPGPPRPSFLLGHLPCFWKKDEVGGRVLQDVFLDWAKKYGPVVRVNVFHKTSVIVTSPESVKKFLMSTKYNKDSKMYRALQTVFGERLFGQGLVSECNY
ERWHKQRRVIDLAFSRSSLVSLMETFNEKAEQLVEILEAKADGQTPVSMQDMLTYTAMDILAKAAFGMETSMLLGAQKPLSQAVKLMLEGITASRNTLAKFLPGKRKQLREVRESIRFLRQVGRDWVQRRR
EALKRGEEVPADILTQILKAEEGAQDDEGLLDNFVTFFIAGHETSANHLAFTVMELSRQPEIVARLQAEVDEVIGSKRYLDFEDLGRLQYLSQVLKESLRLYPPAWGTFRLLEEETLIDGVRVPGNTPLLFSTYV
MGRMDTYFEDPLTFNPDRFGPGAPKPRFTYFPFSLGHRSCIGQQFAQMEVKVVMAKLLQRLEFRLVPGQRFGLQEQATLKPLDPVLCTLRPRGWQPAPPPPPC' 
40. cp4ab human (519 residues): 
'MSVSVLSPSRLLGDVSGILQAASLLILLLLLIKAVQLYLHRQWLLKALQQFPCPPSHWLFGHIQELQQDQELQRIQKWVETFPSACPHWLWGGKVRVQLYDPDYMKVILGRSDPKSHGSYRFLAPWIGYGLLL
LNGQTWFQHRRMLTPAFHYDILKPYVGLMADSVRVMLDKWEELLGQDSPLEVFQHVSLMTLDTIMKCAFSHQGSIQVDRNSQSYIQAISDLNNLVFSRVRNAFHQNDTIYSLTSAGRWTHRACQLAHQHTD
QVIQLRKAQLQKEGELEKIKRKRHLDFLDILLLAKMENGSILSDKDLRAEVDTFMFEGHDTTASGISWILYALATHPKHQERCREEIHSLLGDGASITWNHLDQMPYTTMCIKEALRLYPPVPGIGRELSTPVTF
PDGRSLPKGIMVLLSIYGLHHNPKVWPNPEVFDPFRFAPGSAQHSHAFLPFSGGSRNCIGKQFAMNELKVATALTLLRFELLPDPTRIPIPIARLVLKSKNGIHLRLRRLPNPCEDKDQL' 
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41. cp4am human (519 residues): 
'MSVSVLSPSRRLGGVSGILQVTSLLILLLLLIKAAQLYLHRQWLLKALQQFPCPPSHWLFGHIQEFQHDQELQRIQERVKTFPSACPYWIWGGKVRVQLYDPDYMKVILGRSDPKSHGSYKFLAPRIGYGLLLL
NGQTWFQHRRMLTPAFHNDILKPYVGLMADSVRVMLDKWEELLGQDSPLEVFQHVSLMTLDTIMKSAFSHQGSIQVDRNSQSYIQAISDLNSLVFCCMRNAFHENDTIYSLTSAGRWTHRACQLAHQHTDQ
VIQLRKAQLQKEGELEKIKRKRHLDFLDILLLAKMENGSILSDKDLRAEVDTFMFEGHDTTASGISWILYALATHPKHQERCREEIHGLLGDGASITWNHLDQMPYTTMCIKEALRLYPPVPGIGRELSTPVTFP
DGRSLPKGIMVLLSIYGLHHNPKVWPNLEVFDPSRFAPGSAQHSHAFLPFSGGSRNCIGKQFAMNQLKVARALTLLRFELLPDPTRIPIPMARLVLKSKNGIHLRLRRLPNPCEDKDQL' 
42. cp4b1 human (511 residues): 
'MVPSFLSLSFSSLGLWASGLILVLGFLKLIHLLLRRQTLAKAMDKFPGPPTHWLFGHALEIQETGSLDKVVSWAHQFPYAHPLWFGQFIGFLNIYEPDYAKAVYSRGDPKAPDVYDFFLQWIGRGLLVLEGPK
WLQHRKLLTPGFHYDVLKPYVAVFTESTRIMLDKWEEKAREGKSFDIFCDVGHMALNTLMKCTFGRGDTGLGHRDSSYYLAVSDLTLLMQQRLVSFQYHNDFIYWLTPHGRRFLRACQVAHDHTDQVIRE
RKAALQDEKVRKKIQNRRHLDFLDILLGARDEDDIKLSDADLRAEVDTFMFEGHDTTTSGISWFLYCMALYPEHQHRCREEVREILGDQDFFQWDDLGKMTYLTMCIKESFRLYPPVPQVYRQLSKPVTFVD
GRSLPAGSLISMHIYALHRNSAVWPDPEVFDSLRFSTENASKRHPFAFMPFSAGPRNCIGQQFAMSEMKVVTAMCLLRFEFSLDPSRLPIKMPQLVLRSKNGFHLHLKPLGPGSGK' 
43. cp4fb human (524 residues): 
'MPQLSLSWLGLGPVAASPWLLLLLVGGSWLLARVLAWTYTFYDNCRRLQCFPQPPKQNWFWGHQGLVTPTEEGMKTLTQLVTTYPQGFKLWLGPTFPLLILCHPDIIRPITSASAAVAPKDMIFYGFLKPWL
GDGLLLSGGDKWSRHRRMLTPAFHFNILKPYMKIFNKSVNIMHDKWQRLASEGSARLDMFEHISLMTLDSLQKCVFSFESNCQEKPSEYIAAILELSAFVEKRNQQILLHTDFLYYLTPDGQRFRRACHLVHDF
TDAVIQERRCTLPTQGIDDFLKNKAKSKTLDFIDVLLLSKDEDGKELSDEDIRAEADTFMFEGHDTTASGLSWVLYHLAKHPEYQEQCRQEVQELLKDREPIEIEWDDLAQLPFLTMCIKESLRLHPPVPVISRC
CTQDFVLPDGRVIPKGIVCLINIIGIHYNPTVWPDPEVYDPFRFDQENIKERSPLAFIPFSAGPRNCIGQAFAMAEMKVVLALTLLHFRILPTHTEPRRKPELILRAEGGLWLRVEPLGANSQ' 
44. cp4fc human (524 residues): 
'MSLLSLPWLGLRPVAMSPWLLLLLVVGSWLLARILAWTYAFYNNCRRLQCFPQPPKRNWFWGHLGLITPTEEGLKDSTQMSATYSQGFTVWLGPIIPFIVLCHPDTIRSITNASAAIAPKDNLFIRFLKPWLGE
GILLSGGDKWSRHRRMLTPAFHFNILKSYITIFNKSANIMLDKWQHLASEGSSRLDMFEHISLMTLDSLQKCIFSFDSHCQERPSEYIATILELSALVEKRSQHILQHMDFLYYLSHDGRRFHRACRLVHDFTDAV
IRERRRTLPTQGIDDFFKDKAKSKTLDFIDVLLLSKDEDGKALSDEDIRAEADTFMFGGHDTTASGLSWVLYNLARHPEYQERCRQEVQELLKDRDPKEIEWDDLAQLPFLTMCVKESLRLHPPAPFISRCCTQ
DIVLPDGRVIPKGITCLIDIIGVHHNPTVWPDPEVYDPFRFDPENSKGRSPLAFIPFSAGPRNCIGQAFAMAEMKVVLALMLLHFRFLPDHTEPRRKLELIMRAEGGLWLRVEPLNVGLQ' 
45. cp4f2 human (520 residues): 
'MSQLSLSWLGLWPVAASPWLLLLLVGASWLLAHVLAWTYAFYDNCRRLRCFPQPPRRNWFWGHQGMVNPTEEGMRVLTQLVATYPQGFKVWMGPISPLLSLCHPDIIRSVINASAAIAPKDKFFYSFLEPW
LGDGLLLSAGDKWSRHRRMLTPAFHFNILKPYMKIFNESVNIMHAKWQLLASEGSACLDMFEHISLMTLDSLQKCVFSFDSHCQEKPSEYIAAILELSALVSKRHHEILLHIDFLYYLTPDGQRFRRACRLVHDF
TDAVIQERRRTLPSQGVDDFLQAKAKSKTLDFIDVLLLSKDEDGKKLSDEDIRAEADTFMFEGHDTTASGLSWVLYHLAKHPEYQERCRQEVQELLKDREPKEIEWDDLAHLPFLTMCMKESLRLHPPVPVIS
RHVTQDIVLPDGRVIPKGIICLISVFGTHHNPAVWPDPEVYDPFRFDPENIKERSPLAFIPFSAGPRNCIGQTFAMAEMKVVLALTLLRFRVLPDHTEPRRKPELVLRAEGGLWLRVEPLS' 
46. cp4fn human (531 residues): 
'MLPITDRLLHLLGLEKTAFRIYAVSTLLLFLLFFLFRLLLRFLRLCRSFYITCRRLRCFPQPPRRNWLLGHLGMYLPNEAGLQDEKKVLDNMHHVLLVWMGPVLPLLVLVHPDYIKPLLGASAAIAPKDDLFYG
FLKPWLGDGLLLSKGDKWSRHRRLLTPAFHFDILKPYMKIFNQSADIMHAKWRHLAEGSAVSLDMFEHISLMTLDSLQKCVFSYNSNCQEKMSDYISAIIELSALSVRRQYRLHHYLDFIYYRSADGRRFRQA
CDMVHHFTTEVIQERRRALRQQGAEAWLKAKQGKTLDFIDVLLLARDEDGKELSDEDIRAEADTFMFEGHDTTSSGISWMLFNLAKYPEYQEKCREEIQEVMKGRELEELEWDDLTQLPFTTMCIKESLRQY
PPVTLVSRQCTEDIKLPDGRIIPKGIICLVSIYGTHHNPTVWPDSKVYNPYRFDPDNPQQRSPLAYVPFSAGPRNCIGQSFAMAELRVVVALTLLRFRLSVDRTRKVRRKPELILRTENGLWLKVEPLPPRA' 
47. cp4f3 human (520 residues): 
'MPQLSLSSLGLWPMAASPWLLLLLVGASWLLARILAWTYTFYDNCCRLRCFPQPPKRNWFLGHLGLIHSSEEGLLYTQSLACTFGDMCCWWVGPWHAIVRIFHPTYIKPVLFAPAAIVPKDKVFYSFLKPWL
GDGLLLSAGEKWSRHRRMLTPAFHFNILKPYMKIFNESVNIMHAKWQLLASEGSARLDMFEHISLMTLDSLQKCVFSFDSHCQEKPSEYIAAILELSALVTKRHQQILLYIDFLYYLTPDGQRFRRACRLVHDF
TDAVIQERRRTLPSQGVDDFLQAKAKSKTLDFIDVLLLSKDEDGKKLSDEDIRAEADTFMFEGHDTTASGLSWVLYHLAKHPEYQERCRQEVQELLKDREPKEIEWDDLAQLPFLTMCIKESLRLHPPVPAVS
RCCTQDIVLPDGRVIPKGIICLISVFGTHHNPAVWPDPEVYDPFRFDPKNIKERSPLAFIPFSAGPRNCIGQAFAMAEMKVVLGLTLLRFRVLPDHTEPRRKPELVLRAEGGLWLRVEPLS' 
48. cp4f8 human (520 residues): 
'MSLLSLSWLGLRPVAASPWLLLLVVGASWLLARILAWTYAFYHNGRRLRCFPQPRKQNWFLGHLGLVTPTEEGLRVLTQLVATYPQGFVRWLGPITPIINLCHPDIVRSVINTSDAITDKDIVFYKTLKPWLGD
GLLLSVGDKWRHHRRLLTPAFHFNILKPYIKIFSKSANIMHAKWQRLAMEGSTCLDVFEHISLMTLDSLQKCIFSFDSNCQEKPSEYITAIMELSALVVKRNNQFFRYKDFLYFLTPCGRRFHRACRLVHDFTDA
VIQERRRTLTSQGVDDFLQAKAKSKTLDFIDVLLLSEDKNGKELSDEDIRAEADTFMFGGHDTTASGLSWVLYNLARHPEYQERCRQEVQELLKDREPKEIEWDDLAQLPFLTMCLKESLRLHPPIPTFARGCT
QDVVLPDSRVIPKGNVCNINIFAIHHNPSVWPDPEVYDPFRFDPENAQKRSPMAFIPFSAGPRNCIGQKFAMAEMKVVLALTLLRFRILPDHREPRRTPEIVLRAEDGLWLRVEPLG' 
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49. cp4v2 human (525 residues): 
'MAGLWLGLVWQKLLLWGAASALSLAGASLVLSLLQRVASYARKWQQMRPIPTVARAYPLVGHALLMKPDGREFFQQIIEYTEEYRHMPLLKLWVGPVPMVALYNAENVEVILTSSKQIDKSSMYKFLEPW
LGLGLLTSTGNKWRSRRKMLTPTFHFTILEDFLDIMNEQANILVKKLEKHINQEAFNCFFYITLCALDIICETAMGKNIGAQSNDDSEYVRAVYRMSEMIFRRIKMPWLWLDLWYLMFKEGWEHKKSLQILHT
FTNSVIAERANEMNANEDCRGDGRGSAPSKNKRRAFLDLLLSVTDDEGNRLSHEDIREEVDTFMFEGHDTTAAAINWSLYLLGSNPEVQKKVDHELDDVFGKSDRPATVEDLKKLRYLECVIKETLRLFPSVP
LFARSVSEDCEVAGYRVLKGTEAVIIPYALHRDPRYFPNPEEFQPERFFPENAQGRHPYAYVPFSAGPRNCIGQKFAVMEEKTILSCILRHFWIESNQKREELGLEGQLILRPSNGIWIKLKRRNADER' 
50. cp4x1 human (509 residues): 
'MEFSWLETRWARPFYLAFVFCLALGLLQAIKLYLRRQRLLRDLRPFPAPPTHWFLGHQKFIQDDNMEKLEEIIEKYPRAFPFWIGPFQAFFCIYDPDYAKTLLSRTDPKSQYLQKFSPPLLGKGLAALDGPKWF
QHRRLLTPGFHFNILKAYIEVMAHSVKMMLDKWEKICSTQDTSVEVYEHINSMSLDIIMKCAFSKETNCQTNSTHDPYAKAIFELSKIIFHRLYSLLYHSDIIFKLSPQGYRFQKLSRVLNQYTDTIIQERKKSLQA
GVKQDNTPKRKYQDFLDIVLSAKDESGSSFSDIDVHSEVSTFLLAGHDTLAASISWILYCLALNPEHQERCREEVRGILGDGSSITWDQLGEMSYTTMCIKETCRLIPAVPSISRDLSKPLTFPDGCTLPAGITVVL
SIWGLHHNPAVWKNPKVFDPLRFSQENSDQRHPYAYLPFSAGSRNCIGQEFAMIELKVTIALILLHFRVTPDPTRPLTFPNHFILKPKNGMYLHLKKLSEC' 
51. cp4z1 human (505 residues): 
'MEPSWLQELMAHPFLLLILLCMSLLLFQVIRLYQRRRWMIRALHLFPAPPAHWFYGHKEFYPVKEFEVYHKLMEKYPCAVPLWVGPFTMFFSVHDPDYAKILLKRQDPKSAVSHKILESWVGRGLVTLDGSK
WKKHRQIVKPGFNISILKIFITMMSESVRMMLNKWEEHIAQNSRLELFQHVSLMTLDSIMKCAFSHQGSIQLDSTLDSYLKAVFNLSKISNQRMNNFLHHNDLVFKFSSQGQIFSKFNQELHQFTEKVIQDRKES
LKDKLKQDTTQKRRWDFLDILLSAKSENTKDFSEADLQAEVKTFMFAGHDTTSSAISWILYCLAKYPEHQQRCRDEIRELLGDGSSITWEHLSQMPYTTMCIKECLRLYAPVVNISRLLDKPITFPDGRSLPAGI
TVFINIWALHHNPYFWEDPQVFNPLRFSRENSEKIHPYAFIPFSAGLRNCIGQHFAIIECKVAVALTLLRFKLAPDHSRPPQPVRQVVLKSKNGIHVFAKKVC' 
52. cp4z2 human (340 residues): 
'MEPSWLQELMAHPFLLLILLCMSLLLFQVIRLYQRRRWTIRAMHLFPAPPAHWFYGHKESYPVKEFEVYPELMEKYPCAVPLWVGPFTMFFNIHDPDYVKILLKRQDPKSAVSHKILESWVGRGLVTLDGSK
WKKHRQIVKPGFNISILKIFITMMSKSVRMMLNKWEEHIAQNSRLELFQHVSLMTLDSIMKCAFSHQGSIQLDSTLDSYLKAVFNLSKISNQRMNNFLHHNDLVFKFSSQGQIFSKFNQELHQFTEKVIQDRKES
LKDKLKQDTTQKRRQDFLDILLSAKSENTKDFSEADLQAEVKTFMFAGHDTTTTAISWIFYCLAKYPEHQQRC' 
53. cp7a1 human (504 residues): 
'MMTTSLIWGIAIAACCCLWLILGIRRRQTGEPPLENGLIPYLGCALQFGANPLEFLRANQRKHGHVFTCKLMGKYVHFITNPLSYHKVLCHGKYFDWKKFHFATSAKAFGHRSIDPMDGNTTENINDTFIKTLQ
GHALNSLTESMMENLQRIMRPPVSSNSKTAAWVTEGMYSFCYRVMFEAGYLTIFGRDLTRRDTQKAHILNNLDNFKQFDKVFPALVAGLPIHMFRTAHNAREKLAESLRHENLQKRESISELISLRMFLNDTL
STFDDLEKAKTHLVVLWASQANTIPATFWSLFQMIRNPEAMKAATEEVKRTLENAGQKVSLEGNPICLSQAELNDLPVLDSIIKESLRLSSASLNIRTAKEDFTLHLEDGSYNIRKDDIIALYPQLMHLDPEIYPD
PLTFKYDRYLDENGKTKTTFYCNGLKLKYYYMPFGSGATICPGRLFAIHEIKQFLILMLSYFELELIEGQAKCPPLDQSRAGLGILPPLNDIEFKYKFKHL' 
54. cp7b1 human (506 residues): 
'MAGEVSAATGRFSLERLGLPGLALAAALLLLALCLLVRRTRRPGEPPLIKGWLPYLGVVLNLRKDPLRFMKTLQKQHGDTFTVLLGGKYITFILDPFQYQLVIKNHKQLSFRVFSNKLLEKAFSISQLQKNHD
MNDELHLCYQFLQGKSLDILLESMMQNLKQVFEPQLLKTTSWDTAELYPFCSSIIFEITFTTIYGKVIVCDNNKFISELRDDFLKFDDKFAYLVSNIPIELLGNVKSIREKIIKCFSSEKLAKMQGWSEVFQSRQDV
LEKYYVHEDLEIGAHHLGFLWASVANTIPTMFWAMYYLLRHPEAMAAVRDEIDRLLQSTGQKKGSGFPIHLTREQLDSLICLESSIFEALRLSSYSTTIRFVEEDLTLSSETGDYCVRKGDLVAIFPPVLHGDPEI
FEAPEEFRYDRFIEDGKKKTTFFKRGKKLKCYLMPFGTGTSKCPGRFFALMEIKQLLVILLTYFDLEIIDDKPIGLNYSRLLFGIQYPDSDVLFRYKVKS' 
55. cp8B1 human (501 residues): 
'MVLWGPVLGALLVVIAGYLCLPGMLRQRRPWEPPLDKGTVPWLGHAMAFRKNMFEFLKRMRTKHGDVFTVQLGGQYFTFVMDPLSFGSILKDTQRKLDFGQYAKKLVLKVFGYRSVQGDHEMIHSASTK
HLRGDGLKDLNETMLDSLSFVMLTSKGWSLDASCWHEDSLFRFCYYILFTAGYLSLFGYTKDKEQDLLQAGELFMEFRKFDLLFPRFVYSLLWPREWLEVGRLQRLFHKMLSVSHSQEKEGISNWLGNMLQ
FLREQGVPSAMQDKFNFMMLWASQGNTGPTSFWALLYLLKHPEAIRAVREEATQVLGEARLETKQSFAFKLGALQHTPVLDSVVEETLRLRAAPTLLRLVHEDYTLKMSSGQEYLFRHGDILALFPYLSVHM
DPDIHPEPTVFKYDRFLNPNGSRKVDFFKTGKKIHHYTMPWGSGVSICPGRFFALSEVKLFILLMVTHFDLELVDPDTPLPHVDPQRWGFGTMQPSHDVRFRYRLHPTE’ 
56. b6a7r5 human (491 residues): 
'MELSVLLFLALLTGLLLLLVQRHPNSHGTLPPGPRPLPLLGNLLQMDRRGLLKSFLRFREKYGDVFTVHLGPRPVVMLCGVEAIREALVDNAEAFSGRGKIVIMDPVYQGYGMLFANGNRWKVLRRFSVTTM
RDFGMGKRSVEERIQDEAQCLIEELRKSKGALVDPTFLFHSITANIICSIIFGKRFHYQDQEFLKTLNLFCQSFLLISSISSQLFELFSGFLKYFPGAHRQVYKNLQEINAYIGHSVEKHRETLDPSAPRDLIDTYLLH
MEKEKSNPHSEFSHQNLIINTLSLFFAGTETTSTTLRYGFLLMLKYPHVAERVYKEIEQVVGPHRPPALDDRAKMPYTEAVIREIQRFADLLPMGVPHIVTQHTSFRGYTIPKDTEVFLILSTALRDPHYFEKPDA
FNPDHFLDANGALKKNEAFIPFSLGKRICLGEGIARAELFLFFTTILQNFSVASPVAPEDIDLTPQECGVGKIPPTYQICFLPR’ 
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Validated Mouse P450 sequences 
1. c11b2 mouse (500 residues): 
'MALRVTADVWLARPWQCLHRTRALGTTATLAPKTLQPFEAIPQYSRNKWLKMIQILREQGQENLHLEMHQVFRELGPIFRHSVGKTQIVSVMLPEDAEKLHQVESMLPRRMHLEPWVAHRELRGLRRGVFL
LNGPEWRLNRLRLNRNVLSPKAVQKFVPMVDMVARDFLETLKEKVLQNARGSLTMDVQQSLFNYTIEASNFALFGERLGLLGHDLSPGSLKFIHALHSMFKSTSQLLFLPKSLTRWTSTRVWKEHFDAWDVI
SEYANRCIWKVHQELRLGSSQTYSGIVAELISQGSLPLDAIKANSMELTAGSVDTTAIPLVMTLFELARNPDVQKALRQESLAAEASIAANPQKAMSDLPLLKAALKETLRLYPVGGFLGRILSSDLVLQNYHV
PAGTLVLLYLYSMGRNPAVFPRPERYMPQRWLERKRSFQHLAFGFGVRQCLGRRLAEVEMMLLLHHILKTFQVETLRQEDVQMAYRFVLMPSSEPVLTFRPVS' 
2. cp11a mouse (526 residues): 
'MLAKGLSLRSVLVKGCQPFLSPTWQGPVLSTGKGAGTSTSSPRSFNEIPSPGDNGWLNLYHFWRESGTQKIHYHQMQSFQKYGPIYREKLGTLESVYIVDPKDASILFSCEGPNPERFLVPPWVAYHQYYQRPI
GVLFKSSDAWKKDRIVLNQEVMAPGAIKNFVPLLEGVAQDFIKVLHRRIKQQNSGNFSGVISDDLFRFSFESISSVIFGERMGMLEEIVDPEAQRFINAVYQMFHTSVPMLNLPPDFFRLLRTKTWKDHAAAWD
VIFNKADEYTQNFYWDLRQKRDFSQYPGVLYSLLGGNKLPFKNIQANITEMLAGGVDTTSMTLQWNLYEMAHNLKVQEMLRAEVLAARRQAQGDMAKMVQLVPLLKASIKETLRLHPISVTLQRYTVNDL
VLRNYKIPAKTLVQVASFAMGRDPGFFPNPNKFDPTRWLEKSQNTTHFRYLGFGWGVRQCLGRRIAELEMTILLINLLENFRIEVQNLRDVGTKFSLILMPENPILFNFQPLKQDLGPAVTRKDNTVN' 
3. cp17a mouse (507 residues): 
'MWELVGLLLLILAYFFWPKSKTPNAKFPRSLPFLPLVGSLPFLPRRGHMHANFFKLQEKYGPIYSLRLGTTTAVIVGHYQLAREVLVKKGKEFSGRPQMVTLGLLSDQGKGVAFADSSSSWQLHRKLVFSTFS
LFRDDQKLEKMICQEANSLCDLILTYDGESRDLSTLIFKSVINIICTICFNISFENKDPILTTIQTFTEGIVDVLGHSDLVDIFPWLKIFPNKNLEMIKEHTKIREKTLVEMFEKCKEKFNSESLSSLTDILIQAKMNAE
NNNTGEGQDPSVFSDKHILVTVGDIFGAGIETTSSVLNWILAFLVHNPEVKRKIQKEIDQYVGFSRTPSFNDRTHLLMLEATIREVLRIRPVAPLLIPHKANIDSSIGEFAIPKDTHVIINLWALHHDKNEWDQPDR
FMPERFLDPTGSHLITPTPSYLPFGAGPRSCIGEALARQELFIFMALLLQRFDFDVSDDKQLPCLVGDPKVVFLIDPFKVKITVRQAWKDAQVEVST' 
4. cp19a mouse (503 residues): 
'MFLEMLNPMQYNVTIMVPETVTVSAMPLLLIMGLLLLIWNCESSSSIPGPGYCLGIGPLISHGRFLWMGIGSACNYYNKMYGEFMRVWISGEETLIISKSSSMFHVMKHSHYISRFGSKRGLQCIGMHENGIIFN
NNPSLWRTIRPFFMKALTGPGLVRMVEVCVESIKQHLDRLGEVTDTSGYVDVLTLMRHIMLDTSNMLFLGIPLDESAIVKKIQGYFNAWQALLIKPNIFFKISWLYRKYERSVKDLKDEIAVLVEKKRHKVSTA
EKLEDCMDFATDLIFAERRGDLTKENVNQCILEMLIAAPDTMSVTLYFMLLLVAEYPEVEAAILKEIHTVVGDRDIKIEDIQNLKVVENFINESMRYQPVVDLVMRRALEDDVIDGYPVKKGTNIILNIGRMHR
LEYFPKPNEFTLENFEKNVPYRYFQPFGFGPRGCAGKYIAMVMMKVVLVTLLRRFQVKTLQKRCIENIPKKNDLSLHPNEDRHLVEIIFSPRNSDKYLQQ' 
5. cp1a1 mouse (524 residues): 
'MPSMYGLPAFVSATELLLAVTVFCLGFWVVRATRTWVPKGLKTPPGPWGLPFIGHMLTVGKNPHLSLTRLSQQYGDVLQIRIGSTPVVVLSGLNTIKQALVRQGDDFKGRPDLYSFTLITNGKSMTFNPDSG
PVWAARRRLAQNALKSFSIASDPTSASSCYLEEHVSKEANYLVSKLQKVMAEVGHFDPYKYLVVSVANVICAICFGQRYDHDDQELLSIVNLSNEFGEVTGSGYPADFIPVLRYLPNSSLDAFKDLNDKFYSF
MKKLIKEHYRTFEKGHIRDITDSLIEHCQDRKLDENANVQLSDDKVITIVLDLFGAGFDTVTTAISWSLMYLVTNPRVQRKIQEELDTVIGRDRQPRLSDRPQLPYLEAFILETFRHSSFVPFTIPHSTTRDTSLNG
FYIPKGCCVFVNQWQVNHDRELWGDPNEFRPERFLTPSGTLDKRLSEKVTLFGLGKRKCIGETIGRSEVFLFLAILLQQIEFKVSPGEKVDMTPTYGLTLKHARCEHFQVQMRSSGPQHLQA' 
6. cp1a2 mouse (513 residues): 
'MAFSQYISLAPELLLATAIFCLVFWMVRASRTQVPKGLKNPPGPWGLPFIGHMLTVGKNPHLSLTRLSQQYGDVLQIRIGSTPVVVLSGLNTIKQALVRQGDDFKGRPDLYSFTLITNGKSMTFNPDSGPVWA
ARRRLAQDALKSFSIASDPTSASSCYLEEHVSKEANHLVSKLQKAMAEVGHFEPVSQVVESVANVIGAMCFGKNFPRKSEEMLNIVNNSKDFVENVTSGNAVDFFPVLRYLPNPALKRFKTFNDNFVLFLQK
TVQEHYQDFNKNSIQDITSALFKHSENYKDNGGLIPEEKIVNIVNDIFGAGFDTVTTAITWSILLLVTWPNVQRKIHEELDTVVGRDRQPRLSDRPQLPYLEAFILEIYRYTSFVPFTIPHSTTRDTSLNGFHIPKER
CIYINQWQVNHDEKQWKDPFVFRPERFLTNNNSAIDKTQSEKVMLFGLGKRRCIGEIPAKWEVFLFLAILLQHLEFSVPPGVKVDLTPNYGLTMKPGTCEHVQAWPRFSK' 
7. cp1b1 mouse (543 residues): 
'MATSLSADSPQQLSSLSTQQTTLLLLFSVLAAVHLGQWLLRQWQRKPWSSPPGPFPWPLIGNAAAVGQASHLYFARLARRYGDVFQIRLGSCPVVVLNGESAIHQALVQQGSIFADRPPFASFRVVSGGRSLA
FGHYSEHWKTQRRSAYSTMRAFSTRHPRSRGLLEGHALAEARELVAVLVRRCAGGAFLDPTQPVIVAVANVMSAVCFGCRYNHDDAEFLELLSHNEEFGRTVGAGSLVDVLPWLQLFPNPVRTTFRKFEQL
NRNFSNFVLDKFLRHRESLVPGAAPRDMTDAFILSAEKKASGDPGDDSSGLDLEDVPATITDIFGASQDTLSTALLWLLILFTRYPDVQARVQAELDQVVGRDRLPCMSDQPNLPYVMAFLYESMRFSSFLPVT
IPHATTANTFVLGYYIPKNTVVFVNQWSVNHDPAKWPNPEDFDPARFLDKDGFINKALASSVMIFSVGKRRCIGEELSKMLLFLFISILAHQCNFKANQNESSNMSFSYGLTIKPKSFRIHVSLRESMELLDNAV
KKLQTEEGCK' 
8. cp20a mouse (462 residues): 
'MLDFAIFAVTFLLALVGAVLYLYPASRQASGIPGLTPTEEKDGNLPDIVNSGSLHEFLVNLHERYGPVVSFWFGRRLVVSLGTTDVLKQHFNPNKTSDPFETMLKSLLGYQSGGGSAGEDHVRRKLYGDAVT
ASLHSNFPLLLQLSEELLDKWLSYPETQHIPLSQHMLGFALKFVTRMVLGSTFEDEQEVIRFQKIHGTVWSEIGKGFLDGSLDKNTTRKKQYQEALMQLESTLKKIIKERKGGNFRQHTFIDSLTQGKLNEQQIL
EDCVVFSLASCIITARLCTWTIHFLTTTGEVQKKLCKEIDQVLGEGPITSEKIEQLSYCQQVLFETVRTAKLTPVSARLQDIEGKVGPFVIPKETLVLYALGVVLQDPSTWPLPHRFDPDRFADEPVMKVFSSLGFS
GTWECPELRFAYMVTAVLVSVLLKRLRLLAVDRQVFEMKYELVTSAREEAWITVSKRH' 
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9. cp21a mouse (487 residues): 
'MLLPGLLLLLLLLAGTRWLWGQWKLRKLHLPPLAPGFLHFLQPNLPIYLLGLTQKLGPIYRIRLGMQDVVVLNSNRTIEEALIQKWVDFAGRPHMLNGKMDLDLSLGDYSLMWKAHKKLSRSALMLGMRD
SMEPLIEQLTQEFCERMRAQAGTPVAIHKEFSFLTCSIISCLTFGDKDSTLVQTLHDCVQDLLQAWNHWSIQILTIIPLLRFLPNPGLQKLKQIQESRDHIVKQQLKQHKDSLVAGQWKDMIDYMLQGVEKQRD
GKDEERLHEGHVHMSVVDLFIGGTETTATTLSWAVAFLLHHPEIQKRLQEELDLKLGPGSQLLYRNRMQLPLLMATIAEVLRLRPVVPLALPHRATRASSISGYDIPKDMVIIPNIQGANLDEMVWELPSKFWP
DRFLEPGKNPRTPSFGCGARVCLGEPLARLELFVVLARLLQAFTLLPPPDGTLPSLQPQPYAGINLPIPPFQVRLQPRNLAPQDQGERP' 
10. cp237 mouse (490 residues): 
'MDPILVLVLTLSCLFLLSLWRQSSERGKLPPGPTPLPIIGNILQIDVKDICQSFTNLSKVYGPVYTLYLGRKPTVVLHGYEAVKEALVDHGEEFAGRGRFPVFDKATNGMGLAFSKGNVWKNTRRFSLMTL
RNLGMGKRSIEDRVQEEARCLVEELRKTNGSPCDPTFILGCAPCNVICSIIFQDRFDYKDRDFLNLMEKLNEITKILSSPWLQICNTYPALLDYCPGSHKQFFKNYACIKNFLLEKIKEHEESLDVTIPRDFIDY
FLINGGQEDGNQPLQNRLEHLAITVTDLFSAGTETTSTTLRYALLLLLKYPHVTAKVQKEIEHVIGKHRSPCMQDRSRMPYTDAMIHEVQRFIDLIPNSLPHEVTCDIKFRNYFIPKGTTVITSLSSVLHDSTEFP
NPEVFDPGHFLDGNGKFKKSDYFMPFSTGKRICAGEGLARMELFLFLTSILQSFNLKPLVHPKDIDVTPMLIGLGSVPPAFQLCFIPS' 
11. cp238 mouse (490 residues): 
'MDLVTFLVLTLSSLILLSLWRQRSRRGRLPPGPTPFPIIGNFLQIDVKNFNQSLTNFSKAYGPVFTLYLGSRPIVVLHGYEAVKEALIDHGEEFSGRGNIPMSEKINNGLGITFSNGNSWKETRHFTLMTLRNLGM
GKRNIEDRVREEAQCLVEELRKTKGSPCDPTFILSCAPCNVICSIIFQDRFHYKDKDFLMLMKKLNENVKILSSPWLQVCNNFPLLIDYCPGSHHKVLKNFKYIRSYLLEKVKEHQASLDFTNPRDFIDYFLIKQK
QANHIEQAEYSLENLVCTINNLFAAGTETTSTTLRYALLLLMKYPDVTAKVQEEIDHVVGRHRSPCMQDRSHMPYTDAMIHEVQRFINLVPNNLPHAVTCDIKFRNYIIPKGTTVVTSLTSVLHDSKEFPNPEM
FDPGHFLDANGNFKKSDYFMTFSAGKRVCAGEGLARMELFLILTTILQNFKLKSLVHPKDIDMMPFVNGLIALPPHYQLCFIPL' 
12. cp239 mouse (490 residues): 
'MDLVTFLVLTLSSLILLSLWRQSCGRGSLPPGPTPFPIIGNFLQIDMKNFSQSLTNFSKAYGPVFTLYLGSRPTVVLHGYEAVKEALIDHGEEFSDRGSIPMVEKINNGLGIVFSNGNRWKEIRRFTLTTLRNL
GMGKRNIEDRVQEEAQCLVEELRKTKGSPCDPTFILSCAPCNVICSIIFQDRFDYKDKDFLMLMEKLNENVKILSSPWLQVCNNFPLLIDYCPGSHHKVLKNVKYIRSYLLEKIKEHQESLDVTNPRDFIDYY
LIKQKQANHIQQAEFSLENLACTINNLFAAGTETTSTTLRYALLLLMKYPDVTAKVQEEIDHVIGRHRSPCMQDRNHMPYTDAMIHEVQRFINLVPNNIPRAVTCDIKFRNYLIPKGTTVVTSLTSVLHDSKEF
PNPELFDPGHFLDANGNFKKSDHFMPFSAGKRVCAGEGLARMELFLFLTTILQNFKLKPLVHPKDIDMIPFVNGLIALPPHYQVCIIPR' 
13. cp240 mouse (491 residues): 
'MDPFVVLVLCLSFLLVLSLWRQRSARGNLPPGPTPLPIIGNYHLIDMKDIGQCLTNFSKTYGPVFTLYFGSQPIVVLHGYEAIKEALIDHGEEFSGRGRIPVFDKVSTGKGIGFSHGNVWKATRVFTVNTLRNL
GMGKRTIENKVQEEAQWLMKELKKTNGSPCDPQFIIGCAPCNVICSIVFQNRFDYKDKDFLSLIGKVNECTEILSSPGCQIFNAVPILIDYCPGSHNKLFKNHTWIKSYLLGKIKEHEESLDVTNPRDFIDYFLIQR
RQKNGIEHMDYTIEHLATLVTDLVFGGTETLSSTMRFALLLLMKHTHITAKVQEEIDNVIGRHRSPCMQDRNHMPYTNAMVHEVQRYIDLGPNGVVHEVTCDTKFRNYFILKGTQVMTSLTSVLHDSTEFPN
PEVFDPGHFLDDNGNFKKSDYFVPFSAGKRICVGESLARMELFLFLTTILQNFKLKPLVDPKDIDMTPKHSGFSKIPPNFQMCFIPVE' 
14. cp24a mouse (514 residues): 
'MSCPIDKRRPLIAFLRRLRDLGQPPRSVTSKAHVKRAPKEVPLCPLMTDGETRNVTSLPGPTNWPLLGSLLEIFWKGGLKKQHDTLAEYHKKYGQIFRMKLGSFDSVHLGSPSLLEALYRTESAHPQRLEIKPW
KAYRDHRNEAYGLMILEGQEWQRVRSAFQKKLMKPVEIMKLDKKINEVLADFMGQIDELRDERGRIQDLYSELNKWSFESICLVLYEKRFGLLQKDTEEEALTFIAAIKTMMSTFGKMMVTPVELHKRLNTK
VWQAHTLAWDTIFKSVKPCIDHRLERYSQQPGADFLCDIYQQDHLSKKELYAAVTELQLAAVETTANSLMWILYNLSRNPQVQQRLLREIQSVLPDNQTPRAEDVRNMPYLKACLKESMRLTPSVPFTTRTL
DKPTVLGEYTLPKGTVLTLNTQVLGSSEDNFEDADKFRPERWLEKEKKINPFAHLPFGVGKRMCIGRRLAELQLHLALCWIIQKYNIVATDSEPVEMLHLGILVPSRELPIAFCPR' 
15. cp254 mouse (490 residues): 
'MDPILVLVLTLSCLFLLSLWRQSYERGKLPPGPTPLPIIGNILQIDVKDICQSFTNLSRVYGPVYTLYLGRKPTVVLHGYEAVKEALVDHGDVFAGRGRLPVFDKATNGMGIGFSNGSVWKNTRHFSLMTL
RNLGMGKRSIEDRVQEEARCLVEELRKTNGSPCDPTFILGCAPCNVICSIIFQDRFDYKDRDFLNLLEKLDEISKILSTPWLQVCNTFPALLDYCPGSHNQFFKNYAYIKNFLLEKIREHKESLDVTIPRDFIDYF
LIKGAQEDDNHPLKNNFEHLAITVTDLFIGGTESMSTTLRYALLLLLKYPHVTAKVQEEIEHVIGKHRRPCMQDRSHMPYTNAMIHEVQRFIDLVPNNLPHEVTCDIKFRNYFIPKGTTVITSLSSVLRDSKEF
PNPEKFDPGHFLDENGKFKKSDYFMPFSTGKRICAGEGLARMELFLFLTSILQNFNLKPLVHPKDIDITPMLIGLGSVPPAFQLCFIPS' 
16. cp255 mouse (490 residues): 
'MDPVLVLVLTLSCLLLLSLWRQNSGRGKLPPGPTPFPIIGNILQIDIKNISKSFNYFSKVYGPVFTLYFGSKPTVVVHGYEAVKEALDDLGEEFSGRGSFQIFERINNDLGVIFSNGTKWKELRRFSIMTLRSFGMG
KRSIEDRIQEEASCLVEELRKANGSLCDPTFILSCAPSNVICSVIFHNRFDYKDEKFLNLMERLNENFKILNSPWMQVYNALPTLINYLPGSHNKVIKNFTEIKSYILGRVKEHQETLDMDNPRDFIDCFLIKMEQE
KHNPHSEFTIESLMATVTDIFVAGTETTNITLRYGLLLLLKHTEVTAKVQAEIDHVIGRHRSPCMQDRTRMPYTDAMVHEIQRYIDLIPNNVPHAATCNVRFRSYFIPKGTELVTSLTSVLHDDKEFPNPEVFDPG
HFLDENGNFKKSDYFMPFSIGKRMCVGEALARTELFLILTTILQNFNLKSLVDTKDIDTTPVANTFGRVPPSYQLYFIPR' 
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17. cp26a mouse (497 residues): 
'MGLPALLASALCTFVLPLLLFLAALKLWDLYCVSSRDRSCALPLPPGTMGFPFFGETLQMVLQRRKFLQMKRRKYGFIYKTHLFGRPTVRVMGADNVRRILLGEHRLVSVHWPASVRTILGAGCLSNLHDSS
HKQRKKVIMQAFSREALQCYVLVIAEEVSSCLEQWLSCGERGLLVYPEVKRLMFRIAMRILLGCEPGPAGGGEDEQQLVEAFEEMTRNLFSLPIDVPFSGLYRGVKARNLIHARIEENIRAKIRRLQATEPDGGC
KDALQLLIEHSWERGERLDMQALKQSSTELLFGGHETTASAATSLITYLGLYPHVLQKVREEIKSKGLLCKSNQDNKLDMETLEQLKYIGCVIKETLRLNPPVPGGFRVALKTFELNGYQIPKGWNVIYSICDT
HDVADIFTNKEEFNPDRFIVPHPEDASRFSFIPFGGGLRSCVGKEFAKILLKIFTVELARHCDWQLLNGPPTMKTSPTVYPVDNLPARFTYFQGDI' 
18. cp270 mouse (489 residues): 
'MALFIFLGIWLSCFLFLFLWNQHRGRGKLPPGPTPLPIVGNILQVDVKNISKSMGMLAKKYGPVFTVYLGMKPTVVLHGYKAMKEALIDQGDEFSDKTDSSLLSRTSQGLGIVFSNGETWKQTRRFSLMVLR
SMGMGKKTIEDRIQEEILYMLDALRKTNGSPCDPSFLLACVPCNVISTVIFQHRFDYNDQTFQDFMENFHRKIEILASPWSQLCSAYPILYYLPGIHNRFLKDVTQQKKFILEEINRHQKSLDLSNPQDFIDYFLIK
MEKEKHNQKSEFTMDNLVVSIGDLFGAGTETTSSTVKYGLLLLLKYPEVTAKIQEEIAHVIGRHRRPTMQDRNHMPYTDAVLHEIQRYIDFVPIPSPRKTTQDVEFRGYHIPKGTSVMACLTSVLNDDKEFP
NPEKFDPGHFLDEKGNFKKSDYFVAFSAGRRACIGEGLARMEMFLILTNILQHFTLKPLVKPEDIDTKPVQTGLLHVPPPFELCFIPV' 
19. cp27a mouse (533 residues): 
'MAAWSRTRLRWTLLDPRVVGRGLCPQGARAKATIPAALQAQESTEGPGTGQDRPRLRSPAELPGTGTLQFLFQLFLQGYVLHLPDLQVLNKTKYGPMWTTSFGTYTNVNLASAPLLEQVMRQEGKYPIRDH
MDQWKDHRDHKGLTYGIFIAQGEQWYHLRQALKQRLLKPDEAALYTDALNEVISDFITRLDQVRAESESGDQVPDMAHLLYHLALEAITYILFEKRIGCLKPSIPEDTAAFIRSVAIMFQNSVYITFLPKWTRPL
LPFWKRYLNGWDNIFSFGKKLIDEKVQELKAQLQETGPDGVRVSGYLHFLLTNELLSTQETIGTFPELLLAGVDTTSNTLTWALYHLSKSPEIQEALHKEVTGVVPFGKVPQHKDFAHMPLLKAVIKETLRLY
PVVPTNSRIITEKETEINGFLFPKNTQFVLCHYVVSRDPSVFPEPNSFQPHRWLRKKEADNPGILHPFGSVPFGYGVRSCLGRRIAELEMQLMLSRLVQKYEIALAPGMGEVKTVSRIVLVPSKKVRLHFLQR
Q' 
20. cp27b mouse (507 residues): 
'MTQAVKLASRVFHRIHLPLQLDASLGSRGSESVLRSLSDIPGPSTLSFLAELFCKGGLSRLHELQVHGAARYGPIWSGSFGTLRTVYVADPTLVEQLLRQESHCPERCSFSSWAEHRRRHQRACGLLTADGEEW
QRLRSLLAPLLLRPQAAAGYAGTLDNVVRDLVRRLRRQRGRGSGLPGLVLDVAGEFYKFGLESIGAVLLGSRLGCLEAEVPPDTETFIHAVGSVFVSTLLTMAMPNWLHHLIPGPWARLCRDWDQMFAFAQ
RHVELREGEAAMRNQGKPEEDMPSGHHLTHFLFREKVSVQSIVGNVTELLLAGVDTVSNTLSWTLYELSRHPDVQTALHSEITAGTRGSCAHPHGTALSQLPLLKAVIKEVLRLYPVVPGNSRVPDRDIRVGN
YVIPQDTLVSLCHYATSRDPTQFPDPNSFNPARWLGEGPTPHPFASLPFGFGKRSCIGRRLAELELQMALSQILTHFEVLPEPGALPIKPMTRTVLVPERSINLQFVDR' 
21. cp2a4 mouse (494 residues): 
'MLTSGLLLVAAVAFLSVLVLMSVWKQRKLSGKLPPGPTPLPFVGNFLQLNTEQMYNSLMKISQRYGPVFTIYLGSRRIVVLCGQEAVKEALVDQAEEFSGRGEQATFDWLFKGYGIAFSSGERAKQLRSFS
IATLRDFGVGKRGIEERIQEEAGFLIDSFRKTNGAFIDPTFYLSRTVSNVISSIVFGDRFDYEDKEFLSLLRMMLGSLQFTATSMGQVYEMFSSVMKHLPGPQQQAFKELQGLEDFITKKVEHNQRTLDPNSP
RDFIDSFLIRMLEEKKNPNTEFYMKNLVLTTLNLFFAGTETVSTTLRYGFLLLMKYPDIEAKVHEEIDRVIGRNRQPKYEDRMKMPYTEAVIHEIQRFADLIPMGLARRVTKDTKFRDFLLPKGTEVFPML
GSVLKDPKFFSNPKDFNPKHFLDDKGQFKKSDAFVPFSIGKRYCFGEGLARMELFLFLTNIMQNFHFKSTQAPQDIDVSPRLVGFVTIPPTYTMSFLSR' 
22. cp2a5 mouse (494 residues): 
'MLTSGLLLVAAVAFLSVLVLMSVWKQRKLSGKLPPGPTPLPFIGNFLQLNTEQMYNSLMKISQRYGPVFTIYLGPRRIVVLCGQEAVKEALVDQAEEFSGRGEQATFDWLFKGYGVVFSSGERAKQLRRF
SIATLRDFGVGKRGIEERIQEEAGFLIDSFRKTNGAFIDPTFYLSRTVSNVISSIVFGDRFDYEDKEFLSLLRMMLGSFQFTATSMGQLYEMFSSVMKHLPGPQQQAFKELQGLEDFITKKVEHNQRTLDPNS
PRDFIDSFLIRMLEEKKNPNTEFYMKNLVLTTLNLFFAGTETVSTTLRYGFLLLMKHPDIEAKVHEEIDRVIGRNRQPKYEDRMKMPYTEAVIHEIQRFADMIPMGLARRVTKDTKFRDFLLPKGTEVFPML
GSVLKDPKFFSNPKDFNPKHFLDDKGQFKKNDAFVPFSIGKRYCFGEGLARMELFLFLTNIMQNFHFKSTQAPQDIDVSPRLVGFATIPPTYTMSFLSR' 
23. cp2ac mouse (492 residues): 
'MLGSGLLLLAILAFLSVMVLVSVWQQKIRGKLPPGPIPLPFIGNYLQLNRKDVYSSITQLQEHYGPVFTIHLGPRRVVVLYGYDAVKEALVDHAEEFSGRGEQATFNTLFKGYGVAFSNGERAKQLRRFSIATL
RDFGMGKRGVEEHIQEEAGCLIKMLQGTCGAPIDPTIYLSKTASNVISSIVFGDRFNYEDKEFLSLLQMMGQVNKFAASPTGQLYDMFHSVMKYLPGPQQQIIKDSHKLEDFMIQKVKQNQSTLDPNSPRDFID
SFLIHMQKEKYVNSEFHMKNLVMTSLNLFFAGSETVSSTLRYGFLLLMKHPDVEAKVHEEIDRVIGRNRQPQYEDHMKMPYTQAVINEIQRFSNFAPLGIPRRITKNTSFRGFFLPKATEVFPILGSLMTDPKFF
SSPKDFNPQHFLDDKGQLKKIPAFLPFSTGKRFCLGDSLAKMELFFLFTTILQNFRFKFPRKLEDINESPTPEGFTRIIPKYTMSFVPI’ 
24. cp2b9 mouse (491 residues): 
'MDPSVLLLLAVLLSLFLLLVRGHAKIHGHLPPGPHPLPLLGNLLQMDRGGLLKCFIQLQEKHGDVFTVHLGPRPVVVLCGTQTIREALVDHAEAFSGRGTIAAAQLVMQDYGIFFASGQRWKTLRRFSLATM
KEFGMGKRSVEERIKEEAQCLVEELKKYQGVPLDPTFLFQCITANIICSIVFGERFDYTDDQFLHLLNLMYKIFSLLSSFSGQMFELFSGFLKYFPGVHRQIVKKQQELLDYIAHSVEKHKATLDPSAPRDYIDT
YLLRMEKEKSNHNTEFHHQNLMMSVLSLFFVGTETTSATLHYGVLLMLKYPHVTEKVQKEIDQVIGSHRLPTLDDRTKMPYTDAVIHEIQRFSDLVPIGLPHKVIKDTLFRGYLLPKNTEVYPVLSSALHDPQ
YFEQPDKFNPEQFLDANGALKKCEAFLPFSTGKRICLGESIARNELFIFFTTILQNFSVASPVAPKDIDLTPKESGIGKIPPAHQIYFLAR' 
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25. cp2ba mouse (500 residues): 
'MEPSVLLLLALLVGFLLLLARGHPKSRGNFPPGPRPLPLLGNLLQMDRGGLLKSLIQLREKYGDVFTVHLGPRPVVMLCGTDTIREALVGQAEAFSGRGTVAVVEPTFKEYGVIFANGERWKTLRRFSLATMR
DFGMGKRSVEERIQEEAQCLVEELRKSQGAPLDPTFLFQCITANVICSIVFGERFEYTDRQFLRLLELFYQTFSLISSFSSQMFELFSGFLKYFPGAHRQISKNLQELLDYIGHSVERHKATLDPSVPRDFIDIYLLR
MEKEKSNQNAEFHHQNLMMSVLSLFFVGTETSSTTLHYGFLLMLKYPHVTEKVQKEIDQVIGSHRLPTLDDRTKMPYSDAVIHEIQRFSDLIPIGVPHRVTKDTLFRGYLLPKNTEVYPILSSALHDPQYFEQPD
SFNPDQFLDANGALKKSEAFLPFSTGQIFDQKSVGKRICLGESIARSELFLFFTSILQNFSVASHVAPKDIDLTPKESGIGKIPPTYQICFLAR' 
26. cp2bj mouse (492 residues): 
'MEFSVLLLLALTTGFLIFLVSQSQPKTHGHFPPGPRPLPFLGNLLQMDRRGLLSSFIQLQEKYGDVFTVHLGPRPVVMLCGTDTIREALVNQAEAFSGRGTVAVLDPIVQGYGVIFSSGERWKTLRRFSLATMR
DFGMGKRSVEERIKEEAQCLVEELKKYKGAPLNPTFYFQCIVANIICSIVFGERFDYKDHQFLHLLNLIYQTFSLMSSLSSQVFELFSAILKYFPGAHRQISKNLQEILDYIGHSVEKHRATLDPSAPRDFIDTYLLR
MEKEKSNHHTEFHHQNLVISVLSLFFAGTETTSTTLRYSFLIMLKYPHVAEKVQKEIDQVIGSHRLPTLDDRTKMPYTDAVIHEIQRFTDLAPIGLPHKVTKDTLFRGYLIPKNTEVYPILSSALHDPRYFEQPDSF
NPEHFLDANGALKTNEAFMPFSTGKRICLGEGIARNELFLFFTTILQNFSLASPVAPENIDLIPNNSGATKTPPQYQIHFLSR' 
27. cp2ct mouse (490 residues): 
'MDLVVFLALTLSCLILLSLWRQSSGRGKLPPGPTPLPIIGNFLQIDVKNISQSFTNFSKAYGPVFTLYLGSKPTVILHGYEAVKEALIDRGEEFAGRGSFPMAEKIIKGFGVVFSNGNRWKEMRRFTLMTLR
NLGMGKRNIEDRVQEEAQCLVEELRKTKGSPCDPTFILSCAPCNVICSIIFQNRFDYKDKEFLILMDKINENVKILSSPWLQVCNSFPSLIDYCPGSHHKIVKNFNYLKSYLLEKIKEHKESLDVTNPRDFIDYY
LIKQKQVNHIEQSEFSLENLASTINDLFGAGTETTSTTLRYALLLLLKYPDVTAKVQEEIDRVVGRHRSPCMQDRSHMPYTDAMIHEVQRFIDLLPTSLPHAVTCDIKFRKYLIPKGTTVITSLSSVLHDSKEF
PNPEMFDPGHFLNANGNFKKSDYFMPFSTGKRICAGEGLARMELFLILTTILQNFKLKSLVHPKEIDITPVMNGFASLPPPYQLCFIPL’ 
28. cp2d9 mouse (504 residues): 
'MELLTGTDLWPVAIFTVIFILLVDLTHQRQRWTSRYPPGPVPWPVLGNLLQVDLGNMPYSLYKLQNRYGDVFSLQMAWKPMVVINGLKAMKEMLLTCGEDTADRPPVPIFEYLGVKPGSQGVVLAPYGPE
WREQRRFSVSTLRNFGLGKKSLEDWVTKEANHLCDAFTAQAGQPINPNPMLNKSTCNVIASLIFARRFEYEDPFLIRMLKVLEQSLTEVSGLIPEVLNAFPILLRIPRLADKALQGQKSFIAILDNLLTENRTTW
DPVQAPRNLTDAFLAQIEKAKGNPESSFNDENLLMVVRDLFGAGMLTTSTTLSWALMLMILHPDVQRRVQQEIDEVIGQVRHPEMADQAHMPYTNAVIHEVQRFGDIVPVNLPRITSHDIEVQDFLIPKGTIL
LPNMSSMLKDESVWEKPLRFHPEHFLDAQGHFVKPEAFMPFSAGRRSCLGEALARMELFLFFTCLLQRFSFSVPDGQPQPSNSGVYGILVAPSPYQLCAVVRDQGH' 
29. cp2da mouse (504 residues): 
'MELLTGAGLWSVAIFTVIFILLVDLMHRHQRWTSRYPPGPVPWPVLGNLLQVDLDNMPYSLYKLQNRYGDVFSLQMGWKPMVVINGLKAMKEVLLTCGEDTADRPQVPIFEYLGVKPGSQGVVLAPYGPE
WREQRRFSVSTLRNFGLGKKSLEDWVTKEARHLCDAFTAQAGQPINPNTMLNNAVCNVIASLIFARRFEYEDPYLIRMQKVLEDSLTEISGLIPEVLNMFPILLRIPGLPGKVFQGQKSLLAIVENLLTENRNT
WDPDQPPRNLTDAFLAEIEKVKGNAESSFNDENLRMVVLDLFTAGMVTTSTTLSWALLLMILHPDVQRRVQQEIDAVIGQVRHPEMADQARMPYTNAVIHEVQRFGDIAPLNLPRITSRDIEVQDFLIPK
GSILIPNMSSVLKDETVWEKPLRFHPEHFLDAQGHFVKPEAFMPFSAGRRSCLGEPLARMELFLFFTCLLQHFSFSVPNGQPRPRNLGVFPFPVAPYPYQLCAVMREQGH' 
30. cp2db mouse (505 residues): 
'MELLTGAGLWSVAIFTVIFILLVDLMHRHQHWTSRCPPGPVPWPVLGNLLQVDLDNMPYSLYKLQNRYGDVFSLQMAWKPMVVINGLKAMKEMLLTCGEDTADRPPVPIFEYLGVKPGSQGVVLAPYGPE
WREQRRFSVSTLRNFGLGKKSLEEWVTKEARHLCDAFTAQAGQPINPNPMLNKSTCNVIASLIFARRFEYEDPFLIRMLKMLKECFTEISGFIPGVLNEFPIFLRIPGLADMVFQGQKSFMAILDNLLTENRTTWD
PDQPPRNLTDAFLAEIEKAKGNAESSFNDENLRMVVLDLFTAGMVTTSTTLSWALLLMILHPDVQRRVQQEIDAVIGQVQHPEMADQARMPYTNAVIHEVQRFGTLLHCLCHASQVVTFTQVQDFLVTKGST
LIPNLSSVLKGETVWEKPLRFHPEHFLDAQGHFVKPEAFMPFSAGHRSCLGEALARMELFLFFTCLLQRFSISVPDGQPQPSNYRVHAIPVAPFPYQLCAVMHEQGH' 
31. cp2dq mouse (500 residues): 
'MGLLVGDDLWAVVIFTAIFLLLVDLVHRRQRWTACYPPGPVPFPGLGNLLQVDFENIPYSFYKLQNRYGNVFSLQMAWKPVVVVNGLKAVRELLVTYGEDTSDRPLMPIYNHIGYGHKSKGVILAPYGP
EWREQRRFSVSTLRDFGLGKKSLEQWVTEEAGHLCDAFTKEAEHPFNPSPLLSKAVSNVIASLIYARRFEYEDPFFNRMLKTLKESLGEDTGFVGEVLNAIPMLLHIPGLPDKAFPKLNSFIALVNKMLIEHD
LTWDPAQPPRDLTDAFLAEVEKAKGNPESSFNDKNLRIVVIDLFMAGMVTTSTTLSWALLLMILHPDVQRRVHQEIDEVIGHVRHPEMADQARMPYTNAVIHEVQRFADIVPTNLPHMTSRDIKFQDFFI
PKGTTLIPNLSSVLKDETVWEKPLRFYPEHFLDAQGHFVKHEAFMPFSAGRRSCLGEPLARMELFLFFTCLLQRFSFSVPDGQPRPSDYGIYTMPVTPEPYQLCAVAR' 
32. cp2e1 mouse (493 residues): 
'MAVLGITVALLVWIATLLLVSIWKQIYRSWNLPPGPFPIPFFGNIFQLDLKDIPKSLTKLAKRFGPVFTLHLGQRRIVVLHGYKAVKEVLLNHKNEFSGRGDIPVFQEYKNKGIIFNNGPTWKDVRRFSLSI
LRDWGMGKQGNEARIQREAHFLVEELKKTKGQPFDPTFLIGCAPCNVIADILFNKRFDYDDKKCLELMSLFNENFYLLSTPWIQAYNYFSDYLQYLPGSHRKVMKNVSEIRQYTLGKAKEHLKSLDINCPR
DVTDCLLIEMEKEKHSQEPMYTMENISVTLADLFFAGTETTSTTLRYGLLILMKYPEIEEKLHEEIDRVIGPSRAPAVRDRMNMPYMDAVVHEIQRFINLVPSNLPHEATRDTVFRGYVIPKGTVVIPTLDSL
LFDNYEFPDPETFKPEHFLNENGKFKYSDYFKAFSAGKRVCVGEGLARMELFLLLSAILQHFNLKSLVDPKDIDLSPVTIGFGSIPREFKLCVIPRS' 
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33. cp2f2 mouse (491 residues): 
'MDGVSTAILLLLLAVISLSLTFSSRGKGQLPPGPKPLPILGNLLQLRSQDLLTSLTKLSKEYGSVFTVYLGSRPVIVLSGYQTVKEALVDKGEEFSGRGAYPVFFNFTRGNGIAFSDGERWKILRRFSVQILRN
FGMGKRSIEERILEEGSFLLEVLRKMEGKPFDPVFILSRSVSNIICSVVFGSRFDYDDERLLTIIHFINDNFKIMSSPWGEMYNIFPSVLDWIPGPHKRLFRNFGGMKDLIARSVREHQDSLDPNSPRDFIDCFLTK
MAQEKQDPLSHFNMDTLLMTTHNLLFGGTETVGTTLRHAFLILMKYPKVQARVQEEIDRVVGRSRMPTLEDRTSMPYTDAVIHEVQRFADVIPMNLPHRVTRDTPFRGFLIPKGTDVITLLNTVHYDSDQ
FKTPQEFNPEHFLDDNHSFKKSPAFMPFSAGRRLCLGEPLARMELFIYFTSILQNFTLQPLVDPEDIDLTPLSSGLGNLPRPFQLCMHIR' 
34. cp2j5 mouse (501 residues): 
'MIMFLSSLVTTFWEALHLKTLVLAVVTFLFLINILRSRHPKNYPPGPWRLPFVGNFFQIDTKQTHLVLQQFVKKYGNVFSLELGQSPVVVVSGLPLIKEMFTHLDQNFVNRFMTPVRERITGKNGLVVSNGQT
WKEQRRLALMALRNFGLGKKSLEERIQEETHHLVEAIREEGGQPFNPHLKLINAVSNIICSVTFGERFDYEDCQFQELLQLLDETMHLMGSSAGQLYNGFPCIMKYLPGPHQKIFRNWGKLKLFVSHIVKKHEK
DWNPDEPRDFIDAFLIEMQKDPDRTTSFNEENLISTTLDLFLGGTETTSSTLRWALLYMSSYPEIQENVQAEIDRVIGHKRQVSLSDRESMPYTNAVIHEVQRMGNIVPLNSSREVTVDTKFNGFHLPKGTMILT
NLTALHRDPKEWATPEVFNPEHFLENGQFKKRESFLPFSMGKRACLGEQLAKSELFIFFSALMQKFTFKPPINEKLSLKFRMGLILSPASYRICAIPRV' 
35. cp2j6 mouse (501 residues): 
'MLAATGSLLATIWAALHPRTLLVAAVTFLLLADYFKNRRPKNYPPGPWGLPFVGNIFQLDFGQPHLSIQPLVKKYGNIFSLNLGDITSVVITGLPLIKEALTQMEQNIMNRPLSVMQERISNKNGLIFSSGQIWK
EQRRFALMTLRNFGLGKKSLEERMQEEASHLVEAIREEEGKPFNPHFSINNAVSNIICSVTFGERFDYHDSRFQEMLRLLDEVMYLETTMISQLYNIFPWIMKYIPGSHQKVFRNWEKLKLFVSCMIDDHRKDW
NPDEPRDFIDAFLKEMTKYPEKTTSFNEENLICSTLDLFFAGTETTSTTLRWALLYMALYPEVQEKVQAEIDRVIGQKRAARLADRESMPYTNAVIHEVRRMGNIIPLNVPREVAMDTNLNGFHLPKGTMVLTN
LTALHRDPKEWATPDVFNPEHFLENGQFKKRESFLPFSMGKRACLGEQLARSELFIFFTSLMQKFTFNPPINEKLSPKFRNGLTLSPVSHRICAVPRQ' 
36. cp2r1 mouse (501 residues): 
'MLELPGARACAGALAGALLLLLFVLVVRQLLRQRRPAGFPPGPPRLPFVGNICSLALSADLPHVYMRKQSRVYGEIFSLDLGGISTVVLNGYDVVKECLVHQSEIFADRPCLPLFMKMTKMGGLLNSRYGRG
WIDHRRLAVNSFHYFGSGQKSFESKILEETWSLIDAIETYKGGPFDLKQLITNAVSNITNLILFGERFTYEDTDFQHMIELFSENVELAASAPVFLYNAFPWIGILPFGKHQRLFRNADVVYDFLSRLIEKAAVNRK
PHLPHHFVDAYLDEMDQGQNDPLSTFSKENLIFSVGELIIAGTETTTNVLRWAILFMALYPNIQGQVHKEIDLIVGHNRRPSWEYKCKMPYTEAVLHEVLRFCNIVPLGIFHATSEDAVVRGYSIPKGTTVITNL
YSVHFDEKYWKDPDMFYPERFLDSNGYFTKKEALIPFSLGRRHCLGEQLARMEMFLFFTSLLQQFHLHFPHELVPNLKPRLGMTLQPQPYLICAERR' 
37. cp2s1 mouse (501 residues): 
'MEAASTWALLLALLLLLLLLSLTLFRTPARGYLPPGPTPLPLLGNLLQLRPGALYSGLLRLSKKYGPVFTVYLGPWRRVVVLVGHDAVREALGGQAEEFSGRGTLATLDKTFDGHGVFFANGERWKQLRKFT
LLALRDLGMGKREGEELIQAEVQSLVEAFQKTEGRPFNPSMLLAQATSNVVCSLVFGIRLPYDDKEFQAVIQAASGTLLGISSPWGQAYEMFSWLLQPLPGPHTQLQHHLGTLAAFTIQQVQKHQGRFQTSGP
ARDVVDAFLLKMAQEKQDPGTEFTEKNLLMTVTYLLFAGTMTIGATIRYALLLLLRYPQVQQRVREELIQELGPGRAPSLSDRVRLPYTDAVLHEAQRLLALVPMGMPHTITRTTCFRGYTLPKGTEVFPLIGS
ILHDPAVFQNPGEFHPGRFLDEDGRLRKHEAFLPYSLGKRVCLGEGLARAELWLFFTSILQAFSLETPCPPGDLSLKPAISGLFNIPPDFQLRVWPTGDQSR' 
38. cp2u1 mouse (530 residues): 
'MSSLGDQRPAAGEQPGARLHVRATGGALLLCLLAVLLGWVWLRRQRACGIPPGPKPRPLVGNFGHLLVPRFLRPQFWLGSGSQTDTVGQHVYLARMARVYGNIFSFFIGHRLVVVLSDFHSVREALVQQAE
VFSDRPRMPLISIMTKEKGIVFAHYGPIWKQQRRFSHSTLRHFGLGKLSLEPRIIEEFAYVKEAMQKHGEAPFSPFPIISNAVSNIICSLCFGQRFDYTNKEFKKVLDFMSRGLEICLHSQLFLINICPWFYYLPFGPF
KELRQIERDISCFLKNIIREHQESLDASNPQDFIDMYLLHMEEEQGASRRSSFDEDYLFYIIGDLFIAGTDTTTNSLLWCLLYMSLNPDVQKKVHEEIERVIGCDRAPSLTDKAQMPYTEATIMEVQRLSMVVPLA
IPHMTSEKTVLQGFTIPKGTVVLINLWSVHRDPAIWEKPDDFCPHRFLDDQGQLLKRETFIPFGIGKRVCMGEQLAKMELFLMFVSLMQTFTFALPEGSEKPVMTGRFGLTLAPHPFNVTISKR' 
39. cp341 mouse (504 residues): 
'MNLFSALSLDTWVLLAIILVLLYRYGTRTHGLFKKQGIPGPTPLPFLGTVLNYYKGLWKFDMECYEKYGKTWGLFDGQMPLFVITDPEMIKNVLVKECFSVFTNRREFGPVGIMSKAISISKDEEWKRYRAL
LSPTFTSGKLKEMFPVIEQYGDILVKYLMQEAEKGKPVTMKDVLGAYSIDVITSTSFGVNVDSLNNPEDPFVEKAKGILRVDFFDPLVFSVVLFPFLTPVYEMLNICMFPKDSIEFFKKFVNRMKESRLDSKQKH
RVDFLQLMMNAHNNSKDKDSHKALSDMEITAQSIVFIFAGYETTSSTLSFTLYCLATHPDIQKKLQEEIDETLPNKAPPTYDTVMEMEYLDMVLNETLRLYPIGNRLERFCKKDVELNGVYIPKGSTVMIPSYA
LHHDPQHWPEPEEFQPERFSKENKGSIDPYLYMPFGIGPRNCIGMRFAFMTMKLALTKVMQNFSFQPCQETQIPLKLSRQGLLQPEKPIVLKVVPRDVVITGA' 
40. cp39a mouse (470 residues): 
'MGIMELFSPIAIAVLGSCVLFLFSRLKNLLGPPCIQGWIPWIGAGLEFGKAPLEFIEKARIKYGPVFTIFAMGNRMTFVSEEEGINVLLKSEHVDFESAVQSPVYHTAWIPKNVFSALHERLYALMKGKMGTFNT
HHFTGPLTEELHEQLEGLGTHGTMDLNDFVRYLLYPATLNTLFKKGLFLTDKRTIKEFYQQFKTYDEGFEYGSQLPEWLLRNWSKSKRWLLALFEKNIGNIKAHGSAGHSGTLLQAILEVVETETRQYSPNYG
LVVLWAALANAPPIAFWTLGYILSHPDIHRTVLESISSVFGTAGKDKIKVSEDDLKKLLIIKWCILESVRLRAPGVITRKVVKPVKILNHTVPSGDLLMLSPFWLHRNPKYFPEPESFKPERWKEANLDKYIFLDY
FMAFGGGKFQCPGRWFALLEIQLCIILVLYKYECSLLDPLPKQSSRHLVGVPQPAGKCRIEYKQRA' 
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41. cp3ab mouse (504 residues): 
'MDLVSALSLETWVLLAISLVLLYRYGTRKHELFKKQGIPGPKPLPFLGTVLNYYKGLWKFDMECYKKYGKTWGLFDGQTPLLAVTDPETIKNVLVKECFSVFTNRRDFGPVGIMSKAISISKDDEWKRYRAL
LSPTFTSGKLKEMFPVIEQYGDILVKYLRQKAKKGKPVTMKDVLGAYSMDVITSTSFGVNVDSLNNPEDPFVEKAKKLLRFDFFDPLLFSVVLFPFLTPVYEMLNICMFPKDSIEFFKKFVDRMKESRLDSKQK
HRVDFLQLMMNSHNNSKDKVSHKALSDMEITAQSIIFIFAGYETTSSTLSFTLHSLATHPDIQKKLQDEIDEALPNKAPPTYDTVMEMEYLDMVLNETLRLYPIANRLERVCKKDVELNGVYIPKGSTVMIPSY
ALHHDPQHWSEPEEFQPERFSKENKGSIDPYVYLPFGNGPRNCLGMRFALMNMKLALTKIMQNFSFQPCKETQIPLKLSRQGLLQPEKPIVLKVVPRDAVITGA' 
42. cp3ad mouse (503 residues): 
'MDLIPNFSMETWMLLATSLVLLYLYGTHSHGIFKKLGIPGPKPLPFLGTILAYQKGFWECDIQCHKKYGKMWGLYDGRQPVLAITDPDIIKTVLVKECYSTFTNRRRFGPVGILKKAISISENEEWKRIRALLSP
TFTSGRLKEMFPIINQFTDVLVRNMRQGLGEGKPTSMKDIFGAYSMDVITATSFGVNIDSLNNPQDPFVEKIKKLLKFDIFDPLFLSVTLFPFLTPVFDALNVSLFPRDVISFFTTSVERMKENRMKEKEKQRVDF
LQLMINSQNYKTKESHKALSDVEIVAQSVIFIFAGYETTSSALSFALYLLAIHPDVQKKLQDEIDAALPNKAPATYDTLLQMEYLDMVVNETLRLYPIAGRLERVCKTDVEINGLFIPKGTVVMIPTFALHKDPK
YWPEPEEFRPERFSKKNQDSINPYMYLPFGSGPRNCIGMRFALINMKVALVRVLQNFTVQPCKETEIPLKLSKQGLLQPENPLLLKVVSRDETVSDE' 
43. cp3ag mouse (504 residues): 
'MNLFSALSLDTLVLLAIILVLLYRYGTYTHGLFKKQGIPGPKPLPFLGTVLNYYKGLWKFDMECYEKYGKTWGLFDGQIPLFVITDPETIKNVLVKECFSVFTNRQDFFPVGIMSKSISLAKDEEWKRYRALLSP
TFTSGNLKEMFPVIEQYGDILVKYLRQEAEKGKPVAVKDVLGAYSMDVIISTTFGVNIDSLNNPEDPFVENAKKVLRFDYFDPLSLSVALFPFLTPIYEMLNICMFPKDSIEFFKKFVDRMTENRLDSKQKHRVD
FIYLMMEAYNKSKDKDSHKALSEIEITAQSIIFIFAGYETTSSILSFTVYSLATHPDIQKKLQEEIDEALPNKAPPTYDTVMAMEYLDMVLNETLRLYPITNRLQRVCKKDVEINGIYIPKGSTVIIPSYVLHHDPQ
HWPEPEEFQPERFSKENKGSIDPYVYLPFGNGPRNCIGMRFALMNMKLALIKVLQNFSFQPCKETQIPLKLSRELLLQPVKPIVLKVVPRDAVITGA' 
44. cp3ap mouse (503 residues): 
'MELIPNLSIETWVLLVTSLVLFYIYGTYSHGLFKKLGIPGPKPLPLLGTIFNYYDGMWKFDEDCYKKYGKIWGFYEGPQPILAIMDPEIIKIVLVKECYSVFTNRRFFGPVGFMKKAITISEDEEWKRLRTLLSPTF
TSGKLKEMFPIMRQYGDILVRNLRREEEKGEPISMKDIFGAYSMDVITGTSFGVNVDSLNNPQDPFVQKAKKILKFKIFDPFLLSIILFPFLTPIYEMLNFSIFPRDSMNFFKKFVKRMKKERLASNQKNRVDFLQL
MMNTQNSKGQESQKALSDLEMAAQAVIFIFGGYDATSTSISLIMYELATHPDVQKKLQDEIDRTLPNKAPVTYDALMDMEYLDMVVNESLRLYPIAIRLERVSKKDVEINGVFIPKGTVVMIPIYPLHRNPEYW
PEPQEFCPERFSKENKGNIDPYIYMPFGNGPRNCIGMRFALISIKLAVIGVLQNFTVQPCEETQIPLKISREPIFQPEKPIILKVVSRDKPRTGS' 
45. cp46a mouse (500 residues): 
'MSPGLLLLGSAVLLAFGLCCTFVHRARSRYEHIPGPPRPSFLLGHLPYFWKKDEDCGRVLQDVFLDWAKKYGPVVRVNVFYKTSVIVTSPESVKKFLMSTKYNKDSKMYRALQTVFGERLFGQGLVSECDY
GRWYKQRKVMDLAFSRSSLVSLMETFNEKAEQLVEILEAKADGQTPVSMQDMLTCATIDILAKAAFGMETSMLLGAQKPLSQAVKVMLEGISASRNTLAKFMPGKRKQLREIRESIRLLRQVGKDWVQRRR
EALKRGEDMPADILTQILKAEEGAQDDEVLLDNFVTFFIAGHETSANHLAFTVMELSRQPEIVARLQAEVDEVVGSKRHLDYEDLGRLQYLSQVLKESLRLYPPAWGTFRLLEEETLIDGVRVPGNTPLLFSTY
VMGRMDTYFEDPLTFNPDRFGPGAPKPRFTYFPFSLGHRSCIGQQFAQMEVKVVMAKLLQRIEFRLVPGQRFGLQEQATLKPLDPVLCTLRPRGWQPAPPPPPC' 
46. cpaa mouse (509 residues): 
'MSVSALSPTRFADSLSGFLQVASVLGLLLLLVKAVQFYLHRQWLLKAFQQFPSPPFHWFFGHEQFKGDHELQEIVSCIENFPSAFPRWFWGSKAYLTVYDPDYMKVILGRSDPKANGAYRLLAPWIGYGLLLL
NGQPWFQHRRMLTPAFHYDILKPYVKNMADSIRLMLDKWERLADQDSSIEIFQHISLMTLDTVMKCAFSHKGSVQVDGNYRTYLQAIGDLNNLFHSRVRNIFHQNDTIYKLSSNGRLAKQACQLAHDHTDG
VIKLRKDQLQDEGELEKIKKKRRLDFLDILLFARMENGDSMSDKDLRAEVDTFMFEGHDTTASGVSWIFYALATHPDHQQRCREEVQSLLGDGSSITWDHLDQIPYTTMCIKEALRLYPPVPGIVRELSTSVTF
PDGRSLPKGVQVTLSIYGLHHNPKVWPNPEVFDPSRFAPDSPRHSHSFLPFSGGARNCIGKQFAMSELKVIVALTLLRFELLPDPTRVPMPLARLVLKSKNGIYLHLKKLH' 
47. cp4ae mouse (507 residues): 
'MGFFLFSPTRYLDGISGFFQWAFLLSLFLVLFKAVQFYLRRQWLLKTLQHFPCMPSHWLWGHHLKDKELQQILIWVEKFPSACLQCLSGSNIRVLLYDPDYVKVVLGRSDPKASGIYQFFAPWIGYGLLLLNG
KKWFQHRRMLTPAFHYDILKPYVKIMADSVNIMLDKWEKLDGQDHPLEIFHCVSLMTLDTVMKCAFSYQGSVQLDENSKLYTKAVEDLNNLTFFRLRNAFYKYNIIYNMSSDGRLSHHACQIAHEHTDGVI
KMRKSQLQNEEELQKARKKRHLDFLDILLFARMEDRNSLSDEDLRAEVDTFMFEGHDTTASGISWIFYALATHPEHQQRCREEVQSILGDGTSVTWDHLGQMPYTTMCIKEALRLYPPVISVSRELSSPVTFPD
GRSIPKGITATISIYGLHHNPRFWPNPKVFDPSRFAPDSSHHSHAYLPFSGGSRNCIGKQFAMNELKVAVALTLLRFELLPDPTRIPVPIARLVLKSKNGIHLCLKKLR' 
48. cp4b1 mouse (511 residues): 
'MALSFLSPSLSRLGLWASVVILMVTVLKLLSLLFRRQKLARALDSFPGPPKHWLFGHALEIQKTGGLDKVVTWTEQFPYAHPLWLGQFIVFLNIYEPDYAKAVYSRGDPKAAYVYDFFLQWIGKGLLVLEGP
KWFQHRKLLTPGFHYDVLKPYVAIFAESTRVMLDKWEKKASENKSFDIFCDVGHMALDTLMKCTFGKGDSGLSHSDNSYYLAVSDLTLLMQQRIDSFQYHNDFIYWLTPHGRRFLRACQIAHDHTDHVIRQ
RKAALQDEKEQKKLQERRHLDFLDILLGARDESGIKLSDADLRAEVDTFMFEGHDTTTSGISWFLYCMALYPMHQQRCREEVREILGDRDSFQWDDLAQMTYLTMCMKECFRLYPPVPQVYRQLSKPVTFV
DGRSLPAGSLISLHIYALHRNSAVWPDPEVFDPLRFSPENMTGRHPFAFMPFSAGPRNCIGQQFAMNEMKVVTALCLLRFEFSPDPSKIPIKVPQLILRSKNGIHLYLKPLGPGSGK' 
 A14 
 
49. cp4ca mouse (508 residues): 
'MSASALSSIRFPGSISEYLQVASVLSLLLLLFKTAQLYLHRQWLLSSTQQFPSPPSHWLFGHKILKDQDLQDILTRIKNFPSACPQWLWGSKVRIQVYDPDYMKLILGRSDPKANGSYRFLAPWIGRGLLLLDGQ
TWFQHRRMLTPAFHYDILKPYTEIMADSVRVMLDKWEQIVGQDSTLEIFRHITLMTLDTIMKCAFSHEGSVQLDRKYKSYIQAVEDLNDLVFSRVRNIFHQNDIIYRVSSNGCKANSACKLAHDHTDQVIKSRR
IQLQDEEELEKLKKKRRLDFLDILLFARMENGKSLSDKDLRAEVDTFMFEGHDTTASGISWIFYALATNPEHQQRCRKEIQSLLGDGTSITWNDLDKMPYTTMCIKEALRIYPPVPSVSRELSSPVTFPDGRSLPK
GIHVMLSFYGLHHNPTVWPNPEVFDPSRFAPGSSRHSHSFLPFSGGARNCIGKQFAMNELKVAVALTLLRFELLPDPTRVPIPIPRIVLKSKNGIHLHLKKLQ' 
50. cp4f3 mouse (524 residues): 
'MSQLSLSWMGLGHTAASPWLLLLLAGASCLLAYILTQIYGVFENSLRLRCFPQPPKRNWILGHLGLIQSSEEGLLYIQSLVRTFRDACCWWVGPLHPVIRIFHPAFIKPVVLAPALVAPKDTVFYRFLKPWLGD
GLLMSTGDKWSRHRRMLTPAFHFNILKPYVKVFNDSTNIMHAKWQRLASKGSAYLNMFEHISLMTLDSLQKCVFSFDSNCQEKPSEYITAILELSALVARRHQRLLLHVDLFYYLTHDGMRFRKACRLVHDF
TDAVIRERRRTLLDQGGDDVLKAKAKAKTLDFIDVLLLSKDEHGKALSDEDIRAEADTFMFGGHDTTASGLSWILYNLARHPEYQERCRQEVRELLRDREPEEIEWDDLAQLPFLTMCIKESLRLHPPVTAISR
CCTQDIVLPDGRVIPKGVISRISIFGTHHNPAVWPDPEVYDPFRFDADNVKGRSPLAFIPFSAGPRNCIGQTFAMSEMKVALALTLLRFRVLPDDKEPRRKPELILRAEGGLWLKVEPLSAGAQ' 
51. cp4fe mouse (524 residues): 
'MSQLSLSWLGLGPEVAFPWKTLLLLGASWILARILIQIYAAYRNYRHLHGFPQPPKRNWLMGHVGMVTPTEQGLKELTRLVGTYPQGFLMWIGPMVPVITLCHSDIVRSILNASAAVALKDVIFYSILKPWLG
DGLLVSAGDKWSRHRRMLTPAFHFNILKPYVKIFNDSTNIMHAKWQRLISDGSARLDMFEHVSLMTLDSLQKCVFSFDSNCQEKSSEYIAAILELSALVAKRHQQPLMFMDLLYNLTPDGMRFRKACNVVHE
FTDAVIRERHRTLPDQGLDDFLKSKAKSKTLDFIDVLLLSKDEDGKELSDEDIRAEADTFMFEGHDTTASGLSWILYNLARHPEYQERCRQEVQELLRGREPEEIEWDDLAQLPFLTMCIKESLRLHPPVTVISR
CCTQDILLPDGRTIPKGIICLISIFGIHHNPSVWPDPEVYDPFRFDPENIKDSSPLAFIPFSAGPRNCIGQTFAMSEMKVALALTLLRFRLLPDDKEPRRQPELILRAEGGLWLRVEPLSAGAH' 
52. cp4v3 mouse (525 residues): 
'MLWLWLGLSGQKLLLWGAASAVSLAGATILISIFPMLVSYARKWQQMRSIPSVARAYPLVGHALYMKPNNAEFFQQLIYYTEEFRHLPIIKLWIGPVPLVALYKAENVEVILTSSKQIDKSFLYKFLQPWLGLG
LLTSTGSKWRTRRKMLTPTFHFTILENFLDVMNEQANILVNKLEKHVNQEAFNCFFYITLCALDIICETAMGKNIGAQSNNDSEYVRTVYRMSDMIYRRMKMPWLWFDLWYLVFKEGRDHKRGLKCLHTFT
NNVIAERVKERKAEEDWTGAGRGPIPSKNKRKAFLDLLLSVTDEEGNRLSQEDIREEVDTFMFEGHDTTAAAINWSLYLLGTNPEVQRKVDQELDEVFGRSHRPVTLEDLKKLKYLDCVIKETLRVFPSVPLF
ARSLSEDCEVGGYKVTKGTEAIIIPYALHRDPRYFPDPEEFRPERFFPENSQGRHPYAYVPFSAGPRNCIGQKFAVMEEKTILACILRQFWVESNQKREELGLAGDLILRPNNGIWIKLKRRHEDDP' 
53. cp51a mouse (503 residues): 
'MVLLGLLQSGGWVLGQAMEQVTGGNLLSTLLIACAFTLSLVYLFRLAVGHMVQLPAGAKSPPHIYSPIPFLGHAIAFGKSPIEFLENAYEKYGPVFSFTMVGKTFTYLLGSDAAALLFNSKNEDLNAEEVYGR
LTTPVFGKGVAYDVPNAIFLEQKKIIKSGLNIAHFKQYVPIIEKEAKEYFQSWGESGERNVFEALSELIILTASHCLHGKEIRSQLNEKVAQLYADLDGGFTHAAWLLPAWLPLPSFRRRDRAHREIKNIFYKAIQ
KRRLSKEPAEDILQTLLDSTYKDGRPLTDEEISGMLIGLLLAGQHTSSTTSAWMGFFLAKDKPLQEKCYLEQKAVCGEDLPPLTYDQLKDLNLLDRCIKETLRLRPPIMTMMRMAKTPQTVAGYTIPPGHQVC
VSPTVNQRLKDSWAERLDFNPDRYLQDNPASGEKFAYVPFGAGRHRCVGENFAYVQIKTIWSTMLRLYEFDLINGYFPTVNYTTMIHTPENPVIRYKRRSK' 
54. cp7a1 mouse (503 residues): 
'MMSISLIWGIAVVVSCCIWFIIGIRRRKVGEPPLDNGLIPYLGCALKFGSNPLEFLRAKQRKHGHVFTCKLMGKYVHFITNSLSYHKVLCHGKYFDWKKFHYTTSAKAFGHRSIDPSDGNTTENINKTFNKTLQ
GDALCSLSEAMMQNLQSVMRPPGLPKSKSAVWVTEGMYAFCYRVMFEAGYLTLFGKDISKTDTQRAFIQNNLDSFKQFDQVFPALVAGVPIHLLKTAHKARERLAESLKHKNLYMRDQVSELIRLRMFLND
TLSTFDDMEKAKTHLVILWASQANTIPATFWSLFQMIRSPEAMKAASEEVNGSLQSAGQELSSGGNAIYLDQEQLNNLPVLDSIIKEALRLSSASLNIRTAKEDFTLHLEDGSYNIRKDDIIALYPQLMHLDPEIY
PDPLTFKYDRYLDESGKAKTTFYRNGNKLKYFYMPFGSGATICPGRLFAVQEIKQFLILMLSYFELELVESHTKCPPLDQSRAGLGILPPLNDIEFKYKLKH' 
55. cp7b1 mouse (507 residues): 
'MQGATTLDAASPGPLALLGLLFAATLLLSALFLLTRRTRRPREPPLIKGWLPYLGMALKFFKDPLTFLKTLQRQHGDTFTVFLVGKYITFVLNPFQYQYVTKNPKQLSFQKFSSRLSAKAFSVKKLLTDDDLNE
DVHRAYLLLQGKPLDALLETMIQEVKELFESQLLKITDWNTERIFAFCGSLVFEITFATLYGKILAGNKKQIISELRDDFFKFDDMFPYLVSDIPIQLLRNEESMQKKIIKCLTSEKVAQMQGQSKIVQESQDLLKR
YYRHDDSEIGAHHLGFLWASLANTIPAMFWAMYYILRHPEAMEALRDEIDSFLQSTGQKKGPGISVHFTREQLDSLVCLESTILEVLRLCSYSSIIREVQEDMNLSLESKSFSLRKGDFVALFPPLIHNDPEIFDAP
KEFRFDRFIEDGKKKSTFFKGGKRLKTYVMPFGLGTSKCPGRYFAVNEMKLLLIELLTYFDLEIIDRKPIGLNHSRMFLGIQHPDSAVSFRYKAKSWRS' 
56. cp8b1 mouse (500 residues): 
'MTLWCTVLGALLTVVGCLCLSLLLRHRRPWEPPLDKGFVPWLGHSMAFRKNMFEFLKGMRAKHGDVFTVQLGGQYFTFVMDPLSFGPIIKNTEKALDFQSYAKELVLKVFGYQSVDGDHRMIHLASTKHL
MGQGLEELNQAMLDSLSLVMLGPKGSSLGASSWCEDGLFHFCYRILFKAGFLSLFGYTKDKQQDLDEADELFRKFRRFDFLFPRFVYSLLGPREWVEVSQLQRLFHQRLSVEQNLEKDGISCWLGYMLQFLR
EQGIASSMQDKFNFMMLWASQGNTGPTCFWVLLFLLKHQDAMKAVREEATRVMGKARLEAKKSFTFTPSALKHTPVLDSVMEESLRLCATPTLLRVVQEDYVLKMASGQEYQIRRGDKVALFPYLSVHMD
PDIHPEPTAFKYDRFLNPDGTRKVDFYKSGKKIHHYSMPWGSGVSKCPGRFFALSEMKTFVLLMIMYFDFKLVDPDIPVPPIDPRRWGFGTSQPSHEVRFLYRLKPVQ' 
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57. cy250 mouse (490 residues): 
'MDPILVLVFTLSCLFLLSLWRQSSERGKLPPGPTPLPIIGNILQINVKDICQSFTNLSKVYGPVYTLYLGNKPTVVLHGYEAVKEALVDHGEEFAGRGRLPVFDKATNGMGIIFSKGNVWKNTRRFSLTTLRN
LGMGKRSIEDRVQEEARCLVEELRKTNGSPCDPTFILGCAPCNVICSIIFQDRFDYKDRDFLNLMEKLNEITKIMSTPWLQVCNTFPVLLDYCPGSHNKVFKNYACIKNFLLEKIKEHEESLDVTIPRDFIDYFLI
NGGQEDGNYPLKNRLEHLAITVTDLFSAGTETTSTTLRYALLLLLKYPHVTAKVQEEIEHVIGKHRSPCMQDRSRMPYTDAMIHEVQRFIDLVPNSLPHEVTCDIKFRNYFIPKGTNVITSLSSVLRDSKEF
PNPEKFDPGHFLDENGKFKKSDYFMPFSTGKRICAGEGLARMELFLFLTSILQNFNLKPLVHPKDIDVTPMLIGLASVPPAFQLCFIPS' 
58. b2rxz2 mouse (492 residues): 
'MLGSGLLLVAILAFLSVMVLVSVWQQKIRGKLPPGPIPLPFIGNYLQLNRKDVYSSITQLQEHYGPVFTIHLGPRRVVVLYGYDAVKEALEDNAEEFSGRGEQATFNTLFKGYGVTFSNGERAKQLRRFSIATL
KDFGLGKRGMEERIQEEAGCLIKMLQGTCGAPIDPTMYLSKTVSNVISSIVFGDRFNYEDKEFLSLLQMMSQMNQFAASPTGQLYDMFHSVMKYLPGPQQQIIKDSHKLEDFMIQKVKHNHSTLDPNSPRGFI
DSFLIHMQKEKNFNSEFHMKNLVMTSLNLFFAGSETVSSLLRYGFLLLMKHPDVEAKVHEEIDRVIGRNRQPQYEDHMKMPYTQAVIHEIQRFSNFAPLGIPRRITKDTSFRGFFLPKGTDVFPIMGSLMIDPKF
FSSPKDFNPQHFLDDKGQLKKIPAFLPFSIGKRSCLGYSLGKMQLFLFFTTILQNFRFKFPRKLEDINESPKPEGFTRIIPKYTMSFVPI' 
59. a6h6j2 mouse (491 residues): 
'MDPSVLLLLAVLLSLFLLLVRGHAKIHGHLPPGPRPLPLLGNLLQMDRGGLLKCFIHLQEKHGDVFTVHLGPRPVVVLCGTQTIREALVNNAEAFSGRGTIAAAQLVMQDYGIFFSSGERWKTLRRFSLATMK
EFGMGKRSVEERIKEEAQCLVEELKKYQGAPLDPTFFFQCVTANIICSIVFGERFDYTDEQFLRLLNLMYQIYSLLRSFSCQMFELFSGLLKYFPGVHRQIAKNQQEILNFITHRVEKHRATLDPSEPRDFIDTYLL
RMEKEKSNHNTEFHHQNLMMSVLSLFFAGTETTSTTLCCGFLLMLMYPHVAEKVQKEIDQVIGSHRLPTLDDRTKMPYTDAVIHEIQRFSDIVPTGAPHRVTKDTMFRGYLLPKNTEVYPILSSALHDPQYFEQ
PDSFNPDHFLDANGALKKSEAFLPFSTGKRICLGESIARNELFLFFTSILQNFSVASPVASKDIDLTPKESGIGKIPPTYQICFLAR' 
60. q497u6 mouse (200 residues): 
'VLSLFFAGTETTSTTLRYGFLLMLKYPHVAEKVQKEIDQVISAHHVPTLEDRIKMPYTEAVIHEIQRFSDLAPIGLPHTVTKDTVFRGYLLPKNTEVYPILSSALHDPQYFEQPDKFNPEHFLDANGALKKSEAFL
PFSTGKRICLGEGIARNELFLFFTALLQNFSLSSPVAPEDIDLTPKESGFVKIPPVYRICFLPR' 
61. q6ief7 mouse (494 residues): 
'MELLGLPTLALLVLVMSLSLLSVWTKMRTGGRLPPGPTPLPIIGNILQLDLKDIPASLSKLAKEYGPVYTLYFGSWPTVVLHGYDVVKEALLNQGDEFLGRGPLPIIEDSQKGHGIVFSEGERWKLLRRFSLMTL
KNFGMGKRSLEERVQEEARCLVEELHKTEAQPFDPTFILACAPCNVICSILFNERFPYNDKTFLNLMDLLNKNFYQLNSIWIKMYNLWPTIMKYIPGKHREFSKRLGGVKNFILEKVKEHQESLDPANPRDYIDC
FLSKIEEEKHNLKSDFNLENLAICGSNLFTAGTETTSTTLRFGLLLLVKHPEVQAKVHEELDRVIGRHQPPSMKDKMKLPYTDAVLHEIQRYITLLPSSLPHAVVQDTKFRHYVIPKGTAVFPFLSSILLDQKEFP
NPEKFDPGHFLDKNGCFKKTDYFVPFSLGKRSCVGEGLARMELFLFFTTILQKFSLKALVEPKDLDIKPVTTGLFNLPPPYKLRLVPR' 
62. q5glz1 mouse (490 residues): 
'MVLGVFLGLLLTCLLLLSLWRQNSQRRNLPPGPTPLPIIGNILQLDLKDISKSLRNFSKVYGPVFTLYLGRNPAVVLHGYEAVKEAFTDHGEEFAGRGVFPVFDKFKKNCGVVFSSGRTWKEMRRFPLMTLRN
FGMGRRSIEDRIQEEARCLVDELRKTKGEPCDPTFILGCAPCNVICSIVFQNRFDYKDQEFLTFLDILNENVEILSSPWIQICNNFPAVIDYLPGRHRKLHKNFAFAEHYFLSKVKQHQESLDINNPRDFIDCFLIKM
EQEKHNPKTEFTCENLVFTASDLFAAGTETTSTTLRYSLLLLLKYPEVTAKVQEEIDCVIGRHRSPCMQDRHSMPYTDAVLHEIQRYIDLLPTSLPHAVTRDVKFREYLIPKGTTVIASLTSVLYDDKEFPNPEKF
DPSHFLDERGKFKKSDYFFPFSTGKRICVGEGLARAELFLFLTTILQNFNLKSPVDLKDLDTTPVANGFASVPPKFQICFIPI' 
63. q569x9 mouse (491 residues): 
'MDPFVVLVLCLSFLLVLSLWRQRSARGNLPPGPTPLPIIGNYHLIDMKDIGQCLTNFSKTYGPVFTLYFGSQPIVVLHGYEAMKEAFIDHGEEFSGRGRFPFFDKVTKGKGIGFSHGNVWKATRVFTINTLRNLG
MGKRTIENKVQEEAQWLMKELKKTNGLPCDPQFIIGCAPCNVICSIVFQNRFDYKDKDFLSLIGKVNECTEILSSPGCQIFNAVPILIDYCPGRHNKFFKNHTWIKSYLLEKIKEHEESLDVTNPRDFIDYFLIQRC
QEKGIEHMEYTIEHLATLVTDLVFGGTESLSSTMRFALLLLMKHTHITAKVQEEIDNVIGRHRSPCMQDRNHMPYTNAMVHEVQRYVDLGPISLVHEVTCDTKFRNYFIPKGTQVMTSLTSVLHDSTEFPNPEV
FDPGHFLDDNGNFKKSDYFVPFSAGKRICVGESLARMELFLFLTTILQNFKLKPLVDPKDIDMTPKHSGFSKIPPNFQMCFIPVE' 
64. q8vcp4 mouse (491 residues): 
'MDPFVVLVLCLSFLLLLSLWRQRSARGNLPPGPTPLPIIGNYHLIDMKDIGQCLTNFSKIYGPVFTLYFGSQPIVILHGYEAMKEAFIDYGEEFSGRGRIPVFDKVSKGKGIGFSHGNVWKATRVFTVNTLRNLG
MGKRTIETKVQEEAQWLMKELKKTNGSPCDPQFIIGCAPCNVICSIVFQNRFDYKDKDFLSLIGKVNECTEILSSPECQIFNAVPILIDYCPGSHNKFLKNHTWIKSYLLEKIKEHEESLDVTNPRDFVDYFLIQRC
QKNGIEHMDYTIEHLATLVTDLVFGGTEPLSSTMRFALLLLMKHTHITAKVQEEIDNVIGRHRSPCMQDRNHMPYTNAMVHEVQRYIDLGPNGVVHEVTCDTKFRNYFIPKGTQVMTSLTSVLHDSTEFPNPE
VFDPGHFLDDNGNFKKSDYFVPFSAGKRICVGESLARMELFLFLTTILQNFKLKPLVDPKDIDMTPKHSGFSKIPPNFQMCFIPVE' 
65. q91w87 mouse (500 residues): 
'MRLPTGAELWPIAIFTVIFLILVNLMHWRQRWTAHYPPGPMPWPVLGNLLHMDFQNMPAGFQKLRGRYGDLFSLQLASESVVVLNGLTALREALVKHSEDTADRPPLHFNDLLGFGPRSQGIVLARYGPAW
RQQRRFSVSTMHHFGLGKKSLEQWVTEEARCLCAAFADHTGHPFSPNTLLDKAVCNVIASLLYACRFEYDDPRFIRLLGLLKETLKEEAGFLPMFLNVFPMLLRIPGLVGKVFPGKRAFVTMLDELLAEHKTT
WDPTQPPRDLTDAFLAEVEKAKGNPESSFNDENLRTVVGDLFSAGMVTTSTTLSWALMLMILYPDVQRRVQQEIDEVIGQVQCPEMADQARMPYTNAVIHEVQRFADILPLGVPHKTSRDIELQGFLIPKGTT
LITNLSSALKDETVWEKPLCFHPEHFLDAQGHFVKPEAFMPFSAGRRSCLGEPLARMELFLFFTCLLQRFSISVPDGQPQPSDHGVFRALTTPCPYQLCALPR' 
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66. q5m8q6 mouse (338 residues): 
'MELLTGTDLWPVAIFTVIFILLVDLLHRRQRWTSRYPPGPVPWPVLGNLLQVDLDNMPYSFYKVVKMFPIVLRIPGLADKIFPGQKTFLTMVDKLVTEHKRTWDPDQPPRDLTDAFMAEMETAKGNPESSFN
EANLRLVVLDLFGGGIVTTSATLTWALLLMILHPDVQRRVQEEIDEVIGQARRPEMADQARMPYTNAVIHEVQRFADIAPMTLPHRTSCDIEVQGFLIPKGTTLICNLSSVLKDETVWEKPLRFYPEHFLDAQG
HFVKPEAFMPFSAGRRACLGEPLVRMELLLFFTCLLQRFSFSVPDGQPLPSDYGIYSMVVSPAPYQLCAVVR' 
67. q9wv19 mouse (494 residues): 
'MMLGGAFSIFMALCLSCLLILIAWKRTSKGGKLPPGPTPIPFLGNFLQVRTDATFQSFQKLQKKYGSVFTVYFGPRPVVVLCGHEAVKEALVDQADDFSGRGEMPTLEKNFQGYGLALSNGERWKILRRFSLT
VLRNFGMGKRSIEERIQEEAGYLLEELHKVKGAPIDPTLYLSRTVSNVICSVVFGKRFDYQDQRFQSLMRMINESFVEMSKPWAQLYDMYWKVMQYFPGRHNYLYNLIEDLKDFIASRVKINEASFDPSNPRD
FIDCFLIKMHQDKSDPHTEFNLKNLVLTTLNLFFAGTETVSSTLRYGFLLLLKYPEVEAKIHEEINQVIGTHRTPRVDDRAKMPYTDAVIHEIQRLTDIVPLGVPHNVTRDTHFRGYLLPKGTDVYPLFGSVLKDP
KYFRYPDAFYPQHFLDEQGRFKKNDAFVVFSSGKRICVGEALARMELFLYFTSILQRFSLRSLVPPADIDIAHKISGFGNIPPVYELCFMAR' 
68. q924d1 mouse (502 residues): 
'MLAAAGSLVAAIWAALHLRILLLSAVTFLFLADFLKNRRPKNYPPGPMRLPFVGCLFHLDPKQPHLSLQQFVKKYGNVLSLDFANIPSVVITGMPLIKEIFTQMEHNFMNRPVTLLRKHLFNKNGLIFSSDQTW
KEQRRFALMTLRNFGLGKRSLEERIQEEAHYLVEAIRDEGGQPFDPHFNISNAVSNIICSITFGERFDYHDSQFQEMLRLLDEAMCLESSMMCQLYNIFPRILQYLPGSHQTLFRNWRKLQLFVSDIVNNHRRDW
DPDEPRDFIDAFLTEMTKYPDKTTTSFNEENLICSTLDLFFAGTETTSTTLRWALLCMALYPEVQEKMQAEIDRVIGQARQPNLADRDSMPYTNAVIHEVQRMGNIIPFNVPREVAVDTQLAGFNLPKGIMVLS
NLTALHRDPSEWTTPDTFNPEHFLENGQFKKRESFLPFSMGKRACLGEQLARSELFIFITTLFQKFTFKPPVNEKLSLQFRMAATVSPVSHRLCAIPRL' 
69. q66jp5 mouse (504 residues): 
'MLAIATCLVANICSAIHLWTLLLTLLTLLLLADYLKNRRPKNYPPGPRRLPFVGNLFQFDLDVSRLHLGIQPFVKKYGNVISVNFGYISSVIISGLPLIKEAITGMEQNFLKRPSLAARQHVFKNNGIVFSSGQTW
KEQRKFALTILKNFGLGKKSLEQCIQEEAYHLVKAIGEEKGQPFDPHFRINNAVGNIICSIIFGERFEYDDNQFQELLKLADEIICSEASMMSVLYNVFPSIFKYLPGPQQKLFSNWEKLKLFVSRMMDSHREDWN
PSAPRDFIDAFLTEMTKYPDKTTTSFNEENLICTALDLFFAGTETTSNTLRWALLYITVNPEVQEKVHSEIDRVIGHGRHPTLDDQDSMPYTNAVIHEVLRMGNIIPLNVPREVTADSTLAGFYLPKGTMVLINLT
DLHRDPKEWDTPNVFNPEHFLENGQFKKKESFLPFSMGKRACPGEQLASCELFIFFTALTQKFTFKSPINEKPSLKFRMGLTLAPVSYRICAVPRL' 
70. q91w71 mouse (374 residues): 
'MLEAADSLAAAFWAALHLRTLLLAAVTFLFLADYLKSRRPKNYPPRPPRLPFVGNSFQMDLTQSHLAVQKFVKKYGNVISLDFGIKSAVIISSLPLIKEAFSHLDENFINRRIFPLQRQIFNGNGLIFSSGQTWKE
QRRFALMTLRNFGLGKKSLEHRIQEEASHLVEAIGEEEGQPFDPHFKIYSAVSNIICSITFGERFEYHDSQFQELLQLLDKAMYLGTTSLMVHYPGKTTTSFNEENLICSTLDLFLAGTETTSSTLRWALLYMALY
PEVQENVQAEIDRVIGQSKHPSLADRDSMPYTNAVVHEILRMGNSVPLNIPREVAVDTTLAGFHLPKESELASENNWPGLSSLFFSLPLCKNLPSSPQPMRT' 
71. q52L54 mouse (504 residues): 
'MDLVSALSLETWVLLAISLVLLYRYGTRKHELFKKQGIPGPKPLPFLGTVLNYYKGLWKFDMECYKKYGKTWGLFDGQTPLLAVTDPETIKNVLVKECFSVFTNRRDFGPVGIMSKAISISKDDEWKRYRAL
LSPTFTSGKLKEMFPVIEQYGDILVKYLRQKAKKGKPVTMKDVLGAYSMDVITSTSFGVNVDSLNNPEDPFVEKAKKLLRFDFFDPLLFSVVLFPFLTPVYEMLNICMFPKDSIEFFKKFVDRMKESRLDSKQK
HRVDFLQLMMNSHNNSKDKVSHKALSDMEITAQSIIFIFAGYETTSSTLSFTLHSLATHPDIQKKLQDEIDEALPNKAPPTYDTVMEMEYLDMVLNETLRVYPIANRLERVCKKDVELNGVYIPKGSTVMIPSY
ALHHDPQHWSEPEEFQPERFSKENKGSIDPYVYLPFGNGPRNCLGMRFALMNMKLALTKIMQNFSFQPCKETQIPLKLSRQGLLQPEKPIVLKVVPRDAVITGA' 
72. q9eqw4 mouse (504 residues): 
'MNLFSALSLDTLVLLAIILVLLYRYGTRTHGLFKKQGIPGPKPLPFLGTVLNYYTGIWKFDMECYEKYGKTWGLFDGQTPLLVITDPETIKNVLVKDCLSVFTNRREFGPVGIMSKAISISKDEEWKRYRALLSP
TFTSGRLKEMFPVIEQYGDILVKYLRQEAEKGMPVAMKDVLGAYSMDVITSTSFGVNVDSLNNPEDPFVEEAKKFLRVDFFDPLLFSVVLFPLLTPVYEMLNICMFPNDSIEFFKKFVDRMQESRLDSNQKHRV
DFLQLMMNSHNNSKDKDSHKAFSNMEITVQSIIFISAGYETTSSTLSFTLYCLATHPDIQKKLQAEIDKALPNKATPTCDTVMEMEYLDMVLNETLRLYPIVTRLERVCKKDVELNGVYIPKGSMVMIPSYALH
HDPQHWPDPEEFQPERFSKENKGSIDPYVYLPFGIGPRNCIGMRFALMNMKLAVTKVLQNFSFQPCQETQIPLKLSRQGILQPEKPIVLKVVPRDAVITGA' 
73. q2hjc6 mouse (506 residues): 
'EASWLETRWARPLHLALVFCLALVLMQAMKLYLRRQRLLRDLSPFPGPPAHWLLGHQKFLQEDNMETLDEIVKKHPCAFPCWVGPFQAFFYIYDPDYAKIFLSRTDPKTQYLHQLLTPCIGRGLLNLDGPRW
FQHRCLLTPAFHQDILKPCVDTMAHSVKVMLDKWEKMWTTQETTIEVFEHINLMALDIIMKCAFGQETNCQINGTYESYVKATFELGEIISSRLYNFWHHHDIIFKLSPKGHCFQELGKVIHQYTEKIIQDRKKI
LKNQVKQDDTQTSQIFLDIVLSAQAEDERAFSDADLRAEVNTFMWAGHDASAASISWLPYCLALNPEHQDRCRTEIRSILGDGSSITWEQLDEMSYTTMCIKETLRLIPPVPSISRELSKPLTLPDGHSLPAGMT
VVLSIWGLHHNPAVWNDPKVFDPLRFTKENSDQRHPCAFLPFSSGPRNCIGQQFAMLELKVAIALILLHFQVAPDLTRPPAFSSHTVLRPKHGIYLHLKKLLEC' 
74. b0g0y2 mouse (508 residues): 
'MSASALSSIRFPGSISEYLQVASVLSLLLLLFKTAQLYLHRQWLLSSTQQFPSPPSHWLFGHKILKDQDLQDILTRIKNFPSACPQWLWGSKVRIQVYDPDYMKLILGRSDPKAHGSYRFLAPWIGRGLLLLDGQ
TWFQHRRMLTPAFHYDILKPYTEIMADSVHVMLDKWEQIVGQDSTLEIFQHITLMTLDTIMKCAFSHEGSVQLDRKYKSYIQAVEDLNNLFFLRVRNIFHQNDIIYRVSSNGCLANSACQLAHDHTDQVIKSRR
SQLQDEEELEKLKMKRRLDFLDILLFARMENGKSLSDKDLRAEVDTFMFEGHDTTASSISWIFYALATNPEHQQRCRKEIQSLLGDGASITWNDLDKMPYTTMCIKEALRIYPPVPSVSRELSSPVTFPDGRSLP
KGIHVMLSFYGLHHNPTVWPNPEVFDPSRFAPGSSRHSHSFLPFSGGARNCIGKQFAMNELKVAVALTLLRFELLPDPTRVPIPIPRIVLKSKNGIHLHLKKLQ' 
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75. q91wu1 mouse (443 residues): 
'MSVSALSLTRFAGSLSGFLQVASVFCLLLLLVKAVQVYLHRKWLLKALQQFPSPPFHWFFGHEQFKGDQELQEIVSCIENFPSAFPRWFWGSKAYLTVYDPDYMKVILGRSGYGLLLLNGQSWFQHRKMLTP
AFHYDILKTYVKNMADSIRLMLDKWERLAGQDSSIEIFQHISLMTLDTVMKCAFSHKGSVQVDGNYKTYLQAIGDLNNLVHSRVRNMFHQNDTIYKLSSNGRLSNQACQLAHDHTDGVIKMRKDQLQDEGE
LENIKKKRRLDFLDILLFARMENEDSMSDKDLRAEVDTFMIEGHDTTASGVSWIFYALATHPEHQQRCREEVQSLLGDGSSITWDHLDQIPYTTMCIKEALRLYPPVPSIGRELSTSVTFPDGCSLPKGVQVTLSI
YGLHHNPKVWPNPEVCTRLSPTQPLIPALLRRSQELHWETICYE' 
76. a2a8t1 mouse (509 residues): 
'MSVSALSPTRFADSLSGFLQVASVLGLLLLLVKAVQFYLHRKWLLKALQQFPSPPFHWFFGHEQFKGEQELKEVVSCIEHFPSAFPCWFWGSNAYLTVYDPDYMKVILGRSDPKANGIYRLLAPWIGYGLLLL
NGQPWFQHRRMLTPAFHYDILKPYVKNMADSIRLMLDKWERLAGQDSSIEIFQHISLMTLDTVMKCAFSHKGSVQVDGNYKTYLQAIGDLNNLFHSRVRNIFHQNDTIYRLSSNGRLAKQACQLAHDHTDG
VIKMRKDQLQDEGELENIKKKRRLDFLDILLFARMENGDSMSDKDLRAEVDTFMFEGHDTTASGVSWIFYALATHPEHQQRCREEVQSLLGDGSSITWDHLDQIPYTTMCIKEALRLYPPVPGIVRELSTSVTF
PDGRSLPKGVQVTLSIYGLHHNPKVWPNPEVFDPSRFAPDSPRHSHSFLPFSGGARNCIGKQFAMSELKVIVALTLLHFELLPDPTRVPEPLARIVLKSKNGIYLHLKKLH' 
77. a6h653 mouse (532 residues): 
'MLPLTDYLLQLLGLEKTAFRVYVVSALLLLVLFFFFRLLVRAFKLFSDFRITCRKLSCFPEPPGRHWLLGHMSMYLPNEKGLQNEKKVLDTMHHIILAWVGPFLPLLVLVHPDYIKPVLGASAAIAPKDEFFYS
FLKPWLGDGLLISKGNKWSRHRRLLTPAFHFDILKPYMKIFNQCTNIMHAKWRRHLAEGSVTSFDMFEHISLMTLDSLQKCVFSYNSDCQERMSDYISSIIELSALVVRRQYRLHHYLDFMYYLTADGRRFRQ
ACDTVHNFTTEVIQERRRALRQQGAEAWLKAKQGKTLDFIDVLLLAKDEEGKELSDEDIRAEADTFMFEGHDTTSSGLSWALFNLAKYPEYQEKCREEIQEVMKGRELEELDWDDLTQLPFTTMCIKESLRQ
FPPVTLISRRCTEDIKLPDGRVIPKGIICLVSIYGTHHNPIVWPDSKVYNPYRFDPDTPQQRSPLAFVPFSAGPRNCIGQSFAMAEMRVVVALTLLRFRLSVDRTHKVRRKPELILRTENGLWLNVEPLPSRA' 
78. q3uk06 mouse (524 residues): 
'MLRLSVSGLDLGSVVTSSWHLLLLGVASWILARILAWTYSFYENCSRLSCFPQPPKKNWFSGHLGMIQSNEEGMQLVTEMGQTFEDVHLFWLGPVIPVLRIVDPAFVAPLLQAPALVAPKDMTFLRFLKPWL
GDGLFLSSGDKWSRHRRLLTPAFHFDILKPYVKIFNQSVNIMHAKWKHLSSEGSARLEMFEHISLMTLDSLQKCLFGFDSNCQESPSEYISAILELSSLIIKRSLQLFLFVDFLYYHTADGRRFRKACDLVHNFTD
AVIRERRHTLSSQNHDEFLKSKTKSKTLDFIDVLLLAKDEHGKELSDEDIQAEADTFMFGGHDTTASALSWILYNLARHPEYQERCRQEVQELLRDREPEEIEWDDLAQLPFLTMCIKESLRLHSPVIDLLRRCT
RDIVLPDGRVIPKGNICVISIFGIHHNPSVWPDPEVYDPFRFDPENPQKRSPLAFIPFSAGPRNCIGQTFAMSEMKVALALTLLRFRILPDDKEPRRKPEIILRAEGGLWLRVEPLSKGAQ' 
79. q3v1f1 mouse (546 residues): 
'MLRLSVSGLDLGSVVTLSWHLLLLGAASWILARILAWTYSFCENCSRLRCFPQPPKRNWFLGHLGMIEHNEEGMQLMTEAGQTYRDVHLCWLGPVIPVLRIVDPAFVAPLLLASALVAPKDTTFHTFVKPWL
GDGLFLNSGDKWSRHRRLLTPAFHFDILKPYVKIFNQSVNIMHAKWKHLSSEGSARLEMFEHISLMTLDSLQKCLFGFDSNCQESPSEYISAILELSSLVIKRSHQLFLFVDFLYYHTADGRRFRKACDLVHNFT
DAVIRERRHTLSSQNHDEFLKSKTKSKTLDFIDVLLLAKDEHGKELSDEDIRAEADTFMFGGHDTTASALSWILYNLARHPEYQERCRQEVQELLRGREPQEIEWDDLAQLPFLTMCIKESLRLHPPVIDLLRRC
TRDIVLPDGRVIPKGNICVISIFGIHHNPSVWPDPEVYDPFRFDPENAHKRPPLAFIPFSAGPRNCIGQTFAMNEMMVALALTLLRFRILPDDKEPRRKPEIILRAEGGLWLRVEPLSTVLKDSKPDLEASLPHPPIV
LSGSQN' 
80. b2ry43 mosue (524 residues): 
'MRYLDLSWLGLGPISASPWLLFFLVGISWFLARFLTQLYTLYAKCQRLCGFPQPPKKNWFWGHLGMSPPTEEGMKQVTELVTTYPQGFMTWLGPIVPLITLCHPDIIRSVLSASAAVAPKDDIFYSFLKPWLGD
GLLVSAGDKWNRHRRMLTPAFHFNILKPYVKIFNDSTNIMHAKWLRLASGGSTRLNMFENISLMTLDTLQKCVFSFNSNCQEKPSQYIAAILELSTLAVKRNEQLLMHVDLLYRLTPDGMRFYKACRLVHDF
TNAVIQERRRTLLKHGGDDIIKAKAKSKTLDFIDVLLLTKDEDGKELSDEDIRAEADTFMFRGHDTTASGLSWILYNLARHPEHQERCRQEVQELLRDRDPKEIEWDDLAQLPFLTMCIKESLRLHPPVTMVSR
CCTQDISLPDGRIIPKGVICIINIFGTHHNPTVWRDPEVYDPFRFDPENIQARSPLSFIPFSAGPRNCIGQTFAMSEMKVALALTLLRFRILPDDKEPRRKPELILRAEGGLWLRVEPLSTQAQ' 
81. q99n18 mouse (534 residues): 
'MGFFRMPQLDLSWLGLRLEASSPWLLLLLIGASWLLARVLTQTYIFYRTYHHLCDFPQPPKWNWFLGHLGMITPTEHGLKEVTNLVATYPQGFMTWLGPIIPIITLCHPDIIRSVLNASASVALKEVVFYSFLKP
WLGDGLLLSDGDKWSSHRRMLTPAFHFNILKPYVKIFNDSTNIMHAKWQHLASGGSARLDVFENISLMTLDSLQKCVFSFDSNCQENPSEYISAILELSALVTKRYHQLLLHIDSLYQLTCSGRRFHKACHLVH
SFTDAVIQDRRRTLPSKHEDDVLKAKAKSKTLDFIDVLLLSKDEDGKELSDEDIRAEADTFMFEGHDTTASGLSWILYNLARHPEYQERCRQEVQELLRDRESTEIECSCAVFLRDDLAQLPFLTMCIKESLRLH
PPVTVISRRCTQDIVLPDGRVIPKGVICIINIFATHHNPTVWPDPEVYDPFRFDPENIKDRSPLAFIPFSAGPRNCIGQTFAMNEMKVALALTLLRFRVLPDDKEPRRKPELILRAEGGLWLRVEPLSTQ' 
82. q9ep75 mouse (524 residues): 
'MSQLSLSWLGLGPEVAFPWKTLLLLGASWILARILIQIYAAYRNYRHLHGFPQPPKRNWLMGHVGMVTPTEQGLKELTRLVGTYPQGFLMWIGPMVPVITLCHSDIVRSILNASAAVALKDVIFYSILKPWLG
DGLLVSAGDKWSRHRRMLTPAFHFNILKPYVKIFNDSTNIMHAKWQRLISDGSARLDMFEHVSLMTLDSLQKCVFSFDSNCQEKSSEYIAAILELSALVAKRHQQPLMFMDLLYNLTPDGMRFRKACNVVHE
FTDAVIRERHRTLPDQGLDDFLKSKAKSKTLDFIDVLLLSKDEDGKELSDEDIRAEADTFMFEGHDTTASGLSWILYNLARHPEYQERCRQEVQELLRGREPEEIEWDDLAQLPFLTMCIKESLRLHPPVTVISR
CCTQDILLPDGRTIPKGIICLISIFGIHHNPSVWPDPEVYDPFRFDPENIKDSSPLAFIPFSAGPRNCIGQTFAMSEMKVALALTLLRFRLLPDDKEPRRQPELILRAEGGLWLRVEPLSAGAH' 
 A18 
 
83. q99ky6 mouse (523 residues): 
'MLQLCLSWLGMGSLTASPWHLLLLGGASWILARILAWIYAFYDNCSRLRCFPQPPKPSWFWGHLALMKNNEESMQFITHLGHDFRDVHLSWVGPVYPILRLVHPNFIAPLLQASAAVAPKEMTLYGFLKPW
LGDGLLMSAGDKWSHHRRLLTPAFHFDILKSYVKIFNKSVNIMHAKWQCLASKGTSRLDMFEHISLMTLDSLQKCIFSVDSNCQESDSKYIAAILELSSLVVKRHRQPFLYLDLLYYLTADGRRFRKACDLVH
NFTDAVIRERRSTLNTQGVEFLKAKAKTKTLDFIDVLLMAEDEHGKGLSNEDIRAEADTFMFGGHDTTTSALSWILYNLARHPEYQERCRQEVQELLRDRDSEEIEWDDLAQLPFLTMCIKESLRLHPPVLLISR
CCTQDILLPDGRAIPKGNICVISIFGVHHNPSVWPDPEVYNPFRFDPENPQKRPPLAFIPFSAGTRNCIGQTFAMSEIKVALALTLLRFRILPDDKEPRRKPELILRAEGGLWLRVEPLSAGAQ' 
84. q9cx67 mouse (162 residues): 
'MGLNLAESGSPLEGGSAPTRREENLGTMYSKMLKPPQPSKTRNWTSWIRRHDEDGKKCWLPLRFLAVRLPGDKGPRRLSALMLRTEGGLWLQVELLTPHRIWNRSTHPSHQDPRINRAVAHARTSPSTSRGR
GGTRLVPLSPRAFLASLSYIDYPIRTTVDV' 
85. thas mouse (533 residues): 
'MEVLGLLKFEVSGTIVTVTLLVALLALLKWYSMSAFSRLEKLGIRHPKPSPFVGNLMFFRQGFWESQLELRERYGPLCGYYLGRRMHVVISEPDMIKQVLVENFSNFSNRMASGLEPKMVADSVLLLRDRRW
EEVRGALMSSFSPEKLDEMTPLISQACELLVAHLKRYAASRDAFNIQRCYCCYTIDVVASVAFGTQVDSQNSPEDPFVQHCRRASTFCIPRPLLVLILSFPSIMVPLARILPNKNRDELNGFFNTLIRNVIALRDQQ
AAEERRRDFLQMVLDAQHSMNSVGVEGFDMVPESLSSSECTKEPPQRCHPTSTSKPFTVDEIVGQAFLFLIAGHEVITNTLSFITYLLATHPDCQERLLKEVDLFMGKHPAPEYHSLQEGLPYLDMVISETLRMY
PPAFRFTREAAQDCEVLGQRIPAGTVLEIAVGALHHDPEHWPNPETFDPERFTAEARLQRRPFTYLPFGAGPRSCLGVRLGLLVVKLTILQVLHKFRFEASPETQVPLQLESKSALGPKNGVYIKIVSR' 
86. q3tg86 mouse (501 residues): 
'MTMALRVTTDVWLARPWQCLHRTRALGTTATLAPKTLQPFEAIPQYSRNKWLKMIQILREQGQENLHLEMHQVFRELGPIFRHSVGKTQIVFVTLPEDVEKLYQVESTHPCRMPLESWIVHRELRGLGRGVF
LLNGPEWYFNRLQLNPNVLSPKAVQKFVPLVDGIARDFVDNLKKKMLESVHGSFSMDFQSSVFNYTIEASHFVLFGERLGLIGRDLSPDSLKFLHTLHSMFKTTTQLLYLPRSLTRWTSTRVWKENLESWDFIS
EYVTKCIKNVYRELAEGRPQSWSVTAELVAERTLSMDAIQANSMELIAGSTDTTSTPLVMTFFELARNPDVQQALRQESLAAEASIAANPQKAMSDLPLLRAALKETLRLYPVGTFLERILSSDLVLQNYHVPA
GTVLNVNLYSMGRNPAVFPRPERYMPQRWLERKRSFKHLAFGFGVRQCLGRRLAEAEMMLLLHHVLKSFHVETQEKEDVRMAYRFVLMPSSSPLLTFRPVN' 
87. q60810 mouse (113 residues): 
'MLLPGLLLLLLLLAGTRWLWGQWKLRKLHLLRLAPGFLHFLQPNLPIYLLGLTQKLGPIYRIRLGLQGKMDLDLSRGLLSHVEGPQETLSVSPDAGHARLHGASDRAADPGVL' 
88. b2rxa7 mouse (518 residues): 
'MISWGLSCLSVLGAAGTTLLCAGLLLGLAQQLWTLRWTLSRDWASTLPLPKGSMGWPFFGETLHWLVQGSRFHSSRRERYGTVFKTHLLGRPVIRVSGAENVRTILLGEHRLVRSQWPQSAHILLGSHTLLG
AVGEPHRQRRKVLARVFSRSSLEQFVPRLQGALRREVRSWCAAQRPVAVYQAAKALTFRMAARILLGLQLDEARCTELAHTFEQLVENLFSLPLDVPFSGLRKGIRARDQLYEHLDEAVAEKLQEKQTAEPG
DALLLIINSARELGHEPSVQELKELAVELLFAAFFTTASASTSLILLLLQHPAAITKIQQELSAQGLGRACTCTPRASGSPPDCGCEPDLSLAMLGRLRYVDCVVKEVLRLLPPVSGGYRTALRTFELDGYQIPKG
WSVMYSIRDTHETAAVYRSPPEGFDPERFGVESGDARGSGGRFHYIPFGGGARSCLGQELAQAVLQLLAVELVRTARWELATPAFPVMQTVPIVHPVDGLLLFFHPLPTSGAGDGLPF' 
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Appendix B: IAM.PC chromatography flow-through and elution fractions (Section 4.2.4). List of proteins identified in E1 fraction with at least 3 peptides, 
MASCOT score ≥45. 
 
 
 
Protein name MW  
(Da) 
Accession  
(Mouse) 
FT Elution 
Score Pep. 
# 
Score Pep. 
# 10-formyltetrahydrofolate dehydrogenase  98.6465 FTHFD 442 23     
2-hydroxyacyl-CoA lyase 1  63.6189 HACL1 48 4     
2-oxoisovalerate dehydrogenase subunit alpha 50.3391 ODBA 82 4     
3-ketoacyl-CoA thiolase, mitochondrial  41.8315 THIM 187 14     
40S ribosomal protein S14 16.2625 RS14 48 3     
40S ribosomal protein S3a  29.8657 RS3A 206 5     
40S ribosomal protein SA  32.8174 RSSA 279 9     
60 kDa heat shock protein, mitochondrial precursor  60.9174 CH60 124 6     
60S ribosomal protein L12  17.7935 RL12 66 3     
60S ribosomal protein L13  24.2905 RL13 88 8     
60S ribosomal protein L18  21.6312 RL18 65 8     
60S ribosomal protein L26  17.2475 RL26 48 6     
60S ribosomal protein L4  47.1240 RL4 71 3     
60S ribosomal protein L6  33.4889 RL6 131 10     
60S ribosomal protein L7  31.3998 RL7 86 4     
78 kDa glucose-regulated protein precursor (GRP 78)  72.3775 GRP78 550 28     
Actin, cytoplasmic 1 (Beta-actin) 41.7097 ACTB 248 12     
Adenosylhomocysteinase  47.6573 SAHH 100 5     
Aldehyde dehydrogenase, mitochondrial precursor  56.5018 ALDH2 130 6     
Alpha-enolase  47.1112 ENOA 88 4     
Annexin A6  75.8384 ANXA6 65 6     
Arginase-1  34.7862 ARGI1 321 16     
Argininosuccinate lyase  51.7066 ARLY 60 3     
Argininosuccinate synthase  46.5550 ASSY 48 8     
Arsenite methyltransferase 41.7662 AS3MT 72 6     
Aspartate aminotransferase, cytoplasmic  46.2025 AATC 131 6     
Aspartate aminotransferase, mitochondrial precursor  47.3812 AATM 49 4     
ATP synthase subunit alpha, mitochondrial precursor  59.7156 ATPA 307 12 
  ATP synthase subunit beta, mitochondrial precursor  56.2655 ATPB 607 19     
Betaine--homocysteine S-methyltransferase 1 44.9919 BHMT1 292 16     
Betaine--homocysteine S-methyltransferase 2 39.8460 BHMT2 128 5     
Calreticulin precursor (CRP55)  47.9649 CALR 262 7     
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Protein name MW  
(Da) 
Accession  
(Mouse) 
FT Elution 
Score Pep. 
# 
Score Pep. 
# Carbamoyl-phosphate synthase [ammonia]  164.5137 CPSM 247 44     
Carbonic anhydrase 3  29.3476 CAH3 184 10     
Carboxylesterase 3 precursor  61.7487 CES3 81 9     
Carnitine O-palmitoyltransferase 2, mitochondrial precursor  73.8805 CPT2     95 3 
Catalase  59.7276 CATA 511 27     
Cystathionine gamma-lyase  43.5392 CGL 133 9     
Cytochrome b5 15.2315 CYB5 161 5 464 6 
Cytochrome c oxidase subunit 5A, mitochondrial precursor  16.0202 COX5A 51 3     
Cytochrome c oxidase subunit VIb isoform 1  10.0649 CX6B1 68 5     
Cytosol aminopeptidase  56.1058 AMPL 79 3     
D-dopachrome decarboxylase  13.0688 DOPD 237 7     
Delta-1-pyrroline-5-carboxylate dehydrogenase  61.7716 AL4A1 81 6     
Dihydrodipicolinate synthase-like, mitochondrial precursor  34.6219 DAPAL 88 3     
Dihydrolipoyl dehydrogenase, mitochondrial precursor  54.2382 DLDH 92 8     
Dihydrolipoyllysine-residue acetyltransferase  67.8987 ODP2 92 4     
Dihydrolipoyllysine-residue succinyltransferase 48.9635 ODO2 145 3     
Electron transfer flavoprotein-ubiquinone oxidoreductase 68.0476 ETFD     74 3 
Endoplasmin precursor  92.4183 ENPL 240 14     
Estradiol 17 beta-dehydrogenase 5  37.0240 DHB5 51 6     
Fatty acid-binding protein, liver (L-FABP)  14.2365 FABPL 128 3     
Ferritin heavy chain  21.0533 FRIH 141 8     
Ferritin light chain 1  20.7895 FRIL1 687 12     
Formimidoyltransferase-cyclodeaminase  58.9015 FTCD 192 7     
Fructose-1,6-bisphosphatase 1  36.8888 F16P1 182 5     
Fructose-bisphosphate aldolase B  39.4821 ALDOB 238 14     
Fumarylacetoacetase  46.0740 FAAA 97 3     
Glutamate dehydrogenase 1, mitochondrial precursor 61.2982 DHE3 318 20     
Glutamine synthetase  42.0923 GLNA 465 15     
Glutathione S-transferase A2  25.5166 GSTA2 49 8     
Glutathione S-transferase A3  25.3443 GSTA3 50 8     
Glyceraldehyde-3-phosphate dehydrogenase  35.7872 G3P 105 3     
Glycine N-methyltransferase  32.6543 GNMT 138 4     
H-2 class I histocompatibility antigen, D-D alpha chain precursor  41.0845 HA12     66 3 
Heat shock 70 kDa protein 1L 70.5932 HS70L 50 4     
Heat shock cognate 71 kDa protein (Heat shock 70 kDa protein 8) 70.8272 HSP7C 151 12     
Hemoglobin subunit alpha (Hemoglobin alpha chain)  15.0758 HBA 498 10     
Hemoglobin subunit beta-1 (Hemoglobin beta-1 chain)  15.8302 HBB1 670 18     
Hemoglobin subunit beta-2 (Hemoglobin beta-2 chain)  15.8683 HBB2 225 10     
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Protein name MW  
(Da) 
Accession  
(Mouse) 
FT Elution 
Score Pep. 
# 
Score Pep. 
# Heterogeneous nuclear ribonucleoproteins A2/B1  37.3797 ROA2     311 10 
Homogentisate 1,2-dioxygenase 49.9576 HGD 170 7     
Hydroxymethylglutaryl-CoA synthase, mitochondrial precursor  56.7865 HMCS2 85 3     
Liver carboxylesterase 1 precursor 62.6400 EST1 60 9     
Liver carboxylesterase 31 precursor  61.4706 EST31 83 9     
Liver carboxylesterase N precursor  61.1330 ESTN 63 4     
Major urinary protein 2 precursor (MUP 2) 20.6503 MUP2 124 7     
Malate dehydrogenase, cytoplasmic  36.4881 MDHC 59 3     
Mannose-binding protein C precursor (MBP-C)  25.9409 MBL2 94 5     
Membrane-associated progesterone receptor component 1 21.6808 PGRC1 117 8 112 5 
Methylcrotonoyl-CoA carboxylase subunit alpha, 79.2934 MCCA 45 6     
MIR-interacting saposin-like protein precursor  20.7543 MSAP 122 4     
Ornithine carbamoyltransferase, mitochondrial precursor  39.7396 OTC 47 4     
Peptidyl-prolyl cis-trans isomerase A  17.9599 PPIA 97 3     
Peroxiredoxin-4  31.0331 PRDX4 133 4     
Peroxiredoxin-6 24.8550 PRDX6 160 7     
Protein disulfide-isomerase A3 precursor  56.6427 PDIA3 184 12     
Protein disulfide-isomerase precursor  57.1078 PDIA1 382 15     
Pyruvate carboxylase, mitochondrial precursor  129.6025 PYC 243 20     
Regucalcin (RC)  33.3855 RGN 208 15     
Ribonuclease UK114 (Heat-responsive protein 12)  14.2466 UK114 183 6     
S-adenosylmethionine synthetase isoform type-1  43.4810 METK1 201 8     
Sarcosine dehydrogenase, mitochondrial precursor  101.6179 SARDH 70 7     
Selenium-binding protein 1 (56 kDa selenium-binding protein)  52.3183 SBP1 46 5     
Serotransferrin precursor (Transferrin)  76.6737 TRFE 118 12     
Serum albumin precursor  68.6477 ALBU 440 24     
Serum amyloid P-component precursor (SAP)  26.2303 SAMP 359 10     
Splicing factor, arginine/serine-rich 1  27.7278 SFRS1     123 9 
Sulfite oxidase, mitochondrial precursor  54.0142 SUOX 88 7     
Superoxide dismutase [Cu-Zn]  15.9328 SODC 301 7     
Transitional endoplasmic reticulum ATPase  89.2657 TERA 117 5     
Transketolase  67.5876 TKT 82 7     
Ubiquinol-cytochrome c reductase iron-sulfur subunit, p  29.3492 UCRI_ 47 4     
Ubiquinol-cytochrome-c reductase complex core protein 1  52.7354 UQCR1 111 4     
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Appendix C: Mass spectrometry data for imidazole elution (E1) fractions from ICT-5074 affinity chromatography experiments. List of proteins 
identified in E1 fraction with at least 3 peptides, MASCOT score ≥45. Inhibitor-bead chromatography experiment IIc (Section 5.2.2.4) trypsin digestion of whole 
300μl sample. Inhibitor-bead chromatography experiment III a1 (Section 5.2.2.5) SDS-PAGE sample separation, in-gel trypsin digestion equivalent to 1ml of 
the 2ml sample. Inhibitor-bead chromatography experiment III a2 whole 2ml sample trypsin digested. Inhibitor-bead chromatography experiment III b1 SDS-
PAGE sample separation, in-gel trypsin digestion equivalent to 1ml of the 2ml sample. Inhibitor-bead chromatography experiment III b2 whole 2ml sample 
trypsin digested 
Protein name Accession Molecular 
weight 
(kDa) 
Inhibitor-bead 
chromatography 
experiment II c 
Inhibitor-bead 
chromatography 
experiment III a1 
Inhibitor-bead 
chromatography 
experiment III a2 
Inhibitor-bead 
chromatography 
experiment III b1 
Inhibitor-bead 
chromatography 
experiment III b2 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
MASCOT 
score 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
Number 
of 
peptides 
26S proteasome non-ATPase regulatory 
subunit 4 
PSMD4_MOUSE 
40.9062 - - - - - - 
- - 57 4 
26S proteasome non-ATPase regulatory 
subunit 9 
PSMD9_MOUSE 
24.8756 - - - - 61 4 
- - 103 4 
40S ribosomal protein S7 RS7_MOUSE 22.1133 - - - - 184 5 - - - - 
40S ribosomal protein S8 RS8_MOUSE 24.1902 - - - - 85 6 - - - - 
40S ribosomal protein S10 RS10_MOUSE 18.9038 - - - - 119 7 - - - - 
40S ribosomal protein S13 RS13_MOUSE 17.2117 - - - - 94 6 - - - - 
40S ribosomal protein S14 RS14_MOUSE 16.2625 - - - - 63 4 - - - - 
40S ribosomal protein S17 RS17_MOUSE 15.5144 - - - - 97 3 - - - - 
40S ribosomal protein S19 RS19_MOUSE 16.0756 - - - - 122 4 - - 54 4 
40S ribosomal protein S24 RS24_MOUSE 15.4134 - - - - 93 3 - - - - 
40S ribosomal protein S26 RS26_MOUSE 13.0071 - - - - 59 4 - - - - 
40S ribosomal protein S30 RS30_MOUSE 6.6438 - - - - - - - - 107 4 
4-trimethylaminobutyraldehyde 
dehydrogenase 
AL9A1_MOUSE 
54.4494 - - - - - - 
- - 115 5 
60 kDa heat shock protein CH60_MOUSE 61.0885 - - - - - - - - 102 4 
60S acidic ribosomal protein P1 RLA1_MOUSE 11.5817 - - - - - - - - 354 4 
60S acidic ribosomal protein P2 RLA2_MOUSE 11.6438 - - - - - - - - 703 14 
60S ribosomal protein L6 RL6_MOUSE 33.4889 - - - - 86 6 - - - - 
60S ribosomal protein L13 RL13_MOUSE 24.3475 - - - - 48 7 - - 61 3 
60S ribosomal protein L18 RL18_MOUSE 21.6882 - - - - - - - - 110 3 
60S ribosomal protein L23 RL23_MOUSE 14.8561 - - - - 114 9 - - - - 
60S ribosomal protein L23a RL23A_MOUSE 17.6841 - - - - - - - - 136 5 
60S ribosomal protein L24 RL24_MOUSE 17.7679 - - - - 49 3 - - - - 
60S ribosomal protein L31 RL31_MOUSE 15.8498 - - - - 67 4 - - - - 
60S ribosomal protein L35 RL35_MOUSE 14.5436 - - - - - - - - 143 5 
60S ribosomal protein L36 RL36_MOUSE 12.2078 - - - - 45 3 - - - - 
60S ribosomal protein L38 RL38_MOUSE 8.1987 - - - - 223 5 - - - - 
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Protein name Accession Molecular 
weight 
(kDa) 
Inhibitor-bead 
chromatography 
experiment II c 
Inhibitor-bead 
chromatography 
experiment III a1 
Inhibitor-bead 
chromatography 
experiment III a2 
Inhibitor-bead 
chromatography 
experiment III b1 
Inhibitor-bead 
chromatography 
experiment III b2 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
MASCOT 
score 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
Number 
of 
peptides 
60S ribosomal protein L39 RL39_MOUSE 6.4027 - - - - 54 3 - - - - 
78 kDa glucose-regulated protein GRP78_MOUSE 72.3775 - - 52 6 121 12 156 5 509 17 
Actin, cytoplasmic 1 ACTB_MOUSE 42.0519 - - 63 7 313 14 - - 203 7 
Acyl-CoA-binding protein (ACBP) ACBP_MOUSE 9.9941 - -   63 3 - - - - 
Aldehyde dehydrogenase ALDH2_MOUSE 57.0149 - - - - - - - - 130 6 
Alpha-1-antitrypsin 1-1 A1AT1_MOUSE 46.1448 - - - - - - - - 110 5 
Alpha-1-antitrypsin 1-2 A1AT2_MOUSE 46.1166 - - - - - - - - 100 4 
Anionic trypsin-2 TRY2_MOUSE 26.8709 - - - - - - - - 58 3 
Apolipoprotein A-I APOA1_MOUSE 30.5687 - - - - - - - - 84 9 
Apolipoprotein A-II APOA2_MOUSE 11.36884 - - - - - - - - 142 3 
Apolipoprotein A-IV APOA4_MOUSE 45.0011 - - - - - - - - 46 4 
Apolipoprotein C-III APOC3_MOUSE 10.9755 - - - - - - - - 200 4 
Apolipoprotein E APOE_MOUSE 35.9014 - - - - 53 7 - - 154 7 
Arginine/serine-rich-splicing factor 10 TRA2B_MOUSE 33.6456 - - - - 144 5 - - - - 
Argininosuccinate synthase ASSY_MOUSE 46.5550 - - - - 375 18 - - - - 
ATP synthase subunit alpha ATPA_MOUSE 59.7156 169 5 - - 496 17 - - - - 
ATP synthase subunit beta ATPB_MOUSE 56.2655 132 5 - - 323 14 305 12 176 8 
ATP synthase subunit d ATP5H_MOUSE 18.7946 - - - - 109 5 - - 155 5 
ATP synthase subunit delta ATPD_MOUSE 17.5891 - - - - - - - - 116 4 
ATP synthase subunit e ATP5I_MOUSE 8.2305 
- - - - 
- - - - 117 6 
ATP synthase-coupling factor 6 ATP5J_MOUSE 12.4886 
- - - - 
494 10 - - 319 6 
Beta-2-microglobulin precursor B2MG_MOUSE 13.8139 
- - - - 
105 3 - - - - 
Betaine--homocysteine S-
methyltransferase 1 
BHMT1_MOUSE 
44.9919 
- - 
77 5 440 18 
109 8 1557 38 
Betaine--homocysteine S-
methyltransferase 2 
BHMT2_MOUSE 
40.4162 
- - 
- - 49 3 
- - 259 14 
Calmodulin CALM_MOUSE 16.8268 
- - 
- - - - - - 196 3 
Calreticulin CALR_MOUSE 47.9649 
- - 
51 4 - - 134 4 177 10 
Calumenin CALU_MOUSE 37.0405 
- - 
- - - - 76 4 812 15 
Carbamoyl-phosphate synthase CPSM_MOUSE 164.5137 
  
- - 440 25 - - - - 
Carboxylesterase 3 CES3_MOUSE 62.0338 
- - 
78 5 - - - - 173 8 
  
 
C3 
 
 
Protein name Accession Molecular 
weight 
(kDa) 
Inhibitor-bead 
chromatography 
experiment II c 
Inhibitor-bead 
chromatography 
experiment III a1 
Inhibitor-bead 
chromatography 
experiment III a2 
Inhibitor-bead 
chromatography 
experiment III b1 
Inhibitor-bead 
chromatography 
experiment III b2 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
MASCOT 
score 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
Number 
of 
peptides 
Carnitine O-palmitoyltransferase 2 CPT2_MOUSE 74.5077 
- - - - 
- - - - 82 3 
Cell death regulator Aven AVEN_MOUSE 37.3433 
- - - - 
- - - - 144 3 
Clathrin light chain A CLCA_MOUSE 25.5984 
- - - - 
- - - - 300 12 
Clathrin light chain B CLCB_MOUSE 25.2702 
- - - - 
- - - - 267 13 
Coatomer subunit epsilon COPE_MOUSE 34.7735 
- - - - 
- - - - 124 7 
Cytochrome b5 CYB5_MOUSE 15.2315 
- - - - 
300 9 109 4 646 12 
Cytochrome b-c1 complex subunit 6 QCR6_MOUSE 10.7131 
- - - - 
- - - - 230 6 
Cytochrome b-c1 complex subunit 7 QCR7_MOUSE 13.5190 - - - - - - - - 107 7 
Cytochrome c oxidase subunit 5A COX5A_MOUSE 16.0202 160 6 - - 107 7 - - 374 9 
Cytochrome c oxidase subunit 5B COX5B_MOUSE 13.8039   - - 59 6 - - - - 
Cytochrome c oxidase subunit 6B1 CX6B1_MOUSE 10.2930 - - - - 179 6 - - 208 8 
D-beta-hydroxybutyrate dehydrogenase BDH_MOUSE 38.2604   - - 158 6 - - - - 
Delta(3,5)-Delta(2,4)-dienoyl-CoA 
isomerase 
ECH1_MOUSE 
36.4373 - - - - - - 
- - 101 8 
Dimethylaniline monooxygenase [N-
oxide-forming] 3 
FMO3_MOUSE 
60.4767 - - 50 3 - - 
- - - - 
DnaJ homolog subfamily A member 3 DNJA3_MOUSE 53.0947 - - - - - - - - 49 4 
Dynactin subunit 2 DCTN2_MOUSE 44.2038 - - - - - - - - 94 6 
Elongation factor 1-alpha 1 EF1A1_MOUSE 50.4242 - - - - - - - - 71 3 
Elongation factor 1-beta EF1B_MOUSE 24.8493 - - - - - - - - 352 10 
Elongation factor 1-delta EF1D_MOUSE 31.3879 - - - - - - - - 271 8 
Elongation factor 2 EF2_MOUSE 96.2223 - - - - - - - - 56 5 
Endoplasmic reticulum resident protein 
44 
ERP44_MOUSE 
47.2225 
- - - - 
- - 
- - 95 5 
Endoplasmin ENPL_MOUSE 92.7037 
- - 
58 7 - - - - 120 6 
Epoxide hydrolase 2 HYES_MOUSE 63.0448 
- - - - 
- - - - 105 5 
Far upstream element-binding protein 2 FUBP2_MOUSE 77.2179 
- - - - 
- - - - 72 5 
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Protein name Accession Molecular 
weight 
(kDa) 
Inhibitor-bead 
chromatography 
experiment II c 
Inhibitor-bead 
chromatography 
experiment III a1 
Inhibitor-bead 
chromatography 
experiment III a2 
Inhibitor-bead 
chromatography 
experiment III b1 
Inhibitor-bead 
chromatography 
experiment III b2 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
MASCOT 
score 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
Number 
of 
peptides 
Ferritin light chain 1 FRIL1_MOUSE 20.8465 
- - - - 
- - - - 174 6 
Fibrinogen beta chain FIBB_MOUSE 55.4020 
- - - - 
- - - - 82 4 
Galectin-1 LEG1_MOUSE 15.1983 
- - - - 
- - - - 50 3 
Glial fibrillary acidic protein GFAP_MOUSE 49.8695 
- - - - 
93 6 - - - - 
Glucosidase 2 subunit beta GLU2B_MOUSE 59.7251 
- - - - 
- - - - 300 9 
Glutamate dehydrogenase 1 DHE3_MOUSE 61.2982 
- - - - 
289 17 - - - - 
Glutathione peroxidase 1 GPX1_MOUSE 22.2683 
- - - - 
60 7 - - - - 
Glutathione S-transferase Mu 1 GSTM1_MOUSE 26.0671 
- - - - 
- - - - 146 9 
Glutathione S-transferase P 1 GSTP1_MOUSE 23.7652 
- - - - 
- - - - 214 6 
Glyceraldehyde-3-phosphate 
dehydrogenase 
G3P_MOUSE 
36.0723 
- - - - 
- - 
- - 87 3 
Glycerol-3-phosphate dehydrogenase 
[NAD+] 
GPDA_MOUSE 
38.1757 
- - - - 
- - 
- - 65 4 
Glycogen phosphorylase, muscle form PYGM_MOUSE 97.2247 
- - - - 
47 4 - - - - 
Group XIIB secretory phospholipase A2-
like protein 
PG12B_MOUSE 
22.5766 
- - - - 
- - 
- - 64 3 
Heat shock cognate 71 kDa protein HSPC7_MOUSE 70.8272 
- - - - 
- - 51 3 - - 
Heat shock protein HSP 90-beta HS90B_MOUSE 83.6153 
- - - - 
- - - - 328 6 
Hemoglobin subunit alpha HBA_MOUSE 15.1328 
- - - - 
186 4 - - 855 16 
Hemoglobin subunit beta-1 HBB1_MOUSE 15.9442 
- - - - 
147 5 - - 376 10 
Hemoglobin subunit beta-2 HBB2_MOUSE 15.9823 
- - - - 
81 3 - - 552 15 
Heterogeneous nuclear 
ribonucleoprotein A/B 
ROAA_MOUSE 
30.9263 
- - - - 
- - 
- - 112 10 
Heterogeneous nuclear 
ribonucleoprotein K 
HNRPK_MOUSE 
51.2295 
- - - - 
- - 
- - 87 5 
Histone H1.2 H12_MOUSE 21.2537 
- - - - 
- - - - 56 3 
Hsc70-interacting protein F10A1_MOUSE 41.8006 
- - - - 
- - - - 224 9 
Inorganic pyrophosphatase IPYR_MOUSE 33.1023 
- - - - 
- - - - 132 7 
Legumain LGMN_MOUSE 49.7405 
- - - - 
- - - - 57 3 
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Protein name Accession Molecular 
weight 
(kDa) 
Inhibitor-bead 
chromatography 
experiment II c 
Inhibitor-bead 
chromatography 
experiment III a1 
Inhibitor-bead 
chromatography 
experiment III a2 
Inhibitor-bead 
chromatography 
experiment III b1 
Inhibitor-bead 
chromatography 
experiment III b2 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
MASCOT 
score 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
Number 
of 
peptides 
L-gulonolactone oxidase GGLO_MOUSE 51.0868 
- - - - 
- - - - 62 3 
Liver carboxylesterase 1 EST1_MOUSE 63.0392 - - - - - - - - 70 4 
Liver carboxylesterase 31 EST31_MOUSE 63.6766 83 4 - - - - - - 144 8 
Liver carboxylesterase 31-like ES31L_MOUSE 63.3655 - - - - - - - - 141 7 
Liver carboxylesterase N ESTN_MOUSE 61.1330 - - - - - - 54 6 141 5 
Mannose-binding protein C MBL2_MOUSE 26.3400 - - - - - - - - 188 7 
Membrane-associated progesterone 
receptor component 1 
PGRC1_MOUSE 
21.6808 96 3 - - 182 4 
- - 264 8 
Microsomal triglyceride transfer protein 
large subunit 
MTP_MOUSE 
99.6638 - - - - - - 
- - 66 6 
Mitochondrial antiviral-signaling protein MAVS_MOUSE 53.8220 - - - - - - - - 81 3 
Mitochondrial import inner membrane 
translocase subunit Tim13 
TIM13_MOUSE 
10.6790 - - - - - - 
- - 177 6 
Mitochondrial import inner membrane 
translocase subunit Tim8 A 
TIM8A_MOUSE 
11.2634 - - - - - - 
- - 271 5 
Myosin light polypeptide 6 MYL6_MOUSE 17.0902 - - - - 210 8 - - 59 4 
Myosin regulatory light chain 2-B MLRB_MOUSE 19.7665 - - - - 56 3 - - - - 
NADH dehydrogenase [ubiquinone] 
flavoprotein 2 
NDUV2_MOUSE 
27.6100 - - - - - - 
- - 146 5 
NADH dehydrogenase [ubiquinone] 
flavoprotein 3 
NDUV3_MOUSE 
11.8063 - - - - 120 3 
- - - - 
NADH dehydrogenase [ubiquinone] iron-
sulfur protein 4 
NDUS4_MOUSE 
19.8292 - - - - 84 4 
- - 58 5 
NADH dehydrogenase [ubiquinone] iron-
sulfur protein 5 
NDUS5_MOUSE 
12.6393 - - - - 67 5 
- - - - 
NADH dehydrogenase [ubiquinone] iron-
sulfur protein 6 
NDUS6_MOUSE 
13.0117 - - - - 252 5 
- - - - 
Non-specific lipid-transfer protein NLTP_MOUSE 59.7150 - - - - - - - - 73 4 
Nucleobindin-1 precursor (CALNUC) NUCB1_MOUSE 53.3759 - - 112 8 55 8 686 23 1534 42 
Nucleobindin-2 NUCB2_MOUSE 50.3872 - - - - - - - - 117 3 
Peroxiredoxin-1 PRDX1_MOUSE 22.1624 
- - - - 
46 4 51 3 298 13 
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Protein name Accession Molecular 
weight 
(kDa) 
Inhibitor-bead 
chromatography 
experiment II c 
Inhibitor-bead 
chromatography 
experiment III a1 
Inhibitor-bead 
chromatography 
experiment III a2 
Inhibitor-bead 
chromatography 
experiment III b1 
Inhibitor-bead 
chromatography 
experiment III b2 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
MASCOT 
score 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
Number 
of 
peptides 
Peroxiredoxin-2 PRDX2_MOUSE 21.9361 
- - - - 
- - - - 54 4 
Peroxiredoxin-6 PRDX6_MOUSE 24.9690 
- - - - 
119 6 - - 366 13 
Peroxisomal biogenesis factor 19 PEX19_MOUSE 32.9407 - - - - - - - - 86 3 
Polyadenylate-binding protein 1 PABP1_MOUSE 70.8259 - - - - - - - - 105 6 
Probable carboxypeptidase PM20D1 P20D1_MOUSE 55.7419 - - - - - - - - 66 9 
Prohibitin  PHB_MOUSE 29.8019 97 5 - - - - - - - - 
Protein canopy homolog 2 CNYP2_MOUSE 21.0964 - - - - - - - - 60 3 
Protein CREG1 CREG1_MOUSE 24.5504 - - - - - - - - 46 3 
Protein disulfide-isomerase PDIA1_MOUSE 57.1078 - - 357 15 197 7 1181 30 1144 41 
Protein disulfide-isomerase A3 PDIA3_MOUSE 57.0989 - - - - - - - - 46 7 
Protein disulfide-isomerase A6 PDIA6_MOUSE 48.4694 - - - - - - - - 86 6 
Protein NipSnap1 NIPS1_MOUSE 33.3420 - - - - 119 7 - - - - 
Ras GTPase-activating-like protein 
IQGAP2 
IQGA2_MOUSE 
181.0998 - - - - - - 
- - 73 6 
Reticulocalbin-2 RCN2_MOUSE 37.2478 - - - - - - - - 361 8 
Ribosomal protein L22-like 1 RL22L_MOUSE 14.4586 
- - - - 
88 3 - - - - 
S-adenosylmethionine synthetase 
isoform type-1 
METK1_MOUSE 
43.4810 
- - - - 
126 5 
99 4 1036 23 
Serotransferrin TRFE_MOUSE 78.8405 
- - - - 
- - - - 63 4 
Small glutamine-rich tetratricopeptide 
repeat-containing protein alpha 
SGTA_MOUSE 
34.5290 
- - - - 
- - 
- - 120 3 
Small nuclear ribonucleoprotein Sm D3 SMD3_MOUSE 13.9073 
- - - - 
48 4 - - - - 
Splicing factor, arginine/serine-rich 1 SFRS1_MOUSE 27.7278 
- - - - 
45 7 - - - - 
Splicing factor, arginine/serine-rich 3 SFRS3_MOUSE 19.3179 
- - - - 
153 6 - - - - 
S-phase kinase-associated protein 1 SKP1_MOUSE 18.8313 
- - - - 
- - - - 91 3 
Sulfite oxidase SUOX_MOUSE 61.2310 
- - - - 
- - - - 164 7 
Superoxide dismutase [Cu-Zn] SODC_MOUSE 16.1039 
- - - - 
53 4 - - 252 3 
Tetratricopeptide repeat protein 36 TTC36_MOUSE 20.1772 
- - - - 
- - - - 226 10 
Thioredoxin-dependent peroxide 
reductase 
PRDX3_MOUSE 
28.3375 
- - - - 
- - 
- - 147 5 
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Protein name Accession Molecular 
weight 
(kDa) 
Inhibitor-bead 
chromatography 
experiment II c 
Inhibitor-bead 
chromatography 
experiment III a1 
Inhibitor-bead 
chromatography 
experiment III a2 
Inhibitor-bead 
chromatography 
experiment III b1 
Inhibitor-bead 
chromatography 
experiment III b2 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
MASCOT 
score 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
Number 
of 
peptides 
Tropomyosin alpha-3 chain TPM3_MOUSE 32.8428 
- - - - 
55 5 - - - - 
Tubulin alpha-2 chain TBA2_MOUSE 50.1196 
- - - - 
128 3 - - - - 
Tubulin alpha-4A chain TBA4A_MOUSE 50.6337 
- - - - 
- - - - 120 4 
Tubulin beta-2A chain TBB2A_MOUSE 50.2741 
- - - - 
- - - - 147 10 
Tubulin beta-2C chain TBB2C_MOUSE 50.2552 
- - - - 
51 7 - - 116 8 
Tubulin beta-5 chain TBB5_MOUSE 50.0951 
- - - - 
- - - - 154 8 
Ubiquilin-1 UBQL1_MOUSE 61.9372 
- - - - 
- - - - 144 4 
Ubiquinol-cytochrome c reductase 
complex 14 kDa protein 
UCR6_MOUSE 
13.5190 
- - - - 
58 5 
  - - 
Ubiquinol-cytochrome c reductase iron-
sulfur subunit, mitochondrial precursor 
UCRI_MOUSE 
29.3492 188 4 
- - 
- - 
- - - - 
Ubiquinol-cytochrome-c reductase 
complex core protein 1, mitochondrial 
precursor 
UQCR1_MOUSE 
52.7354 65 7 
- - 
- - 
- - - - 
Ubiquinone biosynthesis protein COQ9 COQ9_MOUSE 35.2316 
- - - - 
- - - - 195 4 
Uncharacterized protein C1orf50 
homolog 
CA050_MOUSE 
22.0199 
- - - - 
- - 
- - 130 4 
UPF0568 protein C14orf166 homolog CN166_MOUSE 28.2488 
- - - - 
- - - - 65 3 
Vitamin D-binding protein VTDB_MOUSE 53.5650 
- - - - 
- - 66 5 1142 33 
D1 
 
Appendix D: Mass spectrometry data for NADPH removal elution (E5) fractions from ICT-5074 affinity chromatography experiments. List of proteins 
identified in E5 fraction with at least 3 peptides, MASCOT score ≥45. Inhibitor-bead chromatography experiment III a1 (Section 5.2.2.5) SDS-PAGE sample 
separation, in-gel trypsin digestion equivalent to 1ml of the 2ml sample. Inhibitor-bead chromatography experiment III a2 whole 2ml sample trypsin digested. 
Inhibitor-bead chromatography experiment III b1 SDS-PAGE sample separation, in-gel trypsin digestion equivalent to 1ml of the 2ml sample. Inhibitor-bead 
chromatography experiment III b2 whole 2ml sample trypsin digested. P450 identifications are highlighted in red. 
  
Protein name Accession  Molecular 
weight 
(kDa) 
Inhibitor-bead 
chromatography 
experiment III a1 
Inhibitor-bead 
chromatography 
experiment III a2 
Inhibitor-bead 
chromatography 
experiment III b1 
Inhibitor-bead 
chromatography 
experiment III b2 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
Number 
of 
peptides 
3-hydroxyanthranilate 3,4-dioxygenase 3HAO_MOUSE 32.7835 - - - - 46 3 76 7 
40S ribosomal protein SA RSSA_MOUSE 32.8174 99 4 - - - - - - 
40S ribosomal protein S19 RS19_MOUSE 16.0756 - - 58 4 - - - - 
40S ribosomal protein S28 RS28_MOUSE 7.8932 - - - - - - 74 4 
60 kDa heat shock protein CH60_MOUSE 60.9174 61 4 - - - - - - 
60S acidic ribosomal protein P2 RLA2_MOUSE 11.6438 - - - - - - 78 3 
60S ribosomal protein L23a RL23A_MOUSE 17.6841 - - 88 3 - - - - 
60S ribosomal protein L38 RL38_MOUSE 8.1987 - - 62 3 - - - - 
78 kDa glucose-regulated protein GRP78_MOUSE 72.4915 277 14 171 12 - - 247 16 
Actin, cytoplasmic 1 ACTB_MOUSE 41.7097 108 7 182 9 - - - - 
Aldehyde dehydrogenase ALDH2_MOUSE 56.5018 169 10 - - - - - - 
Arginase-1 ARGI1_MOUSE 34.7862 - - 188 7 - - - - 
Argininosuccinate synthase ASSY_MOUSE 46.5550 - - 68 10 - - - - 
ATP synthase subunit alpha ATPA_MOUSE 59.7156 - - 121 6 - - - - 
ATP synthase subunit beta ATPB_MOUSE 56.2654 585 19 110 9 440 15 210 9 
ATP synthase-coupling factor 6 ATP5J_MOUSE 12.4886 - - 333 6 - - 115 5 
Beta-2-microglobulin precursor B2MG_MOUSE 13.8139 - - 144 4 - - - - 
Betaine--homocysteine S-
methyltransferase 1 
BHMT1_MOUSE 45.44805 129 5 667 21 614 13 1281 37 
Betaine--homocysteine S-
methyltransferase 2 
BHMT2_MOUSE 40.4152 - - 48 4 - - 173 7 
Calreticulin CALR_MOUSE 48.1359 114 4 75 5 117 3 73 5 
Calumenin CALU_MOUSE 37.1548 - - - - - - 291 7 
Carbamoyl-phosphate synthase CPSM_MOUSE 164.5137 - - 51 9 - - - - 
Carbonic anhydrase 3 CAH3_MOUSE 29.3476 - - 75 4 - - - - 
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Protein name Accession  Molecular 
weight 
(kDa) 
Inhibitor-bead 
chromatography 
experiment III a1 
Inhibitor-bead 
chromatography 
experiment III a2 
Inhibitor-bead 
chromatography 
experiment III b1 
Inhibitor-bead 
chromatography 
experiment III b2 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
Number 
of 
peptides 
Carboxylesterase 3 CES3_MOUSE 62.0338 145 6 48 4 - - 84 5 
Catalase CATA_MOUSE 59.7276 - - 73 9 - -   
Cysteine-rich with EGF-like domain 
protein 2 precursor 
CREL2_MOUSE 40.3606 - - - - - - 62 5 
Cytochrome b5 CYB5_MOUSE 15.2315 - - 255 8 - - 210 6 
Cytochrome c oxidase subunit 5A COX5A_MOUSE 16.0202 - - 121 6 - - - - 
Cytochrome c oxidase subunit 5B COX5B_MOUSE 13.8039 - - 46 3 - - - - 
Cytochrome c oxidase subunit VIb isoform 
1 
CX6B1_MOUSE 10.0649 - - 285 8 - - - - 
Cytochrome P450 4F3 CP4F3_MOUSE 59.8032 46 3 - - - - - - 
D-dopachrome decarboxylase DOPD_MOUSE 13.0688 - - 93 5 - - - - 
Dihydrolipoyllysine-residue 
succinyltransferase component of 2-
oxoglutarate dehydrogenase complex 
ODO2_MOUSE 48.9635 - - 51 7 - - - - 
Dihydropyrimidinase DPYS_MOUSE 56.6886 - - 105 3 - - - - 
Elongation factor 1-delta EF1D_MOUSE 31.2739 - - - - 53 3 - - 
Endoplasmin precursor ENPL_MOUSE 92.4183 167 14 - - - -   
Ezrin EZRI_MOUSE 69.3636 - - 50 3 - - - - 
Fatty acid-binding protein, liver (L-FABP) FABPL_MOUSE 14.2365 - - 51 6 - - - - 
Ferritin light chain 1 FRIL1_MOUSE 20.8465 - - 270 6 - - 104 5 
Fumarylacetoacetase FAAA_MOUSE 46.0740 - - 112 6 - - - - 
Galectin-9 LEG9_MOUSE 40.0101 - - 46 3 - - - - 
Glial fibrillary acidic protein GFAP_MOUSE 49.8695 - - 72 3 - - - - 
Glucosidase 2 subunit beta GLU2B_MOUSE 58.7558 - - - - 156 3 250 9 
Haptoglobin precursor HPT_MOUSE 38.7275 - - 57 3 - - - - 
Hemoglobin subunit alpha HBA_MOUSE 15.0758 - - 248 5 - - - - 
Hemoglobin subunit beta-1 HBB1_MOUSE 15.8302 - - 141 4 - - - - 
Hemoglobin subunit beta-2 HBB2_MOUSE 15.8683 - - 59 3 - - - - 
Heterogeneous nuclear 
ribonucleoproteins A2/B1 
ROA2_MOUSE 37.4367 - - - - - - 80 3 
Heterogeneous nuclear ribonucleoprotein 
K 
HNRPK_MOUSE 50.9444 - - - - - - 277 6 
Homogentisate 1,2-dioxygenase HGD_MOUSE 49.9576   46 5 - - - - 
Liver carboxylesterase 22 precursor  EST22_MOUSE 61.5426 88 5 - - 88 5 - - 
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Protein name Accession  Molecular 
weight 
(kDa) 
Inhibitor-bead 
chromatography 
experiment III a1 
Inhibitor-bead 
chromatography 
experiment III a2 
Inhibitor-bead 
chromatography 
experiment III b1 
Inhibitor-bead 
chromatography 
experiment III b2 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
Number 
of 
peptides 
Liver carboxylesterase 31 EST31_MOUSE 63.2774 - - - - 74 5 - - 
Liver carboxylesterase 31-like ES31L_MOUSE 61.4182 - - - - 93 4 55 5 
Liver carboxylesterase N precursor ESTN_MOUSE 61.1330 - - - - 127 5 84 7 
Major urinary protein 2 MUP2_MOUSE 20.9354 - - - - - - 54 3 
Major urinary protein 6  MUP6_MOUSE 20.6362   48 4 - - - - 
Membrane-associated progesterone 
receptor component 1 
PGRC1_MOUSE 21.6808 - - 74 4 - - - - 
Mannose-binding protein C MBL2_MOUSE 26.3400 - - - - - - 165 5 
MIR-interacting saposin-like protein 
precursor 
MSAP_MOUSE 20.7543 - - 167 4 - - - - 
Mitochondrial import inner membrane 
translocase subunit Tim8 A 
TIM8A_MOUSE 11.2634 - - 66 4 - - 214 4 
NADH dehydrogenase [ubiquinone] 
flavoprotein 2 
NDUV2_MOUSE 27.2679 - - 55 4 - - - - 
NADH dehydrogenase [ubiquinone] iron-
sulfur protein 4 
NDUS4_MOUSE 19.7722 - - 139 3 - - - - 
NADH dehydrogenase [ubiquinone] iron-
sulfur protein 6 
NDUS6_MOUSE 13.0117 - - 291 4 - - - - 
NADPH--cytochrome P450 reductase NCPR_MOUSE 76.9953 54 3 - - - - - - 
Nucleobindin-1 precursor (CALNUC) NUCB1_MOUSE 53.3759 97 4 - - 241 15 531 23 
Peptidyl-prolyl cis-trans isomerase B PPIB_MOUSE 23.6986 - - 116 9 - - 124 3 
Peroxiredoxin-1 PRDX1_MOUSE 22.3904 102 4 162 4 - - 235 6 
Peroxiredoxin-2 PRDX2_MOUSE 21.7651 - - - - - - - - 
Peroxiredoxin-6 PRDX6_MOUSE 24.9690 - - 161 10 - - 74 3 
Plasminogen precursor PLMN_MOUSE 90.7229   79 11 - - - - 
Protein disulfide-isomerase precursor PDIA1_MOUSE 57.1078 460 17 541 16 473 12 1254 39 
Protein disulfide-isomerase A3 precursor PDIA3_MOUSE 56.6427 94 5 - - - - - - 
Protein disulfide-isomerase A6 precursor PDIA6_MOUSE 48.0703 80 3 149 6 - - - - 
Ribonuclease UK114 UK114_MOUSE 14.2466 - - 91 4 - - - - 
S-adenosylmethionine synthetase isoform 
type-1 
METK1_MOUSE 44.05118 - - - - - - 152 5 
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Protein name Accession  Molecular 
weight 
(kDa) 
Inhibitor-bead 
chromatography 
experiment III a1 
Inhibitor-bead 
chromatography 
experiment III a2 
Inhibitor-bead 
chromatography 
experiment III b1 
Inhibitor-bead 
chromatography 
experiment III b2 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
Number 
of 
peptides 
MASCOT 
score 
Number 
of 
peptides 
Serotransferrin precursor TRFE_MOUSE 76.6737 - - 594 23 - - - - 
Superoxide dismutase [Cu-Zn] SODC_MOUSE 15.9328 - - 200 4 - - - - 
Tetratricopeptide repeat protein 36 TTC36_MOUSE 20.1772 - - - - - - 94 7 
Thioredoxin domain-containing protein 5 
precursor 
TXND5_MOUSE 46.3859 - - 141 7 - - - - 
Tropomyosin-1 alpha chain TPM1_MOUSE 32.6607 - - 110 6 - - - - 
Ubiquinol-cytochrome c reductase iron-
sulfur subunit 
UCRI_MOUSE 29.3492 - - 89 3 - - - - 
UDP-glucuronosyltransferase 1-7C 
precursor 
UD17C_MOUSE 59.7187 45 4 - - - - - - 
Uricase URIC_MOUSE 35.0170 - - 82 4 - - - - 
UTP--glucose-1-phosphate 
uridylyltransferase 2 
UGPA2_MOUSE 56.9437 50 3 - - - - - - 
Vitamin D-binding protein precursor VTDB_MOUSE 53.5650 - - 83 5 - - - - 
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Appendix E: Mass spectrometry data ethanolamine- and glycine-blocked sepharose bead chromatography. List of proteins identified with at least 3 
peptides, MASCOT score ≥45. Beads prepared and processed as described in Section 6.2.2. P450 identifications are highlighted in red. 
 
 
Protein Accession MW [kDa] 
Ethanolamine-
blocked beads 
Glycine-blocked 
beads 
1,4-alpha-glucan-branching enzyme OS=Mus musculus GN=Gbe1 PE=2 SV=1 GLGB_MOUSE 80.76873 
 
128 (5) 
10-formyltetrahydrofolate dehydrogenase (EC 1.5.1.6) (10-FTHFDH) (Aldehyde 
dehydrogenase 1 family member L1) - Mus musculus (Mouse) FTHFD_MOUSE 98.64653 178 (8) 75 (3) 
17-beta hydroxysteroid dehydrogenase 13 precursor (EC 1.1.-.-) (Short-chain 
dehydrogenase/reductase 9) (Alcohol dehydrogenase PAN1B-like) - Mus 
musculus (Mouse) DHB13_MOUSE 33.49689 113 (4) 56 (3) 
2,4-dienoyl-CoA reductase, mitochondrial OS=Mus musculus GN=Decr1 PE=1 
SV=1 DECR_MOUSE 36.47581 
 
149 (4) 
26S protease regulatory subunit 4 (P26s4) (Proteasome 26S subunit ATPase 
1) - Mus musculus (Mouse) PRS4_MOUSE 49.15369 96 (12) 
 26S protease regulatory subunit 6A (Proteasome 26S subunit ATPase 3) (TAT-
binding protein 1) (TBP-1) - Mus musculus (Mouse) PRS6A_MOUSE 49.46156 72 (11) 
 26S protease regulatory subunit 6B (Proteasome 26S subunit ATPase 4) 
(MIP224) (MB67-interacting protein) (TAT-binding protein 7) (TBP-7) (CIP21) - 
Mus musculus (Mouse) PRS6B_MOUSE 47.25154 76 (4) 59 (5) 
26S protease regulatory subunit 7 (Proteasome 26S subunit ATPase 2) 
(Protein MSS1) - Mus musculus (Mouse) PRS7_MOUSE 48.61713 88 (7) 
 26S protease regulatory subunit 8 (Proteasome 26S subunit ATPase 5) 
(Proteasome subunit p45) (p45/SUG) (mSUG1) - Mus musculus (Mouse) PRS8_MOUSE 45.59705 260 (8) 
 26S protease regulatory subunit S10B (Proteasome 26S subunit ATPase 6) 
(Proteasome subunit p42) - Mus musculus (Mouse) PRS10_MOUSE 44.1451 87 (3) 70 (3) 
26S proteasome non-ATPase regulatory subunit 1 (26S proteasome regulatory 
subunit RPN2) (26S proteasome regulatory subunit S1) - Mus musculus 
(Mouse) PSMD1_MOUSE 105.66265 71 (7) 
 26S proteasome non-ATPase regulatory subunit 2 (26S proteasome regulatory 
subunit RPN1) (26S proteasome regulatory subunit S2) (26S proteasome 
subunit p97) - Mus musculus (Mouse) PSMD2_MOUSE 100.13867 99 (8) 85 (6) 
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2-oxoglutarate dehydrogenase E1 component, mitochondrial precursor (EC 
1.2.4.2) (Alpha-ketoglutarate dehydrogenase) - Mus musculus (Mouse) ODO1_MOUSE 116.37452 212 (7) 93 (7) 
2-oxoisovalerate dehydrogenase subunit alpha, mitochondrial precursor (EC 
1.2.4.4) (Branched-chain alpha-keto acid dehydrogenase E1 component alpha 
chain) (BCKDH E1-alpha) - Mus musculus (Mouse) ODBA_MOUSE 50.33905 122 (7) 349 (13) 
3-ketoacyl-CoA thiolase A, peroxisomal precursor (EC 2.3.1.16) (Beta-
ketothiolase A) (Acetyl-CoA acyltransferase A) (Peroxisomal 3-oxoacyl-CoA 
thiolase A) - Mus musculus (Mouse) THIKA_MOUSE 43.92565 129 (6) 94 (3) 
3-ketoacyl-CoA thiolase B, peroxisomal precursor (EC 2.3.1.16) (Beta-
ketothiolase B) (Acetyl-CoA acyltransferase B) (Peroxisomal 3-oxoacyl-CoA 
thiolase B) - Mus musculus (Mouse) THIKB_MOUSE 43.96778 131 (7) 
 3-ketoacyl-CoA thiolase, mitochondrial (EC 2.3.1.16) (Beta-ketothiolase) 
(Acetyl-CoA acyltransferase) (Mitochondrial 3-oxoacyl-CoA thiolase) - Mus 
musculus (Mouse) THIM_MOUSE 41.83147 280 (16) 211 (9) 
40S ribosomal protein S10 - Mus musculus (Mouse) RS10_MOUSE 18.90382 140 (3) 
 40S ribosomal protein S11 - Mus musculus (Mouse) RS11_MOUSE 18.41899 295 (11) 67 (5) 
40S ribosomal protein S13 - Mus musculus (Mouse) RS13_MOUSE 17.21167 196 (12) 
 40S ribosomal protein S14 - Mus musculus (Mouse) RS14_MOUSE 16.26253 309 (6) 
 40S ribosomal protein S15a - Mus musculus (Mouse) RS15A_MOUSE 14.82997 185 (13) 45 (3) 
40S ribosomal protein S16 - Mus musculus (Mouse) RS16_MOUSE 16.43504 366 (12) 
 40S ribosomal protein S17 - Mus musculus (Mouse) RS17_MOUSE 15.51437 134 (3) 
 40S ribosomal protein S18 (Ke-3) (Ke3) - Mus musculus (Mouse) RS18_MOUSE 17.70786 318 (11) 68 (6) 
40S ribosomal protein S19 - Mus musculus (Mouse) RS19_MOUSE 16.0756 242 (7) 77 (3) 
40S ribosomal protein S2 (S4) (LLRep3 protein) - Mus musculus (Mouse) RS2_MOUSE 31.21166 242 (12) 
 40S ribosomal protein S23 - Mus musculus (Mouse) RS23_MOUSE 15.79772 236 (5) 
 40S ribosomal protein S24 - Mus musculus (Mouse) RS24_MOUSE 15.41343 109 (3) 
 40S ribosomal protein S26 - Mus musculus (Mouse) RS26_MOUSE 13.00708 96 (3) 132 (5) 
40S ribosomal protein S27a - Mus musculus (Mouse) RS27A_MOUSE 9.39787 167 (6) 
 40S ribosomal protein S3 - Mus musculus (Mouse) RS3_MOUSE 26.65741 659 (12) 
 40S ribosomal protein S3a - Mus musculus (Mouse) RS3A_MOUSE 29.86572 513 (15) 124 (5) 
40S ribosomal protein S4, X isoform - Mus musculus (Mouse) RS4X_MOUSE 29.57905 1078 (20) 98 (4) 
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40S ribosomal protein S5 - Mus musculus (Mouse) RS5_MOUSE 22.87505 233 (10) 
 40S ribosomal protein S6 (Phosphoprotein NP33) - Mus musculus (Mouse) RS6_MOUSE 28.66299 369 (8) 
 40S ribosomal protein S7 - Mus musculus (Mouse) RS7_MOUSE 22.11326 195 (7) 
 40S ribosomal protein S8 - Mus musculus (Mouse) RS8_MOUSE 24.19016 619 (17) 251 (8) 
40S ribosomal protein S9 - Mus musculus (Mouse) RS9_MOUSE 22.57756 187 (11) 
 40S ribosomal protein SA (p40) (34/67 kDa laminin receptor) (37 kDa oncofetal 
antigen) (OFA/iLRP) - Mus musculus (Mouse) RSSA_MOUSE 32.81744 170 (5) 56 (4) 
5-oxoprolinase (EC 3.5.2.9) (5-oxo-L-prolinase) (Pyroglutamase) (5-OPase) - 
Mus musculus (Mouse) OPLA_MOUSE 137.5245 62 (7) 
 60 kDa heat shock protein, mitochondrial precursor (Hsp60) (60 kDa 
chaperonin) (CPN60) (Heat shock protein 60) (HSP-60) (Mitochondrial matrix 
protein P1) (HSP-65) - Mus musculus (Mouse) CH60_MOUSE 60.91739 121 (8) 
 60S acidic ribosomal protein P0 (L10E) - Mus musculus (Mouse) RLA0_MOUSE 34.19475 75 (4) 
 60S ribosomal protein L10 (QM protein homolog) - Mus musculus (Mouse) RL10_MOUSE 24.58787 715 (25) 
 60S ribosomal protein L10-like OS=Mus musculus GN=Rpl10l PE=2 SV=1 RL10L_MOUSE 24.99809 
 
75 (7) 
60S ribosomal protein L13 (A52) - Mus musculus (Mouse) RL13_MOUSE 24.2905 314 (16) 
 60S ribosomal protein L13 OS=Mus musculus GN=Rpl13 PE=2 SV=3 RL13_MOUSE 24.34753 
 
94 (7) 
60S ribosomal protein L13a (Transplantation antigen P198) (Tum-P198 
antigen) - Mus musculus (Mouse) RL13A_MOUSE 23.44933 133 (12) 48 (5) 
60S ribosomal protein L14 - Mus musculus (Mouse) RL14_MOUSE 23.5492 214 (8) 49 (3) 
60S ribosomal protein L15 - Mus musculus (Mouse) RL15_MOUSE 24.13108 181 (6) 139 (5) 
60S ribosomal protein L17 (L23) - Mus musculus (Mouse) RL17_MOUSE 21.40938 93 (3) 
 60S ribosomal protein L18 - Mus musculus (Mouse) RL18_MOUSE 21.63118 130 (5) 
 60S ribosomal protein L18a - Mus musculus (Mouse) RL18A_MOUSE 20.71889 120 (12) 54 (4) 
60S ribosomal protein L19 - Mus musculus (Mouse) RL19_MOUSE 23.45125 135 (9) 
 60S ribosomal protein L21 - Mus musculus (Mouse) RL21_MOUSE 18.55006 97 (8) 
 60S ribosomal protein L23 - Mus musculus (Mouse) RL23_MOUSE 14.85606 256 (10) 48 (3) 
60S ribosomal protein L24 - Mus musculus (Mouse) RL24_MOUSE 17.7679 76 (4) 
 60S ribosomal protein L26 (Silica-induced gene 20 protein) (SIG-20) - Mus 
musculus (Mouse) RL26_MOUSE 17.24753 160 (6) 
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60S ribosomal protein L27 - Mus musculus (Mouse) RL27_MOUSE 15.78775 110 (5) 
 60S ribosomal protein L27a (L29) - Mus musculus (Mouse) RL27A_MOUSE 16.579 143 (3) 
 60S ribosomal protein L3 (J1 protein) - Mus musculus (Mouse) RL3_MOUSE 46.09481 530 (13) 79 (2) 
60S ribosomal protein L30 - Mus musculus (Mouse) RL30_MOUSE 12.77574 106 (6) 
 60S ribosomal protein L35a - Mus musculus (Mouse) RL35A_MOUSE 12.54575 53 (5) 
 60S ribosomal protein L4 (L1) - Mus musculus (Mouse) RL4_MOUSE 47.12401 566 (13) 316 (8) 
60S ribosomal protein L6 (TAX-responsive enhancer element-binding protein 
107) (TAXREB107) - Mus musculus (Mouse) RL6_MOUSE 33.48892 132 (9) 183 (5) 
60S ribosomal protein L7 - Mus musculus (Mouse) RL7_MOUSE 31.39975 120 (13) 96 (5) 
60S ribosomal protein L7a (Surfeit locus protein 3) - Mus musculus (Mouse) RL7A_MOUSE 29.95798 190 (13) 71 (7) 
60S ribosomal protein L8 - Mus musculus (Mouse) RL8_MOUSE 28.00729 158 (19) 
 60S ribosomal protein L9 - Mus musculus (Mouse) RL9_MOUSE 21.86781 66 (3) 
 6-phosphofructokinase, liver type (EC 2.7.1.11) (Phosphofructokinase 1) 
(Phosphohexokinase) (Phosphofructo-1-kinase isozyme B) (PFK-B) - Mus 
musculus (Mouse) K6PL_MOUSE 85.24636 97 (5) 
 78 kDa glucose-regulated protein precursor (GRP 78) (Heat shock 70 kDa 
protein 5) (Immunoglobulin heavy chain-binding protein) (BiP) - Mus musculus 
(Mouse) GRP78_MOUSE 72.37746 392 (13) 389 (11) 
Acetyl-CoA carboxylase 1 (EC 6.4.1.2) (ACC-alpha) (Acetyl-CoA carboxylase 
265) [Includes: Biotin carboxylase (EC 6.3.4.14)] - Mus musculus (Mouse) COA1_MOUSE 265.08792 112 (14) 
 Actin, cytoplasmic 1 (Beta-actin) - Mus musculus (Mouse) ACTB_MOUSE 41.70973 814 (17) 355 (12) 
Acyl-CoA synthetase family member 2, mitochondrial OS=Mus musculus 
GN=Acsf2 PE=2 SV=1 ACSF2_MOUSE 68.59129 
 
99 (4) 
ADP/ATP translocase 2 (Adenine nucleotide translocator 2) (ANT 2) (ADP,ATP 
carrier protein 2) (Solute carrier family 25 member 5) - Mus musculus (Mouse) ADT2_MOUSE 32.91016 87 (8) 
 Alanyl-tRNA synthetase, cytoplasmic OS=Mus musculus GN=Aars PE=1 SV=1 SYAC_MOUSE 107.69655 
 
69 (9) 
Alcohol dehydrogenase 1 (EC 1.1.1.1) (Alcohol dehydrogenase A subunit) 
(ADH-A2) - Mus musculus (Mouse) ADH1_MOUSE 39.74556 251 (8) 229 (7) 
Aldehyde dehydrogenase family 16 member A1 OS=Mus musculus 
GN=Aldh16a1 PE=2 SV=2 A16A1_MOUSE 85.5009 
 
115 (3) 
Aldehyde dehydrogenase family 8 member A1 OS=Mus musculus 
GN=Aldh8a1 PE=1 SV=1 AL8A1_MOUSE 54.37077 
 
293 (8) 
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Aldehyde dehydrogenase X, mitochondrial precursor (EC 1.2.1.3) (Aldehyde 
dehydrogenase family 1 member B1) - Mus musculus (Mouse) AL1B1_MOUSE 57.51648 140 (6) 185 (8) 
Aldehyde dehydrogenase, mitochondrial precursor (EC 1.2.1.3) (ALDH class 2) 
(AHD-M1) (ALDHI) (ALDH-E2) - Mus musculus (Mouse) ALDH2_MOUSE 56.50175 169 (10) 190 (12) 
Alpha-aminoadipic semialdehyde synthase, mitochondrial OS=Mus musculus 
GN=Aass PE=2 SV=1 AASS_MOUSE 103.6502 
 
124 (9) 
Alpha-enolase (EC 4.2.1.11) (2-phospho-D-glycerate hydro-lyase) (Non-neural 
enolase) (NNE) (Enolase 1) - Mus musculus (Mouse) ENOA_MOUSE 47.11121 234 (8) 122 (4) 
AP-2 complex subunit alpha-1 (Adapter-related protein complex 2 alpha-1 
subunit) (Alpha-adaptin A) (Adaptor protein complex AP-2 alpha-1 subunit) 
(Clathrin assembly protein complex 2 alpha-A large chain) (100 kDa coated 
vesicle protein A) (Plasma me AP2A1_MOUSE 107.59593 64 (12) 
 AP-2 complex subunit mu-1 (Adaptin mu-1) (AP-2 mu-2 chain) (Clathrin coat 
assembly protein AP50) (Clathrin coat-associated protein AP50) (Plasma 
membrane adaptor AP-2 50 kDa protein) (Clathrin assembly protein complex 2 
medium chain) - Mus musculus  AP2M1_MOUSE 49.62303 101 (9) 
 Apolipoprotein A-I OS=Mus musculus GN=Apoa1 PE=1 SV=1 APOA1_MOUSE 30.56865 
 
48 (5) 
Apolipoprotein E precursor (Apo-E) - Mus musculus (Mouse) APOE_MOUSE 35.84435 134 (7) 186 (9) 
Arginase-1 (EC 3.5.3.1) (Type I arginase) (Liver-type arginase) - Mus musculus 
(Mouse) ARGI1_MOUSE 34.78617 62 (6) 49 (4) 
Argininosuccinate lyase OS=Mus musculus GN=Asl PE=2 SV=1 ARLY_MOUSE 51.87764 
 
298 (10) 
Argininosuccinate synthase (EC 6.3.4.5) (Citrulline--aspartate ligase) - Mus 
musculus (Mouse) ASSY_MOUSE 46.55501 695 (26) 684 (25) 
Asparaginyl-tRNA synthetase, cytoplasmic OS=Mus musculus GN=Nars PE=1 
SV=2 SYNC_MOUSE 65.15035 
 
45 (3) 
ATP synthase O subunit, mitochondrial precursor (EC 3.6.3.14) (Oligomycin 
sensitivity conferral protein) (OSCP) - Mus musculus (Mouse) ATPO_MOUSE 23.34874 64 (3) 
 ATP synthase subunit alpha, mitochondrial precursor (EC 3.6.3.14) - Mus 
musculus (Mouse) ATPA_MOUSE 59.71559 624 (23) 356 (11) 
ATP synthase subunit beta, mitochondrial precursor (EC 3.6.3.14) - Mus 
musculus (Mouse) ATPB_MOUSE 56.26547 122 (10) 382 (12) 
ATP-dependent RNA helicase DDX1 (EC 3.6.1.-) (DEAD box protein 1) - Mus 
musculus (Mouse) DDX1_MOUSE 82.44777 109 (8) 
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ATP-dependent RNA helicase DDX3X OS=Mus musculus GN=Ddx3x PE=1 
SV=3 DDX3X_MOUSE 73.45517 
 
70 (3) 
Betaine--homocysteine S-methyltransferase 1 (EC 2.1.1.5) - Mus musculus 
(Mouse) BHMT1_MOUSE 44.99188 173 (7) 389 (12) 
Bifunctional 3'-phosphoadenosine 5'-phosphosulfate synthetase 2 (PAPS 
synthetase 2) (PAPSS 2) (Sulfurylase kinase 2) (SK2) (SK 2) [Includes: Sulfate 
adenylyltransferase (EC 2.7.7.4) (Sulfate adenylate transferase) (SAT) (ATP-
sulfurylase); Adenylyl-s PAPS2_MOUSE 70.24587 63 (8) 63 (7) 
Bifunctional aminoacyl-tRNA synthetase [Includes: Glutamyl-tRNA synthetase 
(EC 6.1.1.17) (Glutamate--tRNA ligase); Prolyl-tRNA synthetase (EC 6.1.1.15) 
(Proline--tRNA ligase)] - Mus musculus (Mouse) SYEP_MOUSE 169.82952 98 (19) 75 (5) 
Bifunctional ATP-dependent dihydroxyacetone kinase/FAD-AMP lyase 
(cyclizing) OS=Mus musculus GN=Dak PE=2 SV=1 DHAK_MOUSE 59.93845 
 
221 (5) 
Bifunctional UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine 
kinase OS=Mus musculus GN=Gne PE=1 SV=1 GLCNE_MOUSE 80.17432 
 
60 (4) 
Biglycan precursor (Bone/cartilage proteoglycan I) (PG-S1) - Mus musculus 
(Mouse) PGS1_MOUSE 41.6126 50 (4) 
 Bile acyl-CoA synthetase (EC 6.2.1.7) (BACS) (Bile acid CoA ligase) (BA-CoA 
ligase) (BAL) (Cholate--CoA ligase) (Very long chain acyl-CoA synthetase-
related protein) (VLACS-related) (VLACSR) (Fatty acid transport protein 5) 
(FATP-5) (Solute carrier  S27A5_MOUSE 76.15399 57 (8) 72 (5) 
C-1-tetrahydrofolate synthase, cytoplasmic (C1-THF synthase) [Includes: 
Methylenetetrahydrofolate dehydrogenase (EC 1.5.1.5); 
Methenyltetrahydrofolate cyclohydrolase (EC 3.5.4.9); Formyltetrahydrofolate 
synthetase (EC 6.3.4.3)] - Mus musculus (Mouse C1TC_MOUSE 101.19205 545 (22) 
 C-1-tetrahydrofolate synthase, cytoplasmic OS=Mus musculus GN=Mthfd1 
PE=1 SV=3 C1TC_MOUSE 101.87631 
 
287 (14) 
Calreticulin OS=Mus musculus GN=Calr PE=1 SV=1 CALR_MOUSE 48.13593 
 
98 (5) 
Carbamoyl-phosphate synthase [ammonia], mitochondrial precursor (EC 
6.3.4.16) (Carbamoyl-phosphate synthetase I) (CPSase I) - Mus musculus 
(Mouse) CPSM_MOUSE 164.51366 1552 (59) 1605 (57) 
Carboxylesterase 3 precursor (EC 3.1.1.1) (Triacylglycerol hydrolase) (TGH) - 
Mus musculus (Mouse) CES3_MOUSE 61.7487 162 (4) 164 (7) 
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Carnitine O-palmitoyltransferase 2, mitochondrial OS=Mus musculus GN=Cpt2 
PE=1 SV=1 CPT2_MOUSE 74.50772 
 
94 (4) 
Clathrin heavy chain - Mus musculus (Mouse) CLH_MOUSE 191.43451 536 (18) 392 (17) 
Coatomer subunit alpha OS=Mus musculus GN=Copa PE=1 SV=1 COPA_MOUSE 140.01149 
 
53 (3) 
Complement C3 OS=Mus musculus GN=C3 PE=1 SV=2 CO3_MOUSE 187.90426 
 
79 (4) 
Cystathionine beta-synthase (EC 4.2.1.22) (Serine sulfhydrase) (Beta-
thionase) - Mus musculus (Mouse) CBS_MOUSE 61.50424 161 (6) 
 Cystathionine gamma-lyase (EC 4.4.1.1) (Gamma-cystathionase) - Mus 
musculus (Mouse) CGL_MOUSE 43.53921 243 (5) 
 Cytochrome b5 OS=Mus musculus GN=Cyb5a PE=1 SV=2 CYB5_MOUSE 15.23153 
 
207 (6) 
Cytochrome P450 2A4 (EC 1.14.14.1) (CYPIIA4) (Testosterone 15-alpha-
hydroxylase) (P450-15-alpha) (P450-IIA3.1) - Mus musculus (Mouse) CP2A4_MOUSE 56.55823 135 (11) 
 Cytochrome P450 2A5 (EC 1.14.14.1) (CYPIIA5) (Coumarin 7-hydroxylase) 
(P450-15-COH) (P450-IIA3.2) - Mus musculus (Mouse) CP2A5_MOUSE 56.70428 82 (6) 
 Cytochrome P450 2C37 (EC 1.14.14.1) (CYPIIC37) - Mus musculus 
(Mouse) CP237_MOUSE 55.47754 63 (9) 117 (4) 
Cytochrome P450 2C37 OS=Mus musculus GN=Cyp2c37 PE=2 SV=1 CP237_MOUSE 56.27584 
  Cytochrome P450 2C54 (EC 1.14.14.1) (CYPIIC54) - Mus musculus 
(Mouse) CP254_MOUSE 55.82176 53 (6) 121 (5) 
Cytochrome P450 2D10 (EC 1.14.14.1) (CYPIID10) (P450-16-alpha) 
(P450CB) (Testosterone 16-alpha hydroxylase) - Mus musculus (Mouse) CP2DA_MOUSE 57.19653 224 (9) 306 (10) 
Cytochrome P450 2D10 OS=Mus musculus GN=Cyp2d10 PE=2 SV=2 CP2DA_MOUSE 57.53866 
  Cytochrome P450 2D26 (EC 1.14.14.1) (CYPIID26) - Mus musculus 
(Mouse) CP2DQ_MOUSE 56.93928 335 (13) 514 (16) 
Cytochrome P450 2D9 OS=Mus musculus GN=Cyp2d9 PE=1 SV=1 CP2D9_MOUSE 57.25446 
 
60 (4) 
Cytochrome P450 2E1 (EC 1.14.14.1) (CYPIIE1) (P450-J) (P450-ALC) - Mus 
musculus (Mouse) CP2E1_MOUSE 56.76864 128 (7) 132 (13) 
Cytochrome P450 2F2 (EC 1.14.14.-) (CYPIIF2) (Naphthalene 
dehydrogenase) (Naphthalene hydroxylase) (P450-NAH-2) - Mus 
musculus (Mouse) CP2F2_MOUSE 55.91296 55 (5) 
 Cytochrome P450 3A11 (EC 1.14.14.1) (CYPIIIA11) (P-450IIIAM1) (P-450UT) 
- Mus musculus (Mouse) CP3AB_MOUSE 57.81699 62 (4) 
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D-beta-hydroxybutyrate dehydrogenase, mitochondrial precursor (EC 1.1.1.30) 
(BDH) (3-hydroxybutyrate dehydrogenase) - Mus musculus (Mouse) BDH_MOUSE 38.2604 47 (8) 227 (8) 
Dehydrogenase/reductase SDR family member 1 (EC 1.1.-.-) - Mus musculus 
(Mouse) DHRS1_MOUSE 33.98336 51 (4) 
 Dehydrogenase/reductase SDR family member 8 precursor (EC 1.1.1.-) (17-
beta-hydroxysteroid dehydrogenase 11) (17-beta-HSD 11) (17-beta-HSD XI) 
(17betaHSDXI) (17bHSD11) (17betaHSD11) - Mus musculus (Mouse) DHRS8_MOUSE 32.85968 253 (5) 
 Delta-1-pyrroline-5-carboxylate dehydrogenase, mitochondrial precursor (EC 
1.5.1.12) (P5C dehydrogenase) (Aldehyde dehydrogenase 4A1) - Mus 
musculus (Mouse) AL4A1_MOUSE 61.77158 338 (11) 383 (11) 
Dihydroxyacetone kinase (EC 2.7.1.29) (Glycerone kinase) (DHA kinase) - Mus 
musculus (Mouse) DAK_MOUSE 59.65335 345 (6) 
 Dimethylaniline monooxygenase [N-oxide-forming] 1 OS=Mus musculus 
GN=Fmo1 PE=1 SV=1 FMO1_MOUSE 60.44617 
 
79 (6) 
Dimethylaniline monooxygenase [N-oxide-forming] 3 OS=Mus musculus 
GN=Fmo3 PE=1 SV=1 FMO3_MOUSE 61.16098 
 
152 (5) 
Dimethylaniline monooxygenase [N-oxide-forming] 5 OS=Mus musculus 
GN=Fmo5 PE=2 SV=3 FMO5_MOUSE 60.56121 
 
177 (6) 
Dynein heavy chain, cytosolic (DYHC) (Cytoplasmic dynein heavy chain 1) 
(DHC1) (Dynein heavy chain 1, cytoplasmic 1) - Mus musculus (Mouse) DYHC_MOUSE 531.68987 157 (24) 
 Electron transfer flavoprotein subunit alpha, mitochondrial OS=Mus musculus 
GN=Etfa PE=1 SV=2 ETFA_MOUSE 35.32963 
 
72 (3) 
Electron transfer flavoprotein subunit beta (Beta-ETF) - Mus musculus (Mouse) ETFB_MOUSE 27.60598 54 (3) 
 Electron transfer flavoprotein-ubiquinone oxidoreductase, mitochondrial 
OS=Mus musculus GN=Etfdh PE=1 SV=1 ETFD_MOUSE 68.90293 
 
82 (6) 
Elongation factor 1-alpha 1 (EF-1-alpha-1) (Elongation factor 1 A-1) (eEF1A-1) 
(Elongation factor Tu) (EF-Tu) - Mus musculus (Mouse) EF1A1_MOUSE 50.0821 514 (10) 204 (6) 
Elongation factor 1-alpha 2 OS=Mus musculus GN=Eef1a2 PE=1 SV=1 EF1A2_MOUSE 50.76444 
 
89 (3) 
Elongation factor 1-gamma (EF-1-gamma) (eEF-1B gamma) - Mus musculus 
(Mouse) EF1G_MOUSE 50.02916 99 (3) 72 (3) 
Elongation factor 1-gamma OS=Mus musculus GN=Eef1g PE=1 SV=3 EF1G_MOUSE 50.37129 
  Elongation factor 2 (EF-2) - Mus musculus (Mouse) EF2_MOUSE 95.25289 233 (13) 49 (4) 
Elongation factor Tu, mitochondrial OS=Mus musculus GN=Tufm PE=1 SV=1 EFTU_MOUSE 49.87612 
 
52 (3) 
  
 
E9 
 
Endoplasmin OS=Mus musculus GN=Hsp90b1 PE=1 SV=2 ENPL_MOUSE 92.70336 
 
98 (4) 
Endoplasmin precursor (Heat shock protein 90 kDa beta member 1) (94 kDa 
glucose-regulated protein) (GRP94) (ERP99) (Polymorphic tumor rejection 
antigen 1) (Tumor rejection antigen gp96) - Mus musculus (Mouse) ENPL_MOUSE 92.41826 566 (22) 
 Eukaryotic initiation factor 4A-I OS=Mus musculus GN=Eif4a1 PE=2 SV=1 IF4A1_MOUSE 46.35264 
 
130 (5) 
Eukaryotic translation initiation factor 3 subunit 10 (eIF-3 theta) (eIF3 p167) 
(eIF3 p180) (eIF3 p185) (eIF3a) (p162 protein) (Centrosomin) - Mus musculus 
(Mouse) IF3A_MOUSE 161.85223 87 (14) 
 Eukaryotic translation initiation factor 3 subunit 7 (eIF-3 zeta) (eIF3 p66) 
(eIF3d) - Mus musculus (Mouse) IF37_MOUSE 63.51811 77 (5) 
 Eukaryotic translation initiation factor 3 subunit 8 (eIF3 p110) (eIF3c) - Mus 
musculus (Mouse) IF38_MOUSE 105.46476 62 (9) 
 Eukaryotic translation initiation factor 3 subunit 9 (eIF-3 eta) (eIF3 p116) - Mus 
musculus (Mouse) IF39_MOUSE 91.31314 57 (4) 
 Fatty acid synthase (EC 2.3.1.85) [Includes: [Acyl-carrier-protein] S-
acetyltransferase (EC 2.3.1.38); [Acyl-carrier-protein] S-malonyltransferase (EC 
2.3.1.39); 3-oxoacyl-[acyl-carrier-protein] synthase (EC 2.3.1.41); 3-oxoacyl-
[acyl-carrier-protei FAS_MOUSE 272.25678 762 (24) 967 (27) 
Fibrinogen beta chain precursor [Contains: Fibrinopeptide B] - Mus musculus 
(Mouse) FIBB_MOUSE 54.7177 175 (5) 568 (15) 
Fibrinogen gamma chain OS=Mus musculus GN=Fgg PE=2 SV=1 FIBG_MOUSE 50.04409 
 
48 (3) 
Formimidoyltransferase-cyclodeaminase (Formiminotransferase-
cyclodeaminase) (FTCD) [Includes: Glutamate formimidoyltransferase (EC 
2.1.2.5) (Glutamate formiminotransferase) (Glutamate formyltransferase); 
Formimidoyltetrahydrofolate cyclodeaminase (E FTCD_MOUSE 58.90153 56 (4) 95 (6) 
Gamma-enolase (EC 4.2.1.11) (2-phospho-D-glycerate hydro-lyase) (Neural 
enolase) (Neuron-specific enolase) (NSE) (Enolase 2) - Mus musculus (Mouse) ENOG_MOUSE 47.267 99 (6) 
 Glutamate dehydrogenase 1, mitochondrial precursor (EC 1.4.1.3) (GDH) - 
Mus musculus (Mouse) DHE3_MOUSE 61.29817 359 (22) 590 (18) 
Glutamine synthetase (EC 6.3.1.2) (Glutamate--ammonia ligase) (GS) - Mus 
musculus (Mouse) GLNA_MOUSE 42.09226 254 (5) 
 Glutaryl-CoA dehydrogenase, mitochondrial OS=Mus musculus GN=Gcdh 
PE=2 SV=1 GCDH_MOUSE 49.07198 
 
167 (4) 
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Glutathione peroxidase 1 (EC 1.11.1.9) (GSHPx-1) (GPx-1) (Cellular 
glutathione peroxidase) - Mus musculus (Mouse) GPX1_MOUSE 22.26829 47 (3) 103 (7) 
Glutathione S-transferase Mu 1 (EC 2.5.1.18) (GST class-mu 1) (Glutathione 
S-transferase GT8.7) (pmGT10) (GST 1-1) - Mus musculus (Mouse) GSTM1_MOUSE 25.95306 57 (4) 46 (5) 
Glutathione S-transferase theta-1 OS=Mus musculus GN=Gstt1 PE=1 SV=3 GSTT1_MOUSE 27.64345 
 
78 (8) 
Glyceraldehyde-3-phosphate dehydrogenase (EC 1.2.1.12) (GAPDH) - Mus 
musculus (Mouse) G3P_MOUSE 35.78721 386 (18) 211 (10) 
Glycogen [starch] synthase, liver (EC 2.4.1.11) - Mus musculus (Mouse) GYS2_MOUSE 80.83348 193 (9) 
 Glycogen phosphorylase, brain form (EC 2.4.1.1) - Mus musculus (Mouse) PYGB_MOUSE 96.66847 172 (7) 
 Glycogen phosphorylase, liver form (EC 2.4.1.1) - Mus musculus (Mouse) PYGL_MOUSE 97.36898 130 (8) 
 Glycogen phosphorylase, muscle form (EC 2.4.1.1) (Myophosphorylase) - Mus 
musculus (Mouse) PYGM_MOUSE 97.22472 212 (9) 
 Heat shock cognate 71 kDa protein (Heat shock 70 kDa protein 8) - Mus 
musculus (Mouse) HSP7C_MOUSE 70.82721 56 (6) 64 (8) 
Heat shock protein HSP 90-beta OS=Mus musculus GN=Hsp90ab1 PE=1 
SV=2 HS90B_MOUSE 83.61525 
 
74 (5) 
Hemoglobin subunit alpha (Hemoglobin alpha chain) (Alpha-globin) - Mus 
musculus (Mouse) HBA_MOUSE 15.07576 575 (12) 214 (4) 
Hemoglobin subunit beta-1 (Hemoglobin beta-1 chain) (Beta-1-globin) 
(Hemoglobin beta-major chain) - Mus musculus (Mouse) HBB1_MOUSE 15.83015 403 (8) 234 (3) 
Hemoglobin subunit beta-1 OS=Mus musculus GN=Hbb-b1 PE=1 SV=2 HBB1_MOUSE 15.94419 
  Hemoglobin subunit beta-2 (Hemoglobin beta-2 chain) (Beta-2-globin) 
(Hemoglobin beta-minor chain) - Mus musculus (Mouse) HBB2_MOUSE 15.86825 412 (12) 
 Heterogeneous nuclear ribonucleoprotein U OS=Mus musculus GN=Hnrnpu 
PE=1 SV=1 HNRPU_MOUSE 88.66102 
 
160 (4) 
Heterogeneous nuclear ribonucleoprotein U-like protein 2 (MLF1-associated 
nuclear protein) - Mus musculus (Mouse) HNRL2_MOUSE 84.94784 76 (5) 
 Hydroxymethylglutaryl-CoA synthase, mitochondrial precursor (EC 2.3.3.10) 
(HMG-CoA synthase) (3-hydroxy-3-methylglutaryl coenzyme A synthase) - Mus 
musculus (Mouse) HMCS2_MOUSE 56.78647 88 (4) 273 (9) 
Hypoxia up-regulated protein 1 OS=Mus musculus GN=Hyou1 PE=1 SV=1 HYOU1_MOUSE 111.34026 
 
155 (7) 
Isocitrate dehydrogenase [NADP] cytoplasmic OS=Mus musculus GN=Idh1 
PE=1 SV=1 IDHC_MOUSE 47.02956 
 
67 (3) 
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Isocitrate dehydrogenase [NADP], mitochondrial precursor (EC 1.1.1.42) 
(Oxalosuccinate decarboxylase) (IDH) (NADP(+)-specific ICDH) (IDP) (ICD-M) 
- Mus musculus (Mouse) IDHP_MOUSE 58.7348 65 (7) 
 Keratin, type II cytoskeletal 8 (Cytokeratin-8) (CK-8) (Keratin-8) (K8) 
(Cytokeratin endo A) - Mus musculus (Mouse) K2C8_MOUSE 54.53146 83 (3) 
 L-gulonolactone oxidase (EC 1.1.3.8) (LGO) (L-gulono-gamma-lactone 
oxidase) (GLO) - Mus musculus (Mouse) GGLO_MOUSE 50.45957 66 (5) 187 (10) 
Lipoamide acyltransferase component of branched-chain alpha-keto acid 
dehydrogenase complex, mitochondrial OS=Mus musculus GN=Dbt PE=2 
SV=1 ODB2_MOUSE 53.46902 
 
47 (6) 
Liver carboxylesterase 1 precursor (EC 3.1.1.1) (Acyl coenzyme A:cholesterol 
acyltransferase) (ES-x) - Mus musculus (Mouse) EST1_MOUSE 62.64 100 (5) 328 (8) 
Liver carboxylesterase 31 precursor (EC 3.1.1.1) (ES-Male) (Esterase-31) - 
Mus musculus (Mouse) EST31_MOUSE 61.47057 80 (5) 241 (8) 
Long-chain-fatty-acid--CoA ligase 1 (EC 6.2.1.3) (Long-chain acyl-CoA 
synthetase 1) (LACS 1) - Mus musculus (Mouse) ACSL1_MOUSE 77.87333 76 (6) 
 Low-density lipoprotein receptor-related protein 1 precursor (LRP) (Alpha-2-
macroglobulin receptor) (A2MR) - Mus musculus (Mouse) LRP1_MOUSE 504.41068 72 (20) 
 L-serine dehydratase/L-threonine deaminase OS=Mus musculus GN=Sds 
PE=1 SV=3 SDHL_MOUSE 34.97037 
 
97 (3) 
Medium-chain specific acyl-CoA dehydrogenase, mitochondrial precursor (EC 
1.3.99.3) (MCAD) - Mus musculus (Mouse) ACADM_MOUSE 46.45162 72 (8) 
 Membrane-associated progesterone receptor component 1 - Mus musculus 
(Mouse) PGRC1_MOUSE 21.68077 166 (3) 225 (5) 
Methionyl-tRNA synthetase, cytoplasmic (EC 6.1.1.10) (Methionine--tRNA 
ligase) (MetRS) - Mus musculus (Mouse) SYMC_MOUSE 101.3662 92 (6) 61 (6) 
Methylcrotonoyl-CoA carboxylase subunit alpha, mitochondrial OS=Mus 
musculus GN=Mccc1 PE=2 SV=2 MCCA_MOUSE 79.6925 
 
188 (7) 
Methylmalonate-semialdehyde dehydrogenase [acylating], mitochondrial 
OS=Mus musculus GN=Aldh6a1 PE=1 SV=1 MMSA_MOUSE 58.33467 
 
181 (6) 
Methyltransferase-like protein 7B precursor (EC 2.1.1.-) - Mus musculus 
(Mouse) MET7B_MOUSE 28.03049 73 (5) 156 (3) 
Microsomal triglyceride transfer protein large subunit OS=Mus musculus 
GN=Mttp PE=2 SV=2 MTP_MOUSE 99.66381 
 
132 (6) 
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Multisynthetase complex auxiliary component p43 [Contains: Endothelial 
monocyte-activating polypeptide 2 (EMAP-II) (Small inducible cytokine 
subfamily E member 1)] - Mus musculus (Mouse) MCA1_MOUSE 33.97587 76 (7) 
 Myosin-Ib (Myosin I alpha) (MMI-alpha) (MMIa) (MIH-L) - Mus musculus 
(Mouse) MYO1B_MOUSE 128.44692 52 (7) 
 NADH-cytochrome b5 reductase (EC 1.6.2.2) (B5R) (Diaphorase-1) 
(Cytochrome b5 reductase 3) [Contains: NADH-cytochrome b5 reductase 
membrane-bound form; NADH-cytochrome b5 reductase soluble form] - Mus 
musculus (Mouse) NCB5R_MOUSE 34.10575 48 (6) 
 NADPH--cytochrome P450 reductase (EC 1.6.2.4) (CPR) (P450R) - Mus 
musculus (Mouse) NCPR_MOUSE 76.99533 165 (10) 91 (7) 
Neutral alpha-glucosidase AB precursor (EC 3.2.1.84) (Glucosidase II subunit 
alpha) (Alpha glucosidase 2) - Mus musculus (Mouse) GANAB_MOUSE 106.84351 82 (12) 
 Peroxiredoxin-1 (EC 1.11.1.15) (Thioredoxin peroxidase 2) (Thioredoxin-
dependent peroxide reductase 2) (Osteoblast-specific factor 3) (OSF-3) 
(Macrophage 23 kDa stress protein) - Mus musculus (Mouse) PRDX1_MOUSE 22.16235 248 (10) 178 (4) 
Peroxiredoxin-4 (EC 1.11.1.15) (Prx-IV) (Thioredoxin peroxidase AO372) 
(Thioredoxin-dependent peroxide reductase A0372) (Antioxidant enzyme 
AOE372) - Mus musculus (Mouse) PRDX4_MOUSE 31.03314 83 (3) 
 Peroxiredoxin-6 OS=Mus musculus GN=Prdx6 PE=1 SV=3 PRDX6_MOUSE 24.96902 
 
125 (3) 
Peroxisomal 2,4-dienoyl-CoA reductase OS=Mus musculus GN=Decr2 PE=1 
SV=1 DECR2_MOUSE 31.62246 
 
48 (3) 
Peroxisomal multifunctional enzyme type 2 OS=Mus musculus GN=Hsd17b4 
PE=1 SV=3 DHB4_MOUSE 79.94515 
 
127 (6) 
Phenylalanine-4-hydroxylase (EC 1.14.16.1) (PAH) (Phe-4-monooxygenase) - 
Mus musculus (Mouse) PH4H_MOUSE 51.89639 110 (11) 267 (15) 
Phosphoenolpyruvate carboxykinase [GTP], mitochondrial precursor (EC 
4.1.1.32) (Phosphoenolpyruvate carboxylase) (PEPCK-M) - Mus musculus 
(Mouse) PPCKM_MOUSE 70.48245 63 (9) 
 Phosphoenolpyruvate carboxykinase, cytosolic [GTP] OS=Mus musculus 
GN=Pck1 PE=2 SV=1 PCKGC_MOUSE 70.05135 
 
134 (8) 
Phosphoribosyl pyrophosphate synthetase-associated protein 1 (PRPP 
synthetase-associated protein 1) (39 kDa phosphoribosypyrophosphate KPRA_MOUSE 39.40668 196 (6) 
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synthetase-associated protein) (PAP39) - Mus musculus (Mouse) 
Probable 2-oxoglutarate dehydrogenase E1 component DHKTD1, 
mitochondrial OS=Mus musculus GN=Dhtkd1 PE=2 SV=1 DHTK1_MOUSE 103.46977 
 
260 (8) 
Probable E3 ubiquitin-protein ligase HECTD3 (HECT domain-containing 
protein 3) - Mus musculus (Mouse) HECD3_MOUSE 97.28557 68 (8) 
 Prolargin precursor (Proline-arginine-rich end leucine-rich repeat protein) - Mus 
musculus (Mouse) PRELP_MOUSE 43.26501 56 (3) 
 Proline oxidase, mitochondrial precursor (EC 1.5.99.8) (Proline 
dehydrogenase) - Mus musculus (Mouse) PROD_MOUSE 56.73732 88 (8) 129 (5) 
Prolow-density lipoprotein receptor-related protein 1 OS=Mus musculus 
GN=Lrp1 PE=1 SV=1 LRP1_MOUSE 523.34181 
 
82 (15) 
Protein disulfide-isomerase precursor (EC 5.3.4.1) (PDI) (Prolyl 4-hydroxylase 
subunit beta) (Cellular thyroid hormone-binding protein) (p55) (Erp59) - Mus 
musculus (Mouse) PDIA1_MOUSE 57.10783 86 (5) 292 (9) 
Protein NipSnap1 - Mus musculus (Mouse) NIPS1_MOUSE 33.34201 324 (9) 260 (8) 
Protein transport protein Sec31A OS=Mus musculus GN=Sec31a PE=1 SV=2 SC31A_MOUSE 134.51195 
 
253 (10) 
Pyruvate carboxylase, mitochondrial precursor (EC 6.4.1.1) (Pyruvic 
carboxylase) (PCB) - Mus musculus (Mouse) PYC_MOUSE 129.60246 251 (23) 369 (24) 
Pyruvate dehydrogenase E1 component subunit alpha, somatic form, 
mitochondrial OS=Mus musculus GN=Pdha1 PE=1 SV=1 ODPA_MOUSE 43.88789 
 
87 (5) 
Pyruvate dehydrogenase E1 component subunit beta, mitochondrial precursor 
(EC 1.2.4.1) (PDHE1-B) - Mus musculus (Mouse) ODPB_MOUSE 38.91202 189 (3) 203 (5) 
Rab GDP dissociation inhibitor beta (Rab GDI beta) (Guanosine diphosphate 
dissociation inhibitor 2) (GDI-2) (GDI-3) - Mus musculus (Mouse) GDIB_MOUSE 50.50469 61 (3) 
 Retinal dehydrogenase 1 (EC 1.2.1.36) (RalDH1) (RALDH 1) (Aldehyde 
dehydrogenase family 1 member A1) (Aldehyde dehydrogenase, cytosolic) 
(ALHDII) (ALDH-E1) - Mus musculus (Mouse) AL1A1_MOUSE 54.43284 56 (6) 
 Retinol dehydrogenase 7 (EC 1.1.1.105) (Cis-retinol/androgen dehydrogenase 
type 2) (CRAD-2) (cis-retinol/3alpha-hydroxysterol short-chain dehydrogenase 
isozyme 2) - Mus musculus (Mouse) RDH7_MOUSE 35.6373 79 (6) 
 Ribose-phosphate pyrophosphokinase 2 OS=Mus musculus GN=Prps2 PE=1 
SV=4 PRPS2_MOUSE 35.16312 
 
61 (4) 
S-adenosylmethionine synthetase isoform type-1 (EC 2.5.1.6) (Methionine METK1_MOUSE 43.48097 406 (8) 323 (12) 
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adenosyltransferase 1) (AdoMet synthetase 1) - Mus musculus (Mouse) 
Sarcosine dehydrogenase, mitochondrial OS=Mus musculus GN=Sardh PE=1 
SV=1 SARDH_MOUSE 102.64426 
 
111 (3) 
Serum amyloid P-component OS=Mus musculus GN=Apcs PE=1 SV=2 SAMP_MOUSE 26.40133 
 
81 (3) 
Splicing factor, arginine/serine-rich 3 (Pre-mRNA-splicing factor SRP20) (X16 
protein) - Mus musculus (Mouse) SFRS3_MOUSE 19.3179 69 (5) 86 (5) 
Splicing factor, arginine/serine-rich 7 OS=Mus musculus GN=Sfrs7 PE=1 SV=1 SFRS7_MOUSE 31.02692 
 
95 (5) 
Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial 
precursor (EC 1.3.5.1) (Ip) (Iron-sulfur subunit of complex II) - Mus musculus 
(Mouse) DHSB_MOUSE 31.79289 60 (3) 
 Sulfotransferase 1A1 (EC 2.8.2.1) (Aryl sulfotransferase) (Phenol 
sulfotransferase) (Sulfokinase) (Phenol/aryl sulfotransferase) (mSTp1) (ST1A4) 
- Mus musculus (Mouse) ST1A1_MOUSE 33.95223 105 (7) 52 (4) 
Surfeit locus protein 4 - Mus musculus (Mouse) SURF4_MOUSE 30.36079 99 (3) 
 TAR DNA-binding protein 43 (TDP-43) - Mus musculus (Mouse) TADBP_MOUSE 44.51929 139 (4) 
 T-complex protein 1 subunit alpha A (TCP-1-alpha) (CCT-alpha) (Tailless 
complex polypeptide 1A) (TCP-1-A) - Mus musculus (Mouse) TCPA1_MOUSE 60.30252 62 (5) 112 (5) 
T-complex protein 1 subunit delta (TCP-1-delta) (CCT-delta) (A45) - Mus 
musculus (Mouse) TCPD_MOUSE 58.02973 105 (5) 
 T-complex protein 1 subunit epsilon (TCP-1-epsilon) (CCT-epsilon) - Mus 
musculus (Mouse) TCPE_MOUSE 59.58592 46 (4) 
 T-complex protein 1 subunit eta (TCP-1-eta) (CCT-eta) - Mus musculus 
(Mouse) TCPH_MOUSE 59.61411 96 (4) 
 T-complex protein 1 subunit gamma (TCP-1-gamma) (CCT-gamma) (Matricin) 
(mTRiC-P5) - Mus musculus (Mouse) TCPG_MOUSE 60.59136 69 (14) 
 T-complex protein 1 subunit theta (TCP-1-theta) (CCT-theta) - Mus musculus 
(Mouse) TCPQ_MOUSE 59.51751 53 (5) 
 Transitional endoplasmic reticulum ATPase (TER ATPase) (15S Mg(2+)-
ATPase p97 subunit) (Valosin-containing protein) (VCP) - Mus musculus 
(Mouse) TERA_MOUSE 89.26572 53 (4) 
 Trifunctional enzyme subunit alpha, mitochondrial OS=Mus musculus 
GN=Hadha PE=1 SV=1 ECHA_MOUSE 83.30172 
 
59 (8) 
Trifunctional enzyme subunit beta, mitochondrial precursor (TP-beta) [Includes: ECHB_MOUSE 51.35341 81 (11) 120 (6) 
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3-ketoacyl-CoA thiolase (EC 2.3.1.16) (Acetyl-CoA acyltransferase) (Beta-
ketothiolase)] - Mus musculus (Mouse) 
Tripeptidyl-peptidase 2 (EC 3.4.14.10) (Tripeptidyl-peptidase II) (TPP-II) 
(Tripeptidyl aminopeptidase) - Mus musculus (Mouse) TPP2_MOUSE 139.7905 96 (6) 
 Tubulin alpha-1A chain OS=Mus musculus GN=Tuba1a PE=1 SV=1 TBA1A_MOUSE 50.78787 
 
253 (5) 
Tubulin alpha-2 chain (Alpha-tubulin 2) (Alpha-tubulin isotype M-alpha-2) - Mus 
musculus (Mouse) TBA2_MOUSE 50.1196 271 (8) 
 Tubulin alpha-4 chain (Alpha-tubulin 4) (Alpha-tubulin isotype M-alpha-4) - Mus 
musculus (Mouse) TBA4_MOUSE 49.89237 229 (9) 
 Tubulin alpha-4A chain OS=Mus musculus GN=Tuba4a PE=1 SV=1 TBA4A_MOUSE 50.63365 
 
212 (5) 
Tubulin beta-2A chain - Mus musculus (Mouse) TBB2A_MOUSE 49.87496 464 (19) 327 (18) 
Tubulin beta-2A chain OS=Mus musculus GN=Tubb2a PE=1 SV=1 TBB2A_MOUSE 50.27411 
  Tubulin beta-2C chain - Mus musculus (Mouse) TBB2C_MOUSE 49.799 425 (18) 368 (17) 
Tubulin beta-5 chain - Mus musculus (Mouse) TBB5_MOUSE 49.63897 445 (16) 
 Tubulin beta-6 chain - Mus musculus (Mouse) TBB6_MOUSE 50.05813 180 (14) 
 UDP-glucose 6-dehydrogenase (EC 1.1.1.22) (UDP-Glc dehydrogenase) 
(UDP-GlcDH) (UDPGDH) - Mus musculus (Mouse) UGDH_MOUSE 54.79727 217 (11) 79 (5) 
UDP-glucuronosyltransferase 1-1 OS=Mus musculus GN=Ugt1a1 PE=2 SV=1 UD11_MOUSE 60.82532 
 
68 (3) 
Urocanate hydratase OS=Mus musculus GN=Uroc1 PE=2 SV=1 HUTU_MOUSE 75.2268 
 
57 (3) 
UTP--glucose-1-phosphate uridylyltransferase 2 (EC 2.7.7.9) (UDP-glucose 
pyrophosphorylase 2) (UDPGP 2) (UGPase 2) - Mus musculus (Mouse) UGPA2_MOUSE 56.94374 178 (13) 
 Valyl-tRNA synthetase OS=Mus musculus GN=Vars PE=2 SV=1 SYVC_MOUSE 141.43858 
 
164 (4) 
Very long-chain acyl-CoA synthetase OS=Mus musculus GN=Slc27a2 PE=1 
SV=1 S27A2_MOUSE 71.11977 
 
58 (4) 
Very-long-chain specific acyl-CoA dehydrogenase, mitochondrial precursor (EC 
1.3.99.-) (VLCAD) (MVLCAD) - Mus musculus (Mouse) ACADV_MOUSE 70.83068 75 (6) 143 (7) 
Vigilin (High density lipoprotein-binding protein) (HDL-binding protein) - Mus 
musculus (Mouse) VIGLN_MOUSE 141.65527 63 (7) 
 Vitronectin OS=Mus musculus GN=Vtn PE=1 SV=2 VTNC_MOUSE 55.61258 
 
79 (4) 
Xylulose kinase OS=Mus musculus GN=Xylb PE=2 SV=1 XYLB_MOUSE 60.30395 
 
88 (4) 
 
 
  
 
F1 
 
Appendix F: Mass spectrometry data for optimisation of sodium chloride buffer concentration in affinity chromatography procedures. List of 
proteins identified with at least 3 peptides, MASCOT score ≥45. Control beads (glycine-blocked beads) and ICT-5074 beads prepared and processed as 
described in Section 6.2.2. P450 identifications are highlighted in red.  
 
 
Protein name Accession  Molecular 
weight 
(kDa) 
0.15M NaCl buffer, 
Control beads 
0.15M NaCl buffer, ICT-
5074 beads 
0.5M NaCl buffer, Control 
beads 
0.5M NaCl buffer, ICT-
5074 beads 
Eluate Beads Eluate Beads Eluate Beads Eluate Beads 
1,4-alpha-glucan-branching enzyme GLGB_MOUSE 80.7687    128 (5)  61 (3)   
10-formyltetrahydrofolate dehydrogenase FTHFD_MOUSE 99.5019    75 (3)     
17-beta-hydroxysteroid dehydrogenase 13 DHB13_MOUSE 33.8390    56 (3)     
2,4-dienoyl-CoA reductase DECR_MOUSE 36.4758    149 (4)     
26S protease regulatory subunit 6B PRS6B_MOUSE 47.3656    59 (5)     
26S protease regulatory subunit S10B PRS10_MOUSE 44.4302    70 (3)     
26S proteasome non-ATPase regulatory subunit 2 PSMD2_MOUSE 100.9370    85 (6)     
26S proteasome non-ATPase regulatory subunit 4 PSMD4_MOUSE 40.9062   57 (4)      
26S proteasome non-ATPase regulatory subunit 9 PSMD9_MOUSE 24.8756   103 (4)      
2-oxoglutarate dehydrogenase ODO1_MOUSE 117.5720    93 (7)    49 (4) 
2-oxoisovalerate dehydrogenase subunit alpha ODBA_MOUSE 50.6242    349 (13)  103 (5)  269 (11) 
3-hydroxyanthranilate 3,4-dioxygenase 3HAO_MOUSE 32.9547       60 (5)  
3-ketoacyl-CoA thiolase A, peroxisomal THIKA_MOUSE 44.3818    94 (3)     
3-ketoacyl-CoA thiolase B THIKB_MOUSE 44.4810        121 (3) 
3-ketoacyl-CoA thiolase THIM_MOUSE 42.2876    211 (9)  46 (2)  165 (10) 
40S ribosomal protein S10 RS10_MOUSE 18.9038 56 (3)        
40S ribosomal protein S11 RS11_MOUSE 18.5901    67 (5)     
40S ribosomal protein S12 RS12_MOUSE 14.8577       83 (6)  
40S ribosomal protein S14 RS14_MOUSE 16.4336      83 (4)  217 (7) 
40S ribosomal protein S15a RS15A_MOUSE 14.9440    45 (3)     
40S ribosomal protein S16 RS16_MOUSE 16.5491        53 (4) 
40S ribosomal protein S18 RS18_MOUSE 17.7079    68 (6)  61 (3)  56 (5) 
40S ribosomal protein S19 RS19_MOUSE 16.0756 102 (4)  54 (4) 77 (3)     
40S ribosomal protein S26 RS26_MOUSE 13.2922    132 (5)     
40S ribosomal protein S28 RS28_MOUSE 7.8932   74 (4)      
40S ribosomal protein S30 RS30_MOUSE 6.6438   107 (4)      
40S ribosomal protein S3a RS3A_MOUSE 30.0938    124 (5)    119 (5) 
40S ribosomal protein S4 RS4X_MOUSE 29.8071    98 (4)     
40S ribosomal protein S5 RS5_MOUSE 23.0461        117 (4) 
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Protein name Accession  Molecular 
weight 
(kDa) 
0.15M NaCl buffer, 
Control beads 
0.15M NaCl buffer, ICT-
5074 beads 
0.5M NaCl buffer, Control 
beads 
0.5M NaCl buffer, ICT-
5074 beads 
Eluate Beads Eluate Beads Eluate Beads Eluate Beads 
40S ribosomal protein S8 RS8_MOUSE 24.4753  66 (3)  251 (8)     
40S ribosomal protein SA RSSA_MOUSE 32.9315    56 (4)    313 (5) 
4-trimethylaminobutyraldehyde dehydrogenase AL9A1_MOUSE 54.4494   115 (5)      
60 kDa heat shock protein CH60_MOUSE 61.0885   102 (4)     78 (3) 
60S acidic ribosomal protein P1 RLA1_MOUSE 11.5817   354 (4)    144 (4)  
60S acidic ribosomal protein P2 RLA2_MOUSE 11.6438   703 (14)    106 (5)  
60S ribosomal protein L10 RL10_MOUSE 25.0440        105 (8) 
60S ribosomal protein L10-like RL10L_MOUSE 24.9981   75 (7)      
60S ribosomal protein L13 RL13_MOUSE 24.3475  61 (4) 61 (3) 94 (7)  50 (4)  49 (4) 
60S ribosomal protein L13a RL13A_MOUSE 23.5634    48 (5)     
60S ribosomal protein L14 RL14_MOUSE 23.6633    49 (3)     
60S ribosomal protein L15 RL15_MOUSE 24.2451    139 (5)     
60S ribosomal protein L18 RL18_MOUSE 21.6882   110 (3)      
60S ribosomal protein L18a RL18A_MOUSE 21.0040    54 (4)     
60S ribosomal protein L19 RL19_MOUSE 23.5653        81 (3) 
60S ribosomal protein L23 RL23_MOUSE 14.9701    48 (3)     
60S ribosomal protein L23a RL23A_MOUSE 17.6841   136 (5)      
60S ribosomal protein L26 RL26_MOUSE 17.2475    45 (3)   79 (3)  
60S ribosomal protein L27 RL27_MOUSE 15.7878       93 (3)  
60S ribosomal protein L3 RL3_MOUSE 46.3799    79 (3)     
60S ribosomal protein L35 RL35_MOUSE 14.5436 149 (4)  143 (5)      
60S ribosomal protein L4 RL4_MOUSE 47.4091    316 (8)   46 (3)  
60S ribosomal protein L6 RL6_MOUSE 33.5460 54 (3)   183 (5)     
60S ribosomal protein L7 RL7_MOUSE 31.4568    96 (5)     
60S ribosomal protein L7a RL7A_MOUSE 30.1291    70 (7)   70 (3)  
78 kDa glucose-regulated protein GRP78_MOUSE 72.4915 151 (8)  509 (17) 389 (11)  104 (6) 222 (15) 198 (12) 
Actin, cytoplasmic 1 ACTB_MOUSE 42.0519 89 (5) 160 (6) 203 (7)   214 (7) 98 (4) 273 (11) 
Acyl-CoA synthetase family member 2 ACSF2_MOUSE 68.5913    99 (4)     
Alanyl-tRNA synthetase SYAC_MOUSE 107.6966    69 (9)     
Alcohol dehydrogenase 1 ADH1_MOUSE 40.6009    229 (7)    79 (7) 
Aldehyde dehydrogenase family 16 member A1 A16A1_MOUSE 85.5009    115 (3)    59 (3) 
Aldehyde dehydrogenase family 8 member A1 AL8A1_MOUSE 54.3708    293 (8)    66 (5) 
Aldehyde dehydrogenase X AL1B1_MOUSE 58.0867    185 (8)     
Aldehyde dehydrogenase ALDH2_MOUSE 57.0149   130 (6) 190 (12)    149 (7) 
Alpha-1-antitrypsin 1-1 A1AT1_MOUSE 46.1446   110 (5)      
  
 
F3 
 
Protein name Accession  Molecular 
weight 
(kDa) 
0.15M NaCl buffer, 
Control beads 
0.15M NaCl buffer, ICT-
5074 beads 
0.5M NaCl buffer, Control 
beads 
0.5M NaCl buffer, ICT-
5074 beads 
Eluate Beads Eluate Beads Eluate Beads Eluate Beads 
Alpha-1-antitrypsin 1-2 A1AT2_MOUSE 46.1166   100 (4)      
Alpha-aminoadipic semialdehyde synthase AASS_MOUSE 103.6502    124 (9)    122 (6) 
Alpha-enolase ENOA_MOUSE 47.4533    122 (4)     
Anionic trypsin-2 TRY2_MOUSE 26.8709   58 (3)      
Apolipoprotein A-I APOA1_MOUSE 30.5687   84 (9) 48 (5)  90 (5) 173 (10)  
Apolipoprotein A-II APOA2_MOUSE 11.3688   142 (3)      
Apolipoprotein A-IV APOA4_MOUSE 45.0011   46 (4)      
Apolipoprotein C-III APOC3_MOUSE 10.9755 145 (3)  200 (4)    134 (4)  
Apolipoprotein E APOE_MOUSE 35.9013   154 (7) 186 (9)    61 (5) 
Arginase-1 ARGI1_MOUSE 34.9572    49 (4)   80 (4) 60 (3) 
Argininosuccinate lyase ARLY_MOUSE 51.8776  45 (4)  298 (10)    90 (5) 
Argininosuccinate synthase ASSY_MOUSE 46.8401  97 (9)  684 (25)  312 (20) 66 (3) 255 (17) 
Asparaginyl-tRNA synthetase SYNC_MOUSE 65.1504    45 (3)     
ATP synthase subunit alpha ATPA_MOUSE 59.8296  91 (7)  356 (11)  320 (12) 60 (3) 434 (19) 
ATP synthase subunit beta ATPB_MOUSE 56.2655 63 (6) 53 (4) 209 (9) 382 (12)   196 (13) 98 (4) 
ATP synthase subunit d ATP5H_MOUSE 18.7946 76 (4)  155 (5)    126 (3)  
ATP synthase subunit delta ATPD_MOUSE 17.5891   116  (4)      
ATP synthase subunit e ATP5I_MOUSE 8.2305   117 (6)      
ATP synthase-coupling factor 6 ATP5J_MOUSE 12.4886 167 (3)  319 (6)  147 (4)    
ATP-dependent RNA helicase DDX3X DDX3X_MOUSE 73.4552    70 (3)     
Beta-actin-like protein 2 ACTBL_MOUSE 42.3191        117 (3) 
Beta-enolase ENOB_MOUSE 47.3374        147 (6) 
Betaine--homocysteine S-methyltransferase 1 BHMT1_MOUSE 45.4481 496 (14)  1557 (38) 389 (12)  67 (7) 993 (25) 334 (13) 
Betaine--homocysteine S-methyltransferase 2 BHMT2_MOUSE 40.4162   259 (14)    176 (8)  
Bifunctional 3'-phosphoadenosine 5'-phosphosulfate 
synthase 2 
PAPS2_MOUSE 70.8731    63 (7)    49 (4) 
Bifunctional aminoacyl-tRNA synthetase SYEP_MOUSE 171.7133    75 (5)     
Bifunctional ATP-dependent dihydroxyacetone 
kinase/FAD-AMP lyase 
DHAK_MOUSE 59.9385    221 (5)    215 (5) 
Bifunctional UDP-N-acetylglucosamine 2-epimerase/N-
acetylmannosamine kinase 
GLCNE_MOUSE 80.1743    60 (4)     
Bile acyl-CoA synthetase S27A5_MOUSE 77.1234    72 (5)     
C-1-tetrahydrofolate synthase C1TC_MOUSE 101.8763  62 (4)  287 (14)    135 (8) 
Calmodulin CALM_MOUSE 16.8268   196 (3)    283 (3)  
Calreticulin CALR_MOUSE 48.1359 169 (12)  177 (10) 98 (5)   80 (6)  
  
 
F4 
 
Protein name Accession  Molecular 
weight 
(kDa) 
0.15M NaCl buffer, 
Control beads 
0.15M NaCl buffer, ICT-
5074 beads 
0.5M NaCl buffer, Control 
beads 
0.5M NaCl buffer, ICT-
5074 beads 
Eluate Beads Eluate Beads Eluate Beads Eluate Beads 
Calumenin CALU_MOUSE 37.1546   812 (15)    157 (6)  
Carbamoyl-phosphate synthase CPSM_MOUSE 165.7111  273 (28)  1605 (57) 160 (14) 610 (36) 126 (9) 1061 (44) 
Carboxylesterase 3 CES3_MOUSE 62.0338 70 (5)  173 (8) 164 (7)    83 (5) 
Carnitine O-palmitoyltransferase 2 CPT2_MOUSE 74.5077   82 (3) 94 (4)     
Cell death regulator Aven AVEN_MOUSE 37.3433   144 (3)      
Clathrin heavy chain 1 CLH_MOUSE 193.2022    392 (17)    86 (9) 
Clathrin light chain A CLCA_MOUSE 25.5984 77 (5)  300 (12)    147 (6)  
Clathrin light chain B CLCB_MOUSE 25.2702   266 (13)    140 (6)  
Coatomer subunit alpha COPA_MOUSE 140.0115    53 (3)     
Coatomer subunit epsilon COPE_MOUSE 34.7735   124 (7)      
Complement C3 CO3_MOUSE 187.9043    79 (4)     
Cytochrome b5 CYB5_MOUSE 15.2315 254 (7) 121 (4) 646 (12) 207 (6)  90 (3) 160 (7) 225 (4) 
Cytochrome b-c1 complex subunit 6 QCR6_MOUSE 10.7131   230 (6)    143 (4)  
Cytochrome b-c1 complex subunit 7 QCR7_MOUSE 13.5190 63 (9)  107 (7)    88 (5)  
Cytochrome c oxidase subunit 5A COX5A_MOUSE 16.3194 246 (10)  374 (9)      
Cytochrome c oxidase subunit 6B1 CX6B1_MOUSE 10.2930   208 (8)    181 (6)  
Cytochrome c, somatic CYC_MOUSE 11.7121 54 (3)        
Cytochrome P450 2C37 CP237_MOUSE 56.2758    117 (4)     
Cytochrome P450 2C54 CP254_MOUSE 56.5631    121 (5)     
Cytochrome P450 2D10 CP2DA_MOUSE 57.5387  47 (4)  306 (10)    230 (6) 
Cytochrome P450 2D26 CP2DQ_MOUSE 57.2244  53 (6)  514 (16)   54 (3) 202 (6) 
Cytochrome P450 2E1 CP2E1_MOUSE 57.1678    132 (13)    55 (3) 
D-beta-hydroxybutyrate dehydrogenase BDH_MOUSE 38.6025  49 (4)  227 (8)  87 (3)  90 (4) 
Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase ECH1_MOUSE 36.4373 67 (7)  101 (8)      
Delta-1-pyrroline-5-carboxylate dehydrogenase AL4A1_MOUSE 62.2278    383 (11)  57 (6)  345 (11) 
Dimethylaniline monooxygenase [N-oxide-forming] 1 FMO1_MOUSE 60.4462    79 (6)     
Dimethylaniline monooxygenase [N-oxide-forming] 3 FMO3_MOUSE 61.1610    152 (5)     
Dimethylaniline monooxygenase [N-oxide-forming] 5 FMO5_MOUSE 60.5612    177 (6)    69 (3) 
DnaJ homolog subfamily A member 3 DNJA3_MOUSE 53.0947   49 (4)      
Dynactin subunit 2 DCTN2_MOUSE 44.2038   94 (6)      
Electron transfer flavoprotein subunit alpha ETFA_MOUSE 35.3296    72 (3)     
Electron transfer flavoprotein-ubiquinone 
oxidoreductase 
ETFD_MOUSE 68.9029 93 (3)   82 (6)     
Elongation factor 1-alpha 1 EF1A1_MOUSE 50.4242 188 (7)  71 (3) 204 (6)   63 (3)  
Elongation factor 1-alpha 2 EF1A2_MOUSE 50.7644    89 (3)     
  
 
F5 
 
Protein name Accession  Molecular 
weight 
(kDa) 
0.15M NaCl buffer, 
Control beads 
0.15M NaCl buffer, ICT-
5074 beads 
0.5M NaCl buffer, Control 
beads 
0.5M NaCl buffer, ICT-
5074 beads 
Eluate Beads Eluate Beads Eluate Beads Eluate Beads 
Elongation factor 1-beta EF1B_MOUSE 24.8493 56 (6)  352 (10)    98 (7)  
Elongation factor 1-delta EF1D_MOUSE 31.3879   271 (8)      
Elongation factor 1-gamma EF1G_MOUSE 50.3713    72 (3)     
Elongation factor 2 EF2_MOUSE 96.2223   56 (5) 49 (4)   87 (3)  
Elongation factor Tu EFTU_MOUSE 49.8761    52 (3)     
Endoplasmic reticulum resident protein 44 ERP44_MOUSE 47.2225   95 (5)      
Endoplasmin ENPL_MOUSE 92.7034  63 (6) 120 (6) 98 (4)    75 (7) 
Epoxide hydrolase 2 HYES_MOUSE 63.0448   105 (5)      
Eukaryotic initiation factor 4A-I IF4A1_MOUSE 46.3526    130 (5)     
Far upstream element-binding protein 2 FUBP2_MOUSE 77.2179   72 (5)      
Fatty acid synthase FAS_MOUSE 274.9938    967 (27)   111 (4) 377 (16) 
Ferritin light chain 1 FRIL1_MOUSE 20.8465 156 (4)  174 (6)    121 (5)  
Fibrinogen beta chain FIBB_MOUSE 55.4020   82 (4) 568 (15)    270 (6) 
Fibrinogen gamma chain FIBG_MOUSE 50.0441    48 (3)     
Formimidoyltransferase-cyclodeaminase FTCD_MOUSE 59.5288    95 (6)     
Fructose-bisphosphate aldolase B ALDOB_MOUSE 39.9383  128 (3)       
Galectin-1 LEG1_MOUSE 15.1983   50 (3)      
Glucosidase 2 subunit beta GLU2B_MOUSE 59.7251   300 (9)    50 (3)  
Glutamate dehydrogenase 1 DHE3_MOUSE 61.6403  288 (11)  590 (18)  80 (4) 120 (4) 285 (6) 
Glutaryl-CoA dehydrogenase GCDH_MOUSE 49.0720    167 (4)     
Glutathione peroxidase 1 GPX1_MOUSE 22.5443    103 (7)    50 (5) 
Glutathione S-transferase Mu 1 GSTM1_MOUSE 26.0671   146 (9) 46 (5)     
Glutathione S-transferase P 1 GSTP1_MOUSE 23.7652 75 (3)  214 (6)    201 (5)  
Glutathione S-transferase theta-1 GSTT1_MOUSE 27.6435    78 (8)     
Glyceraldehyde-3-phosphate dehydrogenase G3P_MOUSE 36.0723   87 (3) 211 (10)  128 (4)  99 (7) 
Glycerol-3-phosphate dehydrogenase [NAD+] GPDA_MOUSE 38.1757   65 (4)      
Group XIIB secretory phospholipase A2-like protein PG12B_MOUSE 22.5766   64 (3)      
Guanine nucleotide-binding protein subunit beta-2-like 
1 
GBLP_MOUSE 35.5107        46 (3) 
Heat shock cognate 71 kDa protein HSP7C_MOUSE 71.0553    64 (8)    59 (5) 
Heat shock protein HSP 90-beta HS90B_MOUSE 83.6153   328 (6) 74 (5)     
Heme-binding protein 1 HEBP1_MOUSE 21.1534       52 (3)  
Hemoglobin subunit alpha HBA_MOUSE 15.1328 620 (11)  855 (16) 214 (4) 62 (5)  1143 (18) 114 (5) 
Hemoglobin subunit beta-1 HBB1_MOUSE 15.9442 295 (14) 47 (3) 376 (10) 234 (3)  164 (7) 291 (11) 127 (5) 
Hemoglobin subunit beta-2 HBB2_MOUSE 15.9823 410 (13)  552 (15)    484 (16)  
  
 
F6 
 
Protein name Accession  Molecular 
weight 
(kDa) 
0.15M NaCl buffer, 
Control beads 
0.15M NaCl buffer, ICT-
5074 beads 
0.5M NaCl buffer, Control 
beads 
0.5M NaCl buffer, ICT-
5074 beads 
Eluate Beads Eluate Beads Eluate Beads Eluate Beads 
Heterogeneous nuclear ribonucleoprotein A/B ROAA_MOUSE 30.9263   112 (10)      
Heterogeneous nuclear ribonucleoprotein K HNRPK_MOUSE 51.2295   277 (6)      
Heterogeneous nuclear ribonucleoprotein U HNRPU_MOUSE 88.6610    160 (4)     
Heterogeneous nuclear ribonucleoproteins A2/B1 ROA2_MOUSE 37.4367   80 (3)    105 (3)  
Histone H1.2 H12_MOUSE 21.2537   56 (3)      
Hsc70-interacting protein F10A1_MOUSE 41.8006   224 (9)      
Hydroxymethylglutaryl-CoA synthase HMCS2_MOUSE 57.2997  51 (4)  273 (9)  94 (3)  177 (6) 
Hydroxysteroid dehydrogenase-like protein 2 HSDL2_MOUSE 54.5160        53 (4) 
Hypoxia up-regulated protein 1 HYOU1_MOUSE 111.3403    155 (7)     
Inorganic pyrophosphatase IPYR_MOUSE 33.1023   132 (7)      
Isocitrate dehydrogenase [NADP] cytoplasmic IDHC_MOUSE 47.0296    67 (3)    108 (4) 
Legumain LGMN_MOUSE 49.7405   57 (3)      
L-gulonolactone oxidase GGLO_MOUSE 51.0868   62 (3) 187 (10)    167 (3) 
Lipoamide acyltransferase component of branched-
chain alpha-keto acid dehydrogenase complex 
ODB2_MOUSE 53.4691    47 (6)     
Liver carboxylesterase 1 EST1_MOUSE 63.0392   70 (4) 328 (8)    146 (7) 
Liver carboxylesterase 31 EST31_MOUSE 63.6766   144 (8) 241 (8)    168 (8) 
Liver carboxylesterase 31-like ES31L_MOUSE 63.3655   141 (7)    45 (4)  
Liver carboxylesterase N ESTN_MOUSE 61.4182   141 (5)    143 (3)  
Long-chain-fatty-acid--CoA ligase 1 ACSL1_MOUSE 78.8997        63 (5) 
L-serine dehydratase/L-threonine deaminase SDHL_MOUSE 34.9704    97 (3)     
Major urinary protein 2 MUP2_MOUSE 20.9354 116 (5)  54 (3)      
Mannose-binding protein C MBL2_MOUSE 26.3400   188 (7)    218 (5)  
Membrane-associated progesterone receptor 
component 1 
PGRC1_MOUSE 21.7948 222 (5) 127 (5) 264 (8) 225 (5)   182 (5) 181 (5) 
Methionyl-tRNA synthetase SYMC_MOUSE 102.7347    61 (6)     
Methylcrotonoyl-CoA carboxylase subunit alpha MCCA_MOUSE 79.6925    188 (7)     
Methylmalonate-semialdehyde dehydrogenase 
[acylating] 
MMSA_MOUSE 58.3347    181 (6)     
Methyltransferase-like protein 7B MET7B_MOUSE 28.4867    156 (3)    100 (3) 
Microsomal triglyceride transfer protein large subunit MTP_MOUSE 99.6638   66 (6) 132 (6)    59 (4) 
Mitochondrial antiviral-signaling protein MAVS_MOUSE 53.8220   81 (3)      
Mitochondrial import inner membrane translocase 
subunit Tim13 
TIM13_MOUSE 10.6790   177 (6)    122 (2)  
Mitochondrial import inner membrane translocase TIM8A_MOUSE 11.2634 175 (5)  271 (5)    171 (4)  
  
 
F7 
 
Protein name Accession  Molecular 
weight 
(kDa) 
0.15M NaCl buffer, 
Control beads 
0.15M NaCl buffer, ICT-
5074 beads 
0.5M NaCl buffer, Control 
beads 
0.5M NaCl buffer, ICT-
5074 beads 
Eluate Beads Eluate Beads Eluate Beads Eluate Beads 
subunit Tim8 A 
Myosin light polypeptide 6 MYL6_MOUSE 17.0902   59 (4)      
NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 8 
NDUA8_MOUSE 20.4353 45 (5)        
NADH dehydrogenase [ubiquinone] flavoprotein 2 NDUV2_MOUSE 27.6100   146 (5)      
NADH dehydrogenase [ubiquinone]iron-sulfur protein4 NDUS4_MOUSE 19.8292   58 (5)      
NADPH--cytochrome P450 reductase NCPR_MOUSE 77.3945    91 (7)    45 (3) 
Non-specific lipid-transfer protein NLTP_MOUSE 59.7150   73 (4)      
Nucleobindin-1 NUCB1_MOUSE 53.3759 94 (7)  1534 (42)    489 (18)  
Nucleobindin-2 NUCB2_MOUSE 50.3872   117 (3)      
Peptidyl-prolyl cis-trans isomerase B PPIB_MOUSE 23.6986   124 (3)      
Peroxiredoxin-1 PRDX1_MOUSE 22.3904 170 (12)  298 (13) 178 (4)  46 (3) 216 (9) 64 (5) 
Peroxiredoxin-2 PRDX2_MOUSE 21.9361   54 (4)      
Peroxiredoxin-4 PRDX4_MOUSE 31.2612        118 (3) 
Peroxiredoxin-6 PRDX6_MOUSE 24.9690  49 (3) 366 (13) 125 (3)   271 (8)  
Peroxisomal 2,4-dienoyl-CoA reductase DECR2_MOUSE 31.6225    48 (3)     
Peroxisomal biogenesis factor 19 PEX19_MOUSE 32.9407   86 (3)      
Peroxisomal multifunctional enzyme type 2 DHB4_MOUSE 79.9452    127 (6)     
Phenylalanine-4-hydroxylase PH4H_MOUSE 52.4096    267 (15)    73 (6) 
Phosphoenolpyruvate carboxykinase PCKGC_MOUSE 70.0514    134 (8)  50 (4)  84 (7) 
Polyadenylate-binding protein 1 PABP1_MOUSE 70.8259   105 (6)    54 (3)  
Probable 2-oxoglutarate dehydrogenase E1 component 
DHKTD1 
DHTK1_MOUSE 103.4698    260 (8)  48 (5)  162 (7) 
Probable carboxypeptidase PM20D1 P20D1_MOUSE 55.7419 72 (3)  66 (9)      
Prohibitin PHB_MOUSE 29.8589        63 (3) 
Proline dehydrogenase PROD_MOUSE 57.2505    129 (5)     
Prolow-density lipoprotein receptor-related protein 1 LRP1_MOUSE 523.3418    82 (15)     
Protein canopy homolog 2 CNPY2_MOUSE 21.0964   60 (3)      
Protein CREG1 CREG1_MOUSE 24.5504   46 (3)      
Protein disulfide-isomerase A3 PDIA3_MOUSE 57.0989   46 (7)    77 (4)  
Protein disulfide-isomerase A6 PDIA6_MOUSE 48.4694  60 (3)  86 (6)     
Protein disulfide-isomerase PDIA1_MOUSE 57.5070 593 (18)  1254 (39) 292 (9)  45 (3) 1372 (36)  
Protein NipSnap homolog 1 NIPS1_MOUSE 33.5701    260 (8)  106 (6)  149 (6) 
Protein transport protein Sec31A SC31A_MOUSE 134.5120    253 (10)    129 (4) 
Pyruvate carboxylase PYC_MOUSE 130.3437  75 (6)  369 (24)    179 (13) 
  
 
F8 
 
Protein name Accession  Molecular 
weight 
(kDa) 
0.15M NaCl buffer, 
Control beads 
0.15M NaCl buffer, ICT-
5074 beads 
0.5M NaCl buffer, Control 
beads 
0.5M NaCl buffer, ICT-
5074 beads 
Eluate Beads Eluate Beads Eluate Beads Eluate Beads 
Pyruvate dehydrogenase E1 component subunit alpha ODPA_MOUSE 43.8879    87 (9)  101 (11)   
Pyruvate dehydrogenase E1 component subunit beta ODPB_MOUSE 39.2542    203 (5)    147 (4) 
Ras GTPase-activating-like protein IQGAP2 IQGA2_MOUSE 181.0998   73 (6)      
Reticulocalbin-2 RCN2_MOUSE 37.2478   361 (8)    153 (3)  
Ribose-phosphate pyrophosphokinase 2 PRPS2_MOUSE 35.1631    61 (4)     
S-adenosylmethionine synthetase isoform type-1 METK1_MOUSE 44.0512 292 (12) 161 (7) 1036 (22) 323 (12)  165 (5) 549 (16) 241 (8) 
Sarcosine dehydrogenase SARDH_MOUSE 102.6443    111 (3)     
Serum amyloid P-component SAMP_MOUSE 26.4013    81 (3)  60 (3)  84 (3) 
Small glutamine-rich tetratricopeptide repeat-
containing protein alpha 
SGTA_MOUSE 34.5290   120 (3)      
S-phase kinase-associated protein 1 SKP1_MOUSE 18.8313   91 (3)      
Splicing factor, arginine/serine-rich 1 SFRS1_MOUSE 27.8419  99 (5)       
Splicing factor, arginine/serine-rich 3 SFRS3_MOUSE 19.5460  129 (6)  86 (5)     
Splicing factor, arginine/serine-rich 7 SFRS7_MOUSE 31.0269  147 (6)  95 (5)  61 (3)   
Sulfite oxidase, mitochondrial SUOX_MOUSE 61.2310 51 (4)  164 (7)      
Sulfotransferase 1A1 ST1A1_MOUSE 34.1803    52 (4)    67 (6) 
Superoxide dismutase SODC_MOUSE 16.1039   252 (3)      
T-complex protein 1 subunit alpha A TCPA1_MOUSE 60.9298    112 (5)     
Tetratricopeptide repeat protein 36 TTC36_MOUSE 20.1772   226 (10)    75 (4)  
Thioredoxin-dependent peroxide reductase PRDX3_MOUSE 28.3375   147 (5)      
Trifunctional enzyme subunit alpha ECHA_MOUSE 83.3017    59 (8)    125 (5) 
Trifunctional enzyme subunit beta ECHB_MOUSE 51.6385    120 (6)    60 (6) 
Tubulin alpha-1A chain TBA1A_MOUSE 50.7879    253 (5)  81 (3)  145 (4) 
Tubulin alpha-4A chain TBA4A_MOUSE 50.6337   120 (4) 212 (5)    150 (5) 
Tubulin beta-2A chain TBB2A_MOUSE 50.2741   147 (10) 327 (18)  83 (3)  320 (12) 
Tubulin beta-2C chain TBB2C_MOUSE 50.2552   116 (8) 368 (17)   79 (5) 366 (14) 
Tubulin beta-5 chain TBB5_MOUSE 50.0951   154 (8)     228 (14) 
Ubiquilin-1 UBQL1_MOUSE 61.9372   144 (4)    120 (3)  
Ubiquinone biosynthesis protein COQ9 COQ9_MOUSE 35.2316   195 (4)      
UDP-glucose 6-dehydrogenase UGDH_MOUSE 55.4815    79 (5)     
UDP-glucuronosyltransferase 1-1 UD11_MOUSE 60.8253 56 (5)   68 (3)     
Uncharacterized protein C1orf50 homolog CA050_MOUSE 22.0199   130 (4)      
UPF0568 protein C14orf166 homolog CN166_MOUSE 28.2488   65 (3)      
Urocanate hydratase HUTU_MOUSE 75.2268    57 (3)     
Valyl-tRNA synthetase SYVC_MOUSE 141.4386    165 (4)    109 (6) 
  
 
F9 
 
Protein name Accession  Molecular 
weight 
(kDa) 
0.15M NaCl buffer, 
Control beads 
0.15M NaCl buffer, ICT-
5074 beads 
0.5M NaCl buffer, Control 
beads 
0.5M NaCl buffer, ICT-
5074 beads 
Eluate Beads Eluate Beads Eluate Beads Eluate Beads 
Very long-chain acyl-CoA synthetase S27A2_MOUSE 71.1198    58 (4)     
Very long-chain specific acyl-CoA dehydrogenase ACADV_MOUSE 71.2298    143 (7)    129 (5) 
Vitamin D-binding protein VTDB_MOUSE 55.1616 701 (19)  1142 (33)    409 (12)  
Vitronectin VTNC_MOUSE 55.6126    79 (4)     
Xylulose kinase XYLB_MOUSE 60.3040    88 (4)     
Cysteine-rich with EGF-like domain protein 2 CREL2_MOUSE 40.3606   62 (5)      
G1 
 
Appendix G: Mass spectrometry data histamine- and ICT-5074 streptavidin agarose bead chromatography. List of proteins identified with at least 3 
peptides, MASCOT score ≥45. Histamine-beads and ICT-5074 beads prepared and processed as described in Section 7.3.2. P450 identifications are 
highlighted in red. 
Protein 
Accession 
(Mouse) 
Histamine-bead 
experiment IVa 
ICT-5074-bead 
experiment IVb 
Alpha-1-antitrypsin 1-1  A1AT1 247 (5) - 
Alpha-enolase  ENOA 126 (6) - 
Argininosuccinate lyase  ARLY 51 (8) - 
Basigin  BASI 47 (5) - 
Calreticulin  CALR 73 (4) - 
Cytochrome b-c1 complex subunit 1, 
mitochondrial  QCR1 191 (11) 
- 
Cytochrome P450 1A2  CP1A2 164 (11) 98 (3) 
Cytochrome P450 2A4  CP2A4 187 (9) 73 (4) 
Cytochrome P450 2A5  CP2A5 187 (8) - 
Cytochrome P450 2C29  CP2CT 335 (29) 76 (5) 
Cytochrome P450 2C37  CP237 422 (27) 76 (6) 
Cytochrome P450 2C39  CP239 260 (19) 77 (5) 
Cytochrome P450 2C40  CP240 161 (7) - 
Cytochrome P450 2C50  CY250 455 (20) 76 (6) 
Cytochrome P450 2C54  CP254 342 (20) 53 (5) 
Cytochrome P450 2D10  CP2DA 240 (10) 70 (6) 
Cytochrome P450 2D11  CP2DB 122 (7) - 
Cytochrome P450 2D26  CP2DQ 109 (6) - 
Cytochrome P450 2E1  CP2E1 289 (13) 117 (7) 
Cytochrome P450 2F2  CP2F2 190 (14) 63 (6) 
  
 
G2 
 
 
Protein 
Accession 
(Mouse) 
Histamine-bead 
experiment IVa 
ICT-5074-bead 
experiment IVb 
Dihydrolipoyllysine-residue 
succinyltransferase component of 2-
oxoglutarate dehydrogenase complex  ODO2 50 (5) 
- 
Dynactin subunit 2  DCTN2 55 (4) - 
Fatty aldehyde dehydrogenase  AL3A2 173 (11) 47 (7) 
Gamma-enolase  ENOG 119 (3) - 
H-2 class I histocompatibility antigen, D-D 
alpha chain  HA12 118 (9) 
- 
H-2 class I histocompatibility antigen, D-P 
alpha chain  HA14 50 (5) 
- 
H-2 class I histocompatibility antigen, K-D 
alpha chain  HA1D 78 (9) 
- 
Methylmalonate-semialdehyde 
dehydrogenase [acylating], mitochondrial  MMSA 53 (4) 
- 
Phenylalanine-4-hydroxylase  PH4H 96 (7) - 
Protein disulfide-isomerase A6  PDIA6 406 (14) 64 (7) 
S-adenosylmethionine synthase isoform 
type-1  METK1 50 (3) 
- 
T-complex protein 1 subunit beta  TCPB 67 (6) - 
Tubulin alpha-4A chain TBA4A 57 (4) - 
Tubulin beta-2A chain  TBB2A 267 (15) 88 (6) 
Tubulin beta-2C chain  TBB2C 240 (19) 88 (5) 
UDP-glucuronosyltransferase 1-1 UD11 254 (14) - 
UDP-glucuronosyltransferase 2B17  UDB17 152 (6) - 
Vimentin  VIME 189 (16) - 
  
 
H1 
 
Appendix H: Mass spectrometry data histamine- and ICT-5074 dynabead chromatography. List of proteins identified with at least 3 peptides, MASCOT 
score ≥45. Histamine-beads and ICT-5074 beads prepared and processed as described in Section 7.3.3. P450 identifications are highlighted in red. 
 
Protein 
Accession 
(Mouse) 
Histamine-bead 
experiment Va 
ICT-5074-bead 
experiment Vb 
Actin, alpha cardiac muscle 1  ACTC - 179 (8) 
Actin, aortic smooth muscle  ACTA - 140 (5) 
Actin, cytoplasmic 1 ACTB 55 (6) 227 (11) 
Apolipoprotein E  APOE 105 (9) 
 Argininosuccinate synthase  ASSY - 185 (11) 
Calreticulin  CALR - 146 (4) 
Cytochrome P450 1A2  CP1A2 367 (13) 52 (6) 
Cytochrome P450 1B1  CP1B1 255 (17) 144 (11) 
Cytochrome P450 2C29  CP2CT 228 (15) - 
Cytochrome P450 2C37  CP237 56 (6) - 
Cytochrome P450 2D10  CP2DA 851 (25) 152 (8) 
Cytochrome P450 2E1 CP2E1 90 (9) - 
Cytochrome P450 3A11 CP3A 78 (6) - 
Delta(3,5)-Delta(2,4)-dienoyl-CoA 
isomerase, mitochondrial  ECH1 - 101 (4) 
Protein disulfide-isomerase A6  PDIA6 - 143 (6) 
UDP-glucuronosyltransferase 1-1  UD11 46 (3) 46 (9) 
